

# ASRM 2022

*Genes, Gametes, and Genetics*

Anaheim, California

October 22-26, 2022



ANAHEIM CONVENTION CENTER

## Final Program



**Sunday, October 23**  
**6:00 PM PST**

**Hilton – Anaheim, CA**

*Cocktails, Dinner, ASRM Awards Presentation and After Party*  
*Black tie optional*

ASRM President, Dr. Marcelle Cedars invites all Congress attendees to join us as we turn back the clock 50 years to celebrate historical milestones in reproductive rights and lay the foundation for leading policy discussions now and into the future.

All funds raised at the President's Gala will benefit the ASRM Center for Policy and Leadership.

Tickets are \$500 per person and include After Party. Purchase your tickets or table at [www.asrmcongress.org](http://www.asrmcongress.org) when you register for the Congress. For more information or for sponsorship opportunities, contact Brynne MacCann 205-978-7702 or [bmaccann@asrm.org](mailto:bmaccann@asrm.org).


### Join Us as the Party Continues!

Immediately following the Gala, Dr. Cedars will host an After Party with cocktails, dessert and music. Tickets are \$150 per person.

**Purchase your tickets at [www.asrmcongress.org](http://www.asrmcongress.org).**

9:00 PM PST | Hilton Anaheim | Cocktail Attire





**THIS YEAR, WE WELCOME YOU TO ANAHEIM, CALIFORNIA,** a city built on imagination, for the 78th annual meeting of the American Society for Reproductive Medicine! This year's ASRM Scientific Congress & Expo theme is GENES, GAMETES, AND GENETICS. Dr. Jim Segars, Scientific Congress Program Chair, and Dr. Erica Johnstone, Postgraduate Program Chair, and their teams have designed a comprehensive and exciting program for Congress attendees. The richness of the program is designed to address the educational and practice needs of physicians, nurses, andrology and embryology laboratory personnel, genetic counselors, mental health practitioners, practice managers, as well as practitioners in public health, allied health, law, and ethics.



OUR WEEKEND BEGINS with an exciting on-site Postgraduate Courses. The Postgraduate Program Committee has collaborated with our affiliated societies and professional special interest groups, and several International Societies, as well as, other outside Societies to present a wide range of multi-disciplinary Postgraduate Courses designed to meet the needs of all of our members. Course topics range from the latest on ex vivo reproduction, genetic and cell therapy in regenerative medicine, omic diagnostics, trauma informed infertility, technical advances for obstructive and non-obstructive azoospermia, and social media and digital technology your patients. Additionally, we will have several hands-on courses including the Embryo Transfer Simulation Program, a day-long vitrification course, and a course that will focus on office-based procedures and opportunities for surgery in low resource settings. We anticipate a full house and look forward to having you participate.


In keeping with our ASRM 2022 Scientific Congress theme of "Genes, Gametes, and Genetics" we have ensured a diverse dynamic line up of plenary speakers this year that will engage us in a variety of topics including early embryo development and cell fate determination, molecular determinants of ovarian aging, and big data in reproductive medicine. With an awareness of the current national environment, and an acknowledgement of the new ASRM Center for Policy and Leadership, we have special talks on reproductive rights and the politics of science and its place in society. Lastly, we'll focus on, the future of surgery.

The Scientific Congress Continuing Medical Education (CME) course offerings will include morning plenary and dual-afternoon lectures,

symposia, and interactive sessions. You will hear innovative lectures that focus on communicating about genetics to patients, diversifying the reproductive medicine workforce, human genome editing, dietary and exercise implications on male reproduction, moving novel therapies from bench to bedside, and fertility preservation for our transgender patients. CME sessions will be complemented by non-CME activities including intimate roundtable luncheons covering the breadth and depth of reproductive medicine; and oral and poster-format scientific abstract presentations. Top posters will be presented in lightning round talks. New features this year will include ASRMed Talks and a series on 'The Business of Medicine'.

We welcome our members, trainees, and colleagues from around the world to the ASRM 2022 Scientific Congress & Expo! We look forward to seeing you in person, after so long, and value your participation and engagement in all of the educational and networking opportunities provided.

I look forward to seeing you in the beautiful city of Anaheim, where together we will mark ASRM's 78th Annual Congress. I also hope you will join us on Sunday night, October 23rd, 2022, at the President's Gala Celebration in support of the ASRM Center for Policy and Leadership and the new post-gala after party.

Sincerely,  
  
Marcelle I. Cedars, MD  
ASRM President, 2021-2022

JOIN US FOR OUR  
**Opening  
Ceremony**

Monday, October 24th,  
7:45 am – 8:30 am

Plenary 1 will immediately  
follow in the same room.

A complimentary continental  
breakfast will be available  
7:00 am – 7:45 am

**Inside this Program**

ASRM PRESIDENT'S GALA .....	2
ASRM WELCOME .....	3
OPENING CEREMONY.....	4
ASRM SCIENTIFIC CONGRESS PLANNING COMMITTEES .....	6
ASRM OFFICERS AND BOARD OF DIRECTORS .....	6
ASRM 2022 AWARDS.....	7-16
SCHEDULE-AT-A-GLANCE .....	17-20
SCIENTIFIC CONGRESS DAILY SCHEDULE .....	21-27
ASRM SCIENTIFIC CONGRESS POLICIES AND DISCLAIMERS .....	30
REGISTRATION AND MEETING INFORMATION.....	30
HOUSING INFORMATION .....	31
SPOTLIGHT EVENTS.....	33
TICKETED EVENTS .....	34
NEW EDUCATION OFFERINGS .....	35
CONTINUING MEDICAL EDUCATION/CONTINUING EDUCATION..	37,38
POSTGRADUATE PROGRAM .....	39-57
NEEDS ASSESSMENT AND LEARNING OBJECTIVES .....	58
TRACKS.....	66
ROUNDTABLES .....	68-71
ASRM IS PAPERLESS .....	149
FUTURE ASRM SCIENTIFIC CONGRESS & EXPO DATES .....	158



# Committees and Awards

- ASRM Scientific Congress Program Planning Committee 6
- ASRM Officers and Board of Directors 6
- ASRM Awards 7-16
- Schedule-at-a-Glance 17-20
- Daily Schedule 21-27
- ASRM Scientific Congress Policies and Disclaimers 30

SPONSORED BY  
THE AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE





## ASRM 2022 Scientific Congress Program Planning Committees

- Marcelle I. Cedars, MD, ASRM 2022 President
- James Segars, MD, 2022 SC Program Chair
- Ruben Alvero, MD, 2022 Interactive Sessions Chair
- Genevieve Neal-Perry, MD, PhD, 2022 Roundtables Chair
- Erica Johnstone, MD, MHS, Postgraduate Program Chair
- Samantha Butts, MD, MSCE., Postgraduate Co-Chair
- Erica Marsh, MD, MSCI, FACOG, Postgraduate Coordinating Chair
- G. David Ball, PhD, Ad Hoc Member
- Julia Woodward, PhD, Ad Hoc Member
- Karen Berkowitz, MD, Ad Hoc Member
- Timothy Hickman, MD, SART Representative
- James Smith, MD, SMRU Representative
- Amy Jones, MSc, SRBT Representative
- Steve Young, MD, SREI Representative
- J. Preston Parry, MD, MPH, SRS Representative
- Mahshid Albrecht, MBA, ARM Representative
- Jenna Miller, MS, CGC, GCPG Representative
- Nidhi Desai, JD, LPG Representative
- Melanie Mikkelson, LICSW, MSW, MHPG Representative
- Tamara Tobias, NP, NPG Representative
- Jared C. Robins, MD, MBA, Executive Director (Ex Officio)
- Chevis Shannon, DrPH, MBA, MPH, MERC, CESO (Ex Officio)
- Jody Thrash, MBA, ASRM Staff

## ASRM VIDEO COMMITTEE

- Michael I Eisenberg, MD, Video Program Chair
- Victor Beshay, MD
- Bala Bhagavath, MD
- Tien-Cheng Chang, PhD
- James Hotaling, MD, MS
- Kathleen Hwang, MD
- Anthony Imudia, MD
- Edward Kim, MD
- Phillip S. Li, MD
- Steven R. Lindheim, MD
- Marius Meintjes, DVM, PhD
- Charles Miller, MD
- Ceana Nezhat, MD

## ASRM Officers and Board of Directors 2021 – 2022

### ASRM OFFICERS

- Marcelle I. Cedars, MD, President
- Michael A. Thomas, MD, President-Elect
- Paula Amato, MD, Vice President
- Hugh S. Taylor, MD, Immediate Past President
- Catherine Racowsky, PhD, Past President
- James P. Toner, MD, PhD, Secretary/Treasurer

### ASRM BOARD OF DIRECTORS AT-LARGE MEMBERS

- Amy E. Sparks, PhD
- Alan S. Penzias, MD
- Akanksha Mehta, MD
- Lee Rubin Collins, JD
- Lauri A. Pasch, PhD
- Kim L. Thornton, MD

### ASRM BOARD OF DIRECTORS AFFILIATED SOCIETY MEMBERS

- Timothy N. Hickman, MD (SART)
- Phillip S. Li, MD (SMRU)
- Liesl Nel-Themaat, PhD (SRBT)
- Micah J. Hill, DO (SREI)
- Kathleen Y. Hwang, MD (SRS)

### ASRM EXECUTIVE DIRECTOR

- Jared C. Robins, MD, MBA

### ASRM CHIEF EDUCATION AND SCIENCE OFFICER

- Chevis N. Shannon, DrPH, MBA, MPH, MERC

- John Nichols, Jr, MD
- John Petrozza, MD
- Marc P. Portmann, MT
- Salli Tazuke, MD
- Mark Trolice, MD
- Togas Tulandi, MD





### American Society for Reproductive Medicine 2022 Society Awards

#### **DISTINGUISHED RESEARCHER AWARD**

#### **KYLE E. ORWIG, PH.D.**

The 2022 recipient of the ASRM Distinguished Researcher Award is **Kyle E. Orwig, Ph.D.** This award recognizes a member of the American Society for Reproductive Medicine who has made outstanding contributions to clinical or basic research in reproduction published during the previous 10 years. The recipient will have demonstrated sustained long-term commitment to advancing the frontiers of research in reproductive sciences and educating future scholars in the field.



Dr. Orwig is a Professor of Obstetrics, Gynecology and Reproductive Sciences. He directs the UPMC Fertility Preservation Program and the UPMC Magee Center for Reproduction and Transplantation. Dr. Orwig received his Ph.D. in Animal Sciences and Biochemistry/Biophysics at Oregon State University where his research focused on ovarian function in cows and sheep. He conducted postdoctoral studies at the University of Kansas Medical Center characterizing prolactin family genes in the uterine decidual and placenta of rodents before starting his life's work on stem cells and spermatogenesis in a senior postdoc/junior faculty position at the University of Pennsylvania. He was recruited to Magee-Womens Research Institute and the University of Pittsburgh as a tenure track assistant professor in 2003. Dr. Orwig's lab has been continuously funded by NIH and other Sources. His research focuses on stem cells, germ lineage development, fertility and infertility. His lab is recognized for its leadership in translating stem cell and testicular tissue transplantation technologies to nonhuman primates and to the clinic. He currently serves as Chair of the ASRM Research Institute Advisory Committee and is honored to be recognized with the ASRM Distinguished Researcher Award.

#### **LIFETIME ACHIEVEMENT AWARD**

#### **ROBERT W. REBAR, M.D.**

The 2022 recipient of ASRM's Lifetime Achievement Award is **Robert W. Rebar, M.D.** This award honors a member of the American Society for Reproductive Medicine who has made exemplary contributions to the field of reproduction during his/her career. The recipient has demonstrated innovation, leadership, and other scholarly accomplishments that have a lasting impact on advancing clinical care, the frontiers of research in reproductive sciences, and the education of the scientific community.



Robert W. Rebar, M.D. received his M.D. degree from the University of Michigan, completed his residency in obstetrics and gynecology at Parkland Memorial Hospital in Dallas and at the University of California, San Diego. He completed a fellowship in Reproductive Endocrinology and Infertility at the National Institutes of Health. Dr. Rebar served on the faculties of UCSD and Northwestern medical schools before becoming Chair of Obstetrics and Gynecology at the University of Cincinnati. He served as Executive Director of the ASRM for 11 years. After "retirement," Dr. Rebar assumed the mantle of Founding Chair of the Department of Obstetrics and Gynecology at the new Western Michigan University Homer Stryker M.D. School of Medicine, recruited the initial faculty, and with them developed a medical school clerkship and a residency program in obstetrics and gynecology before stepping down to teach.

Dr. Rebar is a member of numerous professional societies, including ASRM. He served on the Reproductive Endocrinology and Infertility Subspecialty Division of the American Board of Obstetrics and Gynecology and has served on the editorial boards of several journals.






Dr. Rebar has authored over 300 articles on menopause, fertility, and reproductive endocrinology. He has been the Principal or a Co-Investigator on several NIH grants. His research focused on forms of hypothalamic chronic anovulation, polycystic ovary syndrome, premature ovarian insufficiency, menopause, and contraception. He has received lifetime awards from the International Federation of Fertility Societies and the Association of Professors of Gynecology and Obstetrics.

### IRA AND ESTER ROSENWAKS NEW INVESTIGATOR AWARD

*supported by an endowment from Zev Rosenwaks, M.D.*

#### AUDREY J. GASKINS, SC.D.

**Audrey Gaskins, Sc.D.** is an Assistant Professor in the Department of Epidemiology at the Emory University Rollins School of Public Health. She earned her Doctoral Degree in Nutrition and Epidemiology from the Harvard T.H. Chan School of Public Health. This training was preceded by a Bachelor's Degree in Engineering from Duke University. As a reproductive and environmental epidemiologist, Dr. Gaskins' research uses creative study designs and methodologies to advance the science in environmental, dietary, and lifestyle influences on human reproduction. Her research, which includes 145 papers, has been cited over 3,500 times and resulted in many awards including multiple NIEHS Extramural Science Papers of the Month, the Best New Researcher Award from the International Society of Environmental Epidemiology, and the Rising Star Award from the Society of Pediatric and Perinatal Research. She has been the principal investigator of three research grants from the NIEHS including a recently completed K99/R00 award on maternal exposure to air pollution and early pregnancy outcomes, an ongoing R01 focused on air pollution and fertility among couples undergoing donor oocyte ART, and a newly awarded R21 on extreme heat and human reproduction using national ART surveillance data.




Dr. Gaskins serves on the executive board of the Nutrition and Environmental Special Interest Group of ASRM and as a member-at-large for the Society for Pediatric and Perinatal Epidemiologic Research. She is currently a methodological editor for Fertility & Sterility and on the editorial board for the International Journal of Hygiene and Environmental Health.

### KAVOUSSI FAMILY OUTSTANDING TEACHER AWARD

*This award is made possible through an educational endowment from K.M. Kavoussi, M.D., Homa Kavoussi, Shahryar Kavoussi, M.D., M.P.H., Mehryar Kavoussi, J.D., Parviz Kavoussi, M.D., and Austin Fertility & Reproductive Medicine/Westlake IVF.*

#### LARRY I. LIPSHULTZ, M.D.

**Larry I. Lipshultz, M.D.** is Professor of Urology and Chief of the Scott Department of Urology's Division of Male Reproductive Medicine and Surgery at Baylor College of Medicine in Houston, Texas. Dr. Lipshultz, who holds the Lester and Sue Smith Chair in Reproductive Medicine, is a well-known authority on abnormalities of male reproduction, erectile dysfunction, and male hormone therapy. He completed his medical training and urology residency at the University of Pennsylvania and was the first American Urological Association (AUA) research scholar. He is a member of the American Association of Genitourinary Surgeons, a founder of the Society for the Study of Male Reproduction and the American Society of Andrology, and he is the second urologist elected President of the American Society for Reproductive Medicine.



Dr. Lipshultz has been an active member of the AUA and ASRM throughout his career. In 2010 he was honored by the AUA as "one of the most respected surgeon scientists and mentors in Urology." He received the ASRM Service Award in 2011, the AUA's Hugh Hampton Young Award in 2005, the F. Brantley Scott Award of Excellence in 2015, and the American Association of Genitourinary Surgeons Spence Award for outstanding lifetime achievements in urology in 2022. He has published more than 440 journal articles, edited over 10 books, and has instituted a fellowship training program in male reproductive medicine and surgery that has trained more than 120 physicians, who are now in practice both here and abroad.





### **ARNOLD P. GOLD FOUNDATION HUMANISM IN MEDICINE AWARD FOR PRACTICING PHYSICIANS**

*supported by a gift from the Arnold P. Gold Foundation*

#### **SAMUEL C. PANG, M.D.**

After earning his B.Sc. (Biochemistry) and M.D. from the University of British Columbia, **Samuel C. Pang, M.D.** completed a rotating internship followed by a residency in Obstetrics & Gynecology at the University of Toronto. He completed his fellowship in Reproductive Endocrinology at UCLA. He is board certified in Obstetrics & Gynecology and in Reproductive Endocrinology & Infertility. In 1993, he joined IVF America Boston (later, Reproductive Science Center of New England) and was appointed Medical Director of RSCNE in 2007. In October 2014, he joined Boston IVF following a merger with RSCNE.



Dr. Pang has a reputation for commitment to excellence and meticulous attention to detail in patient care, and he is respectful, empathic, sensitive and compassionate in communicating with patients, engendering their trust and confidence. While his career focused on patient care, he has also mentored junior physician colleagues and advocated for patients. Working with RESOLVE New England, he played an instrumental role in the 2011 revision to the Massachusetts Infertility Insurance Mandate.

Dr. Pang is a pioneer in providing reproductive care to LGBTQ+ patients. In 1998, he was among the earliest physicians applying ART to gay men who sought parenthood via donor eggs and gestational surrogacy. In 2007, he began providing IVF services to lesbian couples without infertility, coining the term “reciprocal IVF” for one person providing oocytes and the other gestating. In 2012, he began treating transgender men for fertility preservation and reciprocal IVF, and transgender men who choose to gestate themselves. He was a charter member and second chairperson of the LGBTQSIG at ASRM.

### **SUHEIL J. MUASHER, M.D., DISTINGUISHED SERVICE AWARD**

*supported by an endowment from Suheil J. Muasher, M.D.*

#### **ASRM COVID-19 TASK FORCE**

The 2022 recipient of the Suheil J. Muasher, M.D., Distinguished Service Award is The ASRM COVID-19 Task Force. Each year, ASRM honors individuals who have provided distinguished service to ASRM. Recipients are selected based on their scientific, leadership, organizational, political or societal service contributions to the ASRM, reproductive medicine and/or reproductive medicine patients.

In March 2020, the American Society for Reproductive Medicine established the COVID-19 Task Force. The task force, comprised of experts in reproductive medicine and patient representatives, is being recognized for their expertise, commitment, and for their time in staying ahead of the curve to provide guidance and recommendations to preserve the health and safety of patients and health care workers throughout the time of the pandemic.



**Amanda J. Adeleye, M.D.**  
*Assistant Professor of Obstetrics and Gynecology  
The University of Chicago*



**Natan Bar-Chama, M.D.**  
*Associate Clinical Professor  
Icahn School of Medicine at Mount Sinai  
Director, Male Reproductive Health  
Reproductive Medicine  
Associates of New York*





## 2022 AWARDS



**Marcelle I. Cedars, M.D.**  
Professor, Dept. of Obstetrics & Gynecology  
Director of Reproductive Endocrinology, School of Medicine, University of California



**Christos Coutifaris, M.D., Ph.D.**  
The Celso Ramon Garcia Professor of Obstetrics and Gynecology  
Perelman School of Medicine at the University of Pennsylvania



**Mark Cozi, M.B.A.**  
Patient Representative  
Founder and CEO of CentoVentiCinque LLC



**Jodie Dionne-Odom, M.D.**  
Associate Professor in Infectious Diseases  
Chief of Women's Health, 1917 HIV Clinic  
Associate Director of Global Health Center for Women's Reproductive Health  
University of Alabama at Birmingham



**Kevin J. Doody, M.D.**  
Director – CARE Fertility



**Eve C. Feinberg, M.D.**  
Associate Professor Northwestern University Feinberg School of Medicine



**Elizabeth Hern, M.B.A.**  
Patient Representative  
Proud Mom to Addi



**Jennifer F. Kawwass, M.D.**  
Division Director and Medical Director Emory Reproductive Center, REI Division, Emory University Department of Gyn/OB, Emory University School of Medicine in Atlanta



**Sigal Klipstein, M.D.**  
InVia Fertility Specialists



**Paul C. Lin, M.D.**  
Founding partner, Seattle Reproductive Medicine





## 2022 AWARDS



**Anne F. Malave, Ph.D.**  
*Clinical Psychologist-  
Psychoanalyst, Private Practice,  
New York City*



**Alan S. Penzias, M.D.**  
*Reproductive Endocrinologist,  
Associate Professor, Harvard  
Medical School*



**Samantha M. Pfeifer, M.D.**  
*Associate Professor  
Clinical Reproductive Medicine  
Weill Cornell Medicine*



**John C. Petrozza, M.D.**  
*Chief, Division of Reproductive  
Medicine & IVF Director, MGH Fertility  
Center Co-Director, MGH Integrated  
Fibroid Program Massachusetts General  
Hospital Harvard Medical School*




**Catherine Racowsky, Ph.D.**  
*Professor of Obstetrics and  
Gynecology, Emerita  
Harvard Medical School  
University Consultant for Hospital  
Foch, Suresnes, France*



**Enrique Schisterman, Ph.D.**  
*Perelman Professor in Biostatistics,  
Epidemiology and Informatics  
Chair, Department of Biostatistics,  
Epidemiology and Informatics (DBEI)  
Perelman School of Medicine,  
University of Pennsylvania*



**Peter N. Schlegel, M.D.**  
*James J. Colt Professor of Urology  
Weill Cornell Medicine*



**James H. Segars, Jr., M.D.**  
*Howard and Georgeanna Jones  
Professor and Director  
Division of Reproductive Sciences  
Department of Gynecology and  
Obstetrics, Johns Hopkins University  
School of Medicine*



**Hugh S. Taylor, M.D.**  
*Anita O'Keeffe Professor of Women's  
Health and Chair Department  
of Obstetrics, Gynecology and  
Reproductive Sciences Yale School  
of Medicine  
Chief of Obstetrics and Gynecology  
Yale-New Haven Hospital*



**Shane Zozula, B.S.**  
*Technical Supervisor  
Southern California Center for  
Reproductive Medicine*



### 2022 ASRM Star Award

The ASRM Star Award recognizes members who have presented during at least nine of the ASRM Scientific Congresses/Annual Meetings from 2012-2021. Presentations may include postgraduate courses/seminars, Scientific Program symposia, posters and/or oral abstracts.

### 2022 ASRM Star Award Recipients

- |  |                                   |                                    |
|--|-----------------------------------|------------------------------------|
| Ashok Agarwal, Ph.D.                     | Alicia Christy, M.D.              | Frank Gonzalez, M.D.               |
| Ali Ahmady, Ph.D.                        | Pak Chung, M.D.                   | Linnea Goodman, M.D.               |
| Ayman Al-Hendy, M.D., Ph.D.              | Amber Cooper, M.D.                | Clarisa Gracia, M.D.               |
| Ruben Alvero, M.D.                       | Alan Copperman, M.D.              | Jamie Grifo, M.D., Ph.D.           |
| Raymond Anchan, M.D., Ph.D.              | Christos Coutifaris, M.D., Ph.D.  | Karen Hammond, D.N.P.              |
| Sharon Anderson, Ph.D.                   | Susan Crockin, J.D.               | Carol Hanna, Ph.D.                 |
| Robert Anderson, M.D.                    | John Csokmay, M.D.                | Karl Hansen, M.D., Ph.D.           |
| David Archer, M.D.                       | Michael Dahan, M.D.               | Avner Hershlag, M.D.               |
| Yoshimasa Asada, M.D., Ph.D.             | Said Daneshmand, M.D.             | George Hill, M.D.                  |
| Baris Ata, M.D.                          | Hal Danzer, M.D.                  | Micah Hill, D.O.                   |
| Awoniyi Awonuga, M.B.B.S.                | Maria J. De Los Santos, Ph.D.     | Brooke Hodes-Wertz, M.D., M.P.H    |
| Johnny Awwad, M.D.                       | Alan Decherney, M.D.              | Kathleen Hong, M.D.                |
| Valerie Baker, M.D.                      | Nina Desai, Ph.D., H.C.L.D.       | Toshitaka Horiuchi, Ph.D.          |
| G. David Ball, Ph.D.                     | Laura Detti, M.D.                 | James Hotaling, M.D.               |
| David Barad, M.D.                        | Kathleen Devine, M.D.             | Heather Huddleston, M.D.           |
| Kurt Barnhart, M.D.                      | Michael Diamond, M.D.             | Bradley Hurst, M.D.                |
| Jason Barritt, Ph.D.                     | Anuja Dokras, M.D., Ph.D.         | Kathleen Hwang, M.D.               |
| Alison Bartolucci, Ph.D.                 | Alice Domar, Ph.D.                | Anthony Imudia, M.D.               |
| Mohamed Bedaiwy, M.D., Ph.D.             | Kevin Doody, M.D.                 | Mohamad Irani, M.D.                |
| Barry Behr, Ph.D.                        | Daniel Dumesic, M.D.              | Kristen Ivani, Ph.D.               |
| Angeline Beltsos, M.D.                   | Randall Dunn, M.D.                | Jeffrey Jensen, M.D., M.P.H        |
| Claudio Benadiva, M.D., H.C.L.D.         | Jennifer Eaton, M.D.              | Sangita Jindal, Ph.D.              |
| Kristin Bendikson, M.D.                  | Lawrence Engmann, M.D.            | Lauren Johnson, M.D.               |
| Dara Berger, Ph.D., M.P.H.               | Navid Esfandiari, Ph.D., H.C.L.D. | Emily Jungheim, M.D.               |
| Bala Bhagavath, M.B.B.S.                 | Sandro Esteves, M.D., Ph.D.       | Mandy Katz-Jaffe, Ph.D.            |
| Cecily Bishop, Ph.D.                     | Tommaso Falcone, M.D.             | David Keefe, M.D.                  |
| Christina Boots, M.D.                    | Tarek Farghaly, M.D.              | Zaraq Khan, M.D.                   |
| Edson Borges, M.D., Ph.D.                | Eve Feinberg, M.D.                | Chung-Hoon Kim, M.D., Ph.D.        |
| Charles Bormann, Ph.D.                   | Rui Alberto Ferriani, M.D., Ph.D. | Rashmi Kudesia, M.D.               |
| Paul Brezina, M.D., M.B.A.               | Rebecca Flyckt, M.D.              | Anver Kuliev, M.D.                 |
| Christine Briton-Jones, Ph.D.            | Eric Forman, M.D., H.C.L.D.       | Joanne Kwak-Kim, M.D., M.P.H       |
| William Buckett, M.B.B.Ch., M.D.         | Jason Franasiak, M.D., H.C.L.D.   | Koichi Kyono, M.D.                 |
| Samantha Butts, M.D.                     | Aisaku Fukuda, M.D., Ph.D.        | Dolores Lamb, Ph.D.                |
| Erkan Buyuk, M.D.                        | Noritaka Fukunaga, Ph.D.          | Michael Lanham, M.D.               |
| Douglas Carrell, Ph.D.                   | Juan Garcia-Velasco, M.D.         | Ruth Lathi, M.D.                   |
| William Catherino, M.D., Ph.D.           | Forest Garner, M.S.               | Angela Lawson, Ph.D.               |
| Marcelle Cedars, M.D.                    | Nicolas Garrido Puchalt, Ph.D.    | Maw-Sheng Lee, M.D.                |
| Gerard Celia, Ph.D.                      | Audrey Gaskins, Sc.D.             | Richard Legro, M.D.                |
| Jessica Chan, M.D.                       | William Gibbons, M.D.             | Bruce Lessey, M.D., Ph.D.          |
| T. Arthur Chang, Ph.D., E.L.D., H.C.L.D. | Elizabeth Ginsburg, M.D.          | Joseph Letourneau, M.D.            |
| Samuel Chantilis, M.D.                   | Michael Glassner, M.D.            | Michael Levy, M.D.                 |
| Subodhsingh Chauhan, M.D.                | Norbert Gleicher, M.D.            | Clifford Librach, M.D.             |
| Jorge Chavarro, M.D., D.Sc.              | Jeffrey Goldberg, M.D.            | Frederick Licciardi, M.D.          |
| Jerome Check, M.D.                       | James Goldfarb, M.D., M.B.A.      | Steven Lindheim, M.D.              |
| Stephanie Cheung, B.S.                   | Kara Goldman, M.D.                | Barbara Luke, D.Sc., Sc.D., M.P.H. |
| Mindy Christianson, M.D., M.B.A.         | Marc Goldstein, M.D.              | Martha Luna Rojas, M.D.            |



## 2022 AWARDS

Monica Mainigi, M.D.  
Melissa Maisenbacher, M.S.  
Erica Marsh, M.D.  
Antonio Martinez, M.D., Ph.D.  
Beth Mcavey, M.D.  
Caroline Mccaffrey, Ph.D., H.C.L.D.  
Blair Mccallie, D.Phil.  
David Mcculloh, Ph.D.  
Akanksha Mehta, M.D.  
Zaher Merhi, M.D.  
Katrina Merrion, M.S., B.A.  
Jennifer Mersereau, M.D.  
Marcos Meseguer, Ph.D.  
Stacey Missmer, Sc.D.  
Molly Moravek, M.D., M.P.H  
Dean Morbeck, Ph.D., M.B.A.  
Yoshiharu Morimoto, M.D., Ph.D.  
Eduardo Motta, M.D.  
Tanmoy Mukherjee, M.D.  
Sunni Mumford, Ph.D.  
Santiago Munne, Ph.D.  
Zsolt Nagy, M.D., Ph.D., H.C.L.D.  
Kanad Dev Nayar, M.D.  
Taraneh Nazem, M.D.  
Nicole Noyes, M.D.  
John Nulsen, M.D.  
Kutluk Oktay, M.D., Ph.D.  
Kenan Omurtag, M.D.  
Kyle Orwig, Ph.D.  
Lubna Pal, M.B.B.S.  
Gianpiero Palermo, M.D., Ph.D.  
Jason Parks, Ph.D.  
Lauri Pasch, Ph.D.  
Pasquale Patrizio, M.D.  
Richard Paulson, M.D.  
Mary Ellen Pavone, M.D.  
Lindsay Penrose, Ph.D.  
Alan Penzias, M.D.

John Petrozza, M.D.  
Samantha Pfeifer, M.D.  
Simon Phillips, Ph.D.  
Margareta Pisarska, M.D.  
Torie Plowden, M.D., M.P.H  
Staci Pollack, M.D.  
Alex Polotsky, M.D.  
Samuel Prien, Ph.D.  
Elizabeth Puscheck, M.D.  
Catherine Racowsky, Ph.D.  
Kevin Richter, Ph.D.  
Jared Robins, M.D., M.B.A.  
Randal Robinson, M.D.  
Zev Rosenwaks, M.D.  
Carmen Rubio Lluesa  
Ginny Ryan, M.D.  
Denny Sakkas, Ph.D.  
Mary Sammel, D.Sc., Sc.D.  
Mary Samplaski, M.D.  
Benjamin Sandler, M.D.  
Jay Sandlow, M.D.  
Nanette Santoro, M.D.  
Glenn Schattman, M.D.  
Mitchel Schiewe, Ph.D.  
Peter Schlegel, M.D.  
William Schoolcraft, M.D.  
Richard Scott, M.D.  
James Segars, M.D.  
David Seifer, M.D.  
Lucky Sekhon, M.D.  
Emre Seli, M.D.  
Suneeta Senapati, M.D.  
Divya Shah, M.D., M.Ed.  
Bruce Shapiro, M.D., Ph.D.  
Fady Sharara, M.D.  
Mark Sigman, M.D.  
Carlos Simon, Ph.D.  
Ov Slayden, Ph.D.

James Smith, M.D.  
Irene Souter, M.D.  
Steven Spandorfer, M.D.  
Laurel Stadtmauer, M.D., Ph.D.  
Daniel Stein, M.D.  
Anne Steiner, M.D., M.P.H  
Judy Stern, Ph.D.  
Irene Su, M.D.  
Mark Surrey, M.D.  
Jason Swain, Ph.D.  
Takumi Takeuchi, M.D., Ph.D.  
Reshef Tal, M.D., Ph.D.  
Atsushi Tanaka, M.D., Ph.D.  
Xin Tao, Ph.D., H.C.L.D.  
Tyl Taylor, Ph.D.  
Hugh Taylor, M.D.  
Michael Thomas, M.D.  
Thomas Toth, M.D.  
Nathan Treff, Ph.D.  
Michael Tucker, Ph.D.  
Togas Tulandi, M.D.  
Bradley Van Voorhis, M.D.  
Denis Vaughan, M.B.B.Ch.  
Matthew Vermilyea, Ph.D., H.C.L.D.  
Erica Wang, M.D.  
Rachel Weirnerman, M.D.  
Dagan Wells, Ph.D.  
Marie Werner, M.D.  
Brian Whitcomb, Ph.D.  
Eric Widra, M.D.  
Robert Wild, M.D.  
Lauren Wise, Sc.D.  
Wan-Song Wun, Ph.D., H.C.L.D.  
Tae Ki Yoon, M.D., Ph.D.  
Steven Young, M.D., Ph.D.  
Nikica Zaninovic, Ph.D.  
John Zhang, Ph.D.  
Shane Zozula, B.S.

## 2022 ASRM Service Milestone Award

The ASRM Service Milestone Award recognizes 10, 15, and 20-year milestones for service on boards and/or committees of ASRM or its affiliated societies, professional groups, or special interest groups.

### 20-Year ASRM Service Milestone Award Recipient

Valerie Baker, M.D.  
Tommaso Falcone, M.D.  
William Petok, Ph.D.  
Samantha Pfeifer, M.D.  
Catherine Racowsky, Ph.D.  
Michael Thomas, M.D.  
James Toner, M.D., Ph.D.

### 15-Year ASRM Service Milestone Award Recipient

Ayman Al-Hendy, M.D., Ph.D.  
Paula Amato, M.D.  
William Catherino, M.D., Ph.D.  
Kutluk Oktay, M.D., Ph.D.  
Lisa Rinehart, J.D., R.N.  
Steven Spandorfer, M.D.  
Laurel Stadtmauer, M.D., Ph.D.  
Judy Stern, Ph.D.

### 10-Year ASRM Service Milestone Award Recipients

Emilio Fernandez, M.D.  
Antonio Gargiulo, M.D.  
Marc Portmann, M.H.A., B.S.





### **SOCIETY FOR MALE REPRODUCTION AND UROLOGY TRAVELING SCHOLARS PROGRAM**

The annual Society for Male Reproduction and Urology Traveling Scholars Program allows a diverse group of young clinical physicians and basic science researchers the opportunity to explore a career in male reproductive medicine. The primary purpose of the program is to stimulate the scientific interests of residents and fellow in the study of male reproduction. Scholars are selected by the SMRU Research Committee based on the scores of their abstracts submitted for the Scientific Congress.

### **CAPPY ROTHMAN, M.D., CHUCK SIMS, M.D., AND THE CALIFORNIA CRYOBANK TRAVELING SCHOLAR AWARD**

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The recipient for 2022 is **Jason Huang, MD**.

### **SMRU LIPSHULTZ/LAMB TRAVELING SCHOLAR AWARD**

This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The recipient for 2022 is **Christian Ramsoomair, MD**.

**WEILL CORNELL MALE REPRODUCTIVE SURGERY AND UROLOGY TRAVELING FELLOW AWARD** This award allows a junior physician or basic science researcher to explore a career in male reproduction and urology. The primary purpose of the award is to stimulate the scientific interests of students, residents and fellows in the study of male reproduction. The 2022 recipient is **Shinnosuke Kuroda, MD** for DEVELOPMENT OF A NOVEL ROBUST ARTIFICIAL INTELLIGENCE DEVELOPED SPERM DNA FRAGMENTATION TEST – PRELIMINARY FINDINGS.

### **SMRU TRAVELING SCHOLARS**

- Samuel Donnenfeld, MD
- Adrienne Shami, MD
- John Sigalos, MD

### **SREI PRIZE PAPER**

**Jessie Hoxie, BS**

THE RELATIONSHIP BETWEEN ESTROGEN AND SUBSEQUENT GROWTH RESTRICTION AMONG ADOLESCENTS WITH HEAVY MENSTRUAL BLEEDING

### **SMRU PRIZE PAPER**

**Cara Nicholson, MSc, BSc**

IDENTIFICATION AND TREATMENT OF COUPLES SUFFERING TOTAL FERTILISATION FAILURE (TFF): A CLINICAL SERVICE EVALUATION AND PROPOSED PHENOTYPIC SCREENING SOLUTION

### **SART PRIZE PAPER**

**Johnny Awwad, MD, HCLD/TS(ABB)**

A THREE-DOSE GnRH AGONIST TRIGGERING PROTOCOL TO IMPROVE LIVE BIRTHS IN HYPER-RESPONDERS UNDERGOING FRESH EMBRYO TRANSFER AND INTENSIVE LUTEAL SUPPORT: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL

### **SRBT PRIZE PAPER**

**Nuno Costa Borges, PhD**

FIRST PRE-CLINICAL AND CLINICAL VALIDATION OF AN AUTOMATED SPERM INJECTION ROBOT (ICSI-A) IN HUMAN OOCYTES

### **SRBT PRIZE PAPER**

**Manuel Viotti, PhD**

UPDATE ON THE INTERNATIONAL REGISTRY OF MOSAIC EMBRYO TRANSFERS

### **MHPG PRIZE PAPER (BEST OVERALL)**

**Jennifer B. Bakkensen, MD**

PSYCHOLOGICAL STRESS AND INFERTILITY: WHAT DO WOMEN IN MEDICINE BELIEVE?

### **MHPG PRIZE PAPER (MOST IMPACTFUL)**

**Kirby Adlam, CNM, MSN**

A MIXED-METHODS EVALUATION OF EGG DONORS' PHYSICAL, PSYCHOSOCIAL, AND DISCLOSURE EXPERIENCES POST-DONATION

### **NPG PRIZE PAPER IN RESEARCH**

**Kirby Adlam, CNM, MSN**

A MIXED-METHODS EVALUATION OF EGG DONORS' PHYSICAL, PSYCHOSOCIAL, AND DISCLOSURE EXPERIENCES POST-DONATION

### **ARM PRIZE PAPER**

**Louisa Drake, DO**

TELEMEDICINE HAS MADE ASSISTED REPRODUCTIVE TECHNOLOGY FAR MORE CONVENIENT FOR PATIENTS, WITH HIGH PATIENT SATISFACTION AND SUCCESS RATES



## 2022 AWARDS

### **SRS PRIZE PAPER**

**Mary McKenna, MD**

EFFECTS OF FIBRIN SEALANT COMPARED WITH SUTURING OR NO HEMOSTATIC INTERVENTION ON OVARIAN RESERVE IN PATIENTS UNDERGOING OVARIAN CYSTECTOMY: A RETROSPECTIVE COHORT STUDY

### **SRS IN-TRAINING AWARDS FOR RESEARCH**

**Jeremy Applebaum, MD**

FIBROID BURDEN DOES NOT AFFECT THE RISK PROFILE OF SAME-DAY DISCHARGE AFTER MINIMALLY INVASIVE MYOMECTOMY: A COMPARISON OF POST-OPERATIVE COMPLICATION RATES BY LENGTH OF STAY

### **SRS IN-TRAINING AWARDS FOR RESEARCH**

**Ali Bazzi, MD**

THE ASSOCIATION BETWEEN FIBROIDS, OBESITY AND ADIPOSITY IN A LATINA/LATINX POPULATION

### **SRS IN-TRAINING AWARDS FOR RESEARCH**

**Christine Hur, MD**

HYSTEROSCOPIC MYOMECTOMY IS NOT ASSOCIATED WITH INTRAPERITONEAL DISSEMINATION OF MYOMETRIAL CELLS

### **SRS TRAVELING SCHOLARS FOR REPRODUCTIVE SURGERY**

**Anthony Bui, MD, MS**

RACIAL DISPARITIES IN ENDOMETRIOSIS SURGERY

### **SRS/SMRU TRAVELING SCHOLAR**

**Daniel Greenberg, MD**

MACHINE-LEARNING ENABLED PREDICTION OF SUCCESSFUL SPERM RETRIEVAL FOR MICRODISSECTION TESTICULAR SPERM EXTRACTION

### **SMRU TRAVELING SCHOLAR**

**Samuel Donnenfeld, MD**

THE UROLOGIST'S GUIDE TO RELIGION AND MALE FERTILITY TREATMENTS

### **SMRU TRAVELING SCHOLAR**

**Christian K Ramsoomair, BA**

MECHANISTIC INSIGHTS INTO A RARE MUTATION IN NACAD AS A POSSIBLE CAUSE OF COVID ORCHITIS

### **SMRU TRAVELING SCHOLAR**

**John Sigalos, BA, MD**

SPERM DNA METHYLATION PREDICTS HUMAN AGING IN FERTILE AND INFERTILE MEN

### **SMRU TRAVELING SCHOLAR**

**Adrienne Shami, BSc**

BREAKING IT DOWN: ADHERENCE TO GUIDELINES FOR DNA FRAGMENTATION TESTING IN MALE INFERTILITY PATIENTS

### **SMRU TRAVELING SCHOLAR**

**Jason Huang, MD**

IMPROVING ONCOLOGY FERTILITY PRESERVATION - AREAS OF IMPACT

### **SMRU TRAVELING SCHOLAR**

**Shinnosuke Kuroda, MD, PhD**

DEVELOPMENT OF A NOVEL ROBUST ARTIFICIAL INTELLIGENCE DEVELOPED SPERM DNA FRAGMENTATION TEST – PRELIMINARY FINDINGS

### **ENDOSIG – BEST BASIC SCIENCE**

**Marina Segura-Benítez, MSc**

HUMAN BLASTOCYSTS UPTAKE EXTRACELLULAR VESICLES SECRETED BY PRIMARY ENDOMETRIAL EPITHELIAL CELLS CONTAINING MIRNAS RELATED TO IMPLANTATION AND EARLY EMBRYO DEVELOPMENT

### **ENDOSIG – BEST IN CLINICAL/POPULATION SCIENCE**

**Mary McKenna, MD**

EFFECTS OF FIBRIN SEALANT COMPARED WITH SUTURING OR NO HEMOSTATIC INTERVENTION ON OVARIAN RESERVE IN PATIENTS UNDERGOING OVARIAN CYSTECTOMY: A RETROSPECTIVE COHORT STUDY

### **RISIG (REPRODUCTIVE IMMUNOLOGY)**

**Atsushi Fukui, MD, PhD**

PREDICTION AND DIAGNOSIS OF REPRODUCTIVE FAILURES BASED ON NKp46 EXPRESSION IN ENDOMETRIAL OR DECIDUAL NK CELLS

### **NUTRISIG (NUTRITION)**

**Benjamin Jackson, MS**

NUTRITIONAL EDUCATION (FACE-TO-FACE AND VIDEO INSTRUCTION) FOR POLYCYSTIC OVARY SYNDROME RESULTS IN GREATER REDUCTION IN BMI AND HEMOGLOBIN A1C THAN CALORIC RESTRICTION, EXERCISE AND METFORMIN



## 2022 AWARDS

### HDSIG (HEALTH DISPARITIES)

**Caiyun Liao, MD, MPH**

STATE MANDATED INSURANCE IS ASSOCIATED WITH REDUCED RACIAL DISPARITIES IN ACCESS AND LIVE BIRTH RATES FOR EGG RECIPIENTS -AN ANALYSIS OF 44,033 CYCLES FROM THE SARTCORS DATABASE FOR 2014-2016

### FSIG (FIBROID)

**Lena Chen, MD**

MECHANICAL AUGMENTATION OF PROGESTERONE ACTION IN UTERINE FIBROID CELLS REQUIRES PROGESTERONE RECEPTOR B (PRB) AND IS ASSOCIATED WITH PRB PHOSPHORYLATION

### FPSIG (FERTILITY PRESERVATION)

**Ivy L Lersten, MD**

OVARIAN RESPONSE AND ANTI-MULLERIAN HORMONE IN FERTILITY PRESERVATION VERSUS ELECTIVE OOCYTE CRYOPRESERVATION CYCLES: A SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY REGISTRY STUDY OF 10,040 CYCLES

### EPSIG (EARLY PREGNANCY)

**Camille Zeitouni, BSc**

CANNABIS USE AND PREGNANCY LOSS: A SYSTEMATIC REVIEW AND META-ANALYSIS

### EPSIG (EARLY PREGNANCY)

**Rachel Warwar, MD**

MISCARRIAGE AFTER EMBRYO TRANSFER: HOW MUCH TIME IS LOST?

### RESIDENT IN-TRAINING AWARD

**Francesca Barrett, MD, MBA**

A RESILIENT WOMB: MATERNAL AGE AT TRANSFER FOLLOWING AUTOLOGOUS OOCYTE (AO) CRYOPRESERVATION (CRYO) DOES NOT IMPACT ONGOING PREGNANCY + LIVE BIRTH RATES (LBRS)

### IN-TRAINING AWARDS FOR RESEARCH

**Gabriela Beroukhim, MD**

INCREASED EXPOSURE TO ENDOCRINE DISRUPTORS AMONG BLACK WOMEN MAY LEAD TO GREATER INCIDENCE OF UTERINE FIBROIDS

### IN-TRAINING AWARDS FOR RESEARCH

**Dhanalakshmi Thiyagarajan, MD**

RISK OF ECTOPIC PREGNANCY IN PATIENTS WITH A TRANSIENT DIAGNOSIS OF PREGNANCY OF UNKNOWN LOCATION

### IN-TRAINING AWARDS FOR RESEARCH

**Connie Odetta Rees, MD, MSc**

WAVES STUDY – QUANTITATIVE ULTRASOUND MEASUREMENT OF ENDOMETRIAL WAVES IN ADENOMYOSIS VERSUS WOMEN WITH NORMAL UTERI

### IN-TRAINING AWARDS FOR RESEARCH

**Ruth Habte, MD**

ENDOMETRIAL RECEPTIVITY ANALYSIS TESTING: A SINGLE CENTRE EXPERIENCE

### IN-TRAINING AWARDS FOR RESEARCH

**Eduardo Hariton, MD, MBA**

THE EFFECT OF THE COVID-19 VACCINE AND COVID-19 INFECTION ON MENSTRUAL CYCLE LENGTH: AN ANALYSIS OF 10,922 PATIENTS

### VIDEO PRESENTATION AWARD FIRST PLACE

**Phillip Romanski, MD, MSc**

AN INTRODUCTION AND VIDEO TUTORIAL TO THE NEW AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE MÜLLERIAN ANOMALIES CLASSIFICATION 2021 INTERACTIVE WEBSITE

### VIDEO PRESENTATION AWARD SECOND PLACE

**Aojun Jiang, Ms**

IDENTIFYING VIABILITY OF IMMOTILE SPERM AT ONE GLANCE: SPERM VIABILITY CLASSIFIER POWERED BY DEEP LEARNING

### VIDEO PRESENTATION AWARD THIRD PLACE

**Michael Franklin Neblett, II, MD**

A STEP-BY-STEP APPROACH TO A FROZEN PELVIS



# SCHEDULE-AT-A-GLANCE POSTGRADUATE

## SATURDAY, OCTOBER 22, 2022

1:00 PM - 5:00 PM

PG01	Trauma Informed Infertility Care: How to Provide Optimal Treatment for Patients with a Trauma History	CME APA NASW
PG02	Apps, Websites, Social Media, Oh My! Digital Technology Your Patients Use and Why You Need to Know About It.	CME ABB APA NASW NSGC
PG03	IVF for Genetic Disease Prevention	CME NSGC
PG04	Preimplantation Genetic Testing: Outcomes, Current Technologies, Future Developments	CME ABB APA NSGC
PG05	An Evidence-Based Integrative Approach to Fertility and Preconception Care	CME ACOG APA NPWH

## SUNDAY, OCTOBER 23, 2022

8:00 AM - 12:00 PM

PG06	Advances in Clinical and Laboratory Techniques for Obstructive and Non-Obstructive Azoospermia	CME ABB
------	--	---------

8:00 AM - 5:00 PM

PG07	Recurrent Miscarriages: The Workup Beyond the Usual Whats Next If She Still Miscarries after a Negative Workup?	CME ACOG
PG08	Update on Uterine Fibroids: From Pathogenesis to Treatment	CME ACOG
PG09	Taking the Operating Room to the Office: Obtaining Best Outcomes, Patient Experience, & Economic Sustainability.	CME ABB ACOG
PG10	More Than Metformin: Optimizing Lifestyle Interventions for Metabolic and Psychological Health in Women with PCOS	CME ACOG APA NPWH
PG11	Creating a Culturally-Responsive ART Practice: Legal, Ethical and Clinical Determinants in the Patient Experience	CME ABB APA LPG NASW NSGC
PG12	Enhancing the Patient Experience, It's All about Expectations.	CME
PG13	Evidence-Based Personalization of the IVF Process: What You Need to Know and What the Future Holds	CME NSGC
PG14	Leading the Way – Modernizing REI Practice Management for the Future	CME
PG15	Adventures in Ex Vivo Reproduction – Recent Developments and Prospects for Reproductive Medicine	CME
PG16	The New Frontier in ART, Genetic and Cell Therapy Approaches in Reproductive and Regenerative Medicine	CME NSGC
PG17	Vitrification Workshop: Understanding and Troubleshooting Device Warming Issues	CME ABB
PG18	Emerging Methods for Embryo Selection	CME

1:00 PM - 5:00 PM

PG19	The Power and Promise of 'Omic Diagnostics for Male Reproductive Medicine	CME ABB NSGC
------	---	--------------

## SCHEDULE-AT-A-GLANCE SUNDAY, OCTOBER 23, 2022

8:00 am - 12:00 pm	Society for Reproductive Endocrinology and Infertility (SREI) Members' Retreat: To the Future and Beyond in REI
8:00 am - 12:00 pm	Embryo Transfer Simulation (Hands-on Simulation) – Morning Session
1:00 pm - 4:00 pm	2nd Annual Social Media Summit
6:00 pm - 9:00 pm	ASRM 2022 President's Gala
9:00 pm	President's Gala After Party

# SCHEDULE-AT-A-GLANCE MONDAY, OCTOBER 24, 2022

7:00 am - 7:45 am	ASRM 2022 Opening Ceremony Continental Breakfast	
7:45 am - 8:30 am	ASRM 2022 Opening Ceremony	
8:30 am - 9:15 am	Plenary	President's Guest Lecture: Health & Life Science Priorities, from the White House Office of Science and Technology Policy <b>CME</b> <b>ABB</b> <b>ACOG</b>
9:15 am - 10:00 am	Plenary	Camran Nezhat, M.D. Lectureship in Innovations in Medicine: Live Imaging Preimplantation Development <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b>
10:00 am - 10:45 am	Break	
10:45 am - 12:15 pm		Scientific Congress Prize Paper Session 1 Oral Abstract Sessions
10:45 am - 12:15 pm		Video Abstract Session 1
10:45 am - 12:15 pm		SMRU Traveling Scholar Abstract Session
11:00 am - 12:00 pm	Clinical Sessions	MHPG Clinical Session: The Mental Health Professional as Gate Keeper in Third Party Assisted Reproduction: Managing Our Ethical Responsibility, Conflicts of Interest and Perceived Power <b>APA</b> <b>LPG</b> <b>NASW</b> NPG Clinical Session: The REI Nurse Triage
12:15 pm - 1:30 pm	Break/Lunch	
12:20 pm - 1:20 pm	Roundtable Discussions	RTM01 – RTM25
12:20 pm - 1:20 pm	Resident Learning Session	
1:30 pm - 2:30 pm	Interactive Sessions	Which is Best for the Ovarian Insufficiency Patient Planning Pregnancy: Fresh or Frozen Donor Eggs? <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b> Optimizing Laboratory Teams, Procedures and Quality Management: Commonly Used and Lab Derived Tools <b>CME</b> <b>ABB</b> <b>ACOG</b> Lifestyle Interventions in Women with Polycystic Ovary Syndrome - Translating Data to Best Practices <b>CME</b> Not Just Stress - Supporting Non-birthing Partners During Infertility & With (Non)Desired Outcomes <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>APA</b> <b>NASW</b> <b>NSGC</b> PGT-A, Mosaicism, and Patient Facebook Groups: What Are Clinicians Missing? <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NSGC</b> Risk Mitigation to Protect Your Practice - What Are You Missing? <b>CME</b> <b>ABB</b> <b>ACOG</b> A Multidisciplinary Approach to Endometriosis Management <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b> Beyond the Karyotype: Genetic Issues of rSABs - What Should We Test? <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b>
1:30 pm - 2:45 pm	Symposia	KY Cha Symposium in Stem Cell Technology and Reproductive Medicine: Building and Editing Gametes and Embryos <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b> Fertility Preservation in Adolescents and Children with Cancer and Genetic Conditions <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b> <b>NSGC</b> Talking to Patients About Genetics: A Multidisciplinary Guide <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b> <b>LPG</b> Mentorship and Pipeline Programs: Roadmap to Successfully Diversifying the Reproductive Medicine Workforce <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b> Identifying and Breaking down Barriers to Utilization of Male Fertility Care <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NFPH</b> Advanced Imaging of Endometriosis and Adenomyosis: Revolutionizing Surgical Planning and Patient Outcomes <b>CME</b> <b>ABB</b> <b>ACOG</b> MEFS Symposium: Artificial Intelligence and Machine Learning in ART: Opportunities, Limitations and Challenge <b>CME</b> <b>ABB</b> <b>ACOG</b> ESHRE Symposium: Fertility Preservation in Women with BRCA Gene Mutations <b>CME</b> <b>ABB</b> <b>ACOG</b>
2:45 pm - 3:30 pm	Break	
3:00 pm - 4:30 pm	Lecture	The Business of Medicine: How I Run My Practice
3:30 pm - 4:15 pm	Plenary Session	The David and Rosemary Adamson Lecture on Excellence in Reproductive Medicine : Leveraging Molecular and Clinical Data to Study Adverse Pregnancy Outcomes in the Era of Precision Medicine <b>CME</b> <b>ABB</b> <b>ACOG</b>
3:30 pm - 4:15 pm	Plenary Session	Herbert H. Thomas Plenary Lecture : The Catholic Case for Equitable Access to Comprehensive Reproductive Healthcare <b>CME</b> <b>ABB</b> <b>ACOG</b>



# SCHEDULE-AT-A-GLANCE TUESDAY, OCTOBER 25, 2022

7:00 am - 8:00 am	Women's Council Breakfast	
8:00 am - 8:30 am	Plenary Session	From Genomic Junk to Rising Stars: Noncoding RNAs in Ovarian Aging <b>CME</b> <b>ABB</b> <b>ACOG</b>
8:30 am - 9:15 am	Plenary Session	Telomere Maintenance in the Context of Human Aging Processes <b>CME</b> <b>ABB</b> <b>ACOG</b>
9:15 am - 10:00 am	Plenary Session	Linking Heterogeneity in Fetal Development to Oocyte Fate and Fitness <b>CME</b> <b>ABB</b> <b>ACOG</b>
10:00 am - 10:45 am	Break	
10:45 am - 12:15 pm		Scientific Congress Prize Paper Session 2 Oral Abstract Sessions
10:45 am - 12:15 pm		Video Abstract Session 2
11:00 am - 12:00 pm	Clinical Sessions	MHPG Clinical Session: Quality Improvement: Improving Patient and Provider Experiences <b>APA</b> <b>NASW</b> NPG Clinical Session: Mosaicism for Nurses <b>NPWH</b> <b>NSGC</b>
12:15 pm - 1:30 pm	Break/Lunch	
12:20 pm - 1:20 pm	Roundtable Discussions	RTT01 – RTT21
12:20 pm - 1:20 pm	Resident Learning Session	
1:30 pm - 2:30 pm	Interactive Sessions	The Genetics of a Successful FET: Ultrasound Imaging and PGT-a or Endometrial Gene Profile? <b>CME</b> Ovarian Tissue Cryopreservation for Emerging Primary Ovarian Insufficiency: How, When and Why? <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Building Diversity, Equity and Inclusion into a Reproductive Practice <b>CME</b> Complex Reproductive Genetics Case Discussions <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Understanding the Complex Role of Progesterone Supplementation in the Recurrent Miscarriage Patient <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Macroscopic Vs Microscopic: Which Matters More for Uterine Factor Infertility? <b>CME</b> <b>ABB</b> <b>ACOG</b> Human Genome Editing: Current State, Future, and Concerns <b>CME</b> Updating Your Toolkit: Fertility Preservation Advocacy, Access and Advancing Mandates for Coverage <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b>
1:30 pm - 2:45 pm	Symposia	The Howard and Georgeanna Jones Symposium on Assisted Reproductive Technology (ART): IVF Lab Benchmarking – Key Performance Indicators for Future Success <b>CME</b> <b>ABB</b> <b>ACOG</b> The Society for the Study of Reproduction (SSR) Symposium: Use of Single-Cell RNA Sequencing to Probe Cell Identity & Function and Reveal Tissue Organization <b>CME</b> <b>ABB</b> <b>ACOG</b> The Role of Nutrition, Obesity, Exercise, Environment, and Overall Health in Male Reproduction <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Gamete and Embryo Donation for the 21st Century <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>APA</b> <b>NASW</b> <b>NPWH</b> <b>NSGC</b> Precision Medicine Approaches to Addressing Disparities in Uterine Fibroids <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Moving Novel Therapies from Bench to Bedside: Collaboration Between Basic, Pharma, and Clinical Efforts <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Strengthening Fertility Education and Awareness Globally: A Joint WHO / ASRM Symposium <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>APA</b> <b>LPC</b>
2:45 pm - 3:30 pm	Break	
3:00 pm - 4:30 pm	Lecture	The Business of Medicine: Panel Discussion and Insight Session
3:30 pm - 4:15 pm	Plenary Session	Menopause Keynote Lecture: Menopause Keynote Lecture: The Menopause Transition: Shifting Scientific Paradigms <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b>
3:30 pm - 4:15 pm	Plenary Session	American Urological Association (AUA) Bruce Stewart Memorial Lecture: A New Paradigm <b>CME</b> <b>ABB</b> <b>ACOG</b>





# SCHEDULE-AT-A-GLANCE WEDNESDAY, OCTOBER 26, 2022

8:00 am - 8:45 am	Plenary Session	The Society of Reproductive Surgeons Lecture: Evolution of Surgical Treatments for Severe Male Infertility and Coordination with Assisted Reproduction <b>CME</b> <b>ABB</b> <b>ACOG</b>
8:45 am - 9:15 am	ASRM 2022 Members Business Meeting	
9:15 am - 10:00 am	Plenary Session	Growing Up in a Hostile Environment: The Science Behind and History of IVF in America <b>CME</b> <b>ABB</b> <b>ACOG</b>
10:00 am - 10:45 am	Break	
10:45 am - 12:15 pm		Oral Abstract Sessions
12:15 pm - 1:30 pm	Break/Lunch	
12:20 pm - 1:20 pm	Roundtable Discussions	RTW01 – RTW21
12:20 pm - 1:20 pm	Resident Learning Session	
1:30 pm - 2:30 pm	Clinical Sessions	MHPG Clinical Session: The Good, the Bad and the Ugly of Psychological Assessment in Third Party Reproduction <b>APA</b> <b>NASW</b> NPG Clinical Session: Understanding Ovarian Cysts <b>NPWH</b>
1:30 pm - 2:30 pm	Interactive Sessions	"Right to Do": Ethics, Law, and Fertility Preservation for AYA and Transgender Patients <b>CME</b> <b>ABB</b> <b>ACOG</b> PGTA for All Patients with Recurrent Miscarriages: What Does the Scientific Evidence Suggest? <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> <b>NSGC</b> Do We TRUST Data on Uterine Septum Repair? <b>CME</b> Complex Family Planning Fellow Research Showcase <b>CME</b> Too Many Embryos, Too Few Choices: Viable Embryo Donation Options In The United States <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>APA</b> <b>LPC</b> <b>NASW</b>
1:30 pm - 2:45 pm	Symposia	The ABOG Ken Ryan Ethics Symposium: Extending the 14 Day Rule - Will Unlocking the "Black Box" Improve Reproductive Care? <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>LPC</b> PGTA for All Patients with Recurrent Miscarriages: What Does the Scientific Evidence Suggest? <b>CME</b> <b>ABB</b> <b>ACOG</b> Unifying Experimental Endometriosis Models to Improve Translational Relevance <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Battling Ovarian Aging and Primary Ovarian Insufficiency <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b> Diversity & Inclusion - Breaking Down Barriers for Patients and Staffing <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NSGC</b> Insights into Primary Ovarian Insufficiency and Ovarian Aging: Genetic and Environmental Factors <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NSGC</b> Automation, Artificial Intelligence and Lab-on-a-Chip <b>CME</b> <b>ABB</b> <b>ACOG</b> I Found My Donor on Facebook: Considerations for Alternative Models of Sperm Donation <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>LPC</b> <b>NASW</b> <b>NSGC</b> Genes Controlling Reproductive Aging, Reproductive Aging Controlling Genes
3:00 pm - 3:45 pm	Plenary Session	The Society for the Study of Reproduction (SSR) Keynote Exchange Lecture: Molding the next generation: drivers and consequences of calcium signaling at fertilization <b>CME</b> <b>ABB</b> <b>ACOG</b>
3:00 pm - 3:45 pm	Plenary Session	Contraception Keynote Lecture: The La Brea Tar Pits and Contraception: 62 years after FDA approval of "The Pill" <b>CME</b> <b>ABB</b> <b>ACOG</b> <b>NPWH</b>





### Daily Schedule Key to Abbreviations

#### AFFILIATED SOCIETIES

SART	Society for Assisted Reproductive Technology
SMRU	Society for Male Reproduction and Urology
SRBT	Society of Reproductive Biologists and Technologists
SREI	Society for Reproductive Endocrinology and Infertility
SRS	Society of Reproductive Surgeons



**Indicates a ticket event**

#### PROFESSIONAL GROUPS

ARM	Association of Reproductive Managers
GCPG	Genetic Counseling Professional Group
LPG	Legal Professional Group
MHPG	Mental Health Professional Group
NPG	Nurses' Professional Group



**Indicates session offers education credits**

#### SPECIAL INTEREST GROUPS

Special Interest Groups are ASRM-member groups centered around a specific topic.

ATCSIG	Access to Care Special Interest Group
AESIG	Androgen Excess Special Interest Group
CIMSIG	Complementary and Integrative Medicine Special Interest Group
CFPSIG	Complex Family Planning Special Interest Group
ChSIG	Chinese Special Interest Group
EndoSIG	Endometriosis Special Interest Group
EPSIG	Early Pregnancy Special Interest Group
ERSIG	Environment and Reproduction Special Interest Group
FPSIG	Fertility Preservation Special Interest Group
FSIG	Fibroids Special Interest Group
HDSIG	Health Disparities Special Interest Group
ISIG	Indian Special Interest Group
IRMSIG	Imaging in Reproductive Medicine Special Interest Group
LGBTQSIG	LGBTQ Special Interest Group
MOISIG	Menopause and Ovarian Insufficiency Special Interest Group
NutriSIG	Nutrition Special Interest Group
PAGSIG	Pediatric and Adolescent Gynecology Special Interest Group
PGTSIG	Preimplantation Genetic Testing Special Interest Group
PSSIG	Physician-Scientists' Special Interest Group
RISIG	Reproductive Immunology Special Interest Group
RMSCBSIG	Regenerative Medicine and Stem Cell Biology Special Interest Group
TSIG	Turkish Special Interest Group
UTSIG	Uterine Transplant Special Interest Group (Forming)
WC	Women's Council

#### PARTNER GROUPS

AE-PCOS Society	Androgen Excess and Polycystic Ovary Syndrome Society
ALMER	Latin American Association for Reproductive Medicine
AMMR	Mexican Association of Reproductive Medicine
ASPIRE	Asia Pacific Initiative in Reproduction
CFAS	Canadian Fertility and Andrology Society
CSRM	Chinese Society of Reproductive Medicine
ESHRE	European Society of Human Reproduction and Embryology
ISAR	Indian Society for Assisted Reproduction
JSAR	Japan Society of Assisted Reproduction
MEFS	Middle East Fertility Society
SSR	Society for the Study of Reproduction





### SUNDAY, OCTOBER 23, 2022

1:00 PM – 4:00 PM  
2nd Annual Social Media Summit

6:00 PM – 9:00 PM  
ASRM 2022 President's Gala

9:00 PM  
President's Gala After Party

### MONDAY, OCTOBER 24, 2022

6:30 AM – 7:30 AM  
Monday E-poster Session and Continental Breakfast

7:00 AM – 7:45 AM  
ASRM 2022 Opening Ceremony Continental Breakfast

7:45 AM – 8:30 AM  
ASRM 2022 Opening Ceremony  
Marcelle I. Cedars, MD  
University of California San Francisco

8:30 AM – 9:15 AM  
Plenary Session  
**President's Guest Plenary Lecture: Health & Life Science Priorities, from the White House Office of Science and Technology Policy**   
*Endowed by a 1987 grant from Ortho Women's Health*

9:15 AM – 10:00 AM  
Plenary Session  
**Camran Nezhat, MD Lectureship in Innovations in Medicine: Live Imaging Preimplantation Development**   
*Endowed by a 2011 Gift from Camran Nezhat, MD. Dr. Camran Nezhat pioneered techniques of video-assisted endoscopic surgery, which revolutionized modern day surgery. He, along with his brothers, Drs. Farr and Ceana Nezhat, performed some of the most advanced procedures with these techniques for the first time, thus opening the vistas for endoscopic surgeons all over the world.*  
Nicolas Plachta, PhD  
University of Pennsylvania

10:00 AM – 10:45 AM  
Morning Break

10:45 AM - 12:15 PM  
Monday Oral Abstract Sessions

Scientific Congress Prize Paper Session 1

Video Abstract Session 1

SMRU Traveling Scholar Abstract Session

11:00 AM – 12:00 PM  
Clinical Sessions

**MHPG Clinical Session: The Mental Health Professional as Gate Keeper in Third Party Assisted Reproduction: Managing Our Ethical Responsibility, Conflicts of Interest and Perceived Power**

Kim Bergman, PhD, (Chair)  
Growing Generations  
Lauren Magalnick Berman, PhD  
Fertility Psychology Center of Atlanta, LLC  
Rich Vaughn, Attorney, Esq

**NPG Clinical Session: The REI Nurse Triage**   
Roxanne Buckmaster, RN  
Spring Fertility

12:15 PM – 1:30 PM  
Lunch Break

12:15 PM – 1:15 PM  
Fertility & Sterility Journal Club  
Global LIVE at ASRM 2022

12:20 PM – 1:20 PM  
Roundtables

1:30 PM – 2:30 PM  
Interactive Sessions

**Not Just Stress - Supporting Non-birthing Partners During Infertility & With (Non)Desired Outcomes**

Leigh Lewis, ND, LAc, NCMP, FABORM, (Chair)  
Arcadia Women's Wellness  
Julie Bindeman, PsyD Independent Practice

**PGT-A, Mosaicism, and Patient Facebook Groups: What Are Clinicians Missing?**

Nabil Arrach, PhD, (Chair)  
Fertility & Genetics  
Kaitlyn Wald, MD  
University of California San Francisco  
Jennifer L Garbarini, MS, CGC  
CooperSurgical

**Optimizing Laboratory Teams, Procedures and Quality Management: Commonly Used and Lab Derived Tools**

Mitchel C. Schiewe, MS, PhD, (Chair)  
California Fertility Partners  
Bill Venier, MSc, ELD (ABB)  
San Diego Fertility Center  
Graham Wright, BS

**Risk Mitigation to Protect Your Practice - What Are You Missing?**

Griffin Jones, BA, (Chair)  
ASRM and ARM Member  
Breanne Ross, NA  
Jeff Issner, NA

**Lifestyle Interventions in Women with Polycystic Ovary Syndrome - Translating Data to Best Practices**

Kathleen Hoeger, MD, (Chair)  
University of Rochester  
Richard S. Legro, MD  
Penn State College of Medicine  
Jorge E. Chavarro, MD, ScD  
Harvard T.H. Chan School of Public Health  
Shana Perman, PA  
Shady Grove Fertility

**Beyond the Karyotype: Genetic Issues of rSABs - What Should We Test?**

Sony Sierra, MD, MSc, (Chair)  
University of Toronto  
James Kashanian, MD  
New York-Presbyterian Hospital/  
Weill Cornell Medical Center  
Peter Schlegel, MD  
Weill Cornell Medicine  
Alexis Melnick, MD  
Weill Cornell Medicine



### A Multidisciplinary Approach to Endometriosis Management

CME ABB ACOG NFWH

Ceana Nezhat, MD, (Chair)  
Nezhat Medical Center  
Rebecca Flyckt, MD  
University Hospitals Cleveland  
Medical Center/Case Western  
Reserve University  
Laurel Stadtmauer, MD, PhD  
Eastern Virginia Medical School

### Which is Best for the Ovarian Insufficiency Patient Planning Pregnancy: Fresh or Frozen Donor Eggs?

CME ABB ACOG NFWH

Jennifer F Kawwass, MD, (Chair)  
Emory University (Emory GYN / OB,  
Emory Reproductive Center)  
Jennifer Mersereau, MD  
University of North Carolina at  
Chapel Hill  
Nicole Noyes, MD  
Northwell Health

### 1:30 PM – 2:45 PM Symposia

#### Identifying and Breaking Down Barriers to Utilization of Male Fertility Care

CME ABB ACOG NFWH

Mary Katherine Samplaski, MD, (Chair)  
University of Southern California  
James M Dupree IV, MD, MPH  
Michigan Medicine  
Jerrine R. Morris, MD, MPH  
University of California, San  
Francisco School of Medicine

#### Talking to Patients About Genetics: A Multidisciplinary Guide

CME ABB ACOG LPG NSGC

Amber Gamma, MS, CGC, (Chair)  
Northwell Health Fertility  
Eric J. Forman, MD  
Columbia University Fertility Center  
Lisa A Rinehart, RN, JD  
Legal Care Consulting, Inc.  
Jordanna Lipschitz, BSN, RN  
IVI/RMA

### KY Cha Symposium in Stem Cell Technology and Reproductive Medicine: Building and Editing Gametes and Embryos

CME ABB ACOG NSGC

Ali Ahmady, PhD, (Chair)  
Washington University Fertility and  
Reproductive  
M Kiho Lee, PhD  
University of Missouri  
Duygu B. Özpolat, PhD  
Washington University in St. Louis

### Fertility Preservation in Adolescents and Children with Cancer and Genetic Conditions

CME ABB ACOG NFWH NSGC

Kutluk H Oktay, MD, PhD, (Chair)  
Yale University School of Medicine  
Kirsten Tryde Macklon, MD, PhD  
Alla Vash-Margita, MD  
Yale University School of Medicine

### Mentorship and Pipeline Programs: Roadmap to Successfully Diversifying the Reproductive

Medicine Workforce

CME ABB ACOG NSGC

Gloria Richard-Davis, MD, (Chair)  
UAMS  
Michael K. Simoni, MD  
University of Pennsylvania  
Tiencheng Arthur Chang, PhD,  
HCLD, ELD  
University of Texas Health Science  
Center

### Advanced Imaging of Endometriosis and Adenomyosis: Revolutionizing Surgical Planning and Patient Outcomes

CME ABB ACOG

Wendaline M. Vanburen, MD, (Chair)  
Mayo Clinic  
Luciana Pardini Chamie, MD, PhD  
Chamie Imagem da Mulher  
Myra Feldman, MD  
Cleveland Clinic  
Zaraq Khan, MBBS  
Mayo Clinic

### MEFS Symposium: Artificial Intelligence and Machine Learning in ART: Opportunities, Limitations and Challenges

CME ABB ACOG

Johnny T Awwad, MD, (Chair)  
Sidra Medical & Research Center  
Nikica Zaninovic, PhD  
Weill Cornell Medicine  
Carol Lynn Curchoe Burton, PhD, TS  
CCRM Network- Orange County  
Mohamed A Aboulghar, MD  
Cairo University, Egyptian IVF Center

### ESHRE Symposium: Fertility Preservation in Women with BRCA Gene Mutations

CME ABB ACOG

### 2:45 PM – 3:30 PM Afternoon Break

### 3:00 PM – 4:30 PM Lecture

The Business of Medicine: How I Run My Business

### 3:30 PM – 4:15 PM Plenary Sessions

#### The David and Rosemary Adamson Lecture on Excellence in Reproductive Medicine

CME ABB ACOG

Endowed by Advanced Reproductive Care, Inc. and Rosemary and David Adamson, MD  
Marina Sirota, PhD  
University of California, San Francisco

#### Herbert H. Thomas Plenary Lecture: The Catholic Case for Equitable Access to Comprehensive

Reproductive Healthcare

CME ABB ACOG

Endowed by a 1992 grant from EMD Serono, Inc.

Shannon Russell, JD  
Catholics for Choice

### 4:30 – 6:30 PM ASRM Live Events





TUESDAY, OCTOBER 25, 2022

6:30 AM – 7:45 AM
Tuesday E-poster Session and Continental Breakfast

7:00 AM – 8:00 AM
Women's Council Breakfast

7:50 AM – 8:00 AM
ASRM 2022 Giving Day Kick-Off Presentation

8:00 AM – 8:30 AM
Plenary Session

Pre-Plenary Lecture
From Genomic Junk to Rising Stars: Noncoding RNAs in Ovarian Aging
Amanda Nicole Kallen, MD
Yale University School of Medicine

8:30 AM – 9:15 AM
Plenary Lecture: Telomere Maintenance in the Context of Human Aging Processes
Endowed by a 1990 grant from TAP Pharmaceutical

9:15 AM – 10:00 AM
Plenary Lecture: Linking Heterogeneity in Fetal Development to Oocyte Fate and Fitness
Diana J Laird, PhD
University of California, San Francisco

10:00 AM – 10:45 AM
Morning Break

10:45 AM – 12:15 PM
Tuesday Oral Abstract Sessions
Scientific Congress Prize Paper Session 2

Video Abstract Session 2

11:00 AM – 12:00 PM
Clinical Sessions

NPG Clinical Session: Mosaicism for Nurses
Rachel Donnell, MMSc, CGC
Seattle Reproductive Medicine
Lauren Thomas Garrett, MS, CGC
Pacific Northwest Fertility

MHPG Clinical Session: Quality Improvement: Improving Patient and Provider Experiences
Amelia Swanson, PhD, (Chair)
Northwestern University
Vickie Schafer, PhD
Private Practice

12:15 PM – 1:30 PM
Tuesday Lunch Break

12:15 PM - 2:00 PM
Tuesday Resident Learning Session

12:20 PM – 1:20 PM
Roundtables

1:30 PM – 2:30 PM
Interactive Sessions
Building Diversity, Equity and Inclusion into a Reproductive Practice
Stan Honig, MD, (Chair)
Yale University
Tolu Bakare, MD
UT Southwestern Medical Center
Jerrine R. Morris, MD, MPH
University of California, San Francisco School of Medicine

Human Genome Editing: Current State, Future, and Concerns
David L Keefe, MD, (Chair)
NYU Grossman School of Medicine
David L Keefe, MD
NYU Grossman School of Medicine

Understanding the Complex Role of Progesterone Supplementation in the Recurrent Miscarriage Patient

Steven D Spandorfer, MD, (Chair)
Weill Cornell Medicine
Ruth Bunker Lathi, MD
Stanford University Medical Center
Winifred Mak, MD, Ph.D
University of Texas Austin
Dana B. McQueen, MD, M.A.S.
Northwestern University

Updating Your Toolkit: Fertility Preservation Advocacy, Access and Advancing Mandates for Coverage

Joyce Reinecke, JD, (Chair)
Alliance for Fertility Preservation
Mitchell P. Rosen, MD, HCLD
University of California, San Francisco
Mary Elizabeth Fino, MD
NYU Langone Prelude Fertility Center

The Genetics of a Successful FET: Ultrasound Imaging and PGT-a or Endometrial Gene Profile?

Ilan Tur-Kaspa, MD(Chair)
Institute for Human Reproduction, (IHR)
Richard T. Scott Jr., MD
IVI RMA New Jersey
Carlos Simon, MD, PhD

Complex Reproductive Genetics Case Discussions

Nathan R Treff, PhD, HCLD, (Chair)
Genomic Prediction, Inc.
Jamie Dokson, MS, LCGC
Navigate Genetic Counseling
Amy C Vance, M.S., L.C.G.C.
Bay Area Genetic Counseling
Jennifer Eccles, LCGC
Genomic Prediction

Ovarian Tissue Cryopreservation for Emerging Primary Ovarian Insufficiency: How, When and Why?

Mindy S Christianson, MD, (Chair)
Johns Hopkins Medical Institutions
Jacqueline Yano Maher, MD, MA
Johns Hopkins University, School of Medicine





### Macroscopic Vs Microscopic: Which Matters More for Uterine Factor Infertility? CME ABB ACOG

Steven R. Lindheim, MD, MMM, *(Chair)*  
Wright State University, Boonshoff  
School of Medicine  
Eric J. Forman, MD  
Columbia University Fertility Center  
Salvatore Giovanni Vitale, MD PhD  
University of Catania  
John C Petrozza, MD  
Massachusetts General Hospital  
Fertility Center

### 1:30 PM – 2:45 PM Symposia

#### Gamete and Embryo Donation for the 21st Century

CME ABB ACOG APA NASW NPWH NSGC

Margaret Swain, JD RN, *(Chair)*  
Law Offices of Margaret Swain  
Ariadna Cymet Cymet Lanski, PsyD  
Solo Private Practice  
Angie Beltsos, MD

#### Moving Novel Therapies from Bench to Bedside: Collaboration Between Basic, Pharma, and Clinical Efforts CME ABB ACOG NPWH

William Catherino, MD, PhD, *(Chair)*  
Uniformed Services University of the  
Health Sciences  
Bradley S Hurst, MD  
Atrium Health Carolinas Medical  
Center  
Thomas M D'Hooghe, MD, PhD  
Merck Healthcare KGaA

#### The Role of Nutrition, Obesity, Exercise, Environment, and Overall Health in Male Reproduction CME ABB ACOG NPWH

Cigdem Tanrikut, MD, *(Chair)*  
Shady Grove Fertility  
Timothy N. Hickman, MD  
CCRM-Houston  
Christina E Boots, MD, MSCI  
Northwestern University

### Precision Medicine Approaches to Addressing Disparities in Uterine Fibroids CME ABB ACOG NPWH

Digna R. Velez Edwards, PhD, *(Chair)*  
Vanderbilt University Medical Center  
Ayman Al-Hendy, MD, PhD  
University of Illinois College of  
Medicine  
Todd L. Edwards, M.S., PhD  
Vanderbilt University Medical Center

### The Society for the Study of Reproduction (SSR) Symposium: Use of Single-Cell RNA Sequencing to Probe Cell Identity & Function and Reveal Tissue Organization CME ABB ACOG

Peter Hansen, PhD, *(Chair)*  
Andrea Messina, PhD  
University of Lausanne  
Philippa Saunders, PhD, FMedSci,  
FRSE, FRCOG ad eundem  
University of Edinburgh Queen's  
Medical Research Institute

### The Howard and Georgeanna Jones Symposium on Assisted Reproductive Technology (ART): IVF Lab Benchmarking – Key Performance Indicators for Future Success CME ABB ACOG

Sara Mooney, BA, *(Chair)*  
Seattle Reproductive Medicine  
G. David Ball, PhD  
Seattle Reproductive Medicine  
Center  
Bo Yu, MD  
Stanford University

### Strengthening Fertility Education and Awareness Globally: A Joint WHO / ASRM Symposium CME ABB ACOG APA LPG

### 2:45 PM – 3:30 PM Tuesday Afternoon Break

### 3:00 PM – 4:30 PM Lecture

### The Business of Medicine: Panel Discussion and Insight Session

### 3:30 PM – 4:15 PM Plenary Sessions

#### Menopause Keynote Lecture: The Menopause Transition: Shifting Scientific Paradigms CME ABB ACOG NPWH

Nanette F Santoro, MD  
University of Colorado Denver

#### American Urological Association (AUA) Bruce Stewart Memorial Lecture: Fertility Preservation in the Male Across the Lifespan: A New Paradigm CME ABB ACOG

Supported by a grant from the American  
Urological Association  
Robert Brannigan, MD  
Northwestern University, Feinberg  
School of Medicine





### WEDNESDAY, OCTOBER 26, 2022

6:30 AM – 7:45 AM

**Wednesday E-poster Session and Continental Breakfast**

8:00 AM – 8:45 AM

**Plenary Sessions**

**The Society of Reproductive Surgeons Lecture: Evolution of Surgical Treatments for Severe Male Infertility Coordinated with Assisted Reproduction** CME ABB ACOG

Endowed by a 1990 grant from Ethicon Endo-Surgery, Inc.

Peter N Schlegel, MD  
Weill Cornell Medicine

8:45 AM – 9:15 AM

**ASRM Live Events**

**ASRM 2022 Members Business Meeting**

9:15 AM – 10:00 AM

**Plenary Sessions**

**Plenary Lecture: Growing Up in a Hostile Environment: The Science Behind and History of IVF in America** CME ABB ACOG

Endowed by a 1992 grant from Wyeth

10:00 AM – 10:45 AM

**Wednesday Morning Break**

10:45 AM – 12:15 PM

**Wednesday Oral Abstract Sessions**

10:45 AM – 12:15 PM

**Wednesday Resident Learning Session**

12:15 PM – 1:30 PM

**Wednesday Lunch Break**

12:20 PM – 1:20 PM

**Roundtables**

1:30 PM – 2:30 PM

**Clinical Sessions**

**NPG Clinical Session: Understanding Ovarian Cysts** NFWH

Monica Moore, MSN, NP  
Fertile Health Expert

**MHPG Clinical Session: The Good, the Bad and the Ugly of Psychological Assessment in Third Party Reproduction** APA NASW

Andrea Mechanick Braverman, PhD, (Chair)  
Thomas Jefferson University Hospital  
Carrie Eichberg, PsyD  
Julie Bindeman, PsyD  
Independent Practice

1:30 PM – 2:30 PM

**Interactive Sessions**

**PGTA for All Patients with Recurrent Miscarriages: What Does the Scientific Evidence Suggest?**

CME ABB ACOG NFWH NSGC

Paul Robert Brezina, MD, (Chair)  
Fertility Associates of Memphis  
Glenn Schattman, MD  
Weill Cornell Medicine  
Paul Robert Brezina, MD  
Fertility Associates of Memphis

**Do We TRUST Data on Uterine Septum Repair?** CME

Samantha M Pfeifer, MD, (Chair)  
Weill Medical College of Cornell University  
Lusine Aghajanova, MD PhD  
Stanford University School of Medicine  
Luis Alonso Pacheco, MD  
Collège Marocain de Fertilité

**Too Many Embryos, Too Few Choices: Viable Embryo Donation Options In The United States**

CME ABB ACOG APA LPG NASW

Melanie Mikkelsen, MSW, LICSW, (Chair)  
Seattle Reproductive Medicine,  
Spokane Office  
Eve C. Feinberg, MD  
Northwestern University  
Ellan Trachman, JD  
Trachman Law Center  
Gaya Murugappan, MD  
Anjali Wignarajah, MS

**Right to Do: Ethics, Law, and Fertility Preservation for AYA and Transgender Patients** CME ABB ACOG

Pasquale Patrizio, MD, MBE, HCLD, (Chair)  
University Hospitals Cleveland Medical Center/Case Western Reserve University  
Ranjith Ramasamy, MD  
University of Miami Miller School of Medicine  
Judith Daar, JD  
Chase College of Law

**Complex Family Planning Fellow Research Showcase** CME

Aaron Lazorwitz, MD, MSCS, (Chair)  
University of Colorado Anschutz Medical Campus  
Kelsey Petrie, MD, MPH  
University of Washington  
Michael Belmonte, MD  
University of Colorado Anschutz Medical Campus  
Melissa Myo, MD  
University of Southern California

1:30 PM – 2:45 PM

**Symposia**

**I Found My Donor on Facebook: Considerations for Alternative Models of Sperm Donation**

CME ABB ACOG LPG NASW NSGC

Lauren Isley, MS, CGC, (Chair)  
Generate Life Sciences  
Jaime M. Shamonki, MD  
Generate Life Sciences  
Lauren Magalnick Berman, PhD  
Fertility Psychology Center Of Atlanta, LLC  
Nidhi Desai, JD  
Desai & Miller



## Insights into Primary Ovarian Insufficiency and Ovarian Aging: Genetic and Environmental Factors

CME ABB ACOG NSGC

Lawrence Layman, MD, (Chair)  
Medical College of Georgia at Augusta University

Kamaria C Cayton Vaught, MD  
Johns Hopkins University School of Medicine

Audrey Jane Gaskins, ScD  
Emory Rollins School of Public Health  
Alleigh L.H. Boyd, MS  
Stanford University

## Automation, Artificial Intelligence and Lab-on-a-Chip

CME ABB ACOG

Matthew David VerMilyea, PhD, (Chair)  
Ovation Fertility

Charles L Bormann, PhD  
Massachusetts General Hospital  
Barry Behr, PhD  
Stanford University

## Diversity & Inclusion - Breaking Down Barriers for Patients and Staffing

CME ABB ACOG NSGC

Linsey McBain, BA(Chair)  
RMANJ

Christina Robertson, MS  
Reproductive Medicine Associates of Philadelphia

Tia Jackson-Bey, MD MPH  
Reproductive Medicine Associates of New York

## Unifying Experimental Endometriosis Models to Improve Translational Relevance

CME ABB ACOG

Stacey A Missmer, ScD, (Chair)  
Michigan State Univ and Harvard T.H. Chan SPH and Boston Ctr for Endometriosis

Kaylon Bruner-Tran, PhD  
Vanderbilt University  
Juan Gnecco, PhD  
Tufts University

## The ABOG Ken Ryan Ethics Symposium: Extending the 14 Day Rule - Will Unlocking the "Black Box" Improve Reproductive Care?

CME ABB ACOG LPG

Eli Y Adashi, MD(Chair)  
The Warren Alpert Medical School, Brown University

Ellen Wright Clayton, JD MD  
Vanderbilt University  
Insoo Hyunh, PhD  
Case Western Reserve

## Genes Controlling Reproductive Aging, Reproductive Aging Controlling Genes

Francesca E Duncan, PhD, (Chair)  
Center for Reproductive Science, Northwestern University  
Aleksandar Rajkovic, MD  
University of California, San Francisco  
Francesca E Duncan, PhD  
Center for Reproductive Science, Northwestern University

3:00 PM – 3:45 PM

## Plenary Sessions

### The Society for the Study of Reproduction (SSR) Keynote Exchange Lecture: Molding the Next Generation: Drivers And Consequences of Calcium Signaling at Fertilization

CME ABB ACOG

Carmen J. Williams, MD, PhD  
National Institute of Environmental Health Science

### Contraception Keynote Lecture: The La Brea Tar Pits and Contraception: 62 years after FDA approval of "The Pill"

CME ABB ACOG NFWH





# Your company is invited to become a member of the ASRM Corporate Member Council

The Mission of the ASRM Corporate Member Council reflects a partnership between the ASRM Officers and Directors and the Corporate Members and is designed to facilitate open and ongoing dialogue between the two; to identify and maximize common interests related to reproductive medicine; and to develop collaborative educational initiatives which serve to enhance the practice of reproductive medicine.

## 2022 ASRM Corporate Member Council

AbbVie

CooperSurgical Companies

EMD Serono, Inc.

Elsevier

Ferring Pharmaceuticals, Inc.

Growing Generations

International Fertility Law

INVO Bioscience

Organon

VirtaMed

### WHY BECOME A CORPORATE MEMBER?

- Participation in Collaborative Initiatives
- Visibility
- Networking
- Website Link on ASRM Website
- Interaction/Collaboration with ASRM Board of Directors
- Special Recognition
- Preferred Support Opportunities
- Two (full) ASRM Memberships (CMC Representatives)

### MAKING A DIFFERENCE ONE INITIATIVE AT A TIME

- Patient Education Fact Sheets
- Patient Education Videos
- [www.ReproductiveFacts.org](http://www.ReproductiveFacts.org)
- In-Training Awards
- Question-based Learning Program
- Webinar Training
- Industry-Specific Sessions

For more information please contact Keith Ray at [kray@asrm.org](mailto:kray@asrm.org) or call 205-978-5001



## The Premier Supporters of the ASRM 2022 Exhibition

### DIAMOND SPONSORS

EMD Serono  
Ferring Pharmaceuticals, Inc.  
Organon LLC

### GOLD SPONSORS

CooperSurgical  
Myovant Sciences, Inc. and Pfizer, Inc.  
Vitrolife, Inc.

### SILVER SPONSORS

Akorn Pharmaceuticals  
BabySentry  
Hamilton Thorne, Inc.  
MyEggBank  
Ovation Fertility  
Thermo Fisher Scientific  
ZyMōt Fertility

# ASRM Scientific Congress Policies and Disclaimers

## CANCELLATION POLICY

The American Society for Reproductive Medicine reserves the right to cancel this activity due to unforeseen circumstances. In the event of such cancellation, the full registration fee will be returned to the registrant.

## REFUND/NON-ATTENDANCE POLICY

Cancellations received on or before September 11th, will receive a full refund minus a \$150 processing fee. Cancellation requests must be submitted in writing. Cancellations received after September 11th will not be eligible for a refund.

## ADA STATEMENT

The American Society for Reproductive Medicine fully complies with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Please notify the American Society for Reproductive Medicine, 1209 Montgomery Highway,

Birmingham, Alabama, USA, 35216, telephone 1-205-978-5000, a minimum of 10 working days in advance of the event if a reasonable accommodation for a disability is needed.

## EQUAL OPPORTUNITY STATEMENT

The American Society for Reproductive Medicine values and promotes diversity among its members, officers, and staff. The Society prohibits discrimination toward any member or employee due to race, color, religion, age, gender, sexual orientation, national origin, citizenship, disability, military status, or other basis prohibited by law. ASRM strives to achieve gender, racial, and ethnic balance in hiring and governance. ASRM maintains policies, procedures, and personnel actions that conform to the letter and spirit of all laws and regulations pertaining to equal opportunity and nondiscrimination in employment, appointments, and elections to office.

## DISCLAIMER STATEMENT

The content and views presented in this educational activity are those of the faculty/authors and do not necessarily reflect those of the American Society for Reproductive Medicine. This material is prepared based on a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity to make clinical decisions about individual patients.

## HOW TO REGISTER



Register online at [www.asrmcongress.org](http://www.asrmcongress.org) and receive immediate confirmation!



On-site in Anaheim, CA

## Registration and Information

*Choices may be limited on-site. Pre-registration is recommended.*

### ON-SITE REGISTRATION DESK: ANAHEIM CONVENTION CENTER

Saturday, October 22 . . . . . 8:30 am – 6:00 pm  
Sunday, October 23 . . . . . 7:00 am – 5:00 pm  
Monday, October 24 . . . . . 7:00 am – 5:00 pm  
Tuesday, October 25 . . . . . 7:00 am – 5:00 pm  
Wednesday, October 26 . . . . . 7:00 am – 2:00 pm

### BE SURE TO VISIT THE EXPO HALL

Monday, October 24 . . . . . 9:00 am – 5:00 pm  
Tuesday, October 25 . . . . . 9:00 am – 5:00 pm  
Wednesday, October 26 . . . . . 9:00 am – 2:00 pm

*Children under 16 are allowed on the Expo Floor only when accompanied/ supervised by an adult. No strollers allowed.*




2022  
Official Map




# ASRM 2022

## OCTOBER 22-26TH, 2022

- 1**  
Anaheim Marriott  
0 blocks
- 2**  
Cortona Inn & Suites  
Anaheim Resort  
2 blocks
- 3**  
Hilton Anaheim   
0 blocks
- 4**  
Homewood Suites by Hilton  
Anaheim Resort-Convention  
Center  
3 blocks
- 5**  
Hyatt House at Anaheim  
Resort/Convention Center  
4 blocks
- 6**  
Hyatt Place at Anaheim  
Resort/Convention Center  
3 blocks
- 7**  
Residence Inn Anaheim  
Resort/Convention Center  
4 blocks
- 8**  
Sheraton Park Hotel at  
the Anaheim Resort  
3 blocks
- 9**  
Springhill Suites Anaheim  
Resort/Convention Center  
4 blocks

*city blocks to  
the Convention Center*





## Journal Club Global LIVE

Monday, October 24, 2022

12:15 pm to 1:15 pm

Join *Fertility and Sterility* live at ASRM for an interactive discussion between authors and experts on hot topic or recent seminal article from the F&S family of journals.



## Discounted ASRM Membership for Reproductive Care Specialists in Low- and Lower-Middle Income Countries

Residence in low-income countries: 75% discount

Residence in lower-middle income countries: 25% discount


Individuals joining or renewing membership in ASRM that reside in low or low-middle income countries (as defined by the World Bank) now receive discount on ASRM membership!

Members receive online access to *Fertility and Sterility* and other society journals, free access to our extensive library of single ASRM Academy™ modules, discounts on certificate courses and the ASRM Scientific Congress & Expo, and more!

### To join at a discounted rate:

1. Go to [www.asrm.org](http://www.asrm.org) and log in to your ASRM account.
2. Click on the "My Account" tab and click the red "Join" button.
3. Choose the appropriate membership that includes the online journal.
4. Complete information and pay. (The discounted price will show at checkout.)





# spotlight on asrm 2022

## What you should know about the ASRM 2022 Scientific Congress & Expo

- **New at ASRM 2022!**
  - Additional meeting content, including **ASRMed Talks**, **live ASRM QBoost**, and **talks focusing on the business of medicine**.
  - **Top Poster Lightning Round**—Individuals selected for the new Top Poster category will have the opportunity to present in the Product Theater.
  - Multiple social and networking opportunities, including a SIG reception, networking lounge, and a **President's Gala After Party**.
- **The Postgraduate Program**, consisting of 18 diverse courses, will be fully in-person this year. Separate registration is required for these.
- **Lunch** is at a designated time, 12:15 pm - 1:30 pm, for either a ticketed lunchtime activity or for you to grab lunch and network with colleagues. Anaheim offers many local spots to enjoy close to the convention center!
  - Check out our ticketed Roundtable discussions – Monday, Tuesday, and Wednesday!
- **Our fully interactive and very useful meeting app** is a must-have for all Congress attendees. Complete your in-app profile and network with other attendees, locate your next in-person session easily with directions from where you are to where you need to be, build a personalized schedule in the app of events you want to attend, and play the **Expo Passport Game** in the app while at the Congress.
- **Virtual poster area and in-person e-poster presentations** – all posters will be available online and at our E-Poster Abstract Stations including audio for each poster.
- **The President's Gala** will be in-person on Sunday, October 23rd. Tickets are \$500 per person up to six individuals with all proceeds benefiting the ASRM Center for Policy and Leadership. Purchase your ticket at [www.asrmcongress.org](http://www.asrmcongress.org) when you register for the Congress. For larger groups or table sales, contact Brynne MacCann at [bmaccann@asrm.org](mailto:bmaccann@asrm.org).
- Join us after the President's Gala for the all-new **After Party** hosted by Dr. Cedars with cocktails, dessert, and music. The party starts at 9:00 pm. Tickets are \$150 per person and can be purchased at registration.



# TICKETED EVENTS

Ticketed events listed in the daily schedule are marked with a  icon.

## SATURDAY, OCTOBER 22, 2022

### Postgraduate Courses

## SUNDAY, OCTOBER 23, 2022

### Postgraduate Courses

### Half-day Embryo Transfer Workshop *(Limited In-person access only)*

### Society for Reproductive Endocrinology and Infertility (SREI) Members' Retreat: To the Future and Beyond in REI

8:00 am – 12:00 pm

\$250 for SREI Members / \$300 for Non-SREI Members

### 2nd Annual Social Media Summit

1:00 pm – 4:00 pm. \$25 registration required

## DAILY

### Resident Learning Sessions

Monday, Tuesday, and Wednesday  
(Lunch provided • registration required)

## TUESDAY, OCTOBER 25, 2022

7:00 am - 8:45 am

### Women's Council Breakfast

\$50 Fee



6:00 pm

### ASRM 2022 President's Gala

Tickets are \$500 per person up to six individuals with all proceeds benefiting the ASRM Center for Policy and Leadership. Purchase your ticket at [www.asrmcongress.org](http://www.asrmcongress.org) when you register for the Congress. For larger groups or table sales, contact Brynne MacCann at [bmaccann@asrm.org](mailto:bmaccann@asrm.org).

9:00 pm

### President's Gala After Party

Immediately following the Gala, Dr. Cedars will host an After Party with cocktails, dessert and music. Tickets are \$150 per person. Purchase your tickets at [www.asrmcongress.org](http://www.asrmcongress.org).



## Roundtable Discussions

### Roundtable Luncheons

Monday, Tuesday, and Wednesday  
12:15 pm - 1:15 pm

\$60 Fee/day

See pages 48-51 for a list of roundtable titles and speakers

# Education



**ASRM Today:** Catch up on the latest each week by subscribing on your favorite podcast app.



**F&S On Air:** Hit the highlights from the table of contents each month and catch up on Journal Club Global debates!



**SART Fertility Experts:** Share this patient-oriented podcast with your patients!



**ASRM Webinars:** Educational interactive presentations and moderated Q&A from leading experts in the field. Webinars are thematically aligned to keep you abreast on major National or International discussions, campaigns, and causes.

Are you interested in hosting a webinar? Email sub: host a webinar to [webinars@asrm.org](mailto:webinars@asrm.org).

Certificate of attendance and CME credits coming soon!

**Embryo transfer simulator** course: On the move again! Contact us for details.

## ASRM EMBRYO TRANSFER SIMULATOR Certificate Course



**QBoost:** New question banks catering to our multidisciplinary audience such as nurses, residents, and fellows are being published all the time. Just in time learning on recently published ASRM guidelines, practice and committee opinions, and ASRM courses. Access interactive learning on your phone!





# Continuing Education/ CME Sessions

- Continuing Medical Education/  
Continued Education 37,38
- Postgraduate Courses 39-57
- Scientific Congress Needs Assessment  
and Learning Objectives 58
- ASRM 2022 Congress Grid 59
- Speaker Index 60-62
- Speaker Disclosures 63-65
- Specialty Tracks 66



## Continuing Professional Development: Continuing Medical Education | Continuing Education Credits

### ASRM Continuing Education Programs

The goal of ASRM is to sponsor educational activities that provide learners with the tools needed to conduct research, practice the best medicine, and provide the best, most current care to patients.

ASRM adheres to the Essentials and Policies of the Accreditation Council for Continuing Medical Education (ACCME). CME activities must address specific, documented, clinically important gaps in physician knowledge, competence, or performance; be documented to be effective at increasing physician knowledge, competence, performance, or outcomes; and conform to the ACCME Standards for Commercial Support.

All planners and presenters disclose commercial and financial relationships pertaining to reproductive medicine. These disclosures were reviewed by the Subcommittee for Standards for Commercial Support of the ASRM CME Committee and the Executive Program Committee, which resolved perceived potential conflicts of interest.

### How to Claim

#### Continuing Medical Education/Continuing Education Credits or Print a Certificate of Attendance

For Postgraduate (PG) Courses:

- Attend Postgraduate Courses
- Complete a post-course assessment using a web link emailed to your registration email address.
- Download and print your certificate.

For the Scientific Congress (SC):

- Attend the Congress sessions of your choice.
- Complete a post-session assessment for the sessions you attended using a web link emailed to your registration email address.
- Download and print your certificate

**Final date to claim credit for ASRM 2022 is November 28, 2022.**

Email questions to [education@asrm.org](mailto:education@asrm.org).

The following may receive honoraria and/or discounted or free registration: Plenary, Symposia, and Interactive Session speakers, and Pre-Congress faculty. Honoraria are not provided for Roundtable presenters, Oral and Poster Abstract presenters, and Video presenters.

Disclosures of faculty and presenters for the Post Graduate and Scientific Congress may be in a presentation slide, printed material, or oral statement, and will be printed in the ASRM Final Program. Abstract authors' disclosures will be printed in the 2022 Program. Roundtable and Expert Encounter presenters should provide a copy of their disclosure to participants at their table.



## How to Claim Continuing Medical Education/ Continuing Education Credits

### ASRM CONTINUING EDUCATION PROGRAMS

The goal of ASRM is to sponsor educational activities that provide learners with the tools needed to conduct research, practice the best medicine, and provide the best, most current care to patients. ASRM adheres to the Essentials and Policies of the Accreditation Council for Continuing Medical Education (ACCME). CME activities must address specific, documented, clinically important gaps in physician knowledge, competence, or performance; be documented to be effective at increasing physician knowledge, competence, performance, or outcomes; and conform to the ACCME Standards for Commercial Support. All planners and presenters disclose commercial and financial relationships pertaining to reproductive medicine. These disclosures were reviewed by the Subcommittee for Standards for Commercial Support of the ASRM CME Committee and the Executive Program Committee, which resolved perceived potential conflicts of interest.

### THE ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (ACCME)

The American Society for Reproductive Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

### ASRM 2022 SCIENTIFIC CONGRESS DESIGNATION STATEMENT

The American Society for Reproductive Medicine designates this activity for a maximum of 11 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### ASRM 2022 POSTGRADUATE PROGRAM DESIGNATION STATEMENT

The American Society for Reproductive Medicine designates Post Graduate Courses 06-18 for a maximum range of 6.5 to 6.75 AMA PRA Category 1 Credits™ per course. Post Graduate Courses 01-05 and 19 are approved for a maximum range of 3.0 to 3.5 AMAPRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS

The American College of Obstetricians and Gynecologists has assigned 11 Cognates to the Scientific Congress; 6.75 Cognates each to Post Graduate Courses 7, 8, 10. 6.50 Cognates to course 9. 3.50 Cognates to course 5.

### AMERICAN BOARD OF BIOANALYSIS (ABB)

The American Society for Reproductive Medicine has been approved to provide Professional Enrichment Education Renewal (PEER) credit through the American Board of Bioanalysis for this event. Up to 0.65 PEER CEUs (6.5 hours each) will be recognized for Post Graduate Courses 11 & 13. Post Graduate courses 9 and 17 will be recognized for 0.60 PEER CEUs (6 hours each). Post Graduate courses 4, 6, & 19 will be recognized for 0.35 PEER CEUs and 2 will be recognized for 0.30 PEER CEUs. Scientific Congress, Roundtables and Abstracts have been approved for up to 1.75 PEER CEUs or 17.50 hours.

### NURSING CREDITS: NATIONAL ASSOCIATION OF NURSE PRACTITIONERS IN WOMEN'S HEALTH (NPWH)

The Continuing Education Approval Program of the National Association of Nurse Practitioners in Women's Health has evaluated and approved the following continuing education credits. Post Graduate Course 5: *An Evidence-Based Integrative Approach to Fertility and Preconception Care* for 3.5 contact hours and Post Graduate Course 10: *More Than Metformin: Optimizing*

*Lifestyle Interventions for Metabolic and Psychological Health in Women with PCOS* for 6.75 contact hours. The ASRM 2022 Congress, NPG Clinical Sessions CSM02, CST02 and CSW02 has been for up to 18.25 contact hours including 4.5 contact hours of pharmacology content. NPWH Activity no. 22-07.

### AMERICAN PSYCHOLOGICAL ASSOCIATION (APA)

The Mental Health Professional Group (MHPG) of the American Society for Reproductive Medicine is approved by the American Psychological Association to sponsor continuing education for psychologists. MHPG maintains responsibility for this program and its content. CE credits will be available for select sessions of Scientific Congress; Post Graduate Courses 01, 02, 05, 10, and 11; MHPG Clinical Sessions CSM01, CST01, CSW01; and other selected scientific congress sessions.

### NATIONAL ASSOCIATION OF SOCIAL WORKERS (NASW)

Post Graduate courses 1 and 2 for 3.25 contact hours and 11 for 6.75 contact hours have been approved by The National Association of Social Workers (Approval #: 886496548-1263).

### NATIONAL SOCIETY OF GENETIC COUNSELORS (NSGC)

Application will be made to the National Society of Genetic Counselors (NSGC) for Category 1 contact hours for Postgraduate Course 2, 3, 4, 11, 13, 16, and 19 in addition to selected sessions in the Scientific Congress. Participants requesting NSGC CEUs will have a service fee of \$30 added to their meeting registration to cover payment to the National Society of Genetic Counselors for the filing and awarding of CEU certificates.

The CME icon designates that continuing education credits are available, check the online schedule or app to see which types are available for that session.

**Final date to claim credit is November 28, 2022.**  
Questions? email [education@asmr.org](mailto:education@asmr.org)





## ASRM 2022 POSTGRADUATE PROGRAM POSTGRADUATE PROGRAM COMMITTEE

Erica Johnstone, MD, MHS  
Chair

Samantha Butts, MD, MSCE  
Co-Chair

Erica Marsh, MD, MSCI, FACOG  
Coordinating Chair

**SATURDAY, OCTOBER 22 HALF DAY COURSES 1:00 PM - 5:00 PM (NO LUNCH)**

### PG01 Trauma Informed Infertility Care: How to Provide Optimal Treatment **CME** for Patients with a Trauma History

Developed in cooperation with the Mental Health Professional Group (MHPG)

#### Faculty

Amelia Swanson, PhD, (Chair)  
Northwestern University  
Julia Taylor Woodward, PhD  
Duke University Health System  
Dana B. McQueen, MD, MAS  
Northwestern University

#### Target Audience

Mental Health Providers, Physicians, Nurses,  
Reproductive Managers, Legal Professionals

#### Needs Assessment

Many fertility patients have experienced a variety of types of trauma that continue to impact them. Over 40% of women are survivors of sexual assault during their lifetime (CDC, 2015), and many patients have experienced trauma from pregnancy loss, discrimination based their sexual orientation or gender identity, or during previous medical treatment. Providing trauma informed care is important in fertility centers given the invasive, sensitive nature of fertility treatment and vulnerability of our patients. Although Trauma Informed Care has become best practice in the larger medical community, specific training on how to incorporate Trauma Informed Care for fertility treatment providers and professionals is needed. This course will teach participants about trauma, trauma informed care, and specific strategies for incorporating trauma informed care into work with fertility patients. Additionally, the course will outline targeted strategies for frequent types of trauma.

#### Description

This course will discuss types of trauma and patient reactions to trauma. It will outline ways to tailor care to different populations including patients with a history of sexual trauma, medical trauma, pregnancy loss and discrimination based on gender identity or sexual orientation. Faculty will summarize the practices of trauma informed care and describe how to integrate these strategies into a fertility practice. Finally, faculty will highlight strategies for supporting patients with a history of trauma who are navigating the fertility process.

#### ACGME Competencies

Interprofessional: Communication, Interprofessional: Roles/Responsibilities, Interprofessional: Teams and Teamwork, Interprofessional: Values/Ethics, Physician: Interpersonal and Communication Skills, Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement, Physician:

#### Learning Objectives

1. Define the theory and concepts of Trauma Informed Care in medical settings
2. Explain common behaviors and emotions related to experiencing different types of trauma
3. Identify strategies to incorporate trauma informed care to fertility practice settings
4. Apply strategies when communicating with patients
5. Summarize specific strategies for patients with varied trauma histories





**SATURDAY, OCTOBER 22 HALF DAY COURSES 1:00 PM - 5:00 PM (NO LUNCH)**

## **PG02 Apps, Websites, Social Media, Oh My! Digital Technology Your Patients Use and Why You Need to Know About It. CME**

Developed in cooperation with the Society for Assisted Reproductive Technology (SART) and the Mental Health Professional Group (MHPG)

### **Faculty**

William D. Petok, PhD, *(Chair)*  
Thomas Jefferson University  
Teni Davoudian, PhD  
Oregon Health & Science University  
Amanda Kallen, MD  
Yale University School of Medicine  
Reproductive Care

### **Target Audience**

Mental health providers, nurses, physicians

### **Needs Assessment**

The average of patients seeking reproductive medicine services remains stable while the age of active providers does not. Providers with significant time in the field may not be aware of trends in digital information patients seek. Often social media and other digital tools is managed by individuals or groups hired by clinics for that specific purpose. This practice leaves providers out of the loop and without knowledge that is relevant for optimal care of patients. This course is designed to explore and explain a range of tools patients utilize and offer providers insight into how to best employ them with their patients, as well as evaluate which tools may be unhelpful.

### **Description**

Patients frequently access digital tools before reaching a reproductive medicine provider's office. These tools may provide useful information, or they may lead patients astray. This course is designed to explore and explain a range of tools patients utilize and offer providers insight into how to best employ them with their patients, as well as evaluate which tools may be unhelpful.

### **ACGME Competencies**

Interprofessional: Communication, Interprofessional: Roles/Responsibilities, Interprofessional: Teams and Teamwork, Physician: Interpersonal and Communication Skills, Physician: Professionalism

### **Learning Objectives**

1. Identify apps that both male and female patients currently access
2. Explain the quality of apps patients utilize
3. Describe how to use the SART Patient Predictor
4. Describe how to use the SART Clinic Summary Report to assist patients decision making
5. Identify websites and forums patients frequent
6. Evaluate websites and forums patients use prior to seeking care



**SATURDAY, OCTOBER 22 HALF DAY COURSES 1:00 PM - 5:00 PM (NO LUNCH)**

## **PG03 IVF for Genetic Disease Prevention** **CME**

Developed in cooperation with the Genetic Counseling Professional Group (GCPG)

### **Faculty**

Andria G. Besser, MS, CGC, (Chair)  
NYU Langone Health Fertility Center  
Emily L. Mounts, MS, CGC  
ORM Fertility  
David Sable, MD  
Columbia University

### **Target Audience**

This interprofessional course is designed for physicians, practice managers, embryologists, mental health professionals, nurses, allied health providers, genetic counselors, and attorneys.

### **Needs Assessment**

There are ~10,000 known monogenic disorders, accounting for a global prevalence of approximately 1% at birth and almost 20% of pediatric mortality. PGT for monogenic disorders (PGT-M) can select against embryos at increased reproductive risk for such diseases. Over the past two decades, widespread adoption of genomic technologies has contributed to rapid increases in the identification of PGT-M candidates and uptake of PGT-M. Although its initial applications were intended to select against embryos with severe, often life-threatening childhood-onset disorders, use of the technology has now expanded to include milder and later onset conditions of greater clinical variability (and controversy). As the scope of conditions widens, clinics are more likely to be faced with patient requests to transfer embryos that test positive for a monogenic condition. The ASRM Ethics Committee determined that these decisions are the responsibility of the IVF physician. ASRM has identified gaps in knowledge that are related to PGT utilization, methodology, ethics, and counseling; disposition of embryos following PGT; ethical clinical decision-making; and keeping up with rapid changes in testing practices. While previous courses have improved education about other types of PGT (primarily, aneuploidy screening or PGT-A), these knowledge gaps still exist among providers ordering PGT-M.

### **Description**

This course will examine use of IVF in genetic disease prevention, from historical, technical, economic, practical, psychosocial, and ethical perspectives. It will explore the impact of genetic disease on public health and how reproductive medicine can be utilized for purposes of prevention; provide an in-depth explanation of various technologies used for PGT-M; outline essential counseling points and strategies for IVF practices to manage PGT-M cases; and apply strategies for practitioners to transfer and dispose of embryos with abnormal genetic results within an ethical framework. Case presentations will be used to examine complex situations and provide practical strategies for clinical management.

### **ACGME Competencies**

Interprofessional: Communication, Interprofessional: Roles/Responsibilities, Interprofessional: Teams and Teamwork, Interprofessional: Values/Ethics, Physician: Interpersonal and Communication Skills, Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement, Physician:

### **Learning Objectives**

1. Explain clinical and laboratory challenges associated with PGT-M cases, from initiation through completion of testing and results reporting.
2. Examine the scope of conditions for which PGT-M is performed, and how and why these have changed over time.
3. Evaluate situations in which the use of PGT-M may be of questionable benefit, such as with variants of uncertain significance.
4. Assess the global economic burden and public health impact of genetic disease and identify how IVF can be employed as a prevention strategy.
5. Summarize barriers to genetic disease prevention and the necessity of diversity, equity, and inclusion in IVF.
6. Identify ethical challenges associated with PGT-M performance and embryo storage, transfer, and embryo disposition.
7. Utilize knowledge gained from this course to real-life case examples that reproductive endocrinologists, nurses, embryologists, genetic counselors, mental health professionals, and legal professionals may face.



**SATURDAY, OCTOBER 22 HALF DAY COURSES 1:00 PM - 5:00 PM (NO LUNCH)**

## **PG04 Preimplantation Genetic Testing: Outcomes, Current Technologies, CME Future Developments**

Developed in cooperation with the Society of Reproductive Biologists and Technologists (SRBT)

### **Faculty**

Amy Jones, MS, ELD(ABB), *(Chair)*

*Ovation Fertility*

Nathan R. Treff, PhD, HCLD

*Genomic Prediction, Inc.*

Santiago Munne, PhD

*Overture Life*

### **Target Audience**

The target audience for this course includes embryologists, physicians, genetics counselors and nurses.

### **Needs Assessment**

While PGT is widely used, it remains highly controversial. Many IVF programs have transitioned to nearly 100% freeze-all PGT-A cycles while other programs only offer the test to patients above a certain age or with specific etiologies. The field of genetics outside of reproductive medicine is developing at a rapid pace, and while clinical application of these technologies may not be feasible or advisable at this time, IVF professionals should have a basic understanding of current technologies in use as well technologies in development. Improving clinician understanding of all steps in the process can reduce stress levels and improve patient satisfaction.

### **Description**

The use and utility of Preimplantation Genetic Testing (PGT) is still a highly debated topic in the field of reproductive medicine. While significant strides have been made over the last few decades, all three areas of clinical application continue to be controversial: embryo biopsy, reporting results including counseling, and development of new methodologies. Here we will provide a detailed description of current technologies as well as technologies in development.

### **ACGME Competencies**

Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills

### **Learning Objectives**

1. Explain risks and benefits of new and old PGT technologies
2. Describe new technologies such as PGT-P and metabolomics and have an understanding of their application in reproductive medicine
3. Describe CRISPR technology and its potential applications in reproductive medicine



**SATURDAY, OCTOBER 22 HALF DAY COURSES 1:00 PM - 5:00 PM (NO LUNCH)**

## **PG05 An Evidence-Based Integrative Approach to Fertility and Preconception Care** **CME**

Developed in cooperation with the Nutrition Special Interest Group

### **Faculty**

Ashley Eskew, MD, MSCI, (*Chair*)  
Atrium Health  
Audrey Jane Gaskins, ScD  
Emory University, Rollins School of Public Health  
Alice D Domar, PhD  
Boston IVF

### **Target Audience**

Health-care providers

### **Needs Assessment**

The most recent Center for Disease Control National Survey of Family Growth estimates that approximately 1.5 million married women, aged 15-44 suffer from infertility. While the use and scientific advancement of assisted reproductive technologies (ART) have increased exponentially over the past decade, less emphasis has been placed on modifiable lifestyle factors that impact reproductive outcomes. Studies have demonstrated that certain dietary patterns and environmental toxins have had a negative impact on ART outcomes. Further, the diagnosis of infertility has been shown to be as stressful as a cancer diagnosis, and many couples identify the associated anxiety and depression as a primary reason for discontinuing treatment. Simple yet effective lifestyle and mind/body strategies have been shown to be associated with improved fertility outcomes and decreased anxiety and depression scores with reduced patient burnout. Additional strategies must be recognized by providers and incorporated to daily practice to optimize reproductive outcomes. Course discussion will propose tactical ways to integrate these elements in current practice patterns more a more integrative approach to patient centered care. Participant understanding

will be assessed through use of the audience response system (ARS) and an active Q&A session. Audience participation will also be facilitated during the panel discussion.

### **Description**

This course will review an evidence-based approach to dietary modifications and reducing exposure to environmental toxins that have been associated with reproductive outcomes. The mind/body component of infertility will be addressed while covering ways to improve the patient experience and quality of life throughout treatment. Participants will learn practical ways to apply learning in their practice to improve the patient experience and reproductive outcomes. Understanding will be assessed through use of the audience response system at the conclusion of each lecture. Participants will also have the ability to participate in Q&A sessions and panel discussion.

### **ACGME Competencies**

Physician: Medical Knowledge

### **Learning Objectives**

1. Show the existing evidence surrounding dietary patterns and environmental toxins associated with fertility-related outcomes.
2. Explain how to effectively counsel patients on dietary and lifestyle modifications associated with fertility-related outcomes and integrate into daily practice.
3. Illustrate the role of the mind/body component of the fertility journey and how to integrate ways to optimize the patient experience and improve patient retention.





**SUNDAY, OCTOBER 23 HALF DAY COURSE 8:00 AM - 12:00 PM**

## **PG06 Advances in Clinical and Laboratory Techniques for Obstructive and Non-Obstructive Azoospermia** **CME**

Developed in cooperation with the Society for Male Reproduction and Urology (SMRU)

### **Faculty**

Kathleen Hwang, MD, *(Chair)*  
University Pittsburgh, Urology  
Nikica Zaninovic, PhD  
Weill Cornell Medicine  
Ranjith Ramasamy, MD  
University of Miami Miller School of Medicine

### **Target Audience**

Urologists, laboratory andrologists, embryologists

### **Needs Assessment**

Azoospermia is a common clinical problem for laboratory andrologists, embryologists and reproductive urologists. For obstructive azoospermia, a range of surgical reconstructive and sperm retrieval techniques are available to practitioners. Each of these approaches has a set of advantages and disadvantages that are relevant to patients and laboratory staff. For these patients, laboratory staff have several established and cutting-edge techniques to identify sperm. Among non-obstructive azoospermia, microsurgical testicular sperm extraction is established as the gold standard. Developing new techniques to identify sperm in these men and improve the probability of success preoperatively is critical. From a laboratory standpoint, a number of standard and advanced techniques should be used to improve success.

### **Description**

Caring for men with obstructive and non-obstructive azoospermia is a common clinical challenge for reproductive urologists, andrologists, and embryologists. This half day course will explore guideline-based approach to extracting sperm from obstructive and nonobstructive azoospermia patients, and advanced reconstructive techniques for obstructive azoospermia. It will also examine lab techniques to best identify sperm from azoospermia patients.

### **ACGME Competencies**

Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills

### **Learning Objectives**

1. Identify the best surgical practices for extracting sperm from obstructive and nonobstructive azoospermia patients.
2. Explain advanced reconstructive surgical options for difficult obstructive azoospermia patients.
3. Summarize the standard of care and cutting-edge techniques for isolating sperm in NOA and OA patients in the andrology lab



**SUNDAY, OCTOBER 23 HALF DAY COURSE 1:00 PM - 5:00 PM**

## **PG19 The Power and Promise of 'Omic Diagnostics for Male Reproductive Medicine** **CME**

Developed in cooperation with the Society for Male Reproduction and Urology (SMRU) and the Environment and Reproduction Special Interest Group and the Regenerative Medicine and Stem Cell Biology Special Interest Group

### **Faculty**

Dolores J. Lamb, PhD, *(Chair)*  
Weill Cornell Medical College  
Carmen Messerlian, PhD  
Harvard T.H. Chan School of Public Health  
Ali Ahmady, PhD  
Keck School of Medicine, University of Southern California

### **Target Audience**

Urologists, REI, andrologists, environmental experts, reproductive scientists

### **Needs Assessment**

Significant gaps exist in our understanding of male fertility. "'Omic" study is a very broad field that offers a great deal of opportunity to investigate the underlying etiology of male reproductive, develop new diagnostic modalities, and eventually, novel treatments. Specifically, gaps exist in the fields of genomics and epigenomics; transcriptomics and their use as a diagnostic test, spermatogenesomics (focused on diagnostic opportunities, e.g. TEX101 for sperm identification for non-obstructive azoospermia), lipomics and the study of DNA damage, and environmental omics (e.g. role of environmental toxicants on sperm health). Each of these topics will be explored in detail with respect to their relevance in male reproductive function.

### **Description**

This full day post graduate course will highlight the opportunities and challenges that "'omic" research offers the reproductive field. Collaborating with several other societies and special interest groups, these lectures will cover genomic, epigenomics, proteomics, spermatogenesomics, lipomics, and environmental omics with an eye toward identifying novel diagnostic tests, utilizing tools that exist in other fields for male reproductive testing, and future therapeutic interventions.

### **ACGME Competencies**

Interprofessional: Teams and Teamwork, Physician: Medical Knowledge, Physician: Practice-based Learning and Improvement

### **Learning Objectives**

1. Explain the role of a range of 'Omic fields in male reproduction
2. Identify targets for collaboration between scientists and clinicians to develop new diagnostic tests
3. Utilize targets for novel therapeutic interventions in these 'Omic fields



**SUNDAY, OCTOBER 23 FULL DAY COURSES 8:00 AM - 5:00 PM**

## **PG07** **Recurrent Miscarriages: The Workup Beyond the Usual What's Next If She Still Miscarries after a Negative Workup?** **CME**

Developed in cooperation with the Early Pregnancy Special Interest Group

### **Faculty**

Steven D. Spandorfer, MD, *(Chair)*  
Weill Cornell Medicine  
Winifred Mak, MD, PhD  
University of Texas Austin  
Kristin A. Bendikson, MD  
University of Southern California  
Erin Masaba, MD  
University of Rochester

### **Target Audience**

This course is specifically aimed at any practitioner that sees patients clinically for the treatment of infertility or miscarriages.

### **Needs Assessment**

Recurrent miscarriages are very common. Over 1% of all couples attempting conception will experience such. After a full workup, testing reveals a cause in only 50% of couples. The current workup/ therapy modalities across the field are driven by both rigorous evidence-based scientific studies and anecdotal therapies. There is much controversy as to what to do when the workup is negative for patients with recurrent miscarriages and those that fail therapies after the workup has identified a potential cause. This course will dive deeply into what is known and what evidence supports additional testing/ treatments beyond the traditional studies/ workup that currently are very limited in scope. The attendee will get a better understanding on a full, complete workup that may help unravel further causes of miscarriages.

### **Description**

The current workup of rSAB is limited and testing reveals a cause in only 50% of couples. This course will analyze in an evidence-based manner the evidence that supports additional testing/ treatments beyond the traditional. This includes endometrial analysis, genetic causes, male studies, immunologic and others. At the conclusion, the practitioner will have a better idea of how to treat patients that miscarry despite a negative workup or correction of an identified problem. This course will specifically analyze the patient that continues to miscarry despite the usual testing and therapy as outlined by ASRM practice guideline.

### **ACGME Competencies**

Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement, Physician: Systems-based Practice

### **Learning Objectives**

1. Explain the basic evidence based workup of recurrent miscarriages
2. Describe the testing that goes beyond the normal testing in the workup of patients with miscarriages
3. Summarize the treatment options that go beyond the normal options in the workup of patients with miscarriages



## PG08 Update on Uterine Fibroids: From Pathogenesis to Treatment **CME**

Developed in cooperation with the Fibroids SIG and the Imaging in Reproductive Medicine Special Interest Group

### Faculty

Simone Ferrero, MD, PhD, *(Chair)*  
*University of Genova (Chair)*  
Elizabeth A. Stewart, MD  
*Mayo Clinic*  
Salvatore Giovanni Vitale, MD, PhD  
*University of Catania*  
Emad Mikhail, MD  
*University of South Florida, Morsani College of Medicine*  
Stefano Guerriero, MD  
*Department of Obstetrics and Gynecology, University of*

### Target Audience

Gynecologists treating patients with symptomatic uterine fibroids or infertile patients with fibroids

### Needs Assessment

The diagnosis of uterine fibroids is based on transvaginal ultrasound; however, there is a need to increase the skills in assessing the characteristics of fibroids and in detecting the features raising the suspicion of malignancy. Ultrasonography and magnetic resonance imaging may be used to differentiate uterine fibroids and sarcomas. Novel treatments (particularly GnRH antagonists) have been developed for the long-term management of fibroids; physicians need to receive detailed information on these drugs' efficacy and adverse effects. There is a need to educate on the most appropriate surgical management of uterine fibroids, particularly in patients who desire immediate and future fertility. Information on the surgical techniques must be provided to minimize the risk of complications. Interventional alternatives to myomectomy (embolization and MRI-guided focused ultrasound) may also be used in patients wishing to preserve fertility; however, physicians must be informed on the potential effects of these therapies on reproductive outcomes. Finally, physicians must be aware of the impact of different types of fibroids and their treatment on fertility and reproductive outcomes.

### Description

The course will include an update on the pathogenesis of uterine fibroids, including environmental and genetic factors. The participants will learn a standardized approach for evaluating fibroids (including the ultrasonographic and MRI features raising the suspicion of malignancy). The role of hormonal treatment of fibroids will be discussed (indications, expected results and adverse effects). The course will describe the surgical tips and tricks and prevention of complications in hysteroscopic, laparoscopic and robotic myomectomy. The course will explain the interventional alternatives to myomectomy (embolization and MRI-guided focused ultrasound). The evidence on the management of fibroids in infertile women will be presented.

### ACGME Competencies

Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement

### Learning Objectives

1. Discuss the efficacy and adverse effects of the novel treatments for uterine fibroids
2. Name the best instrumentation for hysteroscopic myomectomy
3. Illustrate the best technique for removal of surgical specimens after laparoscopic or robotic myomectomy
4. Identify ways to minimize complications during hysteroscopic, laparoscopic and robotic myomectomy
5. Explain the efficacy of embolization and MRI-guided focused ultrasound in treating symptoms caused by fibroids and the impact of treatment on future fertility and reproductive outcomes
6. Formulate counsel for the infertile patients on the management fibroids
7. Utilize ultrasonography and magnetic resonance imaging to assess uterine fibroids and perform the differential diagnosis between fibroids and sarcomas





## PG09 Taking the Operating Room to the Office: Obtaining Best Outcomes, Patient CME Experience, & Economic Sustainability

Developed in cooperation with the Society for Assisted Reproductive Technology (SART) and the Society for Male Reproduction and Urology (SMRU) and the Society for Reproductive Endocrinology & Infertility (SREI) and the Society of Reproductive Surgeons (SRS)

### Faculty

John Preston Parry, MD, *(Chair)*

*Parryscope Fertility*

Luis Alonso Pacheco, MD

*Collège Marocain de Fertilité*

Sara E. Barton, MD

*Colorado Center for Reproductive Medicine*

Thomas A. Masterson III, MD

*University of Miami Miller School of Medicine*

### Target Audience

This course is designed for reproductive clinicians wishing to enhance patient access to multiple procedures classically performed in the operating room, but that now can be gently, accurately, safely, and affordably offered in office settings.

### Needs Assessment

The goal of the course is to address multiple hands-on surgical techniques identified through gap analysis and discussion with members of affiliated societies. Emphasis is given to the most frequently requested topics, such as office hysteroscopy, testicular biopsy, transabdominal aspiration, opportunities for surgery in low resource settings, and more. Particular emphasis is given to office hysteroscopy (both flexible and rigid) as one of the most highly requested topics in the gap analysis, and will address setup, gentleness, and reimbursement. Numerous papers are emerging for all of these techniques and more, but part of the challenge is simply hands-on familiarity, where expert guidance can help clinicians explore emerging opportunities. Many of the core stations and hands on flows will parallel those developed for success in the SRS/SREI fellow's retreat.

### Description

This hands-on course teaches principles and techniques for multiple office procedures. Topics include, but are not limited to, diagnostic and operative office hysteroscopy, fine needle aspiration of sperm, transabdominal oocyte aspiration, overcoming vaginismus, opportunities in low resource settings, and emerging technologies. Coupled with direct one-on-one training, this full day course will also teach how to enhance gentleness, effectiveness, patient safety, and economic sustainability to improve access to care.

### ACGME Competencies

Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement

### Learning Objectives

1. Utilize multiple office procedures including but not limited to diagnostic and operative office hysteroscopy, fine needle aspiration of sperm, and transabdominal oocyte aspiration.
2. Recommend opportunities for which patients might derive the greatest benefit from these procedures and which may be better served through surgery in the operating room setting.
3. Develop a plan for economic sustainability, where both patients and the clinical practice benefit from these procedures.



## PG10 **More Than Metformin: Optimizing Lifestyle Interventions for Metabolic and Psychological Health in Women with PCOS** **CME**

Developed in cooperation with the Mental Health Professional Group (MHPG) and the Androgen Excess Special Interest Group and the Nutrition Special Interest Group

### Faculty

Wendy S. Vitek, MD, (Chair)

University of Rochester

Heather G. Huddleston, MD

University of California San Francisco, Department of Obstetrics and Gynecology

Christina E. Boots, MD, MSCI

Northwestern University

Ariadna Cymet Lanski, PsyD

Solo Private Practice

### Target Audience

This course is designed for health professional who treat women with PCOS including physicians, advanced practice providers, registered dietitians and psychologists.

### Needs Assessment

Polycystic ovary syndrome (PCOS) is a common condition with metabolic and psychological health consequences. Women with PCOS are at risk for impaired glucose tolerance, type 2 diabetes, dyslipidemia and hypertension. In addition, women with PCOS experience more depressive and anxiety complaints, have lower self-esteem, and experience a more negative body image compared to women without PCOS. Excess weight gain exacerbates the health risks and burdens associated with PCOS. Therefore, weight management, including modest weight loss, maintenance of weight loss and prevention of weight gain, is a first-line treatment for women with PCOS. Optimal lifestyle interventions should include diet, exercise and behavioral strategies. Pharmacological agents, such as anti-obesity medications, can be used as an adjuvant to lifestyle interventions. Psychological factors such as anxiety and depressive symptoms, body image concerns and disordered eating, need consideration and management to optimize engagement and

adherence to lifestyle interventions. Health professional interactions around healthy lifestyle, including diet and exercise, need to be respectful, patient-centered and to value women's individualized healthy lifestyle preferences and cultural, socioeconomic and ethnic differences. Health professionals need to also consider personal sensitivities, marginalization and potential weight-related stigma.

### Description

This course will prepare health professionals, such as physicians, advanced practice providers, registered dietitians and psychologists, to identify common metabolic and psychological co-morbidities in women with polycystic ovary syndrome and to adopt a respectful and patient-centered approach to treating these conditions with optimal lifestyle and medical interventions through expert lectures, case discussions and panel discussions.

### ACGME Competencies

Interprofessional: Communication, Interprofessional: Teams and Teamwork, Physician: Interpersonal and Communication Skills, Physician: Medical Knowledge, Physician: Practice-based Learning and Improvement, Physician: Professionalism

### Learning Objectives

1. Utilize screenings for metabolic and psychological co-morbidities in women with PCOS.
2. Discuss ways to integrate diet, exercise, behavioral therapy and medications to manage metabolic and psychological consequences of PCOS.
3. Practice a respectful and patient-centered approach to prescribing lifestyle interventions and medications to women with PCOS and excess weight.



## PG11 Creating a Culturally-Responsive ART Practice: Legal, Ethical and Clinical Determinants in the Patient Experience CME

Developed in cooperation with the Legal Professional Group (LPG) and the Mental Health Professional Group (MHPG) and the Nurses' Professional Group (NPG)

### Faculty

Danielle A. Kaplan, PhD, *(Chair)*

*NYU Langone*

Jennifer M. Wood, RN, BSN

*Shady Grove Fertility*

Karenne Fru, MD, PhD

Angela Bethea-Walsh, PhD

*Private Practice*

### Target Audience

Mental Health Professionals, Nurses, Reproductive Endocrinologists, Reproductive Managers, Lawyers

### Needs Assessment

Fertility clinics in the United States are largely composed of white medical staff whose education and training has focused on the diagnosis and treatment of infertility symptoms. Meanwhile, over 40% of the U.S. population identifies with a racial category other than white. These patients come to us with histories influenced by upstream determinants of health, including chronic exposure to individual racism, structural and systemic racism and inequity in healthcare. These histories impact patients' downstream experiences in fertility treatment. This course is designed to raise awareness of the factors that influence the experience of people of color in ART, with a focus on Black and Latinx patients.

### Description

For the past decades, the field of assisted reproductive technology has grown and adapted to changes in family composition, allowing single, same sex and transgender patients to access REI services. Less attention has been paid to the experience of people of color. Medical providers

are often unaware of how provider variables, such as implicit bias, intersect with patient variables, such as cultural mistrust and chronic exposure to racial trauma, to impact patient experience and outcomes. The presenters will propose guidelines for culturally-responsive, anti-racist practice and address the federal and state laws and ethical considerations pertaining to cultural competence in healthcare.

### ACGME Competencies

Interprofessional: Communication, Interprofessional: Roles/Responsibilities, Interprofessional: Teams and Teamwork, Interprofessional: Values/Ethics, Physician: Interpersonal and Communication Skills, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement, Physician: Professionalism

### Learning Objectives

1. Identify 4 ways that systematic racism impacts treatment access, outcomes and quality of care in reproductive medicine.
2. Name 3 ways in which racism and implicit bias manifest across the continuum of reproductive care.
3. List 4 benefits to providing trauma-informed and culturally-responsive care.
4. Define 3 ways in which MHPs, REs, Nurses and Attorneys can examine their own cultural worldviews, increase awareness of implicit bias, and improve cultural humility.
5. Describe 4 ways in which MHPs, REs, Nurses, and Attorneys can meet legal and ethical obligations and optimize the patient experience across the continuum of care.



## PG12 **Enhancing the Patient Experience, It's All about Expectations** **CME**

Developed in cooperation with the Society for Male Reproduction and Urology (SMRU) and the Society for Reproductive Endocrinology & Infertility (SREI) and the Association of Reproductive Managers (ARM) and the Nurses' Professional Group (NPG)

### Faculty

Anne Judge, DNP, ARNP, WHNP-BC, (*Chair*)  
*Seattle Reproductive Medicine - Kirkland*  
Kate Devine, MD  
*Shady Grove Fertility*  
Amin S Herati, MD  
*John Hopkins University School of Medicine*  
April M. Rutter  
*Mid-Missouri Reproductive Medicine and Surgery*

### Target Audience

All providers, nurses, managers, and care coordinators.

### Needs Assessment

The 2021 ASRM Gap Analysis identified the following needs that will be addressed in this session: Learn about ways to enhance the patient experience by teaching clinical communication skills. Education on associations between lifestyle and fertility, ART treatment and health outcomes. Continued updates on outcomes related to environment. Education on healthy diet, organic food, fat composition of food and lifestyle on the health of the patient, gametes and fertility outcomes. Lack of knowledge on counseling of men with infertility and best practice for workup. Provide education on tools needed for gathering patient experience data such as patient survey instruments, apps, hardware and other resources.

### Description

Infertility is stressful and infertility treatment carries modest success rates. Much of the success of ART relies on patients undergoing multiple cycles. However, treatment is often overwhelming and financially burdensome resulting in poor patient satisfaction and drop-out. This multidisciplinary course focuses on enhancing patient experience through; setting realistic expectations, maximizing the initial consult, providing empathetic financial counseling, improving counseling for male partners, and engaging in discussions on lifestyle. Tools for measuring patient satisfaction will also be discussed. Education gained will improve patient satisfaction and will benefit providers, clinical and administrative staff.

### ACGME Competencies

Interprofessional: Teams and Teamwork, Physician: Interpersonal and Communication Skills, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement, Physician: Systems-based Practice

### Learning Objectives

1. Outline strategies for improving new patient consults.
2. Show key aspects of the initial male evaluation.
3. Examine healthy lifestyle and how to discuss implications for fertility and treatment.
4. Discuss tools for measuring and tracking patient satisfaction.





## PG13 Evidence-Based Personalization of the IVF Process: What You Need to Know and What the Future Holds CME

Developed in cooperation with the Society for Assisted Reproductive Technology (SART) and the Genetic Counseling Professional Group (GCPG) and the Preimplantation Genetic Testing Special Interest Group

### Faculty

Mandy G. Katz-Jaffe, PhD, *(Chair)*  
Colorado Center for Reproductive Medicine  
Charles L Bormann, PhD  
Massachusetts General Hospital  
Alleigh L.H. Boyd, MS  
Stanford University  
Richard T. Scott, MD  
IVI RMA New Jersey

### Target Audience

This session is intended for physicians, embryologists, nurses, and genetic counselors.

### Needs Assessment

Evidence-based personalized care is the ideal for each IVF patient. Many factors are involved in each patient's IVF journey including fertility diagnosis, genetics, ovarian stimulation, embryo transfer, uterine lining and receptivity, and PGT results. Predominantly what is being offered as personalized treatment for infertility couples may be based on an REI's clinical experience rather than the best evidence-based data generation. The ability to account for a more personalized approach drawing on specific molecular and algorithm generated data for the oocyte, sperm, embryo and uterus could prove helpful to clinician's delivering ART care resulting in a positive impact on treatment outcomes.

### Description

This course will describe best practices for the utilization of evidence-based protocols for ovarian stimulation, embryo transfer, uterine lining preparation and endometrial assessment. IVF laboratory factors will also be addressed including the potential of automation, embryo selection, artificial intelligence, cryopreservation, and robotics in the IVF lab. The discussion will also involve "non-invasive" vs. "invasive" PGT, presumptive mosaics, relationship of genetic

factors to outcomes and the future of gene editing. Communicating results to patients is critical for patient understanding and compliance. Techniques to communicate genetic results will focus on infertility diagnoses, interventions through ART, and relationship of genetic factors to outcomes.

### ACGME Competencies

Physician: Interpersonal and Communication Skills, Physician: Medical Knowledge, Physician: Practice-based Learning and Improvement, Physician: Systems-based Practice

### Learning Objectives

1. Describe best practices in ovarian stimulation protocols, embryo transfer protocols, and uterine lining preparation before embryo transfer.
2. Explain benefits/shortcomings of PGT for embryo selection, including interpretation of mosaic results.
3. Summarize communication techniques to help patients better understand how to interpret results of their genetic testing.
4. Identify future trends in the IVF laboratory including automation, artificial intelligence, gene editing, cryopreservation, robotics, etc.



## PG14 **Leading the Way – Modernizing REI Practice Management for the Future** CME

Developed in cooperation with the Association of Reproductive Managers (ARM) and the Legal Professional Group (LPG)

### Faculty

Mahshid Albrecht, MBA, (Chair)  
UC San Diego Health  
Angeline Beltsos, MD  
Vios Fertility Institute  
Nidhi Desai, JD  
Desai & Miller  
Hary Hokianto, MBA  
Boston IVF

### Target Audience

Managers, Supervisors, and Department Leads from all departments within the REI practice

### Needs Assessment

The Healthcare field in general requires special management knowledge and techniques that are not found in other businesses. REI is a unique sub-specialty that compounds the importance of the clinical and business units working together to achieve a successful practice with patient driven results. Recent advancements in technology are available and able to create greater efficiencies and positive patient experiences. Practice Leaders need to understand the shift in the industry business model, how it impacts their operations and what can be done to stay ahead. This course is designed to provide key skills and business knowledge to modernize and support a manager from any department within a REI practice.

### Description

We are entering a more competitive market as practice managers requiring us to look at new techniques, technologies and approaches. It is important as practice managers to stay ahead of market trends and predict opportunities as well as challenges. This course is aimed to give managers tips and techniques to survive in the new marketplace of acquisitions and consolidations while remaining competitive with recruitment and engagement.

### ACGME Competencies

Interprofessional: Communication, Physician: Practice-based Learning and Improvement

### Learning Objectives

1. Demonstrate basic management techniques that can be used at various levels in Acquisitions and Consolidations in the market place
2. Illustrate tools for addressing Employee Retention Issues in the new Virtual Environment
3. Recommend protocols for patient conversion and patient finance challenges

## Do you know a resident attending the Scientific Congress?

Participants in the **ASRM Resident Learning Sessions** will attend a flipped-classroom, interactive learning session, led by experts in reproductive medicine and medical education (boxed lunch provided), and a related symposium.

This ASRM-sponsored program (no additional cost to participants) is open to the first 100 residents who opt in at the time they register for the Scientific Program using a dialogue box that will open during the registration process.

Questions? Email Sarah Ramaiah at [sramaiah@asrm.org](mailto:sramaiah@asrm.org).





## PG15 Adventures in Ex Vivo Reproduction – Recent Developments and Prospects for Reproductive Medicine CME

Developed in cooperation with the Society for the Study of Reproduction (SSR)

### Faculty

Anna C. Denicol, DVM, MPVM, PhD, (*Chair*)  
*University of California-Davis*

Ariella Shikanov, PhD  
*University of Michigan*

Maria Marcia de Almeida Monteiro Melo Ferraz, DVM, PhD  
*Ludwig-Maximilians University of Munich*

Jose Polo, PhD  
*Monash University*

### Target Audience

Clinicians, basic scientists, trainees, health care professionals, geneticists, toxicologists, epidemiologists

### Needs Assessment

Assisted reproductive technologies (ART) play an important role in human reproduction; 1-4% of births involve ART. Moreover, ART are important for childbearing in infertile populations, including cancer survivors and gay couples. Despite its importance for reproductive medicine, fundamentals of the laboratory procedures for manipulating gametes and embryos are based on those developed in the 1980s and 1990s. This situation is likely to change radically because of advances in tissue engineering, microfluidics, stem cell technology, and other techniques. It may soon be possible to control the environment of gametes and embryos in hitherto unimagined ways. Moreover, assisted reproduction may no longer depend solely upon gametes produced by patients but also upon gametes and embryos generated from stem cells. This course will provide attendees with the knowledge of key advances in tissue engineering, microfluidics and stem cell biology relevant to ART and prepare them for incorporating these technologies in their practice. The course addresses many of the gaps in knowledge identified by ASRM including the artificial embryo, tissue engineering and modelling, therapeutic applications of stem cells in reproduction, progress and outlook in utilizing artificial gametes and embryos, and microfluidics and other technologies to improve gamete and embryo culture outcomes.

### Description

The course is designed for clinicians and researchers in reproductive medicine to enhance understanding of how developments in tissue engineering, microfluidics and stem cell technology may transform assisted reproductive technologies. Participants will be provided the latest information regarding the development of gametes and embryos from cultured stem cells and learn new approaches for constructing artificial environments in the laboratory that improve gamete and embryo culture outcomes. The speakers featured in this course are international leaders at the leading edge of research in these topics. They will review new research discoveries and relate them to possible clinical applications.

### ACGME Competencies

Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement

### Learning Objectives

1. Assess the potential for use of stem cell technology to generate artificial gametes for use in assisted reproduction.
2. Describe new mimetic materials for inclusion in culture systems for allowing folliculogenesis to occur in vitro.
3. Identify new uses of microfluidics and bio-printing to create artificial reproductive tract tissues for oocyte maturation, fertilization, and embryo culture.
4. Evaluate how new culture systems based on mimetic materials, microfluidics and bio-printing can be incorporated into clinical systems for gamete and embryo culture.
5. Describe how embryos can be produced from induced pluripotent stem cells.
6. Explain how embryos produced from induced pluripotent stem cells can be used to develop new approaches to decrease embryonic mortality and optimize embryo culture.



## PG16 The New Frontier in ART, Genetic and Cell Therapy Approaches **CME** in Reproductive and Regenerative Medicine

Developed in cooperation with the Regenerative Medicine and Stem Cell Biology Special Interest Group

### Faculty

Tiencheng Arthur Chang, PhD, HCLD, ELD, *(Chair)*  
*University of Texas Health Science Center*

Charles A. Easley, PhD, MS  
*University of Georgia*

David F Albertini, PhD, MS  
*Bedford Research Foundation*

Monica M Laronda, PhD  
*Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital*

### Target Audience

Laboratory scientists and technologists, reproductive biology researchers, REI and OB/GYN physicians, urologists and other specialty physicians, geneticists, nurses, and legal professionals.

### Needs Assessment

The rapidly progressing science and emerging technologies in stem cells, gene editing, and artificial gametes and embryo, will bring breakthroughs and novel applications to our current practice of reproductive medicine, as well as enter into the era of regenerative medicine. Some of the recent innovations have shown great promise, while others demonstrated uncertainty and foreseeable challenges. This PC course addresses key gap analyses and educational needs recognized by ASRM, including: 1. Stem cell 101: What they are, what types of stem cells are useful for reproductive medicine, what potentials they have, and what the technology progress has been. 2. Therapeutic applications of stem cells in reproduction: Current status of various types of stem cells, major development of research groups worldwide, and promising directions on the horizon. 3. Gene editing and cellular reconstruction: Current progress in basic research, utilization for reproductive medicine from bench to bedside, and ethical concerns. 4. Progress and outlook in utilizing artificial gametes and embryos: Current progress, limitations, ethical concerns, and potential timeline

for utilization of artificial gametes and embryos. 5. New frontiers and next innovative disruption(s) in reproductive and regenerative technology: Where will those innovative disruptions come from and what impact will those have?

### Description

This course is designed to cover the board spectrum of regenerative medicine in ART. The first lectures cover basic concepts of stem cell and regenerative medicine, their molecular mechanisms; followed by in depth lectures in oocyte in vitro maturation, somatic cell-derived spermatogenesis, generation of artificial oocyte, sperm and embryo, as well as technologies for ovarian fertility restoration. The course will wrap up with a panel interactive discussion with the audience to brainstorm on future directions, practical applications, and ethics related to regenerative technologies in reproduction. Researchers and clinical professionals will all gain significant knowledge from this course.

### ACGME Competencies

Interprofessional: Teams and Teamwork, Physician: Medical Knowledge, Physician: Practice-based Learning and Improvement

### Learning Objectives

1. Utilize the concept of stem cell, and mechanisms to derive and generate various types of stem cell.
2. Describe the development of stem cell and regenerative technology in general, and the specialized focus in reproductive medicine.
3. Explain the ovarian microenvironment and how it may affect the development and maturation of oocytes to good quality eggs, as well as new methods and technologies for ovarian fertility restoration.





## PG17 Vitrification Workshop: Understanding and Troubleshooting Device Warming Issues CME

Developed in cooperation with the Society of Reproductive Biologists and Technologists (SRBT)

### Faculty

Shane Zozula, BS, TS (ABB), *(Chair)*

*Ovation Fertility*

Mitchel C. Schiewe, MS, PhD, *(Chair)*

*California Fertility Partners*

Juergen Liebermann, PhD, HCLD

*Fertility Centers of Illinois (Faculty)*

### Target Audience

This course is designed for clinical embryologists

### Needs Assessment

Vitrification (VTF) has become the cryopreservation method of choice for most in vitro fertilization laboratories worldwide. It has proven to produce highly reliable outcomes with over 95% embryo survival and 80+% intact oocyte survival, such that frozen embryo and oocyte cycles have become commonplace. Vitrification is a complex cryobiological process requiring the knowledge base to effectively troubleshoot device-related technical differences and problems that can arise. With a growing cryopreservation business, based on freeze-all cycles, more patients than ever are transporting their embryos and oocytes. Without careful preparation and training, the transition from a slow-rate freeze program to a vitrification program can be very challenging. Most demonstration and training in VTF techniques have come through workshops sponsored by industry, which may be biased toward a specific commercial medium and/or storage vessel. However, there are several media and vitrification vessels that can be used effectively within the IVF laboratory, each with potential strengths and weaknesses. Overview and training with various approaches are essential, especially with growing concerns over the safety of VTF solutions used, cryo-security, and accepting VTF eggs/embryos in unfamiliar VTF devices. We are entering a new era of cryobiology where we are faced with serious quality-control challenges.

### Description

This live course will provide a solid background in the theories and basic science that has led to the current state of VTF in human systems. We will demonstrate good tissue practices and discuss quality-control concerns. Participants will have an opportunity to train on the most common commercially available VTF systems being utilized in the United States. Following hands-on experience, each participant will be able to compare and contrast commonly utilized VTF systems on the market.

### ACGME Competencies

Physician: Medical Knowledge, Physician: Patient Care and Procedural Skills, Physician: Practice-based Learning and Improvement

### Learning Objectives

1. Via a "hands-on" workshop, evaluate, demonstrate and practice with various commercially available VTF systems.
2. Explain the cryobiological/cryophysical principles behind vitrification (VTF) technology and importance of warming relative to CPA concentration and cooling rates.
3. Outline the do's and don'ts of VTF device usage (quality control) as it pertains to potential variables which could influence post-warming recovery and/or survival.
4. Utilize best practice tips and tricks (pre-shipment and pre-thaw) to avoiding problematic warming events. How to best be successful for your potential new patient!



## PG18 Emerging Methods for Embryo Selection **CME**

Developed in cooperation with the European Society of Human Reproduction and Embryology (ESHRE)

### Faculty

Thomas Ebner, PhD, *(Chair)*  
Kepler University Hospital  
Verena Nordhoff, PhD  
Centre of Reproductive Medicine and Andrology  
Danilo Cimadomo, PhD  
Clinica Valle Giulia, GeneraLife IVF

### Target Audience

Embryologists, embryology technicians, clinicians, research scientists involved in selecting embryos for clinical use or for developing new tools for embryo selection.

### Needs Assessment

Ever since the advent of ovarian stimulation, embryologists have been faced with making choices on which embryo to transfer and which to discard. Whilst the overall global success of IVF is indicative of the skill demonstrated in selecting embryos for transfer, success rates remain stubbornly static. Moreover, embryo selection is subjective, and largely reliant on the visual appearance of an embryo. Despite excellent progress in defining and standardizing embryo selection, there remains a need for more objective, quantifiable and accurate means for selecting embryos with the best chance of delivering a healthy baby. Progress has been made in identifying objective markers of embryo viability, however this toolset is still controversial and yet to make a successful translation into every day clinical practice. Many proposed methods remain at the experimental phase of development. The aim of this course will be to provide an up to date, accurate and unbiased reflection on the status of embryo selection methods that are close to application as well as to offer glimpses into new developments over the horizon.

### Description

The aim of this course, Emerging Methods for Embryo Selection, hosted by the ESHRE Embryology Special Interest Group, will be to provide an up to date, accurate, and unbiased reflection on the status of embryo selection methods that are close to application as well as to offer glimpses into new developments over the horizon.

### ACGME Competencies

Interprofessional: Teams and Teamwork,  
Interprofessional: Roles-Responsibilities, Physician:  
Systems-based Practice, Physician: Practice-based  
Learning and Improvement

### Learning Objectives

1. Demonstrate the evidence in support of emerging methods for selecting oocytes and embryos
2. Summarize the main strengths and limitations of existing selection methods
3. Identify the most likely future options for embryo selection
4. Evaluate and explain the translational potential for new and existing methods of embryo selection.



## Needs Assessment and Description

The theme of the 2022 Scientific Congress of the American Society for Reproductive Medicine is "Genes, Gametes and Genetics." The scope of reproductive medicine is broad ranging from puberty to menopause, including males and females, while having a focus that is both molecular and macroscopic. The program is balanced between science at the cellular level and innovation of reproductive medicine in using cutting edge information in the clinical care of patients to promote positive outcomes for families. This live program is designed for physicians, nurses, andrology and embryology laboratory personnel, genetic counselors, social workers, practice, and laboratory managers, as well as specialists in mental health, law, and ethics to advance exemplary medical care and disseminate innovative research. These goals will be addressed by a wide array of educational activities. The CME/CE portion of the Scientific Congress will include plenary, lectures, symposia, and interactive sessions interweaving the theme of the annual Congress. Plenary lectures will feature exceptional speakers covering a wide range of themes in reproductive medicine including reproductive rights, recurrent pregnancy loss, early embryo development, ovarian aging, generational aging, menopause, and fertility preservation for pediatric, adolescent and adults as well as restoration for benign and malignant disease. Congress symposia will provide more in-depth coverage of basic and clinical subjects. Topics range from a wide variety of interests including stem cell technology, fertility preservation in adolescents and children with genetic conditions, advance imaging of endometriosis and adenomyosis, barriers to utilization of male fertility care, use of single cell RNA sequencing to probe cell identity, gamete, and embryo donation in 21st century, disparities in addressing uterine fibroids, addressing systemic inequities in reproductive healthcare, primary ovarian insufficiency, automation, artificial intelligence, and Lab on a chip technology. The interactive sessions cover a wide range of stimulating topics and are meant to be a forum for discussion and interaction, including topics such as ovarian insufficiency planning pregnancy: fresh or frozen egg donor, Polycystic Ovary Syndrome, recognizing and referring IVF patient with anxiety, PGT-A and Mosaicism, endometriosis management, genetic of successful FET: ultrasound imaging and PGT-A or Endometrial gene profile, sperm DNA fragmentation in recurrent miscarriages, diversity, equity, and inclusion in reproductive practice, progesterone supplementation in recurrent miscarriages, macroscopic vs. microscopic: uterine factor infertility, human genome editing, fertility preservation advocacy, access and mandates for coverage, ethics, law, and fertility preservation for AYA and transgender patients, uterine septum repair and viable embryo donation options in United States.

Supplementing the CME/CE program will be non-CME/CE events including roundtable luncheons and Expert Encounters that will provide opportunities for in-depth discussion with experts in small-group settings as well as oral and poster scientific abstract presentations that enable investigators to present cutting-edge scientific research in reproductive medicine and biology. Included in the diverse program are "tracks" for specialty and interest areas to enable participants to focus on specific topics and identify areas to expand their knowledge. The 2022 Scientific Congress should provide a chance for learning, improvement of clinical competence, and reproduction for the future of family fertility care.

## Learning Objectives

At the conclusion of the Scientific Congress, participants should be able to:

1. Explain the relevance of genetics and genomics to reproductive care.
2. Discuss current knowledge of endometriosis, fibroids, adenomyosis, contraception, and polycystic ovary syndrome.
3. Review the latest scientific advances in embryo biology and assessment to the optimization of embryo transfer.
4. Describe the ethical, legal, and psychosocial ramifications of third-party reproduction.
5. Propose appropriate treatments for reproductive dysfunctions in females and males at different ages throughout life—childhood, adolescence, adulthood, and reproductive senescence.
6. Apply strategies that simplify technology, reduce costs, and broaden accessibility
7. Discuss current knowledge of endometriosis, fibroids, adenomyosis, contraception, and polycystic ovary syndrome.

## ACGME Competencies

- Practice-based learning and improvement
- Patient care
- Medical knowledge
- Interpersonal and communication skills
- Systems-based practice
- Professionalism

## Interprofessional Competencies

- Roles/responsibilities
- Interprofessional communication
- Values/ethics for interprofessional practice
- Teams and teamwork



ASRM 2022 SCIENTIFIC CONGRESS SCHEDULE								
DATE TIME	SATURDAY 22-Oct	SUNDAY 23-Oct	TIME	MONDAY 24-Oct	TUESDAY 25-Oct	WEDNESDAY 26-Oct		
0630			0630	Poster Abstract Sessions	Poster Abstract Sessions	Poster Abstract Sessions		
0700			0700	6:30 am - 7:45 am	6:30 am - 7:45 am	6:30 am - 7:45 am		
0715			0715	Opening Ceremony Breakfast				
0730			0730	7:00 am - 7:45 am	Transit Time			
0745			0745	Opening Ceremony	Giving Day 2022 Kick-Off	Transit Time		
0800		Full and Half-day Hands-on Courses	0800	7:45 am - 8:30 am	Pre-Plenary Special Session	Plenary 5: SRS Lecture		
0815			0815		8:00 am - 8:30 am	8:00 am - 8:45 am		
0830				0830	Plenary 1: President's Guest Lecture	Plenary 3	ASRM Members' Meeting	
0845				0845	8:30 am - 9:15 am	8:30 am - 9:15 am		
0900				0900	Plenary 2: Camran Nezhat Lecturship	Plenary 4	Plenary 6	
0915				0915		9:15 am - 10:00 am	9:15 am - 10:00 am	
0930				0930				
0945				0945	9:15 am - 10:00 am			
1000				1000	Break	Prize Poster Lightning Round	Break	
1015				1015		Break		
1030				1030	10:00 am - 10:45 am	10:00 am - 10:45 am	10:00 am - 10:45 am	
1045				1045				
1100				1100	Video & Oral Abstract Sessions	Video & Oral Abstract Sessions	Oral Abstract Sessions	
1115				1115	Scientific Congress Prize Papers	Scientific Congress Prize Papers	Late-breaking Abstracts	
1130				1130	Clinical Sessions	Clinical Sessions	10:45 am - 12:15 pm	
1145				1145	10:45 am - 12:15 pm	10:45 am - 12:15 pm		
1200				1200				
1215				1215	Break/Lunch	Break/Lunch	Break/Lunch	
1230				1230	Roundtables	Roundtables/Non-CME Lunch Events	Roundtables	
1245				1245	F&S Journal Club LIVE		Non-CME Lunch Events	
1300	Half-day Interactive Hands-on Courses			1300	Expert Encounters	Expert Encounters	Expert Encounters	
1315				1315	12:20 pm - 1:20 pm	12:20 pm - 1:20 pm	12:20 pm - 1:20 pm	
1330					1330	Transit Time	Transit Time	Transit Time
1345					1345			
1400					1400	Symposia & Interactive Sessions	Symposia & Interactive Sessions	Symposia & Interactive Sessions
1415					1415	1:30 pm - 2:45 pm	1:30 pm - 2:45 pm	1:30 pm - 2:45 pm
1430				1430				
1445				1445	Break	Break	Transit Time	
1500				1500			Contraception Keynote Lecture	
1515				1515	2:45 pm - 3:30 pm	2:45 pm - 3:30 pm	SSR Exchange Keynote Lecture	
1530				1530	Herbert Thomas Plenary	AUA Stewart Memorial Lecture	3:00 pm - 3:45 pm	
1545			1545	Adamson Lecture	Menopause Keynote Lecture			
1600			1600	The Business of Medicine Sessions	The Business of Medicine Sessions			
1615			1615	3:30 pm - 4:15 pm	3:30 pm - 4:15 pm			
1630			1630					
1645			1645					
1700			1700					
1715			1715					
1730			1730					
1745			1745					
1800		ASRM President's Gala	1800					
1815		6:00 PM	1815					







## SPEAKER INDEX

Aboulghar, Mohamed . . . . .	SYM07	Davis-Kankanamge, Christina . . . . .	RTM11
Adamowicz, Mark . . . . .	PG17	Davoudian, Teni . . . . .	PG02
Adamson, Geoffrey . . . . .	SYT07	Dean, Ursula . . . . .	CSM02
Aghajanova, Lusine . . . . .	INW03, RTM21	Denicol, Anna . . . . .	PG15
Ahmady, Ali . . . . .	PG19, SYM01	Desai, Nidhi . . . . .	PG14, SYW07
Al-Hendy, Ayman . . . . .	SYT05	Desai, Nina . . . . .	PG17
Albertini, David . . . . .	PG16	Devine, Kathleen . . . . .	PG12
Albrecht, Mahshid . . . . .	PG14, LIVT-04	Dokson, Jamie . . . . .	INT04
Alonso, Luis . . . . .	PG09, INW03, RTT20	Domar, Alice . . . . .	PG05, RTM08
Appiah, Leslie . . . . .	INT08	Donnell, Rachel . . . . .	CST02
Arrach, Nabil . . . . .	INM05	Doody, Kevin . . . . .	RTW13
Asafu-Adjei, Denise . . . . .	INT03	Dupree, James . . . . .	SYM05, LIVM-07
Awwad, Johnny . . . . .	SYM07	Dyer, Silke . . . . .	SYT07
Baker, Hailey . . . . .	RTM10	D'Hooghe, Thomas . . . . .	SYT06
Balaban, Basak . . . . .	RTM25	Easley, Charles . . . . .	PG16
Ball, G. David . . . . .	RTW10, SYT01	Eaton, Jennifer . . . . .	RTM14
Bar-Chama, Natan . . . . .	RTM19	Ebner, Thomas . . . . .	PG18
Barrett, C. Brent . . . . .	INM02	Eccles, Jennifer . . . . .	INT04
Barton, Sara . . . . .	PG09	Edwards, Todd . . . . .	SYT05
Belmonte, Michael . . . . .	INW04	Eichberg, Carrie . . . . .	CSW01
Beltsos, Angeline . . . . .	PG14, SYT04	Eisenberg, Michael . . . . .	LIVM-07
Bendikson, Kristin . . . . .	PG07	Eskew, Ashley . . . . .	PG05, SYT03
Bergman, Kim . . . . .	CSM01, LIVM-04	Feinberg, Eve . . . . .	INW05
Berman, Lauren . . . . .	CSM01, SYW07	Feldman, Myra . . . . .	SYM06
Besser, Andria . . . . .	PG03	Ferraz, Marcia . . . . .	PG15
Bethea-Walsh, Angela . . . . .	PG11	Ferrero, Simone . . . . .	PG08, RTM05
Bindeman, Julie . . . . .	CSW01, INM04	Fino, Mary Elizabeth . . . . .	INT08, RTW16
Blackburn, Elizabeth . . . . .	PLT-02	Flyckt, Rebecca . . . . .	INM07, RTM20
Boots, Christina . . . . .	PG10	Forman, Eric . . . . .	INT06, SYM03
Bormann, Charles . . . . .	PG13, SYW06	Frishman, Gary . . . . .	RTM16
Boyd, Allison . . . . .	PG13, SYW05	Fru, KARENNE . . . . .	PG11
Brannigan, Robert . . . . .	PLT-05	Gada, Ravi . . . . .	LIVT-04
Braverman, Andrea . . . . .	CSW01	Gamma, Amber . . . . .	SYM03
Brezina, Paul . . . . .	INW02	Garbarini, Jennifer . . . . .	INM05
Brivanlou, Ali . . . . .	SYW01	Garrett, Lauren . . . . .	CST02
Bruner-Tran, Kaylon . . . . .	SYW02	Gaskins, Audrey . . . . .	PG05, SYW05
Buckmaster, Roxanne . . . . .	CSM02	Gnecco, Juan . . . . .	SYW02
Carlson, Ann . . . . .	RTW09	Goldman, Kara . . . . .	RTM04
Catherino, William . . . . .	SYT06	Green, Lisa . . . . .	RTT13
Cayton Vaught, Kamaria . . . . .	SYW05	Grobel, Maya . . . . .	RTM09
Cedars, Marcelle . . . . .	LIVM-02	Grynberg, Michael . . . . .	SYM08
Chamie, Luciana . . . . .	SYM06	Guerriero, Stefano . . . . .	PG08
Chang, Tiencheng Arthur . . . . .	PG16, RTM23, SYM04	Gurgan, Timur . . . . .	RTW20
Chavarro, Jorge . . . . .	INM03	Halpern, Joshua . . . . .	RTW15
Choy, Kwong Wai . . . . .	RTT09	Hansen, Peter . . . . .	SYT02
Christianson, Mindy . . . . .	INT02	Harton, Gary . . . . .	RTM13, RTW07
Cil, Aylin . . . . .	SYW03	Hebert, Cait . . . . .	RTT07
Cimadomo, Danilo . . . . .	PG18	Herati, Amin . . . . .	PG12
Cohen, I. Glenn . . . . .	LIVT-03	Hipp, Heather . . . . .	INM01, RTM03
Coward, Robert . . . . .	LIVM-07	Hoeger, Kathleen . . . . .	INM03
Crawford, Natalie . . . . .	RTT16	Hokianto, Hary . . . . .	PG14
Crockin, Susan . . . . .	LIVM-04	Honig, Stan . . . . .	RTW14
Curchoe, Carol . . . . .	SYM07, SYW06	Hotaling, James . . . . .	RTM18
Cymet Lanski, Ariadna . . . . .	PG10, SYT04	Huddleston, Heather . . . . .	PG10





SPEAKER INDEX

Hurst, Bradley . . . . . SYT06  
Hwang, Kathleen . . . . . PG06  
Hyun, Insoo . . . . . SYW01  
Isley, Lauren . . . . . SYW07  
Issner, Jeff . . . . . INM06  
Ivani, Kristen . . . . . PG17  
Jackson-Bey, Tia . . . . . SYW04  
Johnson, Hannah . . . . . LIVM-05  
Jones, Amy . . . . . PG04  
Jones, Griffin . . . . . INM06, LIVT-04  
Judge, Anne . . . . . PG12  
Kallen, Amanda . . . . . PG02, SYW03, PLT-01  
Kaplan, Danielle . . . . . PG11  
Kashanian, James . . . . . INM08  
Kastury, Rama . . . . . SYW03  
Katz-Jaffe, Mandy . . . . . PG13  
Keefe, David . . . . . INT07  
Kelk, Dawn . . . . . RTT18, RTW19  
Khan, Zaraq . . . . . SYM06  
Klipstein, Sigal . . . . . SYW01  
Kresowik, Jessica . . . . . RTT12  
Kudesia, Rashmi . . . . . INW01, RTW12, SYT03  
Laird, Diana . . . . . PLT-03  
Lamb, Dolores . . . . . PG19  
Lambertini, Matteo . . . . . SYM08  
Larkin, Derek . . . . . LIVT-04  
Laronda, Monica . . . . . PG16  
Lathi, Ruth . . . . . INT05  
Lawson, Angela . . . . . LIVM-04  
Layman, Lawrence . . . . . SYW05  
Lazorwitz, Aaron . . . . . INW04  
Lee, Kiho . . . . . SYM01  
Legro, Richard . . . . . INM03  
Lefourneau, Joseph . . . . . INT08  
Lewis, Leigh . . . . . INM04, RTT02  
Liebermann, Juergen . . . . . PG17  
Lin, Paul . . . . . RTM17  
Lindheim, Steven . . . . . INT06  
Lipschitz, Jordanna . . . . . SYM03  
Lockwood, Kathryn . . . . . RTW03  
M. Horton, Marcos . . . . . SYT07  
Madero, Daniel . . . . . RTM22  
Maher, Jacqueline . . . . . INT02  
Mak, Winifred . . . . . PG07, INT05, RTT03  
Masaba, Erin . . . . . PG07, RTM02  
Masterson, Thomas . . . . . PG09  
Mburu, Gitau . . . . . SYT07  
McBain, Lindsey . . . . . RTT01, SYW04  
McKnight, Katherine . . . . . RTM15  
McQueen, Dana . . . . . PG01, INT05  
Mehta, Akanksha . . . . . SYM05  
Melnick, Alexis . . . . . INM08  
Mersereau, Jennifer . . . . . INM01  
Messerlian, Carmen . . . . . PG19, SYT03

Mikhail, Emad . . . . . PG08  
Mikkelsen, Melanie . . . . . INW05  
Missmer, Stacey . . . . . SYW02  
Mitalipov, Shoukhrat . . . . . INT07  
Mooney, Sara . . . . . RTW01, SYT01, LIVM-05  
Moore, Monica . . . . . CSW02, INM03  
Moravek, Molly . . . . . INW01  
Morris, Jerrine . . . . . INT03, RTM07, SYM05  
Mounts, Emily . . . . . PG03  
Munne, Santiago . . . . . PG04, PG17  
Murugappan, Gaya . . . . . INW05, RTW02  
Myo, Melissa . . . . . INW04  
Nel-Themaat, Liesl . . . . . RTW18  
Nelson, Anita . . . . . PLW-04  
Nezhat, Ceana . . . . . INM07  
Nordhoff, Verena . . . . . PG18  
Noyes, Nicole . . . . . INM01  
Nusblat, Dina . . . . . RTM06  
Oktay, Kutluk . . . . . INT07, RTT21, SYM02  
Özpolat, B. Duygu . . . . . SYM01  
Parikh, Firuz . . . . . RTT04  
Park, Hang-Soo . . . . . RTT11  
Parry, John Preston . . . . . PG09, INT06  
Patrizio, Pasquale . . . . . INW01  
Perritt, Jamila . . . . . LIVT-03  
Petok, William . . . . . PG02  
Petrie, Kelsey . . . . . INW04  
Petrozza, John . . . . . INT06, RTW21  
Pfeifer, Samantha . . . . . INW03  
Plachta, Nicolas . . . . . PLM-02  
Polo, Jose . . . . . PG15  
Ramasamy, Ranjith . . . . . PG06, LIVM-07  
Rebar, Robert . . . . . PLW-02  
Reindollar, Richard . . . . . LIVS-02  
Reinecke, Joyce . . . . . INT08  
Richard-Davis, Gloria . . . . . SYM04  
Rinehart, Lisa . . . . . SYM03  
Roberts, Deb . . . . . RTM01  
Robertson, Christina . . . . . SYW04  
Robins, Jared . . . . . SYT07, LIVT-04  
Ross, Breanne . . . . . INM06  
Ruf-Zamojski, Frederique . . . . . SYT02  
Russell, Shannon . . . . . PLM-04  
Rutter, April . . . . . PG12  
Sable, David . . . . . PG03  
Sakkas, Denny . . . . . RTT19  
Santoro, Nanette . . . . . PLT-04  
Saunders, Philippa . . . . . SYT02  
Schafer, Vickie . . . . . CST01  
Schattman, Glenn . . . . . INW02  
Schiewe, Mitchel . . . . . PG17  
Schiff, Mark . . . . . RTW06  
Schlegel, Peter . . . . . INM08, PLW-01  
Scott, Richard . . . . . PG13, INT01





## SPEAKER INDEX

Shah, Divya . . . . .	INT02	Zore, Temeka . . . . .	INM08
Shamonki, Jaime . . . . .	SYW07		
Shannon, Chevis . . . . .	LIVT-04		
Shikanov, Ariella . . . . .	PG15		
Sierra, Sony . . . . .	INM08		
Simon, Carlos . . . . .	INT01		
Simoni, Michael . . . . .	SYM04		
Sirota, Marina . . . . .	PLM-03		
Smith, James . . . . .	INT03, RTT15		
Smith, Kristin . . . . .	RTT05		
Smith, Melanie . . . . .	PG17		
Soltész, Danielle . . . . .	INT03, LIVT-04		
Spandorfer, Steven . . . . .	PG07, INT05		
Sparks, Amy . . . . .	RTW11		
Stachecki, James . . . . .	PG17		
Stadtmauer, Laurel . . . . .	INM07		
Stewart, Elizabeth . . . . .	PG08		
Swain, Jason . . . . .	INM02		
Swain, Margaret . . . . .	SYT04		
Swanson, Amelia . . . . .	PG01, CST01, RTW05		
Tanrikut, Cigdem . . . . .	RTT14, SYT03, LIVM-07		
Thomas, Michael . . . . .	SYT07		
Thornton, Kim . . . . .	LIVM-05		
Toner, James . . . . .	LIVS-02		
Trachman, Ellen . . . . .	INW05		
Treff, Nathan . . . . .	PG04, INT04, RTT17		
Tur-Kaspa, Ilan . . . . .	INT01		
VanBuren, Wendaline . . . . .	SYM06		
Vance, Amy . . . . .	INT04		
Vash-Margita, Alla . . . . .	SYM02		
Vaughn, Richard . . . . .	CSM01		
Velez Edwards, Digna . . . . .	RTW04, SYT05		
Venier, Deborah . . . . .	PG17		
Venier, William . . . . .	PG17		
Viotti, Manuel . . . . .	RTT10		
Vitagliano, Amerigo . . . . .	PG08		
Vitek, Wendy . . . . .	PG10		
von Wolff, Michael . . . . .	SYM08		
Wells, Dagan . . . . .	RTT08		
Wiemer, Klaus . . . . .	RTM12		
Wignarajah, Anjali . . . . .	INW05		
Wild, Robert . . . . .	RTT06		
Williams, Carmen . . . . .	PLW-03		
Williams, Daniel . . . . .	RTM24		
Wolinetz, Carrie . . . . .	PLM-01		
Wood, Jennifer . . . . .	PG11		
Woodward, Julia . . . . .	PG01		
Wozniak, Kathryn . . . . .	PG17		
Xu, Kangpu . . . . .	RTW08		
Yakin, Kayhan . . . . .	SYW03		
Yu, Bo . . . . .	SYT01		
Zaninovic, Nikica . . . . .	PG06, SYM07, SYW06		
Zozula, Shane . . . . .	PG17, RTW17		
Young, Steven . . . . .	PG07		





### INVITED SPEAKER DISCLOSURES INDEX

All speakers at the 2022 ASRM Scientific Congress were required to complete a disclosure form.

Each speaker listed below disclosed a relationship pertaining to themselves or their partner/spouse.

<sup>1</sup>Company Officer    <sup>2</sup>Direct Stockholder    <sup>3</sup>Full-Time Company Employee    <sup>4</sup>Grant Recipient    <sup>5</sup>Honoraria  
<sup>6</sup>Paid Consultant    <sup>7</sup>Speaker's Bureau    <sup>8</sup>Other    <sup>a</sup>Self    <sup>a</sup>Immediate Family Member    <sup>b</sup>Institution

Adamson, G.	Advanced Reproductive Care <sup>3a</sup> ; LabCorp <sup>6a</sup>
Al-Hendy, A.	Abbvie <sup>6a</sup> ; Bayer <sup>6a</sup> ; Myovant Sciences, Inc. <sup>6a</sup> ; Novartis <sup>6a</sup> ; OBSEVA <sup>6a</sup>
Alonso, L.	Hologic <sup>6a</sup>
Arrach, N.	Progenisis <sup>12a</sup>
Boyd, A. L.	Fertility Health Tech <sup>6a</sup>
Brannigan, R. E.	American Board of Urology <sup>8a</sup> (Examination Committee Senior Consultant); American Urological Association <sup>8a</sup> (AUA Update Series Editorial Committee Member)
Braverman, A. M.	California Cryobank <sup>6a</sup>
Catherino, W.	American Board of Obstetrics and Gynecology <sup>6a</sup> ; American Society for Reproductive Medicine <sup>6a</sup> ; Bayer <sup>5a</sup> ; EMD Serono <sup>3b</sup> ; Myovant <sup>5a</sup>
Cedars, M. I.	Ferring pharmaceutical <sup>4a</sup>
Choy, K. R.	Basecare Medical Device, China <sup>56a</sup> ; Hong Kong Society of Genetic Counselling <sup>18a</sup>
Doody, K. J.	Ferring Pharmaceutical <sup>6a</sup> ; INVO Bioscience <sup>28a</sup> (Board member ); Organon Pharmaceutical <sup>6a</sup>
Dupree, J. M.	Blue Cross Blue Shield of Michigan <sup>4a</sup> ; Lipocine <sup>2a</sup> ; NICHD <sup>4a</sup> ; Posterity Health <sup>8a</sup> (Medical Advisory Board, with equity)
Ebner, T.	Esco <sup>5a</sup> ; Gynemed <sup>5a</sup> ; Hamilton Thorne <sup>8a</sup> (Scientific Board Member)
Eccles, J.	Genomic Prediction <sup>3a</sup>
Eichberg, C.	Carrie Eichberg, PsyD PLLC <sup>1a</sup> ; Fertility Forms <sup>1a</sup>
Eisenberg, M.	Hannah <sup>8a</sup> (Advisor); Ro <sup>8a</sup> (advisor); Sandstone <sup>8a</sup> (Advisor)
Garbarini, J. L.	CooperSurgical <sup>3a</sup>
Hansen, P.	Cooley Biotech <sup>12a</sup> ; Society for the Study of Reproduction <sup>1a</sup>
Harton, G.	BioSkryb Genomics <sup>23a</sup> ; Cryos International <sup>7a</sup> ; PerkinElmer <sup>28a</sup> (former employee); The World Egg Bank <sup>7a</sup>
Hebert, C.	Wilmer Culter Pickering Hale and Dorr LLP <sup>3b</sup>
Herati, A. S.	Dadi <sup>8a</sup> (Advisor ); Lina <sup>6a</sup>
Hoeger, K.	AEPCOS <sup>8a</sup> (President)
Honig, S.	Clarus <sup>67a</sup> ; coloplast <sup>6a</sup> ; endo <sup>7a</sup> ; Posterity health <sup>2a</sup>
Hotaling, J.	advanced conceptions <sup>2a</sup> ; andro360 <sup>2a</sup> ; coloplasta; FirmTech <sup>1a</sup> ; Maximus <sup>2a</sup> ; StreamDx <sup>2a</sup> ; Turtle Health <sup>6a</sup> ; UCB, Pfizer, Novartis, Abbvie, Janssen, Lilly. <sup>7b</sup>
Isley, L.	Generate Life Sciences <sup>3a</sup>
Issner, J.	EngagedMD <sup>12a</sup>
Judge, A. R.	The Whole Pineapple Podcast <sup>8a</sup> (Co-creator and co-host)







## DISCLOSURES INDEX

Kashanian, J. A.	Roman Health <sup>6a</sup>
Laird, D. J.	Third Pole, Inc <sup>23b</sup>
Lamb, D. J.	American Board Of Bioanalysts <sup>58a</sup> (Board member); American Board of Bioanalysts <sup>5a</sup> ; Fellow Health <sup>26a</sup> ; Roman Health <sup>6a</sup>
Lazorwitz, A.	Dama Health <sup>1a</sup> ; Organon <sup>4a</sup>
Legro, R. S.	Guerbet <sup>4a</sup> ; Insudd <sup>6a</sup> ; Novo Nordisk <sup>6a</sup>
Letourneau, J. M.	Alnylam Pharmaceuticals <sup>6a</sup> ; EMD Serono <sup>6a</sup>
Lin, P. C.	alto pharmacy <sup>2a</sup> ; Win Fertility <sup>8a</sup> (Medical Advisory Board)
Lockwood, K.	Generate Life Sciences <sup>3a</sup>
Madero, D.	Legacy <sup>2a</sup> ; Levy8a(Advisor); Modern Fertility <sup>6a</sup> ; Ovation Fertility <sup>3a</sup>
Masterson, T. A.	endo pharmaceuticals <sup>6a</sup> ; endo pharmaceuticals <sup>4a</sup>
McKnight, K. K.	Ferring Pharmaceuticals <sup>8a</sup> (Advisory Board Member )
Mehta, A.	Posterity Health <sup>8a</sup> (Medical Advisory Board Member)
Missmer, S. A.	Abbotta; AbbViea; AbbVie <sup>4a</sup> ; Frontiers in Reproductive Health <sup>5a</sup>
Moravek, M. B.	NUVO <sup>8b</sup> (Investor)
Morris, J. R.	Evernow <sup>6a</sup>
Munne, S.	Overture Life <sup>1a</sup>
Nelson, A. L.	Agile Pharmaceutical <sup>15678a</sup> (Grants/research); Bayer Healthcare <sup>567a</sup> ; Mayne Pharma <sup>567a</sup> ; Mylan/Viatrix Pharma <sup>4a</sup> ; Myovant/Pfizer <sup>567a</sup> ; Organon/Merck <sup>46a</sup> ; Sagami Rubber Industries <sup>a</sup> ; Sebela Pharmaceutical <sup>4a</sup> ; TherapeuticsMD <sup>57a</sup>
Nezhat, C.	Baxter <sup>8a</sup> (Medical Advisor); Karl Storz Endoscopy <sup>8a</sup> (Medical Advisor); Lumenis <sup>8a</sup> (Medical Advisor); Novuson Surgical <sup>18a</sup> (Medical Advisor); Pfizer, Inc. Speaker Program <sup>78a</sup> (Medical Advisor); Plasma Surgical <sup>8a</sup> (Medical Advisor)
Nusblat, D.	CooperSurgical <sup>23a</sup>
Patrizio, P.	FertileSafe Ltd <sup>8a</sup> (Co-founder)
Pfeifer, S. M.	ASPIRA <sup>a</sup> ; ASPIRA <sup>a</sup> ; Granata Bio <sup>b</sup> ; Posterity Health <sup>6b</sup> ; RESOLVE <sup>6b</sup> ; RESOLVE <sup>8a</sup> (Medical Advisory Board); Roman Health <sup>6b</sup> ; Theralogix <sup>6b</sup>
Polo, J.	CSL <sup>3b</sup> ; ISSCR <sup>8a</sup> (Society Member and Committee member); Mogrify <sup>2a</sup>
Ramasamy, R.	Acerus Pharmaceuticals <sup>4a</sup>
Rebar, R. W.	Various Chinese Universities <sup>a</sup>
Roberts, D.	Embryo Connections <sup>1a</sup>
Rutter, A. M.	Hera Fertility <sup>26a</sup>
Sable, D. B.	Celmatix <sup>12a</sup> ; Cooper Cos. Inc <sup>2a</sup> ; Cryoport <sup>2a</sup> ; Hamilton Thorne <sup>1a</sup> ; Invocell <sup>2a</sup> ; MedAnswers Inc. <sup>12a</sup> ; Monash IVF Group Ltd <sup>2a</sup> ; Oova Inc <sup>2a</sup> ; Progyny <sup>2a</sup> ; TMRW Life Sciences <sup>1a</sup> ; Virtus Health Ltd. <sup>2a</sup> ; Vitrolife <sup>2a</sup>
Sakkas, D.	ALIFE <sup>8a</sup> (Options Holder); EMD Serono <sup>7a</sup> ; Igenomix <sup>8a</sup> (Scientific Advisory Board); Legacy <sup>8a</sup> (Consultant)
Santoro, N.	Amazon (Project Ember) <sup>8a</sup> (Medical Advisory Board); Ansh Labs, Inc <sup>6a</sup> ; Astellas <sup>8a</sup> (Scientific Advisory Board); Menogenix, Inc <sup>4a</sup> ; North American Menopause Society <sup>8a</sup> (Program Committee member); Que Oncology <sup>8a</sup> (Scientific Advisory Board); Society for Reproductive Investigation <sup>8a</sup> (President)
Schiff, M.	Growing Generations <sup>6a</sup>




## DISCLOSURES INDEX

Schlegel, P. N.	Granata Bio <sup>8a</sup> (Consultant); Posterity Health <sup>6a</sup> ; Roman Health <sup>2a</sup> ; Theralogix <sup>5a</sup>
Scott, R. T.	Juno Genetics <sup>8a</sup> (I own stock in a company which owns Juno genetics)
Shamonki, J. M.	CooperCompanies <sup>23a</sup>
Simon, C.	igenomix <sup>12a</sup>
Sirota, M.	Aria Pharmaceuticals <sup>2a</sup> ; Google <sup>3b</sup>
Smith, J.	Fellow Health <sup>48a</sup> (Stock Options); Inherent Biosciences <sup>8a</sup> (Stock Options); Posterity Health <sup>2a</sup>
Sparks, A. E.	Ferring Pharmaceuticals <sup>5a</sup>
Stachecki, J.	Innovative Cryo Enterprises II LLC <sup>1a</sup>
Stewart, E. A.	AbbVie <sup>6a</sup> ; Fibroid Foundation <sup>8a</sup> (Unpaid advisory board); MED-IQ <sup>8a</sup> (CME Faculty); Myovant <sup>6a</sup> ; ObsEva <sup>6a</sup> ; PER <sup>8a</sup> (CME faculty); UpToDate <sup>8a</sup> (Royalties); WEB MD <sup>8a</sup> (CME faculty)
Swain, J. E.	FujiFilm Irvine Scientific <sup>8a</sup> (Key Opinion Leader- lecturer)
Tanrikut, C.	New England Cryogenic Center <sup>a</sup> ; Society for the Study of Male Reproduction <sup>a</sup> ; Swimmers <sup>a</sup>
Treff, N. R.	Genomic Prediction <sup>12a</sup>
Tur-Kaspa, I.	Embryonics <sup>8a</sup> (Medical Baords)
Wells, D.	Juno Genetics <sup>123a</sup>
Wignarajah, A.	Univfy Inc. <sup>3a</sup>
Zozula, S.	SCARB and SRBT Board member <sup>8a</sup> (VP SCARB , Membership Committee Chair SRBT)



# Scientific Congress Tracks

[asrmcongress.org](http://asrmcongress.org)



Scan the QR Code to view tracks online!

**ART - LAB**

**Academic Medicine**

**Access to Care**

**Androgen Excess**

**Andrology**

**Assisted Reproductive Technology**

**Basic Science**

**Clinical & Translational Research**

**Clinical Infertility**

**Complementary and Integrative Medicine**

**Contraception**

**Early Pregnancy**

**Endometriosis**

**Environment and Reproduction**

**Ethics**

**Fertility Preservation**

**Fibroids**

**Genetic Counseling**

**Genetics**

**Health Disparities**

**Hot Topics**

**Imaging**

**Infertility and Cancer**

**Innovation**

**Inter-professional Collaboration**

**LGBTQ**

**Legal**

**Male Reproduction**

**Menopause**

**Mental Health**

**Nursing**

**Nutrition**

**Pediatric and Adolescent Gynecology**

**Polycystic Ovary Syndrome**

**Preimplantation Genetic Testing**

**Primary Ovarian Insufficiency**

**Professional and Practice Development**

**Recurrent Pregnancy Loss**

**Regenerative Medicine and Stem Cells**

**Reproductive Endocrinology**

**Reproductive Immunology**

**Reproductive Managers**

**Reproductive Surgery**

**Third-party Reproduction**

**Turkish Reproductive Medicine**



# Non-CME Educational Sessions

- Roundtable Discussions 67-79
- Video Abstract Sessions 71-72
- Oral Abstract Sessions 73-88
- Poster Presentations and Abstracts 89-124
- Abstract Topic Index 125-133
- Disclosures 134-144



# Roundtable Discussions

MONDAY, OCTOBER 24, 2022

## Association of Reproductive Managers

RTM01

### A “Fresh” Perspective on Embryo Donation

Deb Roberts  
*Embryo Connections*

## Early Pregnancy Special Interest Group

RTM02

### Autoimmune Thyroid Disease: Role in the Patient with rSAB

Erin Masaba, MD  
*University of Rochester*

## Education Committee

RTM03

### Faculty Teaching tools for REI learners

Heather Hipp, MD *Emory University School of Medicine, Department of Gynecology and Obstetrics*

## Fertility Preservation Special Interest Group

RTM04

### How to Do a Lot with a Little : Fertility Preservation Strategies in Women and Girls with DOR and POI

Kara Goldman, MD  
*Northwestern University Feinberg School of Medicine, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility*

## Fibroids Special Interest Group

RTM05

### Non-Surgical Treatments of Uterine Fibroids before IVF/ICSI

*IRCCS Ospedale Policlinico San Martino*

## Genetic Counseling Professional Group

RTM06

### PGT-M for Controversial Indications

Dina Nusblat, MS, CGC  
*CooperSurgical*

## Health Disparities Special Interest Group

RTM07

### Identifying and Reducing Unconscious Bias in the Workforce: Techniques to Improve Equitable Treatment of Women, and Racial, Ethnic and Sexual Minority Physicians in Medicine

Jerrine Morris MD, MPH

## Mental Health Professional Group

RTM08

### Methods to Reduce Infertility Treatment Discontinuation Due to the Emotional Burden of Care

Alice Domar, PhD

RTM09

### Embryo Donation: A Disposition Option and a Family Building Choice

Maya Grobel, MSW, LCSW  
*EM•POWER DONATION*

## Nurses' Professional Group

RTM10

### Improving Fertility Patient Stress Management through Patient Centered Self-Care

Hailey Baker, MSN,ARNP  
*Seattle Reproductive Medicine*

## Pediatric and Adolescent Gynecology Special Interest Group

RTM11

### ASRM Classification of the Mullerian Anomalies: the New Tool for the Pediatric and Adolescent Gynecology Provider

Christina Davis-Kankanamge  
*MMC*

## Preimplantation Genetic Testing Special Interest Group

RTM12

### Misconceptions with PGT-P: Our Experiences.

Klaus Wiemer, PhD, HCLD  
*Poma Fertility*

RTM13

### Current Status of Non-Invasive PGT (niPGT)

Gary Harton, PhD

## Society for Assisted Reproductive Technology

RTM14

### Submitting a SART CORS Research Proposal: Set Yourself up for Success

Jennifer Eaton, MD, MSCI  
*Women & Infants Hospital and Brown University*

RTM15

### PGT-a on All - Pros and Cons

Katherine McKnight, MD  
*Houston IVF*

RTM16

### Evidence-Based Hysteroscopy for Your Office

Gary Frishman, MD  
*Brown University; Women & Infants Hospital*

RTM17

### COVID19 Impact on ART Practice

Paul Lin, MD  
*Seattle Reproductive Medicine*

## Society for Male Reproduction and Urology

RTM18

### Precision Medicine in Male Fertility: Where We Are and What's Needed for the Future

James Hotaling, MD  
*University of Utah School of Medicine Andrology and IVF Laboratories*



# Roundtable Discussions

**RTM19**

**New Advances and Technologies to Optimize Sperm Quality: From Semen Collection and Processing to Cryopreservation**

Natan Bar-Chama, MD  
*Piedmont Reproductive Endocrinology Group*

**Society for Reproductive Endocrinology & Infertility**

**RTM20**

**3D-4K Microscope in Male Fertility Microsurgery**

Philip Li, MD  
*Weill Cornell Medicine, Cornell University, New York Presbyterian Hospital*

**RTM21**

**Thin Endometrium - What, If Anything, Should We Do about It?**

Lusine Aghajanova, MD, PhD  
*Stanford University School of Medicine*

**Society of Reproductive Biologists and Technologists**

**RTM22**

**Third Party Reproduction: How to Improve Patient Experience and Results**

Daniel Madero, BS  
*Ovation Fertility*

**RTM23**

**Common Practices Among High-Performing IVF Programs**

Tiencheng Arthur Chang, PhD, HCLD, ELD  
*University of Texas Health Science Center*

**Society of Reproductive Surgeons**

**RTM24**

**Surgical Sperm Extraction for Pediatric Fertility Preservation**

Daniel Williams, MD  
*Brown University*

**Turkish Special Interest Group**

**RTM25**

**Optimizing Laboratory Outcomes Through Established Performance Indicators**

Basak Balaban, BSc  
*American Hospital*

**TUESDAY, OCTOBER 25, 2022**

**Association of Reproductive Managers**

**RTT01**

**A Balancing Act - Attracting and Integrating New Talent While Developing & Growing Existing Talent**

Linsey McBain, BA  
*RMANJ*

**Complementary and Integrative Medicine Special Interest Group**

**RTT02**

**From Preconception to Post-Partum, How Acupuncture Supports the Fertility Lifecycle**

Leigh Lewis, ND, L.Ac, NCMP, FABORM  
*Arcadia Women's Wellness*

**Early Pregnancy Special Interest Group**

**RTT03**

**Uterine Septum: Always Repair or Has the Dogma Changed?**

Winnifred Mack, MD, PH.D  
*University of Texas Dell Medical School Faculty, Dept of Reproductive Endocrinology and Infertility*

**Indian Special Interest Group**

**RTT04**

**Inflammation & Infertility**

Firuza Parikh, MD, DNB, PhD  
*Jaslok Hospital and Research Centre*

**LGBTQ Special Interest Group**

**RTT05**

**Navigating Transgender Patients Through Fertility Preservation: A Fertility Preservation Patient Navigator's Perspective.**

Kristin Smith, ?BS  
*Northwestern University*

**Menopause and Ovarian Insufficiency Special Interest Group**

**RTT06**

**Modern Management During the Menopause and the Menopausal Transition**

Robert Wild, MD, MPH, PhD  
*Oklahoma University Health Sciences Center*

**Nurses' Professional Group**

**RTT07**

**Pop Culture Picnic - a Discussion How Pop Culture Affects Patient Perceptions.**

Cait Hebert, BA, BSN

**Preimplantation Genetic Testing Special Interest Group**

**RTT08**

**Genome Editing: How Far or How Close to the Clinical Application?**

Dagan Wells, PhD  
*IVI RMA*

**RTT09**

**Identifying Macroscopic and Microscopic Chromosomal Mosaicisms in First-trimester Miscarriages using Low-pass Genome Sequencing**

Kwong Wai Choy, PhD  
*The Chinese University of Hong Kong*

**RTT10**

**Chromosomal Mosaicism and the Five W's (Who, What, When, Where, and Why)**

Manuel Viotti, PhD  
*Zouves Foundation for Reproductive Medicine*



# Roundtable Discussions

## Regenerative Medicine and Stem Cell Biology Special Interest Group

**RTT11**  
**Stem Cell-Based Therapeutics for Premature Ovarian Insufficiency**  
Hang-Soo Park, PhD  
*University of Illinois at Chicago*

## Society for Assisted Reproductive Technology

**RTT12**  
**Advertising Fairly: The Ins/Outs**  
Eli Reshef, MD  
*Henry G. Bennett Jr. Fertility Institute*

**RTT13**  
**Disparities in ART**  
Torie Plowden, MD, MPH  
*NICHD*

## Society for Male Reproduction and Urology

**RTT14**  
**Nutrition, Obesity, and Lifestyle in Male Reproductive Health**  
Cigdem Tanrikut, MD  
*Shady Grove Fertility*

**RTT15**  
**Telemedicine in Reproductive Practice: Common Challenges and Solutions to Them**  
James Smith, MD, MS  
*University of California, San Francisco*

## Society for Reproductive Endocrinology & Infertility

**RTT16**  
**Using Social Media for Patient Outreach and Education**  
Natalie Crawford, MD, MSCR  
*Aspire Fertility Austin*

## Society of Reproductive Biologists and Technologists

**RTT17**  
**PGT-a + Polygenic Risk Scores: Which Patients Benefit the Most**  
Nathan Treff, PhD, HCLD  
*Genomic Prediction, Inc.*

**RTT18**  
**Embryo Storage Tank Failures: How to Minimize Risk**  
Dawn Kelk, PhD, HCLD  
*Yale School of Medicine*

**RTT19**  
**The Impact of New Technologies on Efficiency in the IVF Lab**  
Denny Sakkas, PhD  
*Boston IVF*

## Society of Reproductive Surgeons

**RTT20**  
**Opportunities for Moving from Diagnostic to Operative Office Hysteroscopy: Success, Safety, and Economic Sustainability**  
Luis Pacheco, MD  
*Collège Marocain de Fertilité*

## Turkish Special Interest Group

**RTT21**  
**Fertility Preservation Management for Medical and Elective Indications**  
Kutluk Oktay, MD, PhD  
*Yale University School of Medicine*

### WEDNESDAY, OCTOBER 20, 2021

## Association of Reproductive Managers

**RTW01**  
**Triple Threat: Digital Tools Used to Connect, Create and Increase Productivity**  
Sara Mooney, BA  
*NPG*

## Early Pregnancy Special Interest Group

**RTW02**  
**PGTa for Recurrent Pregnancy Loss Patient: When to Consider**  
Gaya Murugappan, MD

## Genetic Counseling Professional Group

**RTW03**  
**Adverse Prenatal Outcome Reports Following Gamete Donation**  
Kathryn Lockwood, MS  
*LabCorp*

## Health Disparities Special Interest Group

**RTW04**  
**Unpacking #Ancestry: Exploring the Reliability and Accessibility of Genetic Testing in Communities of Color**  
Digna Velez Edwards, MS, PhD  
*Vanderbilt University Medical Center*

## LGBTQ Special Interest Group

**RTW05**  
**Psychoeducational Consultations for Same-Sex Couples Using Donor Gametes: Discrimination or Necessary?**  
Amelia Swanson, PhD  
*Northwestern University*

## Mental Health Professional Group

**RTW06**  
**Beyond the Psychological Screening: Pre- and Post-Screening Counseling of Egg Donors**  
Mark Schiff, MA  
*Growing Generations*

## Preimplantation Genetic Testing Special Interest Group

**RTW07**  
**Improving Universal PGT (-M, -SR, -A and -P) with a Novel WGA method (PTA)**  
Gary Harton, PhD  
*PERKIN ELMER*



# Roundtable Discussions

**RTW08**

**One Size Does Not Fit All:  
Individualized PGT-a Treatment  
Plan Is Needed**

Kangpu Xu, PhD  
Weill Cornell Medical College of  
Cornell University

**RTW09**

**An Imagined Future of Mosaic  
Embryo Transfers**

Ann Carlson, MS, CGC  
Weill Cornell Medical College of  
Cornell University

**Society for Assisted Reproductive  
Technology**

**RTW10**

**CAP/Joint Commission Lab  
Inspections**

G. David Ball, PhD  
Seattle Reproductive Medicine  
Center

**RTW11**

**How to Use SART-CORS for Your  
Clinic's Quality Management  
Program**

Amy Sparks, PhD  
University of Iowa Center for  
Advanced Reproductive Care

**RTW12**

**Lifestyle Modification Prior to ARTs:  
What's the Evidence?**

Rashmi Kudesia, MD  
CCRM Fertility Houston

**RTW13**

**Development of IVF Children**

Kevin Doody, MD  
CARE Fertility

**Society for Male Reproduction and  
Urology**

**RTW14**

**Advances in Home and Mail-in  
Diagnostic Semen Testing**

Stan Honig, MD  
Yale University

**RTW15**

**Current and Future Options for  
Pediatric Fertility Preservation**

Kathleen Hwang, MD  
University Pittsburgh, Urology

**Society for Reproductive  
Endocrinology & Infertility**

**RTW16**

**Fertility Preservation in Transgender  
Individuals**

Mary Fino, MD  
NYU Langone Prelude Fertility  
Center

**Society of Reproductive Biologists  
and Technologists**

**RTW17**

**E-Witness Implementation in a Busy  
IVF Lab**

Shane Zozula, BS, TS (ABB)  
Ovation Fertility

**RTW18**

**Career Development for  
Reproductive Lab Professionals:  
How to Skyrocket Your Career**

Liesl Nel-Themaat, PhD HCLD  
University of Colorado Anschutz  
Medical Campus

**RTW19**

**For Cryo'ing Out Loud: How to  
Minimize Risk**

Dawn Kelk, PhD, HCLD  
Yale School of Medicine

**Turkish Special Interest Group**

**RTW24**

**Approach to Recurrent  
Implantation Failure**

Timur Gurgan, MD  
Ankara University

**Society of Reproductive Surgeons**

**RTW14**

**Fibroid Radiofrequency Ablation vs.  
Surgery- Where Are We Headed?**

John Petrozza, MD  
Massachusetts General Hospital  
Fertility Center

**Preimplantation Genetic Testing  
Special Interest Group**

**RTW15**

**Current Status of Non-Invasive PGT  
(niPGT)**

Gary Harton, PhD  
PERKIN ELMER



# VIDEO ABSTRACT SESSION 1

Moderators: Michael Eisenberg, MD, Salli Tazuke, MD and James Hotaling, MD

**10:45 AM Welcoming Remarks**

**11:00 AM A STEP-BY-STEP APPROACH TO A FROZEN PELVIS.** Michael Franklin Neblett II, M.D.<sup>1</sup>, Youssef Youssef, M.B.B.Ch.<sup>2</sup> and Zaraq Khan, MBBS<sup>1</sup>, <sup>1</sup>Mayo Clinic, Rochester, MN, <sup>2</sup>Hurley Medical Center/ Michigan State University, Flint, MI

**11:08 AM Discussion**

**11:11 AM AN INTRODUCTION AND VIDEO TUTORIAL TO THE NEW AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE MÜLLERIAN ANOMALIES CLASSIFICATION 2021 INTERACTIVE WEBSITE.** Phillip A Romanski, MD, MSc<sup>1</sup>, Pietro Bortoletto, MD, MSc<sup>2</sup>, Samantha M Pfeifer, M.D.<sup>2</sup> and Steven R. Lindheim, M.D., MMM<sup>3</sup>, <sup>1</sup>New York, NY, <sup>2</sup>NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, <sup>3</sup>University of Central Florida College of Medicine, FL

**11:17 AM Discussion**

**11:20 AM IDENTIFYING VIABILITY OF IMMOTILE SPERM AT ONE GLANCE: SPERM VIABILITY CLASSIFIER POWERED BY DEEP LEARNING.** Aojun Jiang, M.S.<sup>1</sup>, Wang Jiaqi, B.S.<sup>2</sup>, Huan Zhao, M.S.<sup>3</sup>, Zhuoran Zhang, PhD<sup>4</sup> and Yu Sun, PhD<sup>5</sup>, <sup>1</sup>The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, China, <sup>2</sup>Shenzhen, China, <sup>3</sup>Luohu People's Hospital, Shenzhen, China, <sup>4</sup>The Chinese University of Hong Kong, Shenzhen, Shenzhen City, Guangdong Province, China, <sup>5</sup>University of Toronto, Toronto, ON, Canada

**11:27 AM Discussion**

**11:30 AM ONCOTESTICULAR SPERM EXTRACTION (ONCOTESE) FOR BILATERAL METACHRONOUS TESTIS CANCER.** Aisha Lynn Siebert, MD, PhD, MPH, Justin M. Dubin, MD, Shilajit D Kundu, MD and Robert E. Brannigan, MD, Northwestern University, Chicago, IL

**11:38 AM AMEARLY PREGNANCY FAILURE: A NOVEL APPLICATION FOR HYSTEROSCOPIC MORCELLATION.** Salomeh M. Salari, MD MS<sup>1</sup>, Kathryn D Coyne, MD<sup>2</sup>, Rebecca K Chung, MD<sup>2</sup>, Joseph Findley, MD<sup>2</sup>, Steven R. Lindheim, M.D., MMM<sup>3</sup> and Rebecca Flyckt, MD<sup>4</sup>, <sup>1</sup>University Hospitals Cleveland Medical Center/ Case Western Reserve University, Beachwood, OH, <sup>2</sup>University Hospitals Fertility Center/Case Western Reserve University, Beachwood, OH, <sup>3</sup>University of Central Florida College of Medicine, FL, <sup>4</sup>University Hospitals Fertility Center/Case Western Reserve University, Beachwood

**11:46 AM Discussion**

**11:49 AM DELINEATION OF UTERINE ISTHMOCELE USING FIREFLY® TECHNOLOGY DURING COMBINED HYSTEROSCOPIC-ROBOTIC ISTHMOPLASTY.** Kelly Dorsey, BS<sup>1</sup>, Zoran J Pavlovic, M.D.<sup>1</sup>, Rachel Sprague, M.D.<sup>1</sup> and Emad Mikhail, MD<sup>2</sup>, <sup>1</sup>University of South Florida, Tampa, FL, <sup>2</sup>University of South Florida, Morsani College of Medicine, Tampa, FL

**11:57 AM ROBOTIC EXCISION OF CESAREAN SCAR DEFECT WITH CO2 LASER AND DA VINCI FIREFLY.** Zachary W Walker, MD and Antonio R Gargiulo, MD, Brigham and Women's Hospital -Harvard Medical School, Boston, MA

**12:04 PM ROUND LIGAMENT PPLICATION FOR IMPROVING EASE OF EMBRYO TRANSFER.** Arielle Yeshua, MD<sup>1</sup>, Karli Provost Goldstein, D.O.<sup>2</sup>, Timur Seckin, BS<sup>3</sup>, Amanda L Chu, B.A., M.D.<sup>4</sup> and Tamer A Seckin, MD<sup>5</sup>, <sup>1</sup>Lenox Hill, Northwell Health, New York, NY, <sup>2</sup>NSLIJ Lenox Hill, New York, <sup>3</sup>Texas Christian University School of Medicine, Fort Worth, TX, <sup>4</sup>New York, NY, <sup>5</sup>Lenox Hill Hospital/Northwell Health, New York, NY

**12:11 PM Discussion**





VIDEO ABSTRACT SESSION 2

Moderators: Steven R. Lindheim, M.D., MMM, Anthony N Imudia, MD and John Petrozza, MD

- 10:45 AM**

**HUMAN BLASTOCYST EUPLOID PREDICTION BASED ON 3D MORPHOLOGICAL EVALUATION.**  
Guanqiao Shan, MASC<sup>1</sup>, Khaled Abdalla, MASC<sup>2</sup>, Justin Tan, MD<sup>2</sup>, Hang Liu, MASC<sup>1</sup>, Changsheng Dai, PhD<sup>1</sup>, Zhuoran Zhang, PhD<sup>3</sup>, Clifford Lawrence Librach, MD<sup>2</sup> and Yu Sun, PhD<sup>1</sup>, <sup>1</sup>University of Toronto, Toronto, ON, Canada, <sup>2</sup>CReATE Fertility Centre, Toronto, ON, Canada, <sup>3</sup>The Chinese University of Hong Kong, Shenzhen, Shenzhen City, Guangdong Province, China

**11:24 AM**

**RESECTION OF DEEP INFILTRATING VAGINAL ENDOMETRIOSIS.** Janet Cruz, MD<sup>1</sup>, Violeta Covarrubias, BS<sup>2</sup>, Mallory A Stuparich, MD<sup>3</sup>, Samar Nahas, MD<sup>1</sup> and Sadikah Behbehani, M.D.<sup>1</sup>, <sup>1</sup>University of California Riverside, Riverside, CA, <sup>2</sup>University of California, Riverside, School of Medicine, Riverside, CA

**11:32 AM**

**Discussion**
- 10:53 AM**

**SURGICAL TECHNIQUES FOR EXCISION OF FUNCTIONAL HORN IN PROXIMITY TO UNICORNUATE UTERUS.** Sabrina Rangi, M.D.<sup>1</sup>, Megan Orlando, M.D.<sup>2</sup>, Natalia C Larena, MD<sup>1</sup>, Marjan Attaran, M.D.<sup>3</sup> and Cara R King, DO, MS<sup>1</sup>, <sup>1</sup>Cleveland Clinic, Cleveland, OH, <sup>2</sup>Cleveland, OH, <sup>3</sup>Cleveland Clinic, Beachwood, OH

**11:35 AM**

**LAPAROSCOPIC EXCISION OF ADVANCED STAGE ENDOMETRIOSIS INVOLVING A FALLOPIAN TUBE ENDOMETRIOMA.** Tinya Lin, MD, MSc, Azraa Banka, Bahi Elbasueny, MD, MSc and Mohamed Ali Bedaiwy, MD, PhD, University of British Columbia, Vancouver, BC, Canada

**11:42 AM**

**NONINVASIVE TIME-LAPSE PREDICTION OF EMBRYONIC MOSAICISM.** Kevin Lambrese, MS<sup>1</sup>, Diego Marin, PhD<sup>2</sup>, Kathleen Miller, DHSc<sup>3</sup> and Nathan R Treff, PhD, HCLD<sup>4</sup>, <sup>1</sup>Eastern Virginia Medical School, Norfolk, VA, <sup>2</sup>Genomic Prediction, Inc., <sup>3</sup>IVF Florida Reproductive Associates, Fort Lauderdale, FL, <sup>4</sup>Genomic Prediction, Inc., North Brunswick, NJ
- 11:01 AM**

**LAPAROSCOPIC TRANSFUNDAL APPROACH TO CERVICAL DILATION: A NOVEL TREATMENT FOR CERVICAL STENOSIS AND CERVICAL FACTOR INFERTILITY.** Christine E Hur, M.D.<sup>1</sup> and Jeffrey M Goldberg, M.D.<sup>2</sup>, <sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH, <sup>2</sup>Cleveland Clinic, Cleveland, OH

**11:49 AM**

**THE FINE BALANCE BETWEEN RADICAL AND FUNCTIONALLY CONSERVATIVE EXCISION OF ENDOMETRIOSIS.** Papri Sarkar, MD and Emad Mikhail, MD, University of South Florida, Morsani College of Medicine, Tampa, FL

**11:56 AM**

**Discussion**
- 11:08 AM**

**Discussion**

**11:11 AM**

**LAPAROSCOPICALLY-ASSISTED HYSTEROSCOPIC REMOVAL OF AN INTERSTITIAL PREGNANCY.** Kaitlin McGrail, M.D.<sup>1</sup> and Ceana Nezhat, MD<sup>2</sup>, <sup>1</sup>Atlanta Center for Minimally Invasive Surgery and Reproductive Medicine, Atlanta, GA, <sup>2</sup>Nezhat Medical Center, Atlanta, GA

**11:16 AM**

**A COMPLICATED AFFAIR: ROBOTIC MYOMECTOMY OF A BROAD LIGAMENT FIBROID COMPLICATED BY ENDOMETRIOSIS AND OTHER UTERINE**







Monday, October 24, 2022

10:45 am - 12:15 pm

# SCIENTIFIC CONGRESS PRIZE PAPER SESSION 1

The first six papers are candidates for the ASRM Scientific Congress Prize Paper Awards. Six additional candidates will be presented during the Prize Paper Candidates' session on Tuesday.

Moderator: TBD

10:45 AM	<b>SUSTAINED IMPROVEMENT IN PHYSICAL FUNCTION AND QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN TREATED WITH RELUGOLIX COMBINATION THERAPY OVER 104 WEEKS: SPIRIT LONG-TERM EXTENSION STUDY.</b> S. As-Sanie	12:00 PM	<b>UNIQUE SET OF GENETIC VARIANTS REFLECT EARLY-ONSET DIMINISHED OVARIAN RESERVE.</b> B. R. McCallie
11:00 AM	<b>RISK OF ECTOPIC PREGNANCY IN PATIENTS WITH A TRANSIENT DIAGNOSIS OF PREGNANCY OF UNKNOWN LOCATION.</b> D. Thiagarajan	11:45 AM	<b>FAMILY HISTORY RISK ASSESSMENT BY A GENETIC COUNSELOR FOR OVUM DONORS: DATA FOR 582 IN HOUSE OVUM DONORS FROM A SINGLE CLINIC DEMONSTRATES ITS VALUE.</b> A. C. Vance
11:15 AM	<b>FAMILY BUILDING AND PARENTHOOD ALTERS THE CAREER TRAJECTORY OF WOMEN IN MEDICINE.</b> J. B. Bakkensen	11:30 AM	<b>EFFECT OF RACE ON OVARIAN RESPONSE TO GONADOTROPIN STIMULATION IN <i>IN VITRO</i> FERTILIZATION.</b> I. T. Lee

Monday, October 24, 2022

10:45 am - 12:15 pm

# ORAL ABSTRACT SESSION 1

## OSM-02 ART LAB 1

10:45 AM	<b>GROWTH HORMONE IS USELESS IN IVF: THE LARGEST RANDOMIZED CONTROLLED TRIAL.</b> A. Mourad
11:30 AM	<b>LOW LACTATE/PYRUVATE MEDIUM IMPROVES GV COMPETENCE.</b> A. Galbete Urrutia
12:00 PM	<b>TURNING THE BLACK BOX INTO A GLASS BOX: USE OF TRANSPARENT ARTIFICIAL INTELLIGENCE TO UNDERSTAND BIOLOGICAL MARKERS USEFUL FOR EMBRYO SELECTION.</b> C. Hickman
11:15 AM	<b>COMPETENCY AND BENCHMARK VALUES FOR VIENNA CONSENSUS ART LABORATORY KEY PERFORMANCE INDICATORS (KPIs) REDEFINED: REAL-WORLD DATA FROM 80 NORTH AMERICAN IVF LABORATORIES.</b> J. K. Au

11:45 AM	<b>FIRST PRE-CLINICAL AND CLINICAL VALIDATION OF AN AUTOMATED SPERM INJECTION ROBOT (ICSI-A) IN HUMAN OOCYTES.</b> N. Costa Borges
11:00 AM	<b>IS HOME-BASED MONITORING OF OVULATION TO TIME FROZEN EMBRYO TRANSFER AN EFFECTIVE ALTERNATIVE FOR HOSPITAL-BASED MONITORING OF OVULATION?</b> T. Zaat

## OSM-03 ENDOMETRIOSIS

12:00 PM	<b>SUMOYLATION MEDIATES PROGESTERONE RESISTANCE IN ENDOMETRIOSIS TREATMENT FAILURE AND IMPAIRED IMPLANTATION.</b> V. A. Flores
10:45 AM	<b>WAVES STUDY – QUANTITATIVE ULTRASOUND MEASUREMENT OF ENDOMETRIAL WAVES IN ADENOMYOSIS VERSUS WOMEN WITH NORMAL UTERI.</b> C. O. Rees





## ORAL ABSTRACTS

11:00 AM **TIME TO MINIMAL OR NO PELVIC PAIN WITH RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM THE SPIRIT PROGRAM.** A. S. Lukes

11:45 AM **EFFECT OF MICRORNAS THAT ARE LINKED TO ENDOMETRIOSIS ON HEPATIC GENE EXPRESSION.** R. Mamillapalli

11:15 AM **DIFFERENTIAL UTERINE UPTAKE OF ESTROGEN AND PROGESTOGEN-BASED RADIOTRACERS ACROSS THE MENSTRUAL CYCLE: MOVING TOWARDS IMPROVED RADIOLOGIC DETECTION OF ENDOMETRIOSIS.** R. C. Wilson

11:30 AM **A PROSPECTIVE STUDY OF PLASMA PROTEIN MARKERS ASSOCIATED WITH RISK OF LAPAROSCOPICALLY CONFIRMED ENDOMETRIOSIS IN THE NURSES' HEALTH STUDY II.** N. Sasamoto

### OSM-04 ENVIRONMENT AND REPRODUCTION

11:45 AM **THE HEART OF THE MATTER: CANNABIS EXPOSURE INITIATES CYCLIC ALTERATIONS IN HUMAN ENDOMETRIAL STROMAL CELLS AND DYSREGULATES PRENATAL CARDIAC DEVELOPMENT.** M. Ho

11:15 AM **CESSATION OF DELTA-9-TETRAHYDROCANNABINOL DIMINISHES THE IMPACT ON TESTICULAR VOLUME IN RHESUS MACAQUES.** J. C. Hedges

11:30 AM **IMPACT OF COVID-19 VACCINATION ON ART OUTCOME IN THE CONTEXT OF MALE PATIENTS.** H. Arora

12:00 PM **EFFECT OF ELECTROMAGNETIC RADIATION EMITTED BY CELL PHONES ON SPERM MOTILITY AND VIABILITY - AN IN VITRO STUDY.** K. Chu

10:45 AM **UNHEALTHY AIR QUALITY SECONDARY TO WILDFIRES IS ASSOCIATED WITH LOWER BLASTOCYST YIELD FROM IN VITRO FERTILIZATION.** M. S. Kornfield

11:00 AM **ENVIRONMENTAL EXPOSURE TO INDUSTRIAL AIR POLLUTION IS ASSOCIATED WITH DECREASED MALE FERTILITY.** J. M. Ramsay

### OSM-05 INFERTILITY AND CANCER

10:45 AM **TRENDS AND CHARACTERISTICS OF OVARIAN CONSERVATION AT HYSTERECTOMY FOR CERVICAL CARCINOMA IN-SITU.** C. Violette

11:15 AM **TO BIOPSY OR NOT TO BIOPSY? PREVALENCE OF ENDOMETRIAL HYPERPLASIA AND CANCER IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME** R. Agarwal

11:00 AM **PLATINUM CHEMOTHERAPY CAUSES REPRODUCTIVE HARM IN FEMALE ADOLESCENT AND YOUNG ADULT CANCER (AYA) SURVIVORS.** B. Zhou

11:30 AM **DO CANCER HEREDITARY SUSCEPTIBILITY SYNDROME (CHSS) CARRIERS HAVE ALTERED MARKERS OF OVARIAN RESERVE?** J. Reich

11:45 AM **MODIFIED RNA ENCODING ANTI-MÜLLERIAN HORMONE CONFERS OVARIAN PROTECTION FROM CYCLOPHOSPHAMIDE VIA TEMPERED APOPTOSIS IN GROWING FOLLICLES.** L. Man

12:00 PM **TRENDS IN FROZEN EMBRYO TRANSFERS (FET) UTILIZATION AND OUTCOMES IN CANCER PATIENTS WHO UNDERWENT FERTILITY PRESERVATION (FP) BEFORE (PRE) AND AFTER (POST) CHEMOTHERAPY.** A. Pruzan

### OSM-06 ORAL IVF OUTCOME PREDICTORS 1

11:45 AM **SHORTER TELOMERE LENGTH IS ASSOCIATED WITH LOWER ANTRAL FOLLICLE COUNT AND POORER IN VITRO FERTILIZATION OUTCOMES IN WOMEN OF ADVANCED REPRODUCTIVE AGE.** X. P. Zhou

12:00 PM **LOW POST-WASH TOTAL PROGRESSIVELY MOTILE SPERM COUNTS YIELD COMPARABLE INTRAUTERINE INSEMINATION PREGNANCY RATES.** P. N. Dietrich



## ORAL ABSTRACTS

11:30 AM **ENDOMETRIN PLUS INTRAMUSCULAR (IM) PROGESTERONE EVERY THIRD DAY HAS SIGNIFICANTLY LOWER PREGNANCY RATES COMPARED TO DAILY IM PROGESTERONE ALONE IN PATIENTS UNDERGOING PROGRAMMED FROZEN EMBRYO TRANSFER.** L. Y. Ying

11:00 AM **TRIGGER TYPE FOR FINAL OOCYTE MATURATION AND EMBRYOLOGICAL OUTCOMES; A RETROSPECTIVE COHORT STUDY WITH PROPENSITY SCORE MATCHING.** M. Ezzati

11:15 AM **THE PREDICTIVE VALUE OF ANTI MULLERIAN HORMONE IN INTRAUTERINE INSEMINATION CYCLES.** C. M. Canon

10:45 AM **INTER-PREGNANCY WEIGHT CHANGE IN ASSISTED REPRODUCTION AND PREGNANCY OUTCOMES.** K. A. Voss

### OSM-07 LEGAL/ETHICAL ISSUES INCLUDING THIRD PARTY REPRODUCTION

10:45 AM **A COMPREHENSIVE REVIEW OF MALPRACTICE LITIGATION INVOLVING INTRAUTERINE INSEMINATION IN THE UNITED STATES.** J. Applebaum

12:00 PM **DIFFERENCES IN GENETIC CARRIER SCREENING (CS) PANELS NECESSITATE INTENDED PARENT (IP) EDUCATION FOR GAMETE DONOR SELECTION.** A. G. Besser

11:45 AM **FACTORS, MOTIVATIONS AND EXPERIENCES OF INFERTILITY PATIENTS WHO INITIALLY CONSIDERED EMBRYO DONATION (ED) WITH SUPERNUMERARY EMBRYOS.** S. J. Barishansky

11:00 AM **LAWSUITS OVER DISPUTED FROZEN EMBRYO OWNERSHIP AFTER DIVORCE OR SEPARATION: CLAIMS BASIS AND RESOLUTIONS.** G. Letterie

11:15 AM **EXPLORING THE REPRODUCTIVE BLACK MARKET: FERTILITY MEDICATIONS ON THE DARK WEB.** B. C. Monseur

11:30 AM **A MIXED-METHODS EVALUATION OF EGG DONORS' PHYSICAL, PSYCHOSOCIAL, AND DISCLOSURE EXPERIENCES POST-DONATION.** K. Adlam

### OSM-08 GENETIC COUNSELING

12:00 PM **REVIEW OF RECOMBINATION EVENTS OBSERVED IN PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M) OVER A 2 YEAR PERIOD.** E. Pai

11:00 AM **DISCOVERY OF GERMLINE MOSAICISM, NON-PENETRANT DISEASE, AND MORE FOLLOWING DIAGNOSIS OF AUTOSOMAL DOMINANT DISORDERS IN DONOR-CONCEIVED OFFSPRING.** J. Park

11:15 AM **CLINICAL IMPLICATIONS OF EXPANDED CARRIER SCREENING (ECS) FOR FERTILITY CARE AND INDIVIDUAL HEALTH.** L. C. Gemmell

11:30 AM **PGT-SR OBSERVED SEGREGATION PATTERNS ALLOWS FOR TAILORED RISK ASSESSMENT.** L. Walters-Sen

11:45 AM **SUITABILITY OF GAMETE DONOR APPLICANTS IDENTIFIED AS CARRIERS AT-RISK FOR SYMPTOMS.** J. Park

10:45 AM **MISCLASSIFICATION OF PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY: A SYSTEMATIC REVIEW AND META-ANALYSIS.** V. Bacal

### OSM-09 LGBTQ

11:15 AM **CURRENT ACCESS TO FERTILITY CARE FOR TRANS AND GENDER DIVERSE PATIENTS ACROSS UNITED STATES HOSPITALS.** S. L. Estevez

11:45 AM **ASSISTED REPRODUCTIVE TECHNOLOGY TREATMENT OUTCOMES IN TRANSGENDER MALES WITH HISTORY OF GENDER AFFIRMING HORMONE THERAPY.** A. Ghofranian

11:30 AM **TRANSGENDER FEMALE PATIENTS WHO UNDERWENT ORCHIECTOMY ARE AT INCREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS (MACE).** T. A. Masterson

12:00 PM **MULTICENTER CASE SERIES OF TRANSGENDER MEN WITH FERTILITY BENEFITS: ACCESS TO CARE AND NAVIGATING OBSTACLES.** E. S. Rubin





## ORAL ABSTRACTS

10:45 AM **CONCURRENT TESTOSTERONE (T) DURING OVARIAN STIMULATION NEGATIVELY AFFECTS EMBRYO DEVELOPMENT AFTER IN VITRO FERTILIZATION (IVF) IN A TRANSMASCULINE MOUSE MODEL.**

A. R. Schwartz

11:00 AM **OPINIONS OF TRANSGENDER, GENDER NON-CONFORMING, AND NON-BINARY PEOPLE ON VALUE OF FERTILITY PRESERVATION: A CROSS SECTIONAL SURVEY.** J. Amir

### OSM-10 MALE REPRODUCTION AND UROLOGY: TRAVELING SCHOLARS

12:00 PM **P-425 IMPROVING ONCOLOGY FERTILITY PRESERVATION - AREAS OF IMPACT.** J. B. Huang

11:15 AM **P-453 BREAKING IT DOWN: ADHERENCE TO GUIDELINES FOR DNA FRAGMENTATION TESTING IN MALE INFERTILITY PATIENTS.** A. N. Shami

10:45 AM **P-464 THE UROLOGIST'S GUIDE TO RELIGION AND MALE FERTILITY TREATMENTS.** S. R. Donnenfeld

11:00 AM **P-469 SPERM DNA METHYLATION PREDICTS HUMAN AGING IN FERTILE AND INFERTILE MEN.** J. T. Sigalos

11:30 AM **P-474 THE EFFECT OF LEPTIN ON TESTICULAR MICROIMMUNE-ENVIRONMENT IS INFLUENCED BY BMI.** D. Seetharam

11:45 AM **P-564 MECHANISTIC INSIGHTS INTO A RARE MUTATION IN NACAD AS A POSSIBLE CAUSE OF COVID ORCHITIS.** C. K. Ramsoomair

### OSM-11 OVARIAN STIMULATION

11:00 AM **OVARIAN STIMULATION OUTCOMES IMPROVE ON SUCCESSIVE RETRIEVAL CYCLES REGARDLESS OF CHANGE IN GONADOTROPIN DOSE OR PROTOCOL.** M. Fanton

11:30 AM **ROLE OF GROWTH HORMONE SUPPLEMENTATION IN POOR OVARIAN RESERVE PATIENTS UNDERGOING IN-VITRO FERTILIZATION- A RANDOMIZED CONTROLLED TRIAL.** N. Malhotra

11:45 AM **OUTCOMES OF DONOR OOCYTE RETRIEVALS FOR RECIPIENT IN VITRO FERTILIZATION (IVF) PATIENTS ARE UNAFFECTED BY COVID-19 VACCINATION.** S. Daneshmand

11:15 AM **DOSE DEPENDENT INFLUENCE OF OVULATION INHIBITOR, CHLORMADINONE ACETATE OR CETRORELIX ON OOCYTE MATURATION IN NORMAL OVARIAN RESERVE PATIENTS: A RETROSPECTIVE STUDY WITH POISSON REGRESSION ANALYSIS.** M. Handa

12:00 PM **OUTCOME OF RANDOM-START OVARIAN STIMULATION IN CASE OF EMERGENCY FERTILITY PRESERVATION DEPENDING ON THE DAY OF PROTOCOL ONSET.** M. Braham

10:45 AM **THE RELATIONSHIP BETWEEN THE NUMBER OF MATURE OR STIMULATED FOLLICLES AND MULTIPLE PREGNANCY RATES IN LETROZOLE INTRAUTERINE INSEMINATION (IUI) CYCLES IN WOMEN 18-40 YEARS OF AGE.** A. M. Digby

### OSM-12 PREIMPLANTATION GENETIC TESTING 1

11:00 AM **IS PGT-A BENEFICIAL FOR PATIENTS WITH ONLY ONE BLASTOCYST? A 2014-2018 NATIONAL STUDY OF OVER 21,000 FREEZE-ALL CYCLES.** A. K. Gadson

12:00 PM **INTERNAL INVESTIGATIONS OVER A 4-YEAR PERIOD HIGHLIGHT THE CONSISTENCY OF PREIMPLANTATION GENETIC TESTING (PGT), THOUGH IDENTIFY PREVENTABLE REPEATED CAUSES OF DISCREPANT PGT RESULTS.** N. C. Paolino

10:45 AM **POLYGENIC EMBRYO RISK SCORES: A SURVEY OF PUBLIC KNOWLEDGE AND PERCEPTION.** A. Peyser





## ORAL ABSTRACTS

- 11:30 AM **TRENDS AND OUTCOMES FOR PRE-IMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS IN THE UNITED STATES, 2014-2018.** A. R. Chada
- 11:45 AM **EMBRYOS DIAGNOSED AS PUTATIVE MOSAIC BY THE PGTSEQ PGT-A PLATFORM HAVE A SIMILAR SUSTAINED IMPLANTATION RATE AS THOSE NEGATIVE FOR PUTATIVE MOSAICISM: A BLINDED NON-SELECTION STUDY.** P. Gill
- 11:15 AM **THE NATURE OF SEX CHROMOSOME ANEUPLOIDIES IN HUMAN BLASTOCYSTS.** A. Korkidakis

### OSM-13 PUBLIC HEALTH AND REPRODUCTION

- 11:45 AM **AN EFFECTIVE TELEHEALTH BASED MULTIDISCIPLINARY APPROACH TO WEIGHT LOSS IN WOMEN WITH OBESITY SEEKING TREATMENT FOR INFERTILITY.** A. Bojko
- 11:30 AM **MODERATE STEP COUNTS ARE ASSOCIATED WITH HIGHER RATES OF LIVE BIRTH IN SUBFERTILE WOMEN.** E. Johnstone
- 10:45 AM **IMPACT OF THE COVID-19 PANDEMIC ON SOCIAL OOCYTE CRYOPRESERVATION TRENDS.** A. Raghunandan
- 11:15 AM **PROCEDURAL SPECIALISTS FAMILY BUILDING PATTERNS AND USE OF ASSISTED REPRODUCTIVE TECHNOLOGY.** P. Sundaram
- 12:00 PM **THE ASSOCIATION BETWEEN HPV INFECTION AND LIVE BIRTH OUTCOMES IN THE INFERTILITY POPULATION.** B. J. Gelvin
- 11:00 AM **VACCINE AND BOOSTER ACCEPTANCE IN WOMEN CONSIDERING OR UNDERGOING FERTILITY TREATMENTS DURING THE OMICRON SURGE OF THE COVID-19 PANDEMIC.** L. A. Kassi

### OSM-14 REPRODUCTIVE SURGERY AND PROCEDURES

- 11:00 AM **SURGICAL AND REPRODUCTIVE OUTCOMES IN A LARGE DECEASED DONOR UTERUS PROGRAM: CLEVELAND CLINIC'S SIX YEAR REPORT.** E. G. Richards
- 10:45 AM **ENDOMETRIAL SCRATCHING IN PATIENTS WITH UNEXPLAINED INFERTILITY UNDERGOING INTRAUTERINE INSEMINATION: PRELIMINARY REPORT OF A RANDOMIZED CONTROLLED TRIAL.** K. Kteily
- 12:00 PM **SURVEYING ERGONOMIC RISK, OPTICS, AND TEACHING IN OPERATING SURGEONS WITH WEARABLE TECHNOLOGY: 4K-3D EXOSCOPE VS OPERATING MICROSCOPES IN MALE FERTILITY MICROSURGERY.** K. Chu
- 11:15 AM **ENDOMETRIAL RECEPTIVITY ANALYSIS TESTING: A SINGLE CENTRE EXPERIENCE.** R. Habte
- 11:45 AM **EFFECTS OF FIBRIN SEALANT COMPARED WITH SUTURING OR NO HEMOSTATIC INTERVENTION ON OVARIAN RESERVE IN PATIENTS UNDERGOING OVARIAN CYSTECTOMY: A RETROSPECTIVE COHORT STUDY.** M. McKenna
- 11:30 AM **COVID-19 INFECTION IN UTERUS TRANSPLANT RECIPIENTS IN THE US.** M. Rush

### OSM-15 REGENERATIVE MEDICINE AND STEM CELLS

- 11:00 AM **A CELL THERAPY ASSISTED NOVEL MICROFLUIDIC DEVICE PROMOTES *IN VITRO* SPERMATOGENESIS IN NEONATAL MICE.** S. Onen
- 11:15 AM **EFFECT OF HUMAN UMBILICAL CORD BLOOD PLATELET-RICH PLASMA COMBINED WITH EXTRACELLULAR MATRIX HYDROGELS ON IMMUNOCOMPETENT ENDOMETRIAL DAMAGE MURINE MODELS.** A. Rodríguez Eguren





## ORAL ABSTRACTS

10:45 AM	<b>PERTURBATION OF DNA METHYLTRANSFERASES IN HUMAN TROPHOBLAST STEM CELLS LEADS TO A FAILURE OF TROPHOBLAST DIFFERENTIATION - A PUTATIVE CAUSE FOR HUMAN MISCARRIAGE.</b> W. Mak	11:45 AM	<b>ACTIVATION OF AKT, MAPK3/1 AND mTOR SIGNALING PATHWAYS IS ASSOCIATED WITH THE SUCCESS OF CAVITY FORMATION DURING HUMAN BLASTOID GENERATION.</b> A. Nahar
11:30 AM	<b>microRNA144-5p OVEREXPRESSIONG MESENCHYMAL STEM CELL-DERIVED SECRETOME REVERSES THE FUNCTION OF OGCS IN AN <i>IN VITRO</i> POI MODEL.</b> F. B. Liakath	12:00 PM	<b>OPTIMIZING EXTENDED CULTURE CONDITIONS OF STEM CELL DERIVED BLASTOIDS TO MIMIC HUMAN IMPLANTATION IN VITRO.</b> D. Logsdon

Tuesday, October 25, 2022

10:45 am - 12:15 pm

## SCIENTIFIC CONGRESS PRIZE PAPER SESSION 2

The first six papers are candidates for the ASRM Scientific Congress Prize Paper Awards. Six additional candidates will be presented during the Prize Paper Candidates' session on Tuesday.

Moderator: TBD

11:45 AM	<b>INCREASED EXPOSURE TO ENDOCRINE DISRUPTORS AMONG BLACK WOMEN MAY LEAD TO GREATER INCIDENCE OF UTERINE FIBROIDS.</b> G. Beroukhim	11:00 AM	<b>THE IMPACT OF AN ADAPTED SPIKES PROTOCOL VERSUS STANDARD OF CARE IN DELIVERING NEGATIVE PREGNANCY TEST RESULTS TO IVF PATIENTS: A MULTICENTER, RANDOMIZED CONTROLLED TRIAL.</b> A. D. Domar
10:45 AM	<b>FIBROID PREVALENCE AND BURDEN BY RACE IN AN ASYMPTOMATIC, DIVERSE COHORT OF REPRODUCTIVE-AGE WOMEN.</b> D. Huang	11:30 AM	<b>INSURANCE MANDATES AND RACIAL AND ETHNIC INEQUITIES IN ASSISTED REPRODUCTIVE TECHNOLOGY UTILIZATION.</b> A. Korkidakis
12:00 PM	<b>COVID-19 VACCINATION STATUS AND MENSTRUAL CYCLE LENGTH IN THE APPLE WOMEN'S HEALTH STUDY.</b> E. A. Gibson	11:15 AM	<b>UBIQUITIN C-TERMINAL HYDROLASE L1 (UCHL1) AND THE TERRIBLE, NO GOOD OVARIAN FOLLICLE.</b> A. K. Gadson

Tuesday, October 25, 2022

10:45 am - 12:15 pm

## ORAL ABSTRACT SESSION 2

<b>OST-02 ORAL ABSTRACT SESSION: ACCESS TO CARE</b>		12:00 PM	<b>EARLY ATTRITION AFTER ACCESS TO FERTILITY CARE: RACIAL DISPARITIES IN COMPLETION RATES OF FERTILITY WORK-UP.</b> A. Acker
11:15 AM	<b>CHARACTERISTICS OF PATIENTS SEEKING FERTILITY CARE IN A LOW-INCOME SETTING.</b> M. Tarrash	11:45 AM	<b>STATE MANDATED INSURANCE IS ASSOCIATED WITH REDUCED RACIAL DISPARITIES IN ACCESS AND LIVE BIRTH RATES FOR EGG RECIPIENTS - AN ANALYSIS OF 44,033 CYCLES FROM THE SARTCORS DATABASE FOR 2014-2016.</b> C. Liao
11:00 AM	<b>FERTILITY PRESERVATION IN AN INSURANCE MANDATED STATE: OUTCOMES FROM THE RHODE ISLAND FERTILITY PRESERVATION REGISTRY.</b> A. K. Gadson		





## ORAL ABSTRACTS

10:45 AM **WHEN STATES REQUIRE FULLY-INSURED EMPLOYERS TO PROVIDE INSURANCE COVERAGE FOR IN-VITRO FERTILIZATION (IVF), DO SELF-INSURED EMPLOYERS FOLLOW SUIT?** J. M. Dupree

11:30 AM **FERTILITY PRESERVATION INSURANCE COVERAGE IN PROFESSIONAL SCHOOLS.** S. Gupta

### OST-03 ANDROGEN EXCESS AND POLYCYSTIC OVARY SYNDROME

11:15 AM **IDENTIFICATION OF NOVEL PCOS-RISK ALLELES BY LARGE-SCALE GENOME WIDE META-ANALYSIS PROVIDES NEW INSIGHTS INTO BIOLOGICAL MECHANISMS AND CLINICAL HEALTH OUTCOMES.** L. Moolhuijsen

11:45 AM **POLYCYSTIC OVARY SYNDROME (PCOS) IS ASSOCIATED WITH AN INCREASED RISK OF EUPLOID PREGNANCY LOSS: A SART CORS ANALYSIS OF 56,564 FROZEN EMBRYO TRANSFERS.** J. B. Bakkensen

11:30 AM **OBESE PCOS DISPLAYED COMPROMISED GLUCOSE METABOLISM ALONG WITH ALTERED FEEDING, SLEEPING AND ACTIVITY PATTERNS.** A. Gannon

11:00 AM **CARDIOVASCULAR AND METABOLIC OUTCOMES AMONG PCOS PARTICIPANTS IN THE CARDIA COHORT.** A. Wang

12:00 PM **POLYCYSTIC OVARY SYNDROME AND DIFFERENCES IN BRAIN HEALTH AT MID-LIFE: RESULTS FROM THE CARDIA COHORT.** H. G. Huddleston

10:45 AM **THE PROINFLAMMATORY CYTOKINE RESPONSE TO SATURATED FAT INGESTION IS INDEPENDENT OF ABDOMINAL ADIPOSITY (AA) IN POLYCYSTIC OVARY SYNDROME (PCOS).** F. Gonzalez

### OST-04 CONTRACEPTION AND COMPLEX FAMILY PLANNING

11:30 AM **THE EFFECT OF HORMONAL CONTRACEPTION USE ON OVARIAN RESERVE MARKERS IN THOSE SEEKING INFERTILITY EVALUATION.** D. R. Siegel

12:00 PM **PREGNANCIES BY ACTS OF INTERCOURSE WITH VAGINAL PH MODULATOR: RESULTS FROM THE AMPOWER STUDY.** M. A. Thomas

11:00 AM **RECENT TREND OF SURGICAL STERILIZATION AND LONG-ACTING REVERSIBLE CONTRACEPTION USE AT VAGINAL DELIVERY.** A. M. McGough

11:45 AM **IMPACT OF QUANTITATIVE POST-VASECTOMY SEMEN ANALYSIS REPORTING ON PATIENT COMPLIANCE AND NEED FOR REPEAT SEMEN ANALYSIS.** J. Hernandez

10:45 AM **FREQUENCY OF CONTRACEPTIVE COUNSELING AND USE OF BIRTH CONTROL IN ADOLESCENTS AND YOUNG ADULTS WITH SICKLE CELL DISEASE.** J. Reich

11:15 AM **DELAYED FAMILY BUILDING AND INFERTILITY AMONG WOMEN IN MEDICINE: KNOWLEDGE IS NOT ENOUGH.** J. B. Bakkensen

### OST-05 EARLY PREGNANCY

11:15 AM **HOW LONG TO CONCEPTION? AN EXAMINATION OF THE INTERVAL PATIENTS ARE COUNSELED TO WAIT AFTER RECEIVING METHOTREXATE FOR AN ECTOPIC PREGNANCY BEFORE ATTEMPTING CONCEPTION** K. Koniarens

12:00 PM **ROLE OF EMBRYO IGF2 IN THE ETIOLOGY OF THE LONG-TERM CONSEQUENCES OF ART IN OFFSPRING.** R. Cannarella

11:00 AM **DOES VAGINAL BLEEDING BEFORE 20 WEEKS GESTATION RESULT IN ADVERSE PERINATAL OUTCOMES FOR WOMEN WITH SINGLETON IVF PREGNANCIES IN BRITISH COLUMBIA?** R. Habte

11:45 AM **CANNABIS USE AND PREGNANCY LOSS: A SYSTEMATIC REVIEW AND META-ANALYSIS.** C. Zeitouni

10:45 AM **MISCARRIAGE AFTER EMBRYO TRANSFER: HOW MUCH TIME IS LOST?** R. E. Warwar

11:30 AM **LACK OF ACCESS TO MIFEPRISTONE LEADS TO SUBOPTIMAL MANAGEMENT OF EARLY PREGNANCY LOSS: SURVEY OF PROVIDERS.** Z. Anderson





## ORAL ABSTRACTS

### OST-06 FIBROIDS

- 11:15 AM **IMPACT OF ELAGOLIX WITH ADD-BACK ON BONE MINERAL DENSITY AT 24 MONTHS: INTERIM RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS.** Y. M. Poindexter
- 11:30 AM **MECHANICAL AUGMENTATION OF PROGESTERONE ACTION IN UTERINE FIBROID CELLS REQUIRES PROGESTERONE RECEPTOR B (PRB) AND IS ASSOCIATED WITH PRB PHOSPHORYLATION.** L. W. Chen
- 12:00 PM **THE ASSOCIATION BETWEEN FIBROIDS, OBESITY AND ADIPOSITY IN A LATINA/ LATINX POPULATION.** A. A. Bazzi
- 10:45 AM **FIBROID BURDEN DOES NOT AFFECT THE RISK PROFILE OF SAME-DAY DISCHARGE AFTER MINIMALLY INVASIVE MYOMECTOMY: A COMPARISON OF POST-OPERATIVE COMPLICATION RATES BY LENGTH OF STAY.** J. Applebaum
- 11:00 AM **INTERIM RESULTS OF A PHASE 3b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING 24-MONTH SAFETY OF ELAGOLIX WITH ADD-BACK FOR HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS.** Y. M. Poindexter
- 11:45 AM **TRANSCRIPTOME ANALYSIS REVEALS THAT VITAMIN D LOW-DOSE TARGETS EXTRACELLULAR MATRIX AND WNT/B-CATENIN PATHWAY IN A XENOGRAFT MOUSE MODEL HARBORING UTERINE FIBROIDS FROM AFRICAN AMERICAN PATIENTS.** A. Corachan

11:00 AM

**“MINING” VUS’S FOR PATHOGENICITY: CAN INTER-LAB CONFLICTS RENDER VARIANTS OF UNCERTAIN SIGNIFICANCE (VUS’S) PATHOGENIC AND THEREFORE, ACTIONABLE?** A. Peysner

12:00 PM

**BEYOND CHROMOSOMAL ABERRATIONS – TRANSCRIPTOMIC PROFILES OF ANEUPLOID, MOSAIC, AND EUPLOID EMBRYOS FROM TROPHECTODERM BIOPSY.** S. Madjunkova

10:45 AM

**RESCUED BY PARAFFIN: WHEN FRESH PRODUCTS OF CONCEPTION (POC) ANALYSIS DOES NOT PROVIDE A RESULT.** K. L. Howard

11:15 AM

**PROFILING THE MALE GERMLINE GENOME TO UNRAVEL ITS REPRODUCTIVE POTENTIAL.** S. Cheung

### OST-08 IMAGING AND REPRODUCTIVE MEDICINE

11:30 AM

**HYPERSPECTRAL IMAGING OF SINGLE SPERMATOZOA AS A PROMISING NON-DESTRUCTIVE OBJECTIVE TOOL FOR SPERM SELECTION PRIOR TO ICSI - DETERMINATION OF REPRODUCIBILITY, SENSITIVITY AND SPECIFICITY.** M. Gil Juliá

11:00 AM

**MONITORING WITH ULTRASOUND AND HUMAN CHORIONIC GONADOTROPIN TRIGGER VERSUS LUTEINIZING HORMONE SURGE TO TIME INTRAUTERINE INSEMINATION: A SYSTEMATIC REVIEW AND META-ANALYSIS.** N. Potapragada

11:15 AM

**THE INFLUENCE OF HORMONAL STIMULATION DURING IVF/ICSI TREATMENT ON UTERINE PERISTALSIS MEASURED BY ULTRASOUND SPECKLE TRACKING.** A. De Boer

11:45 AM

**SINGLE-SPERM MOTILITY ANALYSIS DURING ICSI USING AN ARTIFICIAL INTELLIGENCE SPERM IDENTIFICATION SOFTWARE (SID) AND CORRELATION WITH MORPHOLOGY.** A. Chavez-Badiola

10:45 AM

**UTERINE CONTRACTILE FUNCTION ACROSS THE MENSTRUAL CYCLE IN HEALTHY WOMEN: AN EXPLORATION OF REFERENCE VALUES USING THE WAVES METHOD.** C. O. Rees

### OST-07 GENETICS (NON-PGT)

- 11:30 AM **IDENTIFYING TYPES OF AZOOSPERMIA AND REPRODUCTIVE POTENTIAL BY SCREENING FOR GERMLINE MUTATIONS.** S. Cheung
- 11:45 AM **THE INFLUENCE OF MATERNAL AGE ON THE PREVALENCE OF FOUR DISTINCT MOSAIC RESULT CLASSIFICATIONS.** S. Rutzick





## ORAL ABSTRACTS

12:00 PM **MEASURING SEMINIFEROUS TUBULES DIAMETER USING HIGH FREQUENCY ULTRASOUND IN MURINE MODELS AND MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA AND OBSTRUCTIVE AZOOSPERMIA.** T. Kohn

### OST-09 IVF OUTCOME PREDICTORS 2

11:45 AM **THE EFFECTS OF PLATELET RICH PLASMA (PRP) AND GROWTH HORMONE (GWH) TREATMENTS ON TELOMERASE ACTIVITY AND TELOMERE LENGTH IN PATIENTS WITH DIMINISHED OVARIAN RESERVE.** D. Herkiloglu

10:45 AM **A THREE-DOSE GnRH AGONIST TRIGGERING PROTOCOL TO IMPROVE LIVE BIRTHS IN HYPER-RESPONDERS UNDERGOING FRESH EMBRYO TRANSFER AND INTENSIVE LUTEAL SUPPORT: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL.** J. T. Awwad

11:15 AM **OOCYTE MATURATION DEFECT IN WOMEN UNDERGOING IVF: CONTRIBUTING FACTORS AND EFFECTS ON MATURE SIBLING OOCYTE OUTCOMES.** M. Esbert

11:00 AM **THE ASSOCIATION BETWEEN OOCYTE AGE AND REPRODUCTIVE POTENTIAL IN DONOR OOCYTES BETWEEN 21 TO 32 YEARS.** P. A. Romanski

12:00 PM **ASSESSMENT OF PREGNANCY OUTCOMES IN DONOR OOCYTE THAW CYCLES COMPARING FRESH EMBRYO TRANSFER TO CRYOPRESERVED-THAWED EMBRYO TRANSFER: A SIBLING OOCYTE STUDY.** L. E. Barrison

11:30 AM **TIMING OF MONITORING VISITS PRIOR TO INITIATION OF PROGESTERONE SUPPLEMENTATION IN FROZEN EMBRYO TRANSFER CYCLES.** C. M. Canon

### OST-10 MALE REPRODUCTION AND UROLOGY 1

10:45 AM **TESTOSTERONE THERAPY IS ASSOCIATED WITH DEPRESSION, INTENTIONAL SELF-HARM AND SUICIDALITY: ANALYSIS OF A NATIONAL FEDERATED DATABASE.** S. Nackeeran

12:00 PM **PATIENT SATISFACTION AFTER SWITCHING TO ORAL TESTOSTERONE UNDECANOATE IN MEN CURRENTLY RECEIVING TESTOSTERONE THERAPY: AN OPEN-LABEL SINGLE-CENTER PHASE IV CLINICAL TRIAL.** A. Muthigi

11:45 AM **MACHINE-LEARNING ENABLED PREDICTION OF SUCCESSFUL SPERM RETRIEVAL FOR MICRODISSECTION TESTICULAR SPERM EXTRACTION.** D. R. Greenberg

11:15 AM **PREDICTORS OF A CLINICALLY SIGNIFICANT RESPONSE TO ANASTROZOLE THERAPY IN A MULTI-INSTITUTIONAL COHORT OF MEN WITH IDIOPATHIC INFERTILITY.** B. D. Naelitz

11:00 AM **RNA SEQUENCING IDENTIFIES HOXB9 AND E2F1 TRANSCRIPTIONAL DIFFERENCES IN IDENTICAL TWINS WITH DIFFERENT REPRODUCTIVE CAPACITIES.** K. Khodamoradi

11:30 AM **IDENTIFICATION AND TREATMENT OF COUPLES SUFFERING TOTAL FERTILISATION FAILURE (TFF): A CLINICAL SERVICE EVALUATION AND PROPOSED PHENOTYPIC SCREENING SOLUTION.** C. L. Nicholson

### OST-11 MENOPAUSE AND PRIMARY OVARIAN INSUFFICIENCY

11:30 AM **INFERTILITY AND INVOLUNTARY CHILDLESSNESS ARE ASSOCIATED WITH DEPRESSIVE AND ANXIETY SYMPTOMS IN MENOPAUSE: SWAN ANALYSES.** V. W. Fitz

11:00 AM **FOLLICLE STIMULATING HORMONE TRENDS IN PATIENTS WITH TURNER SYNDROME ARE ASSOCIATED WITH MORE THAN KARYOTYPE AND SPONTANEOUS MENARCHE STATUS: RACE MATTERS.** K. J. Bollig



## ORAL ABSTRACTS

12:00 PM **FOLLICLE STIMULATING HORMONE LEVEL AS A PREDICTOR OF SPONTANEOUS MENARCHE: A RETROSPECTIVE COHORT STUDY OF 133 PATIENTS WITH TURNER SYNDROME.** K. J. Bollig

11:15 AM **ETHNIC DISCORDANCE IN SERUM ANTI-MÜLLERIAN HORMONE IN EUROPEAN HEALTHY CONTROL, INDIAN HEALTHY CONTROL AND INDIAN INFERTILE WOMEN: A POPULATION STUDY FROM INDIA AND EUROPE.** S. M. Nelson

11:45 AM **CHRONIC ENDOMETRITIS IN LATE MENOPAUSE- INCIDENCE AND CLINICOPATHOLOGIC FEATURES.** J. Mahabamunuge

10:45 AM **TIME TO POSTMENOPAUSAL FOLLICLE STIMULATING HORMONE LEVELS AND KARYOTYPE: A LONGITUDINAL STUDY OF PATIENTS WITH TURNER SYNDROME.** K. J. Bollig

TUESDAY, OCTOBER 25, 2022

### OST-12 PRACTICE MANAGEMENT

10:45 AM **INTRAUTERINE INSEMINATION OUTCOMES BETWEEN REPRODUCTIVE ENDOCRINOLOGY & INFERTILITY (REI) FELLOWS AND WOMEN'S HEALTH NURSE PRACTITIONERS (NP).** S. Iyer

12:00 PM **TACKLING E-VISIBILITY OF EMBRYOLOGISTS ON FERTILITY CLINIC WEBSITES: A WEB-BASED CROSS-SECTIONAL ANALYSIS.** F. Choucair

11:00 AM **DON'T DIVIDE THE DOSE: ONCE DAILY (QD) AND TWICE DAILY (BID) EARLY CYCLE GONADOTROPIN (GND) DOSING HAVE EQUIVALENT ASSISTED REPRODUCTIVE TECHNOLOGY (ART) OUTCOMES- A QUALITY IMPROVEMENT (QI) PROJECT.** S. D. Cascante

11:30 AM **EMBRYOLOGIST BURNOUT: PHYSICAL AND PSYCHOLOGICAL SYMPTOMS AND OCCUPATIONAL CHALLENGES CURRENTLY REPORTED BY U.S. EMBRYOLOGISTS.** A. Murphy

11:45 AM **ASSESSING THE EFFECTIVENESS OF A PREGNANCY-SPECIFIC OBSTRUCTIVE SLEEP APNEA SCREENING TOOL IN NON-PREGNANT, REPRODUCTIVE-AGED WOMEN.** L. Bui

11:15 AM **THE ROLE OF ADVANCED PRACTICE PROVIDERS IN THE MODERN IVF PRACTICE, CAN THEY HELP FILL THE DEARTH OF NEW REPRODUCTIVE ENDOCRINOLOGISTS?** T. H. Taylor

### OST-13 PEDIATRIC OR ADOLESCENT

11:30 AM **THE RELATIONSHIP BETWEEN ESTROGEN AND SUBSEQUENT GROWTH RESTRICTION AMONG ADOLESCENTS WITH HEAVY MENSTRUAL BLEEDING.** J. M. Hoxie

12:00 PM **OOCYTE CRYOPRESERVATION WITH IN VITRO MATURATION, A FEASIBLE OPTION FOR FERTILITY PRESERVATION IN ADOLESCENTS WITH MOSAIC TURNER SYNDROME.** S. Gayete Lafuente

11:45 AM **FERTILITY AND REPRODUCTIVE HEALTH COUNSELING FOR ADOLESCENTS AND YOUNG ADULTS WITH SICKLE CELL DISEASE.** J. Reich

11:00 AM **MENTAL HEALTH AND BEHAVIOR IN ADOLESCENTS CONCEIVED AFTER ASSISTED REPRODUCTIVE TECHNOLOGIES (ART).** R. J. Hart

10:45 AM **LEAVING A LEGACY: ALLIED HEALTH PROFESSIONALS' PERCEPTIONS OF FERTILITY PRESERVATION AND POSTHUMOUS REPRODUCTION FOR ADOLESCENT AND YOUNG ADULTS WITH A POOR CANCER PROGNOSIS.** F. Barrett

11:15 AM **TOTAL TESTICULAR VOLUME AND TESTICULAR VOLUME DISCREPANCY IN THE ASSESSMENT OF MALE FERTILITY POTENTIAL IN ADOLESCENT VARICOCELE.** V. Madhusoodanan







## ORAL ABSTRACTS

### OST-14 PROFESSIONAL DEVELOPMENT AND WELLNESS

- |          |   |          |   |
|----------|---|----------|---|
|          |   | 11:30 AM | <b>HUMAN BLASTOCYSTS UPTAKE EXTRACELLULAR VESICLES SECRETED BY PRIMARY ENDOMETRIAL EPITHELIAL CELLS CONTAINING MIRNAS RELATED TO IMPLANTATION AND EARLY EMBRYO DEVELOPMENT.</b> M. Segura-Benítez |
| 11:15 AM | <b>ONE RESULT, MANY EYES: CREATING A RESULTS SAFETY NET IN A UNIVERSITY HOSPITAL-BASED REPRODUCTIVE ENDOCRINOLOGY &amp; INFERTILITY CLINIC.</b><br>B. Vessa |          |   |
|          |   | 12:00 PM | <b>DETERIORATION IN OOCYTE QUALITY WITH CHRONOLOGICAL AGING IS ASSOCIATED WITH TETRAHYDROBIOPTERIN AND ZINC DEFICIENCY IN THE OOCYTES.</b> P. T. Goud   |
| 11:45 AM | <b>SIMULATION IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI): CLOSING THE COUNSELING GAP.</b><br>J. Shaw   |          |   |
|          |   | 11:45 AM | <b>ANTI-CRISPR PROTEIN REGULATES CRISPR Cas9 ACTIVITY IN HUMAN EMBRYOS.</b><br>A. Robles  |
| 11:00 AM | <b>REPRODUCTIVE EXPERIENCES OF PHYSICIANS: WHAT ARE WE MISSING?</b><br>J. Reckhow   |          |   |
|          |   |          |   |
| 12:00 PM | <b>THE OBGYN RESIDENT EXPERIENCE IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY IN 2022: A SURVEY OF RESIDENCY PROGRAM DIRECTORS.</b><br>K. A. Doody         |          |   |
|          |   |          |   |
| 10:45 AM | <b>EXPOSURE TO REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) AMONG OBSTETRICS &amp; GYNECOLOGY RESIDENCY PROGRAMS.</b> R. Zeidman                        |          |   |
|          |   |          |   |
| 11:30 AM | <b>CURRENT STATE OF OBSTETRICS AND GYNECOLOGY RESIDENCY TRAINING EDUCATION IN TRANSGENDER HEALTHCARE: HOW CAN WE IMPROVE?</b><br>A. Lee                     |          |   |

### OST-15 REPRODUCTIVE BIOLOGY: HUMAN STUDIES

- |          |   |  |  |
|----------|---|--|--|
| 10:45 AM | <b>DETECTION OF EUPLOID PREGNANCY LOSS FINGERPRINT FROM SERUM VIA QUANTUM DEFECT-MODIFIED CARBON NANOTUBE ARRAYS.</b> P. Bortoletto |  |  |
|          |   |  |  |
| 11:15 AM | <b>LIVE-IMAGING OF HUMAN EMBRYOS REVEALS NUCLEAR DNA RELEASE.</b> R. Skory  |  |  |
|          |   |  |  |
| 11:00 AM | <b>REFINING CELLULAR IDENTITY IN THE HUMAN BLASTOCYST THROUGH SELECTIVE INNER CELL MASS AND TROPHECTODERM BIOPSY.</b> A. Korkidakis |  |  |





ORAL ABSTRACT SESSION 3

OSW-01 LATE-BREAKING ABSTRACTS

10:45 AM BISPHENOL F INDUCED REPRODUCTIVE TOXICITY BY DISRUPTING STEROIDOGENIC ENZYMES ACTIVITIES AND UPREGULATING XANTHINE OXIDASE/URIC ACID SIGNALING. A. Odetayo

11:00 AM THE UBIQUITOUS MITOCHONDRIAL PROTEIN UNFOLDASE CLPX IS REQUIRED FOR OOCYTE COMPETENCE AND EMBRYO DEVELOPMENT. R. Hua

11:15 AM TRACKING IMMATURE TESTICULAR TISSUE AFTER VITRIFICATION IN VITRO AND IN VIVO FOR PRE-PUBERTAL FERTILITY PRESERVATION: A TRANSLATIONAL TRANSGENIC MOUSE MODEL. B. Lu

11:30 AM MEIOTIC AND MITOTIC ANEUPLOIDIES DRIVE ARREST OF IN VITRO FERTILIZED HUMAN PREIMPLANTATION EMBRYOS. R. C. McCoy

11:45 AM THE SUCCESSFUL DEVELOPMENT AND CLINICAL VALIDATION OF STORK, A RAPID ANEUPLOIDY DETECTION METHOD USING NANOPORE SEQUENCING. Z. Williams

12:00 PM ENHANCED PHOSPHATASE REGENERATING LIVER-1 ACCELERATES VASCULAR REMODELING IN INJURED RAT OVARY VIA PLATELET-DERIVED GROWTH FACTOR SIGNALING PATHWAY. H. Park

OSW-02 ART LAB 2

11:15 AM CHARACTERIZATION OF EXTRACELLULAR VESICLES (EV) IN HUMAN FOLLICULAR FLUID AND EMBRYO CULTURE MEDIA: IMPACT ON ASSISTED REPRODUCTIVE TECHNOLOGY (ART) OUTCOMES. J. Shaw

11:00 AM CHANGE IN PROTOCOL AFTER IVF CYCLE CANCELLATION INCREASES ODDS OF LIVE BIRTH IN FRESH CYCLES: A SART CORS ANALYSIS OF 13,135 AUTOLOGOUS CYCLES. J. Kahn

11:45 AM

A NON-INVASIVE, 2-DIMENSIONAL (2D) IMAGE ANALYSIS ARTIFICIAL INTELLIGENCE (AI) TOOL SCORES MATURE OOCYTES AND CORRELATES WITH THE QUALITY OF SUBSEQUENT BLASTOCYST DEVELOPMENT. N. Mercuri

12:00 PM

INNER CELL MASS SURFACE AREA AUTOMATICALLY DETECTED USING CHLOE EQ™ (FAIRILITY), AN AI-BASED EMBRYOLOGY SUPPORT TOOL, IS ASSOCIATED WITH EMBRYO GRADING, EMBRYO RANKING, PLOIDY AND LIVE BIRTH OUTCOME. C. Hickman

10:45 AM

THE IMPACT OF FRESH VERSUS FROZEN-THAWED EMBRYOS ON MATERNAL SERUM ANALYTES IN IVF TWIN PREGNANCIES. A. Peyser

11:30 AM

COMPARISON OF SECONDARY SEX-RATIO BETWEEN BENCHTOP AND TIME-LAPSE INCUBATOR. DOES FROZEN/THAWED TRANSFER CYCLE HAVE A BETTER SEX-RATIO? L. Bori Arnal

OSW-03 ART TECHNIQUES

11:00 AM

EFFECT OF POST THAW TO EMBRYO TRANSFER CULTURE PERIOD ON EMBRYO METABOLISM AND PREGNANCY OUTCOME. G. Ardestani

12:00 PM

COVID-19 VACCINATION AND ASSISTED REPRODUCTION OUTCOMES: A LITERATURE REVIEW AND META-ANALYSIS. I. J. Chamani

11:45 AM

EMBRYOLOGISTS VERSUS ARTIFICIAL INTELLIGENCE: PREDICTING CLINICAL PREGNANCY OUT OF A TRANSFERRED EMBRYO. WHO PERFORMS IT BETTER? C. K. Jacobs

10:45 AM

SIGNIFICANT DIFFERENCES IN PERCEIVED UTILITY OF DIRECT-TO-CONSUMER FERTILITY TESTS AMONG PATIENTS AND REPRODUCTIVE ENDOCRINOLOGISTS. B. J. Peipert





## ORAL ABSTRACTS

11:30 AM **UTILIZATION OF INTRACITOPLASMIC SPERM INJECTION VERSUS CONVENTIONAL IVF IN NON-MALE INFERTILITY PATIENT POPULATION: AGE BASED ANALYSIS.** P. Sarkar

11:15 AM **SELECTION OF OPTIMAL GONADOTROPIN DOSE USING MACHINE LEARNING MAY BE ASSOCIATED WITH IMPROVED OUTCOMES AND REDUCED UTILIZATION OF FSH.** M. Fanton

### OSW-04 CRYOPRESERVATION

11:00 AM **VITRIFICATION WITH SLUSH NITROGEN DOES NOT IMPROVE REPRODUCTIVE POTENTIAL OF FROZEN EMBRYOS: A RANDOMIZED CONTROLLED TRIAL.** A. M. Klimczak

11:30 AM **EXPANSION GRADE OF POST THAW EMBRYOS AND IMPLANTATION POTENTIAL.** C. M. Canon

11:45 AM **DOES RACIAL DISPARITY EXIST IN PLANNED OOCYTE CRYOPRESERVATION CYCLES? A SART DATABASE ANALYSIS OF 15,806 CYCLES.** B. D. Yilmaz

10:45 AM **DOES TYPE OF TRIGGER INFLUENCE OOCYTE MATURITY IN PATIENTS UNDERGOING OOCYTE CRYOPRESERVATION, EMBRYO BANKING AND IN VITRO FERTILIZATION CYCLES USING LETROZOLE?** L. Ursillo

11:15 AM **REPRODUCTIVE OUTCOMES IN SINGLE EUPLOID EMBRYO TRANSFER CYCLES IS INDEPENDENT OF WHETHER THE EMBRYO ORIGINATED FROM A FRESH OR CRYOPRESERVED OOCYTE.** C. M. Canon

### OSW-05 HEALTH DISPARITIES

10:45 AM **NEIGHBORHOOD DEPRIVATION AND BLACK-WHITE DIFFERENCES IN IN VITRO FERTILIZATION OUTCOMES.** K. E. Andre

11:00 AM **TELEHEALTH CAN IMPROVE ACCESS TO FERTILITY CARE: SURVEY OF PATIENTS IN A LOW INCOME, COUNTY HOSPITAL INFERTILITY CLINIC.** R. Agarwal

11:45 AM **ASSOCIATION BETWEEN FERTILITY SERVICE UTILIZATION AND COUNTY-LEVEL MEDIAN HOUSEHOLD INCOME.** U. L. Franca

11:30 AM **THE ASSOCIATION OF MODIFIABLE RISK FACTORS WITH REPRODUCTIVE HORMONES IN WOMEN UTILIZING AT-HOME SAMPLE COLLECTION FOR LABORATORY TESTING.** K. M. Gavin

12:00 PM **RACIAL DISPARITY IN HEALTHCARE EXPERIENCE AMONG PATIENTS SEEKING FERTILITY CARE DURING THE COVID-19 PANDEMIC.** M. Mouanness

11:15 AM **RACIAL DISPARITIES IN PREIMPLANTATION GENETIC TESTING (PGT).** A. Peyser

### OSW-06 FERTILITY PRESERVATION

10:45 AM **DELAYING CHILDBEARING TO BECOME A DOCTOR: AN EXPLORATION OF MEDICAL STUDENT FAMILY PLANNING GOALS AND KNOWLEDGE OF FERTILITY PRESERVATION OPTIONS.** M. H. Vu

11:15 AM **A RESILIENT WOMB: MATERNAL AGE AT TRANSFER FOLLOWING AUTOLOGOUS OOCYTE (AO) CRYOPRESERVATION (CRYO) DOES NOT IMPACT ONGOING PREGNANCY + LIVE BIRTH RATES (LBRs).** F. Barrett

11:45 AM **FERTILITY PRESERVATION TECHNIQUES WITH OR WITHOUT OVARIAN STIMULATION DO NOT CHANGE DISEASE-FREE SURVIVAL OF YOUNG BREAST CANCER PATIENTS.** M. Grynberg

11:30 AM **TURNER FERTILITY STUDY: FERTILITY PRESERVATION IN YOUNG GIRLS WITH TURNER SYNDROME BY FREEZING OVARIAN CORTEX TISSUE.** S. Nadesapillai

11:00 AM **ATTITUDES TOWARDS FERTILITY PRESERVATION AND FAMILY PLANNING AMONGST ADULT AND PEDIATRIC TRANSGENDER PATIENTS PURSUING GENDER AFFIRMING HORMONE THERAPY.** S. Abhari





## ORAL ABSTRACTS

12:00 PM **OVARIAN RESPONSE AND ANTI-MULLERIAN HORMONE IN FERTILITY PRESERVATION VERSUS ELECTIVE OOCYTE CRYOPRESERVATION CYCLES: A SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY REGISTRY STUDY OF 10,040 CYCLES.** I. L. Lersten

### OSW-07 MALE REPRODUCTION AND UROLOGY 2

11:00 AM **PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY IMPROVES LIVE BIRTH RATE PER TRANSFER IN MALE FACTOR INFERTILITY.** J. Rushing

10:45 AM **TYPES AND RATES OF EMBRYONIC ANEUPLOIDY IN MEN WITH AZOOSPERMIA.** B. Morshedi

11:45 AM **INFLAMMASOME IS ASSOCIATED WITH IMPAIRED FERTILITY DUE TO SPINAL CORD INJURY.** K. Khodamoradi

11:30 AM **CLINICAL OUTCOMES OF MICRODISSECTION TESTICULAR SPERM EXTRACTION (MICRO TESE) AND INTRACYTOPLASMIC SPERM INJECTION (ICSI) IN NON-OBSTRUCTIVE AZOOSPERMIA (NOA) WITH THE HISTORY OF CRYPTORCHIDISM.** T. Ishikawa

12:00 PM **DISCOVERY OF AN EPIGENETIC BIOMARKER PREDICTIVE OF SPERM QUALITY.** K. Brogaard

11:15 AM **DEVELOPMENT OF A MACHINE LEARNING APPLICATION FOR INTRAOPERATIVE OBJECT DETECTION OF POSITIVE SEMINIFEROUS TUBULES IN MICRODISSECTION TESTICULAR SPERM EXTRACTION FOR NONOBSTRUCTIVE AZOOSPERMIA.** T. Takeshima

### OSW-08 MENTAL HEALTH

12:00 PM **PATIENT DECISION-MAKING PROCESS FOR DISPOSITION OF CRYOPRESERVED EMBRYOS.** K. M. Chacon

11:30 AM **THE LIVED EXPERIENCE OF RECURRENT PREGNANCY LOSS ASSESSED BY PHOTO-ELICITATION INTERVIEW.** R. K. Power

11:00 AM **EXPERIENCES AND INTENTIONS OF PATIENTS WHO UNDERWENT MEDICALLY INDICATED OOCYTE OR EMBRYO CRYOPRESERVATION: A QUALITATIVE STUDY.** M. J. Bayefsky

11:15 AM **PSYCHOLOGICAL STRESS AND INFERTILITY: WHAT DO WOMEN IN MEDICINE BELIEVE?** J. B. Bakkensen

10:45 AM **PSYCHOSOCIAL OUTCOMES OF CHILDREN BORN VIA EMBRYO DONATION.** S. M. Salari

11:45 AM **DOES WAITING TO HAVE A BABY CHANGE PARENTING EXPERIENCE? ELUCIDATING EXPERIENCES OF PATIENTS WHO USED FERTILITY TREATMENT IN THEIR 20s, 30s, AND 40s** J. T. Woodward

### OSW-09 PATIENT EDUCATION AND SUPPORT/NURSING

12:00 PM **PATIENT OPINION SURVEY ON POSITIVE AND NEGATIVE ASPECTS OF TELEMEDICINE.** M. Cullere

11:45 AM **OBSTETRIC OUTCOMES OF FERTILITY PATIENTS WITH PELVIC PAIN DISORDERS.** S. L. Estevez

11:15 AM **NUTRITIONAL EDUCATION (FACE-TO-FACE AND VIDEO INSTRUCTION) FOR POLYCYSTIC OVARY SYNDROME RESULTS IN GREATER REDUCTION IN BMI AND HEMOGLOBIN A1C THAN CALORIC RESTRICTION, EXERCISE AND METFORMIN.** B. Jackson

10:45 AM **THE INFLUENCE OF PATIENT EDUCATION LEVEL, PREGNANCY/BREASTFEEDING, AND INFERTILITY TREATMENT ON PERCEPTIONS OF THE COVID-19 VACCINE: A MIXED METHODS STUDY.** D. J. Eggert

11:00 AM **WHAT ARE THE PATIENTS' OPINIONS CONCERNING THE USE OF "ADD-ONS" ON REPRODUCTIVE MEDICINE? A SURVEY OF IVF PATIENTS** A. S. Setti

11:30 AM **THE EFFECT OF MEDIA AIDS IN GENETIC CARRIER SCREENING EDUCATION AMONG INFERTILITY PATIENTS.** M. R. Sax



## ORAL ABSTRACTS

### OSW-10 PREIMPLANTATION GENETIC TESTING 2

		12:00 PM	<b>EXPLORING THE ROLE OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) IN THE ANGIOGENESIS OF ENDOMETRIOSIS.</b> M. Chung
11:30 AM	<b>COMPARATIVE ANALYSIS WITH DIRECT MUTATION AND LINKAGE ANALYSIS REVEALS THAT KARYOMAPPING IS A HIGHLY ACCURATE METHOD OF PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISEASE (PGT-M).</b> O. Whiting	10:45 AM	<b>THREE-DIMENSIONAL (3D) BIOMIMETIC CULTURE ON POLY(EPSILON CAPROLACTONE) (PCL) PATTERNED SCAFFOLDS: A TISSUE ENGINEERING APPROACH TARGETING EARLY STAGE OF FOLLICULOGENESIS UP TO OOCYTE MATURATION.</b> C. Di Berardino
10:45 AM	<b>RHESUS (RH) AND KELL ANTIGEN INCOMPATIBILITY – INDICATIONS FOR PREIMPLANTATION GENETIC TESTING.</b> J. Adsit	11:45 AM	<b>DE NOVO GAMETES GENERATED IN A NOVEL THREE-DIMENSIONAL CULTURE SYSTEM TO CREATE EMBRYOS CAPABLE OF FULL PREIMPLANTATION DEVELOPMENT.</b> M. McKnight
11:45 AM	<b>NONSELECTION, PILOT STUDY TO ASSESS THE CLINICAL EFFICACY OF NONINVASIVE PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY.</b> G. S. Nakhuda	11:30 AM	<b>EVALUATION OF CRISPR/Cas9-INDUCED DNA BREAK REPAIR OUTCOMES IN MOUSE AND HUMAN EMBRYOS.</b> A. Boel
11:00 AM	<b>RNA-SEQ OF BLASTOCOEL FLUID-CONDITIONED MEDIA OBTAINED FROM EUPLOID EMBRYOS FROM ADVANCED MATERNAL AGE PATIENTS REVEALED INCREASED EXPRESSION OF SPECIFIC UBIQUITIN LIGASES AND ANTI-APOPTOTIC GENES.</b> E. Petyak		
			<b>OSW-12 REPRODUCTIVE ENDOCRINOLOGY</b>
12:00 PM	<b>UPDATE ON THE INTERNATIONAL REGISTRY OF MOSAIC EMBRYO TRANSFERS.</b> M. Viotti	11:30 AM	<b>THE EFFECT OF THE COVID-19 VACCINE AND COVID-19 INFECTION ON MENSTRUAL CYCLE LENGTH: AN ANALYSIS OF 10,922 PATIENTS.</b> E. Hariton
11:15 AM	<b>THE IMPORTANCE OF RETROSPECTIVE DATA ANALYSIS IN GENETIC COUNSELLING FOR PGT-SR – MATERNAL AGE IS MORE SIGNIFICANT THAN REARRANGEMENT TYPE.</b> C. A. Lynch	11:15 AM	<b>PHARMACOKINETIC (PK) STUDY OF ORAL LEUPROLIDE DELIVERY WITH OVAREST® ACHIEVES DRUG LEVELS EXCEEDING THOSE OF APPROVED INJECTABLE PRODUCTS.</b> G. A. Shangold
		12:00 PM	<b>NEUREGULIN 1 REGULATES CUMULUS-OOCYTE DIFFERENTIATION DURING IVM AND IMPROVES POST-IVF EMBRYO DEVELOPMENT.</b> J. Buratini
		11:45 AM	<b>RELATIONSHIP OF ANTITHYROID ANTIBODIES AND TSH TO INFERTILITY PHENOTYPES AND OUTCOMES.</b> A. M. Seungdamrong
<b>OSW-11 REPRODUCTIVE BIOLOGY: ANIMAL AND EXPERIMENTAL STUDIES</b>		11:00 AM	<b>ELEVATED ANTI-MÜLLERIAN HORMONE LEVELS ARE NOT ASSOCIATED WITH PRETERM DELIVERY AFTER IN VITRO FERTILIZATION OR OVULATION INDUCTION.</b> A. E. Kim
11:00 AM	<b>REPLICATION OF MAMMALIAN GAMETES OF BOTH SEXES IN A MOUSE MODEL.</b> P. Xie		
11:15 AM	<b>BASEMENT MEMBRANE HETEROGENEITY INFORMS AXIS DETERMINATION IN PREGASTULATING HUMAN EMBRYO.</b> D. Chen		



## ORAL ABSTRACTS

10:45 AM **EFFECTS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) ON MATERNAL SERUM ANALYTES IN AN INFERTILE PATIENT POPULATION.** D. Huang

### OSW-13 REPRODUCTIVE IMMUNOLOGY

10:45 AM **ENDOMETRIAL IMMUNE CELL RATIOS IN RECURRENT PREGNANCY LOSS (RPL) PATIENTS.** R. Ganeva

11:30 AM **DIFFERENCES IN MENSTRUAL CYTOKINE PROFILES OF WOMEN WITH AND WITHOUT UTERINE FIBROIDS.** Z. Dhanani

11:45 AM **DISTINCT CYTOKINE SECRETION PROFILES UPON IMMUNOMODULATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) WITH INTERFERON TAU (IFNT) AND HUMAN CHORIONIC GONADOTROPIN (HCG).** M. Ruseva

11:15 AM **EXOGENOUS LEPTIN TREATMENT ALTERS THE TESTICULAR IMMUNE MICROIMMUNE-ENVIRONMENT.** H. Arora

12:00 PM **ASSOCIATION BETWEEN CYTOKINE LEVELS IN BLOOD PLASMA AND PBMC CULTURE MEDIA.** R. Ganeva

11:00 AM **PREDICTION AND DIAGNOSIS OF REPRODUCTIVE FAILURES BASED ON NKp46 EXPRESSION IN ENDOMETRIAL OR DECIDUAL NK CELLS.** A. Fukui

### OSW-14 PREGNANCY LOSS

11:45 AM **THE ADENO STUDY: ADENOMYOSIS IN DUTCH WOMEN AND ITS EFFECT ON NEONATAL AND OBSTETRIC OUTCOMES: A RETROSPECTIVE POPULATION-BASED STUDY.** C. O. Rees

11:00 AM **APPLICATION OF A MULTIPLEX PLATFORM TO IDENTIFY NOVEL BIOMARKERS FOR PREGNANCY LOCATION AND VIABILITY.** I. T. Lee

12:00 PM **ALTERATIONS OF X-CHROMOSOME INACTIVATION (XCI) IN PREDISPOSITION TO RECURRENT PREGNANCY LOSS (RPL): A TRANSCRIPT LEVEL STUDY IN THE NORTHEAST INDIAN POPULATION.** N. Kashyap

11:15 AM **LEVERAGING ELECTRONIC HEALTH RECORD DATA TO IDENTIFY PHENOTYPES ASSOCIATED WITH PREGNANCY LOSS MAY LEAD TO IMPROVED UNDERSTANDING OF RECURRENT PREGNANCY LOSS.** J. Roger

11:30 AM **IN VITRO FERTILIZATION OUTCOMES AMONG WOMEN WITH RECURRENT PREGNANCY LOSS IN THE UNITED STATES.** D. B. McQueen

10:45 AM **VALIDATION OF BIOMARKERS FOR USE IN DIAGNOSIS OF ECTOPIC PREGNANCY: A CRITICAL STEP TOWARDS CLINICAL IMPLEMENTATION.** K. J. Bollig

### OSW-15 WEIGHT AS A FACTOR

11:45 AM **THE IMPACT OF OBESITY AND ADIPOSITY ON ANTI-MULLERIAN HORMONE (AMH) LEVELS IN A LATINA/LATINX POPULATION.** S. B. Schon

12:00 PM **OBESITY IS ASSOCIATED WITH INCREASED MISCARRIAGE RATES IN PAIRED SIBLING DONOR OOCYTE RECIPIENT CYCLES.** J. M. Kwal

11:15 AM **ON RACE, BMI THRESHOLDS, AND INFERTILITY TREATMENT - EXAMINING THE OUTCOMES OF PATIENTS WHO EXCEED BMI THRESHOLDS AT FIRST VISIT.** O. Kuyoro

11:00 AM **PREGNANCY OUTCOMES DO NOT DECLINE WITH INCREASING BODY MASS INDEX: AN ANALYSIS OF 56,564 SINGLE EUPLOID FROZEN EMBRYO TRANSFERS FROM THE SART CORS DATABASE.** J. B. Bakkensen

10:45 AM **RISK OF GESTATIONAL DIABETES MELLITUS (GDM) IN SINGLETON PREGNANCIES CONCEIVED AFTER INFERTILITY TREATMENT AND VARIATIONS BY RACE AND BMI: A POPULATION-BASED STUDY IN THE UNITED STATES.** D. Sachdev

11:30 AM **WEIGHT CHANGES IN GRAVIDAE CONCEIVING WITH ASSISTED REPRODUCTIVE TECHNOLOGIES (ART) IN MULTIPLE PREGNANCIES.** A. M. Sassin



Monday, October 24, 2022

### POSTER SESSION 1

#### PSM-01 E-POSTER ABSTRACT STATION: 1

- P-1 **CAN MORPHOKINETIC PARAMETERS REFLECT BLASTOCYST PLOIDY STATUS? – A PROSPECTIVE STUDY** M. Hozyen
- P-2 **AN ARTIFICIAL INTELLIGENCE MODEL CAN ANTICIPATE EMBRYO PLOIDY POTENTIAL, USING ITS SCORE AS PREDICTIVE VALUE.** D. J. Sánchez González
- P-3 **APPLICATION OF ARTIFICIAL INTELLIGENCE ON VITRIFIED/WARMED EMBRYOS: PREDICTION OF LIVE BIRTH FROM POST-WARMED BLASTOCYST DYNAMICS.** L. Bori Arnal
- P-4 **A NON-INVASIVE ARTIFICIAL INTELLIGENCE (AI) ALGORITHM CAN PREDICT COMPETENCE OF DENUDED OOCYTES FROM IMAGES TAKEN PRIOR TO INTRACYTOPLASMIC SPERM INJECTION (ICSI).** T. V. Nguyen
- P-5 **COMBINED USE OF ARTIFICIAL INTELLIGENCE (AI) ALGORITHMS FOR EVALUATING EMBRYO VIABILITY AND EMBRYO GENETICS IMPROVES SELECTION OF EMBRYOS LEADING TO CLINICAL PREGNANCY.** S. M. Diakiw
- P-6 **CHLOE EQ™ EFFECTIVELY AND AUTOMATICALLY PREDICTS EMBRYO IMPLANTATION ACROSS ALL PATIENT AGE GROUPS BY COMBINING MORPHOKINETIC AND MORPHOLOGY ALGORITHMS OVER CULTURE TIME.** C. Hickman
- P-7 **DEEP LEARNING ALGORITHMS USING EMBRYO MORPHOLOGY CAN MORE ACCURATELY PREDICT GESTATIONAL SAC (G-SAC) THAN FETAL HEARTBEAT POSSIBLY DUE TO NON-EMBRYO FACTORS.** H. Lee
- P-8 **PREDICTION OF LIVE BIRTH USING AN ARTIFICIAL INTELLIGENCE (AI) ALGORITHM DEVELOPED TO EVALUATE EMBRYO GENETIC STATUS FROM DAY 5 IMAGES.** J. M. Hall

- P-9 **ARTIFICIAL INTELLIGENCE CAN BE USED AS A GUIDE TO SELECT WHICH BLASTOCYSTS TO BIOPSY AND TEST FOR PGT-A.** F. Bahr
- P-10 **CAN CHLOE EQ™, AN AI-BASED EMBRYOLOGIST ASSISTANT TOOL, AUTOMATICALLY PREDICT WHETHER AN EMBRYO WILL BLASTULATE, BE UTILISED AND/OR IMPLANT?** A. Brualla Mora

#### PSM-02 E-POSTER ABSTRACT STATION: 2

- P-11 **CAN CHLOE (AN AI-BASED EMBRYOLOGIST ASSISTANT) AUTOMATICALLY PREDICT ON DAY 3 WHETHER AN EMBRYO WILL BECOME A BLASTOCYST, BE UTILISED AND/OR IMPLANT?** J. Teruel
- P-12 **TRANSPARENT PREDICTION OF BLASTULATION, PLOIDY AND IMPLANTATION: AN INTERNATIONAL MULTISITE VALIDATION AT SIX INDEPENDENT CLINICS.** C. Hickman
- P-13 **WHY SPEND TIME DOING MANUAL ANNOTATIONS WHEN CHLOE EQ™'S AUTOMATIC ANNOTATIONS ARE COMPARABLE TO THAT OF EXPERIENCED EMBRYOLOGISTS? A MULTI-CENTRE COMPARATIVE STUDY** A. Brualla Mora
- P-14 **IS INTELLIGENT DATA ANALYSIS-SCORE (IDA-SCORE) A USEFUL TOOL IN DAILY ROUTINE IVF LABORATORY PRACTICE TO SELECT EMBRYOS?** S. Sarandi
- P-15 **DOES ADMINISTRATION OF PREDNISOLONE TO ANTI-CENTROMERE ANTIBODY-POSITIVE PATIENTS IMPROVE OOCYTE MATURATION AND FERTILIZATION RATES AFTER OVUM PICKUP AND INTRACYTOPLASMIC SPERM INJECTION?** M. Shioya
- P-16 **DEEP LEARNING-ENABLED PREDICTION OF PREGNANCY BASED ON THE CHARACTERISTICS OF PATIENTS IN IVF-ET CYCLES.** S. Lee



## POSTER PRESENTATIONS AND ABSTRACTS

**P-17**     **ANTAGONIST OR PROTAGONIST: ASSESSING STIMULATION PROTOCOLS THROUGH THE LENS OF ARTIFICIAL INTELLIGENCE.** V. S. Jiang

**P-19**     **COMPREHENSIVE COMPARISON OF NUMBER OF EMBRYOLOGY HOURS PER CYCLE AND RISK BEFORE AND AFTER INTRODUCTION OF CHLOE EQ™ (FAIRILITY) INTO A 100% TIME-LAPSE IVF CLINIC.** C. Hickman

**P-20**     **A HIGH KIDSCORE EMBRYO THAT RESULTED IN MONOZYGOTIC DICHOIONIC DIAMNIOTIC PREGNANCY AFTER SINGLE EUPLOID EMBRYO TRANSFER.** R. Trinchant

**P-28**     **TRANSFERRING SINGLE THAWED CLEAVAGE STAGE EMBRYO AT BLASTOCYST STAGE IS AT LEAST SUCCESSFUL AS TRANSFERRING SINGLE THAWED BLASTOCYST IN TERMS OF ART CYCLE OUTCOME.** E. Colak

**P-29**     **DOES TIME OF BLASTOCYST CULTURE POST WARMING HAVE ANY IMPACT ON PREGNANCY OUTCOMES IN FROZEN THAWED CYCLES.** V. V. Mishra

**P-30**     **REPRODUCTIVE OUTCOMES OF POOR GRADE BLASTOCYSTS.** K. Mantravadi

### PSM-04 E-POSTER ABSTRACT STATION: 4

### PSM-03 E-POSTER ABSTRACT STATION: 3

**P-21**     **LIPID SUPPLEMENTATION IN WARMING MEDIA IMPROVES DEVELOPMENTAL POTENTIAL OF MOUSE OOCYTES AND ZYGOTES.** R. Kile

**P-22**     **IMPACT OF FRESH-EMBRYO PARAMETERS ON ONGOING PREGNANCY IN VITRIFIED/WARMED EUPLOID BLASTOCYST CYCLES.** A. Coello

**P-23**     **ADDITIONAL PROTEIN SUPPLEMENTATION IS NOT REQUIRED FOR SUPERIOR OUTCOMES OF POST WARMING CULTURE OF VITRIFIED BLASTOCYSTS.** W. Wang

**P-24**     **INNOVATIVE METHOD FOR VITRIFICATION IN LESS TIME.** L. Clark

**P-25**     **DEGREE OF BLASTOCYST EXPANSION PREDICTS SURVIVAL IN EUPLOID VITRIFIED/WARMED EMBRYOS.** A. Coello

**P-26**     **WHAT IS THE OPTIMAL ENDOMETRIAL PREPARATION PROTOCOLS IN EUPLOID FROZEN EMBRYO TRANSFER (FET)?** J. Lee

**P-27**     **DOES RE-VITRIFICATION OF BLASTOCYSTS AFTER A FIRST CYCLE OF VITRIFICATION OCCURRING AT EARLY CLEAVAGE VERSUS BLASTOCYST STAGE IMPACT IVF OUTCOMES?** F. Hammami

**P-31**     **THE CLINICAL IMPACT OF THE MORPHOLOGICAL PARAMETERS AFTER THAWING OF EUPLOID EMBRYOS IN FROZEN EMBRYO TRANSFER CYCLES.** G. Ozkara

**P-32**     **WORKING WITH FATIGUE: ASSESSMENT OF CYROMANAGEMENT CONDITIONS IN IVF BIOREPOSITORIES.** M. G. Collins

**P-33**     **IMPACT OF EQUILIBRATION DURATION ON THE OUTCOME OF OOCYTE VITRIFICATION/THAWING CYCLES: RESULTS OF AN OBSERVATIONAL PROSPECTIVE SIBLING-OOCYTE STUDY.** Y. Boumerdassi

**P-34**     **PROTECTIVE EFFECT OF L-PROLINE ON HUMAN SPERM CHARACTERISTICS DURING CRYOPRESERVATION.** M. Moradi

**P-35**     **PRELIMINARY DEVELOPMENT RESULTS OF A NEW VITRIFICATION DEVICE FOR OOCYTES AND EMBRYOS: VITRI CARRIER FROM ZURE®.** I. Anduaga Marchetti

**P-36**     **ANTIOXIDANTS IN THE EMBRYO CULTURE MEDIA. A SIBLING OOCYTE STUDY** O. Perez

**P-37**     **THE EFFECT OF DIFFERENT CULTURE VOLUME OF SIBLING HUMAN EMBRYOS ON CLINICAL OUTCOMES.** S. Seok



## POSTER PRESENTATIONS AND ABSTRACTS

**P-38**      **CHARACTERISTICS OF OILS USED FOR ASSISTED REPRODUCTIVE TECHNOLOGY PROCEDURES.** E. White

**P-39**      **PATIENCE IS A VIRTUE: THE CLINICAL VIABILITY OF EMBRYOS DERIVED FROM LATE MATURING OOCYTES.**  
C. Hernandez-Nieto

**P-40**      **ADHERING TO TIMELINE OF MORPHOLOGICAL EVALUATION IS A VITAL FACTOR INFLUENCING IMPLANTATION AND LIVE-BIRTH RATES FOLLOWING TRANSFER OF SINGLE TOP/AVERAGE/POOR QUALITY BLASTOCYST IN FRESH IVF CYCLES.** B. N. Chimote

**P-46**      **MEIOTIC ANEUPLOIDY AND PREIMPLANTATION EMBRYO ARREST FOLLOWING IN VITRO FERTILISATION (IVF).** T. Popa

**P-47**      **MOSAICISM INCIDENCE IS INDEPENDENT OF THE TYPE OF CULTURE MEDIUM – A COMPARISON BETWEEN CONTINUOUS CULTURE MEDIUM (CCM) AND SEQUENTIAL CULTURE MEDIUM (SCM).**  
L. Barbara

**P-48**      **ARTIFICIAL REMOVAL OF ZONA PELLUCIDA AT THE PRONUCLEAR STAGE (ZP-FREE CULTURE) DECREASES THE INCIDENCE OF ABERRANT DIVISION AT THE FIRST CLEAVAGE.** K. Yumoto

**P-49**      **ASSESSMENT OF THE OXIDATIVE STATUS OF SPENT GROUPED EMBRYO CULTURE MEDIA AS A POTENTIAL BIOMARKER OF QUALITY OF BLASTOCYST COHORTS IN ASSISTED REPRODUCTION TREATMENTS.**  
L. Bori Arnal

**P-50**      **HOW MANY EGGS DO I NEED? NUMBER OF OOCYTES REQUIRED TO CREATE ONE EUPLOID BLASTOCYST USING FRESH RETRIEVALS OR FROZEN OOCYTES**  
D. H. McCulloh

### PSM-05 E-POSTER ABSTRACT STATION: 5

**P-41**      **DIFFERENTIAL PROTEIN EXCHANGE BETWEEN SINGLE STEP CULTURE MEDIUM AND THE GROWING EMBRYO BETWEEN EUPLOID AND ANEUPLOID EMBRYOS.**  
M. Meseguer

**P-42**      **EXTERNAL VALIDATION STUDY OF THE ULTRAFAST BLASTOCYST WARMING TECHNIQUE –OPTIMIZING EFFICIENCY WITHOUT COMPROMISING OUTCOMES.**  
M. N. Naert

**P-43**      **SIMPLE AND LOW-COST FABRICATION OF WELL-OF-THE-WELL (WOW) DISHES WITH ARBITRARY SHAPES FOR EMBRYO CULTURE.** Y. Zhao

**P-44**      **DOES IVF SHORT STIMULATION PROTOCOL USING DYDROGESTERONE TO BLOCK THE LH SURGE PROMOTES SIMILAR RESULTS TO STANDARD GnRH ANTAGONIST PROTOCOL? CLINICAL AND LABORATORY EVALUATION.**  
M. S. Tanada

**P-45**      **THE EFFECTS OF L-CARNITINE AND CONDITIONED MEDIUM OF MESENCHYMAL STEM CELL SUPPLEMENTATION ON MATURATION, FERTILIZATION, AND EMBRYO QUALITY OF OOCYTES OBTAINED FROM ENDOMETRIOSIS MICE.** M. Moradi

### PSM-06 E-POSTER ABSTRACT STATION: 6

**P-51**      **POTENTIAL OF A DEEP CONVOLUTIONAL NEURAL NETWORK IN THE SELECTION OF HUMAN BLASTOCYSTS TO PREDICT CLINICAL PREGNANCY AND LIVE BIRTH.**  
T. Ebner

**P-52**      **CAN MITOCHONDRIAL DNA COPY NUMBER PREDICT THE OUTCOMES OF HUMAN EUPLOID EMBRYOS?** J. Ko

**P-53**      **ARE THE MORPHOKINETIC PARAMETERS OF EUPLOID EMBRYOS DIFFERENT FROM THAT OF ANEUPLOID EMBRYOS?** G. Ozer

**P-54**      **COMPARISON OF IMPLANTATION AND PLOIDY RATES OF DAY 5 AND DAY 6 BIOPSIED EMBRYOS.** T. L. Adams



## POSTER PRESENTATIONS AND ABSTRACTS

- P-55** DEVELOPMENTAL POTENTIAL OF OOCYTES THAT ARE IMMATURE (MI) AT THE TIME OF INTRACYTOPLASMIC SPERM INJECTION. T. Saydah
- P-56** A NEW MORPHOLOGICAL TIMING OF DIVISION IN HUMAN EMBRYOS BASED ON THE FORMATION AND QUALITY OF BLASTOCYST. T. Shin
- P-57** GOOD QUALITY SINGLE BLASTOCYST TRANSFER IMPARTS BETTER PREGNANCY OUTCOMES COMPARED TO TRANSFER OF EITHER TWO GOOD QUALITY OR ONE GOOD AND ONE POOR BLASTOCYST IN FRESH IVF CYCLES. N. M. Chimote
- P-58** A COMPARISON OF IVF EMBRYOLOGY OUTCOMES IN LUTEAL PHASE VERSUS FOLLICULAR PHASE CONTROLLED OVARIAN HYPERSTIMULATION CYCLES. F. Gao
- P-59** PERFECT MAY NOT BE THE BEST: AN ANALYSIS OF EMBRYO QUALITY ON PREGNANCY OUTCOMES IN ELECTIVE SINGLE EMBRYO TRANSFER. C. Dupont
- P-60** USE OF A MODIFIED SPECIFIC GRAVITY DEVICE TO DETERMINE VIABILITY AND QUALITY OF HUMAN CRYOPRESERVED EMBRYOS: A PILOT TRIAL. S. D. Prien
- P-65** QUANTIFICATION OF THE BENEFITS OF ASSISTED HATCHING (AH) ON SPONTANEOUS COLLAPSED BLASTOCYST (CB) WITH REDUCED IMPLANTATION POTENTIAL; A MULTIVARIABLE ANALYSIS. A. Tejera
- P-66** PREDICTION OF BLASTULATION, EMBRYO UTILISATION AND LIVE BIRTH FROM SINGLE MORPHOLOGICAL OR MORPHOKINETIC VARIABLES: ANALYSIS OF 31,323 EMBRYOS GIVES INSIGHTS FOR SELECTION AND ALGORITHM DEVELOPMENT. A. J. Campbell
- P-67** USE OF A MOBILE APP TO COMPARE THE CLASSIFICATION OF HUMAN BLASTOCYSTS IN 11 IVF LABORATORIES. S. E. Salter
- P-68** THE EFFECT OF DELAYED MATURATION IN OOCYTES AFTER RETRIEVAL ON EMBRYO POTENTIAL AND PLOIDY STATUS. J. L. Matucha
- P-69** INFLUENCE OF WOMEN'S AGE ON MEIOTIC SPINDLE POSITION AND THE EFFECT OF ICSI BASED ON MEIOTIC SPINDLE VISUALIZATION. H. Oh
- P-70** ROLE OF TRIM71 IN MOUSE OOCYTE MATURATION AND EMBRYO DEVELOPMENT IN VITRO. S. Yoon

### PSM-07 E-POSTER ABSTRACT STATION: 7

- P-61** BLASTOCYST WITH MORPHOKINETIC ABNORMALITIES CAN BE A VIABLE OPTION FOR EMBRYO TRANSFER. e. Ryu
- P-62** SUCCESS RATE OF CLEAVAGE STAGE VS. BLASTOCYST TRANSFERS IN POOR OVARIAN RESPONSE PATIENTS C. R. Alvarez Sedo
- P-63** HOW INCREASING PGT-A UTILIZATION AFFECTS IVF CYCLE OUTCOMES IN U.S. IVF CENTERS P. Patrizio
- P-64** A NOVEL BLASTOMERE MORPHOLOGY MARKER IN CLEAVAGE STAGE EMBRYOS STRONGLY PREDICTS BLASTOCYST DEVELOPMENT AND PREGNANCY OUTCOME. B. Ghoshdastidar

### PSM-08 E-POSTER ABSTRACT STATION: 8

- P-71** CLINICAL FACTORS ASSOCIATED WITH SUBOPTIMAL BLASTULATION RATE IN ICSI CYCLES: A PARAMETRIC MODELING APPROACH. E. Kalafat
- P-72** PREGNANCY OUTCOMES BY DEGREE OF EXPANSION IN THAWED HIGH QUALITY EMBRYOS. R. Rydze
- P-73** 2 PRONUCLEI (2PN) BANKING AS A METHOD TO OPTIMIZE COSTS FOR POOR PROGNOSIS PATIENTS DOING MULTIPLE CYCLES WITH PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) LEADS TO SIMILAR BLASTOCYST YIELD. L. R. Goodman



## POSTER PRESENTATIONS AND ABSTRACTS

- P-74** IMPACT OF ARTIFICIAL SHRINKAGE PRIOR TO FRESH BLASTOCYST TRANSFER: A PROSPECTIVE DOUBLE BLIND RANDOMIZED CONTROLLED TRIAL. A. GALA
- P-75** THE LEVEL OF EXPRESSION OF MESSENGER PLCZ IN SPERM MIGHT BE CORRELATED TO EMBRYONIC DEVELOPMENTAL COMPETENCE IN ART. J. Eum
- P-76** FOLLOW-UP OF BABIES BORN FROM ICSI OOCYTES THAT UNDERWENT ELECTROPORATION. H. KITASAKA
- P-77** DOES LOOKS MATTER? EFFECT OF ISOLATED TERATOZOOSPERMIA ON FERTILIZATION AND EMBRYO OUTCOME IN ICSI CYCLES. C. Chatterjee
- P-78** MICROFLUIDIC SPERM SORTING COMPARED WITH TRADITIONAL DENSITY GRADIENT CENTRIFUGATION: A COST ANALYSIS. C. Ogbejesi
- P-79** ICSI IS ASSOCIATED WITH LOWER BLASTULATION RATES COMPARED TO CONVENTIONAL IVF AMONG COUPLES WITH NON-MALE FACTOR INFERTILITY AND LOW OOCYTE YIELD. G. Beroukhim
- P-80** OVERCOMING FERTILIZATION FAILURE CAUSED BY A COMBINED OOCYTE- AND SPERM-RELATED OOCYTE ACTIVATION DEFICIENCY. P. Xie
- P-86** FERTILIZATION AFTER ARTIFICIAL OOCYTE ACTIVATION BY CALCIUM IONOPHORE IS MORE PRONOUNCED IN CASES OF SURGICALLY RETRIEVED SPERM. T. Takeuchi
- P-86** *IN VITRO* MATURATION OF OOCYTES: A BREAKTHROUGH FOR TREATING INFERTILITY IN INACTIVATING MUTATION OF THE LUTEINIZING HORMONE/ CHORIOGONADOTROPIN RECEPTOR. M. Grynberg
- P-87** NICOTINAMIDE MONONUCLEOTIDE (NMN) *IN VITRO* SUPPLEMENTATION IMPROVES DEFICIENCIES IN NUCLEAR AND CYTOPLASMIC COMPETENCE OF GERMINAL VESICLE OOCYTES. A. Galbete Urrutia
- P-88** GV RECUE FOR ALL? PRELIMINARY REPRODUCTIVE OUTCOME OF THE GV RESCUE APPROACH IN NON-PGT-A PATIENTS A. Galbete Urrutia
- P-89** NON-INVASIVE PREDICTION OF OOCYTE MATURATION TO METAPHASE II (MII) FROM GERMINAL VESICLE (GV) BY MITOCHONDRIAL FUNCTION MARKERS USING FLUORESCENCE LIFETIME IMAGING MICROSCOPY (FLIM). S. Pietroforte
- P-90** FROZEN EMBRYO TRANSFER CYCLES MAY IMPROVE PREGNANCY RATES. F. Li

### PSM-09 E-POSTER ABSTRACT STATION: 9

- P-81** THE EFFECT OF STANDART ICSI AND PICSI ON PGT-A RESULTS DURING IVF CYCLES. F. Gode
- P-82** DOES PHYSIOLOGICAL SELECTION OF SPERMATOZOA FOR ICSI (PICSI) IMPROVE IVF OUTCOMES ? I. Chabchoub
- P-84** A RETROSPECTIVE ANALYSIS OF CHYMOTRYPSIN USE FOR IVF SPERM PREPARATION AND ITS EFFECTS ON FERTILIZATION, BLASTULATON AND PLOIDY. D. L. Shelley
- P-85** EFFECT OF STRONTIUM CHLORIDE ON ICSI OUTCOME IN PATIENTS WITH POOR

### PSM-10 E-POSTER ABSTRACT STATION: 10

- P-91** SEX RATIO IS SIGNIFICANTLY ESCHEWED IN BLASTOCYST TRANSFERS AND CORRELATED TO BLASTOCYST GRADE. Y. Shu
- P-92** COMPARISON OF LABORATORY OUTCOMES FROM DIFFERENT SPERM SOURCES USING FRESH AND FROZEN DONOR EGGS IN A SINGLE HIGH VOLUME LABORATORY. H. Silz
- P-93** OPTIMAL INTERVENTION TO OBTAIN SPERMS WITH GOOD DNA QUALITY – ROLE OF MACS VS MICROFLUIDICS IN SPERM SORTING. K. Mantravadi

## POSTER PRESENTATIONS AND ABSTRACTS

- P-94** SPERM CONCENTRATION, SPERM MOTILITY AND TOTAL MOTILE SPERM COUNT ARE NOT AFFECTED BY CORONAVIRUS DISEASE 2019 (COVID-19) INFECTION. E. Gumusoglu
- P-95** MONOZYGOTIC TWINS AFTER IVF: CAN TIME-LAPSE TECHNOLOGY PREDICT MONOZYGOTIC TWIN PREGNANCY? C. Zarate Nissel
- P-96** ULTRAFAST WARMING PROTOCOL DEMONSTRATES SIMILAR OUTCOMES AND SIGNIFICANTLY DECREASES EMBRYOLOGY WORKLOAD COMPARED TO STANDARD WARMING PROTOCOLS, A RANDOMIZED CONTROL TRIAL WITH EUPLOID BLASTOCYSTS. T. H. Taylor
- P-97** EMBRYO-SPECIFIC CULTURE DISH REDUCES MEDIA EVAPORATION AND RESULTING OSMOLALITY INCREASE IN A DRY INCUBATOR. H. Rogers
- P-98** SPERM PARAMETERS AMONG SEMEN SAMPLES PROCESSED BY MICROFLUIDICS COMPARED TO DENSITY GRADIENT CENTRIFUGATION (DGC): A SECONDARY ANALYSIS OF A DOUBLE-BLINDED PROSPECTIVE RANDOMIZED TRIAL. P. N. Godiwala
- P-99** SPERM PROCESSING BY MACS DOES NOT IMPROVE REPRODUCTIVE OUTCOMES IN CYCLES USING VITRIFIED DONOR OOCYTES WHEN COMPARED TO STANDARD SEMEN PROCESSING. M. Gil Juliá
- P-100** EVALUATION OF OOCYTE FERTILIZATION AND IN VITRO EMBRYO DEVELOPMENT AFTER SPERM PREPARATION USING ZYMOT® PRIOR TO INTRACYTOPLASMIC SPERM INJECTION (ICSI) AND IN VITRO FERTILIZATION (IVF). S. Daneshmand
- P-101** IMPACT OF MICROFLUID SPERM SORTING ON EMBRYO PLOIDY RATES IN COUPLES WITH HIGH SPERM DNA FRAGMENTATION? M. Keskin
- P-102** DOUBLE HOMOLOGOUS IUI WITH COMBINATION OF TWO SPERM PREPARATION METHOD IMPROVES SUCCESS RATE IN IUI CYCLES. C. Budhi
- P-103** A SIMPLE *IN VITRO* INCUBATION OF A SPERM SAMPLE WITH MYO-INOSITOL CAN HELP PREDICT THE CLINICAL OUTCOMES OF AN ICSI CYCLE. P. Rubino
- P-104** NOVEL MICROSENSORS REVEALED THE IMPACT OF HIGH MATERNAL BODY WEIGHT AND ADVANCED MATERNAL AGING ON INDIVIDUAL HUMAN OOCYTE METABOLIC FUNCTION. E. A. Jannaman
- P-105** A NON-COMMERCIAL WITNESSING SYSTEM. A JOURNEY TO CREATE A BAR CODE SYSTEM FROM DISH LABELS TO MICROSCOPIC BAR CODES NEXT TO THE EMBRYO. O. Perez
- P-106** HOW MANY CLONES WILL BE OBTAIN FROM A SPERM? A. Galbete Urrutia
- P-107** URINARY E3G MONITORING WITH THE MIRA FERTILITY TRACKER DURING COH AS AN ALTERNATIVE TO SERUM E2. G. S. Nakhuda
- P-108** EARLY PREGNANCY OUTCOMES IN A HORMONE REPLACEMENT THERAPY AND NATURAL CYCLE FROZEN EMBRYO TRANSFER FOLLOWING IN-VITRO FERTILIZATION TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS. M. Raff
- P-109** IS THERE AN INFLUENCE OF RECIPIENT AGE IN OOCYTE DONATION CYCLES OUTCOMES AFTER CONSTANT OR INCREASING ESTROGEN DOSE FOR ENDOMETRIAL PREPARATION? G. M. Andrade
- P-110** STRONG AGREEMENT BETWEEN MANUAL AND ARTIFICIAL INTELLIGENCE (AI) SUPPORTS AUTOMATED ANNOTATIONS OF TIME-LAPSE CULTURED EMBRYOS AT A SINGLE FERTILITY CLINIC. H. Yelke

### PSM-11 E-POSTER ABSTRACT STATION: 11

- P-101** IMPACT OF MICROFLUID SPERM SORTING ON EMBRYO PLOIDY RATES IN COUPLES WITH HIGH SPERM DNA FRAGMENTATION? M. Keskin



### PSM-12 E-POSTER ABSTRACT STATION: 12

- P-111**     **ARTIFICIAL INTELLIGENCE FOR INTRAUTERINE INSEMINATION AND TIMED INTERCOURSE.** A. Hourvitz
- P-112**     **SEGMENTATION-BASED CLASSIFICATION OF HUMAN BLASTOCYST USING DEEP LEARNING.** E. Paya Bosch
- P-113**     **A LASER-FREE, NOVEL BIOPSY SYSTEM IMPROVES TISSUE SEPARATION AND CONTROL, AND ACCURACY OF PGT-A RESULTS.** S. Russell
- P-114**     **OUTCOMES FOLLOWING THAW, BIOPSY, AND REFREEZE CYCLES OF PREVIOUSLY UNTESTED VITRIFIED BLASTOCYSTS.** M. F. Neblett
- P-115**     **WHAT 400 REBIOPSIED EMBRYOS SHOW US: TECHNICAL AND CLINICAL OUTCOMES.** M. Meseguer
- P-116**     **MEDIA DROP NON-INVASIVE PGT-A AS AN ALTERNATIVE TO BLASTOCYST RE-BIOPSY.** K. Trowbridge
- P-117**     **BIOPSY TECHNIQUE, DAY OF EMBRYO BIOPSY AND BLASTOCYST STAGE ARE ASSOCIATED WITH THE RISK OF INCONCLUSIVE CHROMOSOMAL ASSESSMENT AFTER EMBRYO BIOPSY: ANALYSIS OF 18028 BIOPSIED BLASTOCYSTS.** A. Coello
- P-118**     **STANDARD INSEMINATION (SI) IN IVF PATIENTS WITHOUT MALE FACTOR INFERTILITY (MFI) MAY INCREASE THE EUPLOIDY RATE (ER) AMONG PREIMPLANTATION GENETICALLY TESTED BLASTOCYSTS FOR ANEUPLOIDIES (PGT-A).** A. Taggar
- P-119**     **CORRELATION OF MITOCHONDRIAL DNA QUANTITY AT THE BLASTOCYST STAGE WITH DIFFERENT PLOIDY STATUS.** T. Tao
- P-120**     **THE EFFECT OF THE DAY OF BLASTOCYST FORMATION ON ONGOING PREGNANCY RATES IN PATIENTS RANDOMIZED TO FRESH OR FREEZE-ALL.** L. A. Kaye

### PSM-13 E-POSTER ABSTRACT STATION: 13

- P-121**     **DOES POORLY EXPANDED THAWED EUPLOID EMBRYO AFFECTS GOOD EXPANDED EUPLOID EMBRYO IN TWIN EMBRYO TRANSFER?** S. Gamal
- P-122**     **IMPACT OF EMBRYO TRANSFER CATHETER LOADING TECHNIQUE ON CLINICAL OUTCOMES FOLLOWING SINGLE EUPLOID BLASTOCYST TRANSFER.** M. Abeyta
- P-123**     **ENDOMETRIAL RECEPTIVITY ANALYSIS CAN BE HELPFUL ESPECIALLY IN PATIENTS WITH HISTORY OF HIGH ORDER REPEATED IMPLANTATION FAILURE: REAL WORLD DATA OF SINGLE PRIMARY FERTILITY CENTER IN SOUTH KOREA.** C. Choo
- P-124**     **VERY HIGH SERUM PROGESTERONE LEVELS ON THE DAY OF EMBRYO TRANSFER DO NOT HAVE AN IMPACT ON OUTCOMES IN ARTIFICIALLY PREPARED FROZEN EMBRYO TRANSFER CYCLES.** C. Demirel
- P-125**     **ANTI-MÜLLERIAN HORMONE (AMH) CAN BE A PREDICTABLE PARAMETER OF CLINICAL OUTCOMES AFTER SINGLE VITRIFIED BLASTOCYST TRANSFER CYCLES (SVBT).** M. Baatarsuren
- P-126**     **REPRODUCTIVE OUTCOMES AFTER SWITCHING PHYSICIANS IN THE SETTING OF PRIOR FAILED EMBRYO TRANSFER.** S. Willson
- P-127**     **EFFECT OF AUTOLOGOUS PLATELET-RICH PLASMA TREATMENT ON REFRACTORY THIN ENDOMETRIUM DURING THE FROZEN-EMBRYO TRANSFER CYCLE: A SINGLE ARM SELF-CONTROLLED TRIAL IN 100 PATIENTS.** S. Shin
- P-128**     **IMPACT OF BEDREST VERSUS IMMEDIATE AMBULATION FOLLOWING TRANSFER OF A SINGLE EUPLOID BLASTOCYST.** H. Silz
- P-129**     **OVARIAN PLATELET-RICH PLASMA TREATMENTS MAY REINSTATE OVULATION IN PERIMENOPAUSAL WOMEN AND SIGNIFICANTLY DECREASES SERUM FSH.** Z. Strong

## POSTER PRESENTATIONS AND ABSTRACTS

**P-130** AFTER FAILING IN VITRO FERTILIZATION (IVF) WHAT IS THE SUCCESS RATE OF CONTROLLED OVARIAN STIMULATION (COH) AND INTRAUTERINE INSEMINATION (IUI)? A RETROSPECTIVE STUDY. F. Alorf

**P-140** INTRAUTERINE INFUSION OF G-CSF JUST BEFORE EMBRYO TRANSFER MAY IMPROVE THE EMBRYO IMPLANTATION RATE FOLLOWING IVF/ICSI IN PATIENTS WITH RECURRENT IMPLANTATION FAILURE. C. Kim

### PSM-14 E-POSTER ABSTRACT STATION: 14

**P-131** EFFECT OF DELAYED CHANNEL DISSOLUTION IN OOCYTES AFTER ICSI ON FERTILIZATION AND EMBRYO DEVELOPMENT. C. Chatterjee

**P-132** COMPARISON OF LIVE BIRTH RATES (LBRS) BETWEEN GONADOTROPIN RELEASING HORMONE(GnRH)-ANTAGONIST, GnRH-AGONIST, AND PROGESTINE PRIMED OVARIAN STIMULATION (PPOS) PROTOCOLS IN POSEIDON GROUP-1 PATIENTS. R. Tez

**P-133** ENDOMETRIAL SAMPLING IN IVF/ICSI: AN INDIVIDUAL PARTICIPANT DATA BASED REVIEW. N. E. Van Hoogenhuijze

**P-134** SINGLE DOSE TRIPTORELIN 0.1 MG AS A LUTEAL PHASE SUPPORT IN ANTAGONIST INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLES. S. M. Badran

**P-135** MONOZYGOTIC TWINS IN HUMAN ASSISTED REPRODUCTION: A CONSEQUENCE OF ZONA PELLUCIDA MANIPULATIONS. W. Wang

**P-136** INTRACYTOPLASMIC SPERM INJECTION (ICSI) DOES NOT IMPROVE OUTCOMES IN NON-MALE FACTOR PATIENTS. D. R. Bossa

**P-137** EFFECTIVE UNIVERSAL WARMING-DILUTION OF BLASTOCYSTS VITRIFIED ON AN OPEN DEVICE SYSTEM. M. C. Schiewe

**P-138** ASSISTED HATCHING OF EARLY BLASTOCYTES IMPROVES PREGNANCY OUTCOMES IN FRESH EMBRYO TRANSFERS. S. Zhang

**P-139** SINGLE STEP VERSUS SEQUENTIAL CULTURE MEDIUM: WHICH IS BETTER FOR OLDER PATIENTS TO IMPROVE BLASTOCYST QUALITY AND EUPLOIDY RATE? A PROSPECTIVE STUDY M. Hozyen

### PSM-15 E-POSTER ABSTRACT STATION: 15

**P-141** TRANS MYOMETRIAL INJECTION OF AUTOLOGOUS MESENCHYMAL STEM CELLS IMPROVES ENDOMETRIAL QUALITY AND ART RESULTS IN PATIENTS WITH REFRACTORY ENDOMETRIUM OR ASHERMAN'S SYNDROME. D. Hernandez-Melchor

**P-142** AUTOLOGOUS PLATELET-RICH PLASMA TREATMENT IMPROVES EMBRYO IMPLANTATION AND CLINICAL PREGNANCY RATES IN WOMEN UNDERGOING ASSISTED REPRODUCTION: A PILOT STUDY AND SYSTEMATIC REVIEW. D. Hernandez-Melchor

**P-143** SUBENDOMETRIAL AUTOLOGOUS PLATELET RICH PLASMA INJECTION IN PATIENTS WITH UNRESPONSIVE THIN ENDOMETRIUM UNDERGOING FROZEN-THAWED EMBRYO TRANSFER. Y. Cakiroglu

**P-144** CLUSTER ANALYSIS: RATES OF FAVORABLE AND UNFAVORABLE VAGINAL BLEEDING PATTERNS WITH ONGOING DROSPIRENONE 4mg EXPOSURE BASED ON EARLY BLEEDING PATTERN. M. L. Gilbert

**P-145** PROJECT CARING—COMMUNICATING ABOUT REPRODUCTION AND INHERITED GENES: OUTCOMES OF A PILOT INTERVENTION FOR COUPLES WITH INHERITED CANCER RISK. G. P. Quinn

**P-146** PLANNING FOR THE LONG HAUL: CHILDBEARING INTENTIONS AND FERTILITY CONCERNS AMONG MEDICAL AND NON-MEDICAL GRADUATE STUDENTS. E. Hogenesch

**P-147** LOW ANTIMÜLLERIAN HORMONE LEVEL IS NOT ASSOCIATED WITH ANEUPLOIDY IN MISCARRIAGES FROM PREGNANCIES CONCEIVED WITH ASSISTED REPRODUCTIVE TECHNOLOGY. J. Lin



## POSTER PRESENTATIONS AND ABSTRACTS

**P-148** THE IMPACT OF FRESH VERSUS FROZEN-THAWED EMBRYOS ON MATERNAL SERUM ANALYTES IN IVF SINGLETON PREGNANCIES. A. Peyser

**P-149** DOES THE TROPHECTODERM BIOPSY FOR PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) IMPACT EARLY EMBRYO DEVELOPMENT: AN ASSESSMENT OF EARLY PREGNANCY TRANSVAGINAL ULTRASOUND (TVUS) MEASUREMENTS. M. Pollie

**P-150** YOUNGER WOMEN WITH DIMINISHED OOCYTE RESERVE (DOR) ARE NOT MORE PRONE TO DELIVER BABIES WITH ANEUPLOIDY AS EVIDENCED BY NON-INVASIVE PRENATAL TESTING. N. Weitz

**P-157** METHOTREXATE FOR TREATMENT OF ECTOPIC PREGNANCIES: PRACTICE PATTERNS ACROSS ACADEMIC REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY (REI) PROGRAMS. M. Dellalana

**P-158** FACTORS ASSOCIATED WITH PREGNANCY LOSS AFTER SINGLE EUPLOID EMBRYO TRANSFER. C. M. Canon

**P-159** VANISHING TWIN SYNDROME RESULTS IN HIGHER RISK OF MISCARRIAGE EVEN FOLLOWING EUPLOID EMBRYO TRANSFER. T. Patrick

**P-160** THE EFFECT OF SERUM PROGESTERONE LEVEL WITH AND WITHOUT EMPIRICAL PROGESTERONE TREATMENT ON PREGNANCY OUTCOME IN WOMEN WITH UNEXPLAINED RPL. E. Peero

### PSM-16 E-POSTER ABSTRACT STATION: 16

**P-151** DOES THE OPTIMAL HCG LEVEL FOR DISCRIMINATING NORMAL FROM ABNORMAL IN VITRO FERTILIZATION (IVF) PREGNANCIES DIFFER BETWEEN FRESH AND FROZEN-THAWED EMBRYO TRANSFERS? A SYSTEMATIC REVIEW. S. Galperin

**P-152** IMPLANTATION TIMING AFTER EMBRYO TRANSFER IS DIFFERENT FROM EMBRYO CHARACTERISTICS. N. Enatsu

**P-153** KISSPEPTIN (KISS1) AND KISSPEPTIN RECEPTOR (KISS1R) IMMUNOREACTIVITY IN CHORIO-DECIDUAL TISSUES OF EUPLOID AND ANEUPLOID RECURRENT PREGNANCY LOSSES (RPLS). A. O. Abdelkareem

**P-154** ACTIVE MANAGEMENT OF PERSISTENT PREGNANCIES OF UNKNOWN LOCATION RESULTS IN A SHORTER TIME TO RESUME FERTILITY TREATMENT. M. R. Determan

**P-155** CHRONIC ENDOMETRITIS: WHO SHOULD WE SCREEN, HOW SHOULD WE TREAT, AND WHAT ARE OUTCOMES AFTER TREATMENT? E. Hogenesch

**P-156** ASSOCIATION BETWEEN THE ABSENCE OF CORPUS LUTEUM AND THE RISK OF PLACENTAL INSUFFICIENCY IN PREGNANT WOMEN AFTER ASSISTED REPRODUCTION PROCEDURES. C. R. Alvarez Sedo

### PSM-17 E-POSTER ABSTRACT STATION: 17

**P-161** INCIDENCE OF PREGNANCY LOSS IN WOMEN UNDERGOING INFERTILITY TREATMENT. A. S. Kim

**P-162** ULTRASOUND ASSESSMENT OF ENDOMETRIAL ABNORMALITIES DURING ENDOMETRIAL MATURATION FOR FROZEN EMBRYO TRANSFER (FET). K. Schwartz

**P-163** ALTERATIONS IN THE SERUM REACTIVE OXYGEN SPECIES (ROS) - ANTIOXIDANT BALANCE AS A CAUSE FOR RECURRENT PREGNANCY LOSS (RPL) PATHOGENESIS: A PILOT STUDY IN THE NORTHEAST INDIAN POPULATION OF ASSAM. P. D. Bose

**P-164** COMPARATIVE ASSESSMENT OF CYTOGENETIC AND MOLECULAR APPROACHES FOR PRODUCT OF CONCEPTION: A RETROSPECTIVE STUDY OF 726 CASES. N. N. Gonçalves

**P-165** THE ECONOMIC BURDEN OF RECEIVING RECURRENT MISCARRIAGE CARE IN IRELAND: THE PATIENT'S PERSPECTIVE. K. Odonoghue

**P-166** T REGULATORY, Th17, AND TREG/Th17 RATIO, IN PREGNANT WOMEN WITH RECURRENT PREGNANCY LOSSES AND NORMAL PREGNANT WOMEN. T. V. Luu





## POSTER PRESENTATIONS AND ABSTRACTS

- P-167** AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE (ASRM) MULLERIAN ANOMALIES CLASSIFICATION 2021 (MAC 2021): PREVALENCE IN A RECURRENT PREGNANCY LOSS (RPL) POPULATION. E. C. Yang
- P-168** A NATIONAL SURVEY OF WOMEN AND MEN'S EXPERIENCES OF RECURRENT MISCARRIAGE CARE. K. Odonoghue
- P-169** GESTATIONAL SAC DIAMETER IN EARLY PREGNANCY PREDICTS BIRTHWEIGHT AND PREMATURITY. B. S. Shapiro
- P-170** ASSESSING THE COSTS ASSOCIATED WITH THE IMPLEMENTATION OF A BEST PRACTICE MODEL OF CARE FOR RECURRENT MISCARRIAGE CLINICS IN THE REPUBLIC OF IRELAND. K. Odonoghue

- P-177** INFORMATION WANTED: REI FELLOWSHIP WEBSITES DO NOT DELIVER. E. Allard-Phillips
- P-178** ANALYSIS OF REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY FELLOWS: CHARACTERISTICS FOR CURRENT TRAINEES TO CONSIDER. Z. Anderson
- P-179** DO GENDER DIFFERENCES EXIST IN LETTERS OF RECOMMENDATION FOR REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY FELLOWSHIP? K. M. Bolten
- P-180** THE IMPACT OF COVID-19 ON BURNOUT IN HEALTHCARE WORKERS: A CROSS-SECTIONAL SURVEY. J. Amir

### PSM-19 E-POSTER ABSTRACT STATION: 19

### PSM-18 E-POSTER ABSTRACT STATION: 18

- P-171** ASSOCIATION OF MIR -149 T>C AND MIR-27aA>G GENE POLYMORPHISMS WITH RECURRENT PREGNANCY LOSS RISK IN GREEK POPULATION. P. Drakakis
- P-172** FUTURE PREGNANCY OUTCOMES AFTER RECURRENT FIRST-TRIMESTER MISCARRIAGE. K. Odonoghue
- P-173** ANRIL (ANTISENSE NON-CODING RNA IN THE INK4 LOCUS) GENE POLYMORPHISM rs4977574 IN WOMEN WITH RECURRENT PREGNANCY LOSS (RPL). P. Cherouveim
- P-174** VIRTUAL TRAINING IN SYSTEMATIC REVIEW AND META-ANALYSIS IN BIOMEDICAL RESEARCH: RESULTS OF SELF-EVALUATION BY RESEARCHERS. R. Cannarella
- P-175** GENDER DISPARITY IN LEADERSHIP ROLES: HOW DOES OBSTETRICS & GYNECOLOGY COMPARE TO OTHER SPECIALITIES? O. Vukceвич
- P-176** CHALLENGES AND POTENTIAL PRACTICE GAPS FACED BY HEALTHCARE PROFESSIONALS INVESTIGATING MALE INFERTILITY: A PATIENT-INFORMED EDUCATIONAL STUDY IN EIGHT COUNTRIES. M. S. Kupka

- P-181** TO CANCEL OR NOT TO CANCEL: LIVE BIRTH RATES (LBRs) IN IN VITRO FERTILIZATION (IVF) CYCLES WITH FIVE OR FEWER FOLLICLES. M. J. Bayefsky
- P-182** KNOWLEDGE ON THE RELATIONSHIP BETWEEN HIGHLY PREVALENT SEXUALLY TRANSMITTED INFECTIONS & INFERTILITY AMONG THE DOWNTOWN DETROIT AFRICAN AMERICAN POPULATION. D. C. Gonullu
- P-183** GOOGLE SEARCH QUERIES OF DIFFERENCES BETWEEN COVID-19 VACCINE RELATED MALE AND FEMALE INFERTILITY. N. Dhillon
- P-184** KNOWLEDGE AND ATTITUDES TOWARDS OOCYTE CRYOPRESERVATION AND PROCREATIVE MANAGEMENT AMONG OBSTETRICIAN GYNECOLOGISTS. C. E. Martin
- P-185** IMPROVING RESIDENT EDUCATION IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY. J. Rushing
- P-186** RISK FACTORS FOR INCIDENT POLYCYSTIC OVARY SYNDROME (PCOS) DIAGNOSIS. J. Christ



## POSTER PRESENTATIONS AND ABSTRACTS

- P-187** LONGITUDINAL FOLLOW UP OF PATIENTS DIAGNOSED WITH COVID-19 DEMONSTRATES NO DECREASE IN OVARIAN RESERVE AS DEMONSTRATED BY SERUM ANTI-MÜLLERIAN HORMONE (AMH) AT 3 AND 6 MONTHS: A PILOT STUDY. K. D. Coyne
- P-188** USE OF ELECTROCHEMILUMINESCENCE METHODS TO EVALUATE THE RELATIONSHIP BETWEEN OVARIAN RESPONSE AND ANTI-MULLERIAN HORMONE (AMH) LEVELS WHEN THEY ARE LOWER THAN 1 NG/ML. K. Genesis Ceratto
- P-189** PREVALENCE OF DIGENIC DISEASE IN PATIENTS DIAGNOSED WITH IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM/KALLMANN SYNDROME. A. Poch
- P-190** THE CLINICAL CORRELATION BETWEEN POLYCYSTIC OVARY SYNDROME (PCOS) AND PITUITARY ADENOMA. S. KIM

### PSM-20 E-POSTER ABSTRACT STATION: 20

- P-191** PREVALENCE OF CARDIOVASCULAR DISEASE AMONG WOMEN WITH A CLINICIAN DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME IN A DIGITAL LONGITUDINAL COHORT. S. Mahalingaiah
- P-192** UTILITY OF INSULIN CURVE CHALLENGE TESTING IN INITIAL WORKUP OF PCOS. L. Gray
- P-193** ART OUTCOMES IN LEAN COMPARED TO OBESE PHENOTYPES OF POLYCYSTIC OVARIAN SYNDROME. Y. Fouks
- P-194** CANCER INCIDENCE AMONG PCOS PARTICIPANTS IN THE CARDIA COHORT. A. Wang
- P-195** TRANSGENERATIONAL EFFECTS OF PRENATAL ANDROGEN EXPOSURE IN A LEAN POLYCYSTIC OVARY SYNDROME MOUSE MODEL. J. Bruno-Gaston
- P-196** PREVALENCE, INCIDENCE AND TRENDS IN POLYCYSTIC OVARY SYNDROME (PCOS) DIAGNOSIS. S. D. Reed

- P-197** UTILITY OF INSULIN CURVE CHALLENGE TESTING AND TESTOSTERONE AS INITIAL LABWORK FOR PCOS WORK UP. L. Gray
- P-198** THE EFFECT OF CLOMIPHENE, METFORMIN, OR BOTH ON ANTI-MÜLLERIAN HORMONE (AMH) LEVELS: A NEW LOOK AT THE PREGNANCY IN POLYCYSTIC OVARIAN SYNDROME TRIAL (PPCOS I). L. Hughes

### PSM-21 E-POSTER ABSTRACT STATION: 21

- P-201** THE ROLE OF CIRCULATING MIRNAS IN MECHANISM OF ACTION AND PREDICTION FOR THE THERAPEUTIC RESPONSES OF METFORMIN IN POLYCYSTIC OVARIAN SYNDROME. C. Huang
- P-203** IMPACT OF TSH LEVELS ON IN VITRO FERTILIZATION OUTCOMES IN EUTHYROID INFERTILE WOMEN. B. Bianco
- P-204** ASSESSING THE UTILITY OF SIMULTANEOUS CO-TESTING APPROACH WITH THYROID STIMULATING HORMONE (TSH) AND THYROID PEROXIDASE (TPO) ANTIBODY TESTING IN INFERTILE WOMEN. A. Bader
- P-205** REMOTE MONITORING OF CYCLE TRENDS IN PATIENTS OF ADVANCED MATERNAL AGE - AN OPPORTUNITY TO STREAMLINE ACCESS TO IVF. A. Divaraniya
- P-206** FERTILITY BENEFITS FOR RESIDENTS: PUBLICLY AVAILABLE INFORMATION AT THE TOP 50 US MEDICAL SCHOOLS. M. A. Rasouli
- P-207** WEIGHT LOSS TO MEET BMI THRESHOLDS – IS THIS REQUIREMENT WORSENING RACIAL AND ETHNIC DISPARITIES IN ASSISTED REPRODUCTIVE TECHNOLOGY ACCESS? O. Kuyoro
- P-208** CUMULATIVE PREGNANCY RATES ARE HIGHER IN ENGLISH SPEAKERS UNDERGOING IUI COMPARED TO NON-ENGLISH SPEAKERS: A RETROSPECTIVE COHORT STUDY. M. Jain



## POSTER PRESENTATIONS AND ABSTRACTS

**P-209** THE LIVED EXPERIENCE OF INFERTILITY IN ASIAN AMERICANS: A QUALITATIVE STUDY. M. H. Vu

**P-210** IS AN AGING ENDOMETRIUM MORE LIKELY TO SHOW AN ADVERSE INFERTILITY FACTOR, I.E., A TRIPLE-LINE (TL) ENDOMETRIAL ECHO PATTERN IN MID-LUTEAL PHASE, WHEN TRANSFERRING FROZEN-THAWED EMBRYOS? J. H. Check

### PSM-22 E-POSTER ABSTRACT STATION: 22

**P-211** PAIN, SATISFACTION, AND SPOTTING: COMPARING OF DAILY INTRAMUSCULAR (IM) PROGESTERONE AND VAGINAL PLUS INTERMITTENT IM PROGESTERONE (VIM) FOR FROZEN EMBRYO TRANSFER (FET). J. Chen

**P-212** THE EFFECT OF LOW AMH AS A PREDICTOR OF EARLY PREGNANCY LOSS IN IVF / ICSI CONCEPTIONS— A RETROSPECTIVE OBSERVATIONAL STUDY. D. G. Rao

**P-213** ENDOMETRIAL MICROBIOTA AND CHRONIC ENDOMETRITIS PROFILES FOLLOWED BY INTRAVAGINAL PROBIOTIC SUPPLEMENTATION AND/ OR ANTIBIOTIC ADMINISTRATION AND REPRODUCTIVE OUTCOMES IN 429 IVF CYCLES. M. B. Chehin

**P-214** THE ASSOCIATION BETWEEN SERUM THYROID HORMONE, VITAMIN D, VITAMIN B12, FOLATE, FERRITIN, AND ZINC LEVELS AND FEMALE INFERTILITY. A COMPASSION WITH HEALTHY PREGNANT SUBJECTS M. Sonmezer

**P-215** SCHISTOSOMIASIS INDUCED ASHERMAN'S SYNDROME IN A PATIENT UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGY (ART): A CASE REPORT AND LITERATURE REVIEW. V. A. Go

**P-216** IMPACT OF COVID-19 VACCINATION ON ART OUTCOME. H. Arora

**P-217** THE RATIO BETWEEN THE LENGTH OF THE SECOND AND FOURTH DIGIT (2D:4D RATIO) AS A BIOMARKER OF OVARIAN RESERVE IN INFERTILE PATIENTS. J. Peñarrubia

**P-218** RACIAL DIFFERENCES IN ENDOMETRIOSIS – A REFLECTION OF WHO PROCEEDS WITH SURGERY FOR PELVIC PAIN? A. G. Naik

**P-219** EXTRACELLULAR VESICLES SECRETED BY ENDOMETRIAL ORGANOIDS FROM ADENOMYOSIS PATIENTS CONTAIN MIRNAS IMPLICATED IN DISEASE DEVELOPMENT, EMBRYO IMPLANTATION FAILURE AND PREGNANCY DISORDERS. E. Juárez-Barber

**P-220** RACIAL DISPARITIES IN PRESENTATION TO INFERTILITY CONSULTATIONS AND TELEHEALTH USE DURING THE COVID-19 PANDEMIC. K. D. Coyne



Tuesday, October 25, 2022

### POSTER SESSION 2

#### PLR PRIZE POSTER LIGHTNING ROUND

- P-661** DELAYED INTRACYTOPLASMIC SPERM INJECTION(ICSI) EFFECT IN METHAPHASE II(MII) OOCYTES WITH NO SPINDLE VISUALIZATION. G. Kim
- P-662** RISK PROFILE OF MULTIFETAL IN VITRO FERTILIZATION (IVF) PREGNANCIES VS SPONTANEOUS MULTIFETAL PREGNANCIES, A STUDY OF A LARGE AMERICAN POPULATION DATABASE INCLUDING ALMOST 100,000 MULTIPLE GESTATIONS. S. Mandourah
- P-663** A NEW ENDOMETRIAL TRANSCRIPTOMIC STRATIFICATION IN THE MID-SECRETORY PHASE REVEALS A NEW TAXONOMY FOR ENDOMETRIAL PROGNOSIS IN INFERTILITY. P. Diaz Gimeno
- P-664** IS IT SAFE TO PERFORM OVARIAN CRYOPRESERVATION AND TRANSPLANTATION IN PATIENTS WITH LEUKEMIA. A 5 -YEAR SURVIVAL ANALYSIS DATA M. Sonmezer
- P-665** DNA-BASED ANCESTRY VS SELF-REPORTED ANCESTRY: A CASE FOR PAN-ETHNIC CARRIER SCREENING IN GAMETE DONOR PROGRAMS. N. Zarytska
- P-666** MATERNAL AND PERINATAL OUTCOMES IN ASSISTED REPRODUCTIVE TECHNOLOGY CONCEIVED PREGNANCIES IN BRITISH COLUMBIA. R. Eckler
- P-667** DOES ANTI MULLERIAN HORMONE (AMH) AFFECT EUPLOIDY RATES IN DIFFERENT AGE GROUPS. Y. M. Alhelou
- P-668** RACIAL DISPARITIES IN OUTCOMES OF PREGNANCIES RESULTING FROM PGT-A SINGLE BLASTOCYST TRANSFER - ANALYSIS OF 79, 416 FROZEN-EMBRYO TRANSFER CYLCES IN SART CORS. L. Pal

- P-669** DUAL TRIGGERING (DT) WITH GONADOTROPIN RELEASING-HORMONE AGONIST (GNRHA) AND HUMAN CHORIONIC GONADOTROPIN (HCG) IN AN ULTRASHORT FLARE (USF) PROTOCOL MOUNTS AN EFFECTIVE LUTEINIZING HORMONE (LH) SURGE. A. Taggar
- P-671** DYSREGULATED GATA2 AND GATA6 TRANSCRIPTION FACTOR EXPRESSION IN PATIENTS WITH ADENOMYOSIS: IMPLICATIONS FOR IMPAIRED ENDOMETRIAL RECEPTIVITY. Z. J. Pavlovic
- P-672** SOCIODEMOGRAPHIC AND ECONOMIC CHARACTERISTICS OF INFERTILE PATIENTS REFERRED TO A PUBLIC UNIVERSITY CENTER IN BRAZIL FOR ASSISTED REPRODUCTION THERAPY. B. L. Magalhães

#### PST-01 E-POSTER ABSTRACT STATION: T1

- P-221** COMPARING TRANSABDOMINAL ULTRASOUND AND TRANSVAGINAL ULTRASOUND TO MEASURE ENDOMETRIAL THICKNESS AT EMBRYO TRANSFER. F. I. Sharara
- P-222** EVALUATION OF ULTRAST ULTRASOUND GEL TO INDUCE A TEMPORARY DISTENSION OF THE UTERINE CAVITY TO IMPROVE UTERINE SONOGRAPHY. P. Pirtea
- P-223** THE APPLICABILITY AND EFFECTIVENESS OF SALINE INFUSION SONOGRAPHY IN DIAGNOSIS OF ISTHMOCELE IN PATIENTS WITH SECONDARY INFERTILITY. M. Sonmezer
- P-224** THERAPEUTIC POTENTIALS OF UMBILICAL CORD DERIVED MESENCHYMAL STEM CELLS THROUGH RESTORING MITOCHONDRIAL FUNCTION ON DAMAGED HUMAN GRANULOSA CELLS. J. Seok



## POSTER PRESENTATIONS AND ABSTRACTS

- P-225**     **MARKERS OF OVARIAN RESERVE AS PREDICTORS OF FUTURE FERTILITY.**  
B. S. Harris
- P-227**     **THE NEW FOLLICULAR WAVE: DUOSTIM VS MICRODOSE FLARE CYCLE OUTCOMES IN DIMINISHED OVARIAN RESERVE.** A. Hussain
- P-228**     **THE USE OF ENDOMETRIAL CULTURE FOR TARGETED TREATMENT OF ENDOMETRITIS IN PATIENTS EXPERIENCING INFERTILITY AND RECURRENT PREGNANCY LOSS.**  
S. Hmaidan
- P-229**     **PLACENTAL HISTOLOGY FOLLOWING ASSISTED HATCHING IN IVF FRESH TRANSFER CYCLES.** H. Ganer Herman

- P-237**     **URINARY ESTROGEN AND PROGESTERONE METABOLITE PATTERNS IN OVULATORY AND ANOVULATORY WOMEN.** M. Newman
- P-238**     **COMPARISON OF CYCLIC URINARY ESTROGEN AND PROGESTERONE METABOLITE PATTERNS BETWEEN WOMEN REPORTING MENSES AND WOMEN REPORTING NO MENSES.** M. Newman
- P-239**     **AT-HOME SAMPLE COLLECTION FOR THE DETECTION OF AGE-RELATED CHANGES IN FEMALE REPRODUCTIVE HORMONAL PATTERNS: A COHORT STUDY.**  
K. M. Gavin
- P-240**     **LIPID DROPLET SYNTHESIS ARE ASSOCIATED WITH ANGIOGENESIS IN OVARIAN FOLLICLES.** M. Ibayashi

### PST-02 E-POSTER ABSTRACT STATION: T2

- P-231**     **THE EFFECTIVENESS OF INTRAUTERINE INSEMINATION (IUI) WITH OR WITHOUT OVARIAN STIMULATION (OS) IN WOMEN WITH "OVERT" OR "AT RISK" FOR TUBAL-FACTOR INFERTILITY (TFI).** Y. Lu
- P-232**     **SENSITIVITY, SPECIFICITY, AND PREDICTIVE VALUE OF URINARY ANDROGEN METABOLITES FOR THE DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME.** M. Newman
- P-233**     **PREDICTING THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME (PCOS) AMONG AT RISK WOMEN WITHIN AN ELECTRONIC HEALTH RECORD.** V. S. Jiang
- P-234**     **PRENATAL ANDROGEN EXPOSURE IN MICE LEADS TO A METABOLICALLY DISTINCT PCOS WITHOUT OBESITY.** A. Gannon
- P-235**     **LOW-DOSE FLUTAMIDE ALTERS ABDOMINAL ADIPOGENIC FUNCTION IN NORMAL-WEIGHT POLYCYSTIC OVARY SYNDROME WOMEN (PCOS); A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL.** C. Winnett
- P-236**     **THE DYSREGULATION OF TRYPTOPHAN METABOLISM IN LEIOMYOMAS.** T. Chuang

### PST-03 E-POSTER ABSTRACT STATION: T3

- P-241**     **CONCORDANCE OF REPRODUCTIVE AND THYROID HORMONE MEASUREMENTS BETWEEN VENIPUNCTURE AND CAPILLARY BLOOD SAMPLES THROUGHOUT THE MENSTRUAL CYCLE.** N. Getreu
- P-242**     **REDEFINING LABORATORY REFERENCE RANGES FOR FEMALE REPRODUCTIVE AND THYROID HORMONES.** H. C. O'Neill
- P-243**     **NEW DATA FROM THE PREGNANCY IN POLYCYSTIC OVARY SYNDROME I (PPCOS I) TRIAL: HIGHER ANTI-MÜLLERIAN HORMONE (AMH) LEVEL ASSOCIATED WITH REDUCED ODDS OF OVULATION WITH OVULATION INDUCTION TREATMENT.**  
A. S. Komorowski
- P-244**     **UTILITY OF HORMONE GENETIC RISK SCORES IN IDENTIFYING REPRODUCTIVE DYSFUNCTION ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME.**  
K. V. Actkins
- P-245**     **ESR1 HINGE REGION VARIANT IN A PATIENT WITH UNEXPLAINED INFERTILITY.**  
R. A. Roman



## POSTER PRESENTATIONS AND ABSTRACTS

**P-246** ASSOCIATION OF FOLLICULAR FLUID KISSPEPTIN LEVELS AND OVARIAN RESPONSE TO STIMULATION. E. Ahart

**P-247** REPRODUCTIVE AND METABOLIC EFFECTS OF A NUTRITIONAL INTERVENTION FOR KETOSIS INDUCTION ADDED TO IVF IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME. C. Palafox-Gómez

**P-248** DIET SUPPLEMENTATION RESTORES OBESITY-INDUCED MITOCHONDRIAL DYSFUNCTION IN GRANULOSA CELLS FROM THE EQUINE PREOVULATORY FOLLICLE. K. Fresca

**P-249** IMPACT OF COVID-19 INFECTION AND mRNA VACCINATION ON MENSTRUAL CYTOKINE PROFILES. Z. Dhanani

**P-250** CURRENT PRACTICES IN INFERTILITY AND FERTILITY PRESERVATION COUNSELING AMONG PATIENTS WITH TURNER SYNDROME. G. Beroukhim

**P-257** IS TRILAMINAR ENOUGH? COMPARING FET IMPLANTATION RATES OF PCOS AND NON-PCOS PATIENTS WITH FAVORABLE ENDOMETRIAL LINING K. Hrvojevic

**P-258** PREDICTIVE VALUES OF PROGESTERONE/ ESTRADIOL RATIO ON INTRAUTERINE INSEMINATION OUTCOMES. N. Sayme

**P-259** THE EFFECTIVENESS OF ADDITIONAL INTRAMUSCULAR LUTEAL PROGESTERONE SUPPORT IN WOMEN WITH ENDOMETRIAL CONTRACTILITY ON ULTRASOUND THE DAY PRIOR TO PROGRAMMED FROZEN EMBRYO TRANSFER. J. Jayakumaran

**P-260** DO MATERNAL PRECONCEPTION SERUM ANTI-MÜLLERIAN HORMONE (AMH) LEVELS CORRELATE WITH LIVE BIRTH SEX RATIO AFTER INTRAUTERINE INSEMINATION (IUI) WITH OR WITHOUT OVARIAN STIMULATION (OS)? K. C. Hammer

### PST-05 E-POSTER ABSTRACT STATION: T5

**P-261** ORAL GONADOTROPIN-RELEASING HORMONE ANTAGONISTS IN THE TREATMENT OF ENDOMETRIOSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF EFFICACY PARAMETERS AND ADVERSE EFFECTS. E. Kalafat

**P-262** IMPACT OF ENDOMETRIOSIS SURGERY ON IN VITRO FERTILIZATION (IVF)/INTRA CYTOPLASMIC SPERM INJECTION (ICSI) OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS. M. Bourdon

**P-263** RACIAL DISPARITIES IN ENDOMETRIOSIS SURGERY. A. Bui

**P-264** COMBINED EFFECTS OF AGE AND ENDOMETRIOSIS ON OVARIAN RESERVE IN WOMEN WITH INFERTILITY. I. Feferkorn

**P-265** CO-EXPRESSION OF ACTIVATING AND INHIBITORY RECEPTORS ON PERITONEAL FLUID NK CELLS DIFFERS BETWEEN DEEP ENDOMETRIOSIS AND PERITONEAL ENDOMETRIOSIS. S. Saeki

**P-266** A BAYESIAN NETWORK FOR COMPLEX PAIN-RELATED FEATURES OF ENDOMETRIOSIS. A. C. Kiser

### PST-04 E-POSTER ABSTRACT STATION: T4

**P-251** DETECTION OF THE OVULATION TIME VIA HORMONE LEVELS IN THE PERIPHERAL BLOOD OF THE SUBFERTILE WOMEN WITH REGULAR MENSTRUAL CYCLE. N. Albayrak

**P-252** LUTEINIZING HORMONE SUPPLEMENTATION WITH HUMAN MENOPAUSAL GONADOTROPIN VERSUS LOW-DOSE HUMAN CHORIONIC GONADOTROPIN DURING STIMULATION DOES NOT AFFECT PREGNANCY OUTCOMES AFTER FRESH EMBRYO TRANSFER. L. Fischer

**P-253** WHAT IS THE IDEAL LETROZOLE REGIMEN FOR OVULATION INDUCTION IN WOMEN WITH POLYCYSTIC OVARY SYNDROME? R. S. Mandelbaum

**P-255** CORRELATION OF BASAL SERUM AMH VALUES OF PCOS PATIENTS TO OVARIAN RESPONSE FOLLOWING STIMULATION WITH OVULATION INDUCTION AGENT CLOMIPHENE CITRATE - A PROSPECTIVE COHORT STUDY. P. Sarkar



## POSTER PRESENTATIONS AND ABSTRACTS

**P-267** VALIDATION OF TURKISH VERSION OF QUALITY OF LIFE QUESTIONNAIRE FOR WOMEN WITH ENDOMETRIOSIS: ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE – EHP-30.  
M. Cimsit Kemahli

**P-270** EVALUATION OF THE EFFECT OF RELUGOLIX COMBINATION THERAPY ON BONE MINERAL DENSITY (BMD) OVER TWO YEARS IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: SPIRIT LONG-TERM EXTENSION (LTE) STUDY. J. S. Perry

**P-279** REPRODUCTIVE OUTCOMES AND OVERALL PROGNOSIS OF PATIENTS WITH ASHERMAN'S SYNDROME UNDERGOING IVF CYCLES. Y. Fouks

### PST-07 E-POSTER ABSTRACT STATION: T7

**P-281** SINGLE EUPLOID EMBRYO TRANSFER OUTCOMES AFTER UTERINE SEPTUM RESECTION. S. L. Estevez

**P-282** THE EXCEPTION OR THE RULE? ANASTOMOTIC VAGINAL STRICTURE AFTER UTERUS TRANSPLANT: CASE SERIES AND SYSTEMATIC REVIEW M. Rush

**P-283** RACIAL DISPARITIES IN ABDOMINAL AND LAPAROSCOPIC MYOMECTOMIES. A. Garneau

**P-284** INCIDENCE AND RISK FACTORS OF INTRAUTERINE ADHESIONS FOLLOWING MYOMECTOMY. P. Bortoletto

**P-286** EFFECT OF NON-CAVITY-DISTORTING INTRAMURAL MYOMAS ON PREGNANCY OUTCOMES IN EUPLOID FROZEN EMBRYO TRANSFER CYCLES: A PROSPECTIVE STUDY. M. Moronta

**P-287** TGF-B AND EARLY-LIFE EXPOSURE TO ENDOCRINE-DISRUPTING CHEMICALS IMPAIR NUCLEOTIDE EXCISION REPAIR IN EKER RAT MYOMETRIAL STEM CELLS. M. V. Bariani

**P-288** THE FUNCTIONAL ROLE AND MECHANISM OF BROMODOMAIN-CONTAINING PROTEIN 9 IN HUMAN UTERINE LEIOMYOSARCOMA. Q. Yang

**P-289** PREGNANCY OUTCOMES FOLLOWING IN-VITRO FERTILIZATION IN A POPULATION OF SUBFERTILE WOMEN TREATED FOR UTERINE ADHESIONS WITH HYSTEROSCOPIC ADHESIOLYSIS. E. S. Ginsburg

**P-290** INTER-OBSERVER VARIABILITY IN HYSTEROSCOPIC DIAGNOSIS OF CHRONIC ENDOMETRITIS. A. Halouani

### PST-06 E-POSTER ABSTRACT STATION: T6

**P-271** RELUGOLIX COMBINATION THERAPY IN NORTH AMERICAN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: SPIRIT 1 AND 2 TRIALS. S. As-Sanie

**P-272** ASSESSMENT OF PATIENT-REPORTED PAIN RELIEF IN TREATED ENDOMETRIOSIS PATIENTS: FINDINGS FROM A REAL-WORLD STUDY IN THE UNITED STATES. H. S. Taylor

**P-273** LAPAROSCOPIC PERITONEAL EXCISION OF ENDOMETRIOSIS IMPROVES IN VITRO FERTILIZATION (IVF) LIVE BIRTH RATES IN WOMEN <41 YEARS OF AGE WITH DIMINISHED OVARIAN RESERVE. S. I. Lipari

**P-274** EFFECT OF HEMOSTATIC METHODS USED IN LAPAROSCOPIC SURGERY FOR OVARIAN ENDOMETRIOMA ON OVARIAN RESERVE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED TRIALS. E. Kalafat

**P-275** BEHAVIORAL SYMPTOMS OF EATING DISORDERS AND RISK OF ENDOMETRIOSIS: A PROSPECTIVE COHORT STUDY. S. Thornburgh

**P-277** CURRENT AND FUTURE MEDICAL, SURGICAL, AND INTERVENTIONAL APPROACHES TO MANAGE ASHERMAN'S SYNDROME. E. Neisani Samani

**P-278** HYSTEROSCOPIC MYOMECTOMY IS NOT ASSOCIATED WITH INTRAPERITONEAL DISSEMINATION OF MYOMETRIAL CELLS. C. E. Hur





### PST-08 E-POSTER ABSTRACT STATION: T8

- P-291** PRESENCE OF BRCA MUTATIONS AND A PRE-CHEMOTHERAPY AMH LEVEL OF < 2ng/ML STRONGLY PREDICT RISK OF AMENORRHEA IN WOMEN WITH BREAST CANCER. G. Bedoschi
- P-292** FERTILITY PRESERVATION FOR NEWLY DIAGNOSED CANCER PATIENTS IN WEST AFRICA - A MULTI CENTERED OVERVIEW AMONG RELATED MEDICAL SPECIALISTS IN GHANA. P. E. Sefogah
- P-293** CROWDFUNDING USE IN CANCER PATIENTS SEEKING INFERTILITY TREATMENT. R. A. Frankel
- P-294** IMPACT OF FERTILITY PRESERVATION INSURANCE MANDATES ON UTILIZATION RATES. K. Ramey-Collier
- P-295** IDENTIFYING BARRIERS TO FERTILITY PRESERVATION AND PATTERNS OF SELECTION AMONG INPATIENT ONCOLOGY PATIENTS. L. Hartup
- P-296** FERTILITY INTENTION AND RELATED FACTORS FOR HAVING A SECOND OR THIRD CHILD AMONG CHILDBEARING COUPLES IN SHANGHAI, CHINA. C. Zhu
- P-297** LIVE BIRTH FOLLOWING IVF PREGNANCY IN A TRANSGENDER MAN OF ADVANCED PATERNAL AGE WITH A HISTORY OF PROLONGED TESTOSTERONE USE. A. Johnson
- P-298** CUMULATIVE LIVE BIRTH RATES (CLBR) FROM FROZEN AUTOLOGOUS OOCYTES (AOS): LARGEST COHORT OF PLANNED OOCYTE CRYOPRESERVATION (OC) THAWS FROM A SINGLE CENTER IN THE UNITED STATES. C. M. Parra
- P-299** THE ANALYSIS OF IVF OUTCOMES AFTER FERTILITY-PRESERVING THERAPY FOR ENDOMETRIAL HYPERPLASIA OR CARCINOMA. J. Park
- P-300** UTERINE TRANSPOSITION DURING PELVIC RADIOTHERAPY FOR FERTILITY PRESERVATION. H. Kim

### PST-09 E-POSTER ABSTRACT STATION: T9

- P-301** INCIDENCE OF FERTILITY PRESERVATION PROCEDURES IN PREPUBERTAL INDIVIDUALS WITH CANCER. J. T. White
- P-302** RANDOM-START PROTOCOL IS EFFECTIVE IN ONCOFERTILITY PATIENTS. N. Yilmaz
- P-303** DOES BRCA 1/2 CARRIER STATUS EFFECT OOCYTE CRYOPRESERVATION OUTCOMES? N. Jain
- P-304** FERTILITY PRESERVATION THROUGH SEMEN BANKING IN MEN WITH CANCER OR BENIGN DISEASES - A PROSPECTIVE COHORT STUDY. K. Weibring
- P-305** ANXIETY AND DISTRESS IN YOUNG NEWLY DIAGNOSED CANCER PATIENTS DECREASE AFTER A FERTILITY PRESERVATION CONSULT. A. Wang
- P-306** DO AROMATASE INHIBITORS AND TAMOXIFEN IMPACT THE NUMBER OF OOCYTES RETRIEVED IN OOCYTE OR EMBRYO BANKING CYCLES? M. Sauerbrun-Cutler
- P-307** A COMPARATIVE ANALYSIS OF CENTERS OFFERING ONCOFERTILITY SERVICES IN THE UNITED STATES: IDENTIFYING GAPS AND OPPORTUNITIES TO INCREASE ACCESS TO FERTILITY PRESERVATION CARE. N. Potapragada
- P-308** SUBSTANTIAL VARIABILITY IN OVARIAN CONSERVATION AT HYSTERECTOMY FOR ENDOMETRIAL HYPERPLASIA. C. Violette
- P-309** DO FERTILITY PRESERVATION OUTCOMES IN PATIENTS DIAGNOSED WITH LYMPHOMA DIFFER BASED ON CANCER AGE? M. Pavone
- P-310** RANDOM-START VERSUS CONVENTIONAL OVARIAN HYPERSTIMULATION FOR FERTILITY PRESERVATION IN FEMALE CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. M. Sonmezer



### PST-10 E-POSTER ABSTRACT STATION: T10

- P-311** **CANCER PREDISPOSITION GENE MUTATIONS AND ONCOFERTILITY: PREVALENCE IN REPRODUCTIVE AGE CANCER PATIENTS AND EFFECTS ON OVARIAN RESERVE.** B. Steinberg
- P-312** **COMPARISON OF RANDOM START CONTROLLED OVARIAN STIMULATION WITH STANDARD START IN LETROZOLE GONADOTROPIN CYCLES FOR FERTILITY PRESERVATION IN WOMEN WITH BREAST CANCER.** S. Gayete Lafuente
- P-313** **RNASEQ ANALYSIS OF FACS SORTED SPERMATOGONIAL CELLS USED TO IDENTIFY MELANOCORTIN RECEPTOR 2 AS A NOVEL AND FUNCTIONAL MEMBRANE-ASSOCIATED SPERMATOGONIAL STEM CELL MARKER.** M. Huleihel
- P-314** **UTILIZATION OF EMBRYOS AND EGGS CRYOPRESERVED PRIOR TO GONADOTOXIC TREATMENT: WHY ARE SOME WOMEN NOT RETURNING TO USING THEIR FROZEN EMBRYOS OR EGGS?** M. E. Gornet
- P-315** **INFLUENCE OF FERTILITY PRESERVATION INDICATION ON OOCYTE AND EMBRYO CRYOPRESERVATION: A COMPARISON OF MEDICALLY INDICATED VS ELECTIVE CYCLES.** A. K. Gadson
- P-316** **IN VITRO MATURATION OF OVARIAN TISSUE OOCYTES, AND THE IMPORTANCE OF THE CUMULOUS.** S. Silber
- P-317** **“SINGLE MOTHERS BY CHOICE” AFTER SOCIAL EGG FREEZING: OVERVIEW OF THE LAST 9 YEARS IN A PRIVATE ART SERVICE.** A. R. Lorenzon
- P-318** **FERTILITY PRESERVATION IN ENDOMETRIOSIS: DOES PATIENT SYMPTOMATOLOGY AFFECTS THE EXTENT OF THE OVARIAN RESPONSE.** Y. Fouks
- P-319** **EMBRYO PLOIDY IN THAWED FROZEN VERSUS FRESH OOCYTES: IS THERE A DIFFERENCE?** S. Tsai

- P-320** **ICING ON THE CAKE: CAN OOCYTES “ON ICE” RESULT IN MORE THAN ONE LIVE BIRTH (LB)?** S. D. Cascante

### PST-11 E-POSTER ABSTRACT STATION: T11

- P-321** **HOW MANY EGGS WILL I GET AND HOW MUCH MEDICATION DO I NEED? A SART DATABASE PREDICTOR MODEL FOR EGG FREEZING** B. D. Yilmaz
- P-322** **EVOLUTION OF KNOWLEDGE AND ATTITUDES REGARDING FERTILITY SERVICE UTILIZATION.** A. G. Huttler
- P-323** **SEASONAL VARIATION IMPACT ON OOCYTE RETRIEVAL OUTCOMES.** M. Tarrash
- P-324** **ACCEPTANCE OF GENETIC EDITING OF HUMAN EMBRYOS IN INFERTILITY PATIENTS: PRE- AND POST- COVID-19 ATTITUDES.** Y. Fouks
- P-325** **OPERATING CHARACTERISTICS OF SPERM CONCENTRATION AND FSH FOR PREDICTING CHROMOSOMAL ABNORMALITIES.** C. A. McLain
- P-326** **EVALUATING CURRENT CARRIER SCREENING PROTOCOLS FOR PATIENTS AND FAMILIES UTILIZING DONOR GAMETES.** M. Dean
- P-327** **LOOKING FOR A LOCAL PANEL: FREQUENCY ANALYSIS OF RECESSIVE GENETIC MUTATIONS FOR ARGENTINA.** M. Barbero
- P-328** **SEGMENTAL AND SPECIFIC CHROMOSOMAL ANEUPLOIDIES ARE INCREASED IN EMBRYOS OF CONSANGUINE COUPLES AFTER IVI/ICSI WITH PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDIES (PGT-A).** L. Melado
- P-329** **ATM AND INFERTILITY: ARE THERE ADDITIONAL BARRIERS TO PREGNANCY IN ATAXIA-TELANGIECTASIA MUTATION CARRIERS?** A. Namath
- P-330** **ART OUTCOMES IN NIJMEGEN BREAKAGE SYNDROME MUTATION CARRIERS.** A. Namath



### PST-12 E-POSTER ABSTRACT STATION: T12

- P-331** EVALUATION OF POTENTIAL FACTORS INVOLVED IN VARIABLE PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) RESULTING RATES BETWEEN IVF CLINICS. K. McWilliams
- P-332** FUMARASE DEFICIENCY CARRIERS AND ITS EFFECT ON INFERTILITY. J. Schwartz
- P-333** REPRODUCTIVE DECISIONS OF CARRIERS WITH INHERITED CANCER GENE MUTATIONS. D. Klepacka
- P-334** MOSAIC EMBRYOS: DESCRIPTIVE ANALYSIS AND CLINICAL OUTCOMES AFTER PREIMPLANTATION GENETIC TESTING - ANEUPLOIDES (PGT-A). J. Pla-Victori
- P-335** THE EMBRYO HEALTH STUDY: RATE OF PATIENTS ELECTING POLYGENIC RISK SCORES IN PREIMPLANTATION GENETIC TESTING. J. Eccles
- P-336** MATERNAL FIBROID IMPACT ON CELL FREE DNA (cfDNA) SCREENING. V. Nifibhon
- P-337** ANALYSIS OF PREFERENTIAL ALLELE SEGREGATION ACCORDING TO THE GENDER OF AFFECTED PARENT IN PREIMPLANTATION EMBRYOS WITH MYOTONIC DYSTROPHY TYPE 1, HUNTINGTON DISEASE AND SPINOCEREBELLAR ATAXIA. S. Park
- P-338** THE LANDSCAPE OF CHROMOSOMAL ABERRATIONS IN 10,000 EMBRYOS DERIVED FROM FRESH DONOR OOCYTES. M. Madjunkov
- P-339** FRAGILE X CARRIERS: IS THERE EXPANSION IN UTILIZATION OF PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M)? J. Shaw
- P-340** THE BLASTULATION RATE AND THE RATIO OF 1PN/2PN EMBRYOS ARE ASSOCIATED WITH THE COHORT OF EMBRYOS PLOIDY RATIO. I. Feferkorn

### PST-13 E-POSTER ABSTRACT STATION: T13

- P-341** AMH INDEPENDENTLY PREDICTS ANEUPLOIDY BUT NOT LIVE BIRTH PER TRANSFER IN IVF PGT-A CYCLES. H. J. Li
- P-342** NON-INVASIVE PLOIDY EVALUATION BY ANALYSIS OF EMBRYO CULTURE MEDIUM. H. Watanabe
- P-343** BLASTOCYST PLOIDY IS NOT CORRELATED WITH THE CHOICE OF OVULATORY TRIGGER AGENT AFTER CONTROLLING FOR AGE AND COHORT SIZE. B. S. Shapiro
- P-345** ACCURATE BREAKPOINT MAPPING USING OPTICAL GENOME MAPPING (OGM) HAS THE POTENTIAL TO INCREASE THE ACCURACY OF PREIMPLANTATION GENETIC TESTING FOR STRUCTURAL CHROMOSOMAL REARRANGEMENTS (PGT-SR). X. Tao
- P-346** THE CHROMOSOME ERRORS OF HUMAN BLASTOCYST IN AGE OF 44 YEARS OLD AND BEYOND. H. Liu
- P-347** THAWING BLASTOCYSTS FOR REPEAT OR DE NOVO PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY WITH RE-VITRIFICATION: RESULTS AND OUTCOMES. A. Vanderhoff
- P-348** PGT-M STRATEGY USING GENOME-WIDE HAPLOTYPE KARYOMAPPING ANALYSIS FOR PATIENTS WITH DE NOVO MUTATIONS. M. Kim
- P-349** DETECT CRYPTIC CHROMOSOMAL REARRANGEMENT BY OPTICAL GENOME MAPPING (OGM) IN INFERTILE POPULATION. J. Yan
- P-350** INADEQUATE NUMBER OF INFORMATIVE SNPs IN PRECLINICAL KARYOMAPPING TEST FOR PGT-M DEPENDS ON THE SELECTION OF REFERENCE. M. Kim

### PST-14 E-POSTER ABSTRACT STATION: T14

- P-351** VERIFICATION OF THE CONTENT OF EMBRYONIC CULTURE MEDIUM BY GENOTYPING USING STR MARKER. H. Elloumi





## POSTER PRESENTATIONS AND ABSTRACTS

- P-352** ANALYSIS OF THE mTOR PATHWAY IN OVARIES OF WOMEN WITH BRCA MUTATIONS. M. G. Torres-Velez
- P-353** RECURRENCE RISK AND RISK FACTORS FOR MONOZYGOTIC LIVE BIRTH IN OVER 65,000 SINGLE EMBRYO TRANSFERS. W. S. Vitek
- P-354** ABNORMAL PLACENTATION IN ART PREGNANCIES- PREVALENCE AND PREDICTORS. E. Esencan
- P-355** DNA METHYLATION CHANGES IN EARLY PLACENTA FROM ASSISTED REPRODUCTIVE TECHNOLOGIES ARE NOT ASSOCIATED WITH SIGNIFICANT GENE EXPRESSION CHANGES. A. M. Schaub
- P-356** GnRH AGONIST AS OVULATION TRIGGER IMPROVES NEONATAL OUTCOMES COMPARED TO HCG IN FRESH IVF CYCLES: A SART ANALYSIS. R. K. Chung
- P-357** MATERNAL AND NEONATAL OUTCOMES WITH USE OF HORMONE REPLACEMENT THERAPY AND NATURAL CYCLE IN IN-VITRO FERTILIZATION FROZEN EMBRYO TRANSFER: A SYSTEMATIC REVIEW AND META-ANALYSIS. E. A. Jacobs
- P-358** THE ASSOCIATION BETWEEN SOCIOECONOMIC STATUS AND IN VITRO FERTILIZATION (IVF) SUCCESS RATES IN INFERTILE COUPLES. K. Fendereski
- P-359** FERTILITY SERVICES IN GERMANY AND THE IMPACT OF COVID-19. E. Brachimi
- P-360** DIFFERENCES IN REPRODUCTIVE AND NEONATAL OUTCOMES BASED ON TIME INTERVAL FROM CESAREAN DELIVERY TO FROZEN EMBRYO TRANSFER. L. X. Zalles
- P-362** OBSTETRIC AND PERINATAL OUTCOMES FOLLOWING OVULATION INDUCTION AND UNASSISTED PREGNANCIES IN THE SAME MOTHER. H. Ganer Herman
- P-363** POOLED CONSECUTIVE EJACULATES IN COUPLES WITH SEVERE MALE FACTOR INFERTILITY DOES NOT IMPROVE INTRAUTERINE INSEMINATION OUTCOME. N. Esfandiari
- P-364** MATERNAL EDUCATION AND ITS ASSOCIATION WITH MATERNAL AND NEONATAL ADVERSE OUTCOMES IN LIVE BIRTHS CONCEIVED USING ASSISTED CONCEPTION. C. Hobbs
- P-365** IMPACT OF PATERNAL AGE ON CUMULATIVE OUTCOME OF ASSISTED PRODUCTIVE TECHNOLOGY (ART). C. Farabet
- P-366** RECIPIENT AGE IS NOT ASSOCIATED WITH OUTCOMES IN DONOR EGG IVF CYCLES. E. Clain
- P-367** BLASTOCYST RATE BEFORE AND DURING THE COVID PANDEMIC YEARS: AN INDIRECT ASSESSMENT OF GAMETE AND LABORATORY PERFORMANCE. M. Ibrahim
- P-368** A STUDY TO DETERMINE THE IMPACT OF DIMINISHED OOCYTE RESERVE (DOR) ON PREGNANCY OUTCOME IN WOMEN OF ADVANCED REPRODUCTIVE AGE. J. H. Check
- P-369** DOES AGE MATTER WITH NATURAL CYCLE FROZEN-THAWED EMBRYO TRANSFER (FET) AFTER PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A). K. White
- P-370** GENERATION OF BIG DATA FOR FERTILITY TREATMENT AT THE NATIONAL LEVEL IN SOUTH KOREA. T. Ko

### PST-15 E-POSTER ABSTRACT STATION: T15

- P-361** THE ASSOCIATIONS BETWEEN BODY MASS INDEX AND LIVE BIRTH OUTCOMES AMONG PATIENTS WITH AND WITHOUT OVULATORY DYSFUNCTION UNDERGOING INTRAUTERINE INSEMINATION CYCLES. C. L. Jarshaw

### PST-16 E-POSTER ABSTRACT STATION: T16

- P-371** SIX CONSECUTIVE TIME-LAPSE IMAGES OVER 2 HOURS ON DAY 3 CAN PREDICT BLASTULATION BETTER THAN A SINGLE IMAGE. H. Lee



## POSTER PRESENTATIONS AND ABSTRACTS

- P-372** APPLYING TWO ARTIFICIAL INTELLIGENCE-BASED EMBRYO SELECTION MODELS ON 5,624 BLASTOCYSTS: PREDICTION OF IMPLANTATION POTENTIAL WITH MACHINE LEARNING AND DEEP LEARNING SYSTEMS. L. Bori Arnal
- P-373** A NEW APPROACH TO ESTIMATING CUMULATIVE LIVE BIRTH RATES USING PREDICTED OUTCOMES OF ALL EMBRYOS. J. Cho
- P-374** VITRIFIED-THAWED BLASTOCYST TRANSFER CYCLES MAY IMPROVE REPRODUCTIVE OUTCOMES IN ADVANCED STAGE ENDOMETRIOSIS PATIENTS. E. Pabuccu
- P-375** LIVE DELIVERED PREGNANCY RATES FOLLOWING THE TRANSFER OF FROZEN-THAWED EMBRYOS DERIVED FROM DONOR OOCYTES ACCORDING TO THE MID-LUTEAL PHASE ENDOMETRIAL ECHO PATTERNS. J. H. Check
- P-376** DIAGNOSIS OF DIMINISHED OVARIAN RESERVE AND PREIMPLANTATION GENETIC TESTING IMPACT FROZEN EMBRYO TRANSFER LABORATORY AND CLINICAL OUTCOMES: TRACKING FAILED THAW CYCLES AS A KEY PERFORMANCE INDICATOR. K. A. Wirka
- P-377** FERTILIZATION RATE IS ASSOCIATED WITH THE LIKELIHOOD OF BEING DISCHARGED PREGNANT, BUT NOT WITH EMBRYO QUALITY: ANALYSIS OF 11,210 OOCYTE RETRIEVALS AND 12,968 SINGLE FROZEN EMBRYO TRANSFERS (FET). A. Reig
- P-378** WHAT IS THE IMPACT OF BIOPSY ON POOR-QUALITY EMBRYOS? AN ANALYSIS OF TREATMENT OUTCOME COMPARING THE MORPHOLOGICAL QUALITY OF BIOPSIED AND NON-BIOPSIED EMBRYOS. D. Schapira Wajman
- P-379** WOMEN WITH POOR OVARIAN RESPONSE DIAGNOSED BASED ON POSEIDON OR BOLOGNA CRITERIA: HOW LIKELY ARE THEY TO HAVE AT LEAST ONE EUPLOID BLASTOCYST FOR TRANSFER? A. Reig
- P-380** PREVIOUS INFECTION WITH SARS-COV-2 IMPACTS EMBRYO MORPHOKINETICS IN INTRACYTOPLASMIC SPERM INJECTION CYCLES. A. S. Setti
- PST-17 E-POSTER ABSTRACT STATION: T17**
- P-381** IS THERE AN ADDED BENEFIT WITH EXTENDED EMBRYO CULTURE IN WOMEN OF ADVANCED MATERNAL AGE UNDERGOING IVF-ET? S. R. Lindheim
- P-382** EFFECT OF REDUCED OXYGEN TENSION ON OUTCOMES OF SINGLE, EUPLOID FROZEN BLASTOCYST TRANSFER. N. Raj-Derouin
- P-383** BEST QUALITY VS. SEX SELECTION – WHAT TAKES PRIORITY FOR PATIENTS UNDERGOING PGT-A? A HISTORICAL ANALYSIS OF EMBRYO SELECTION PREFERENCES OVER A TEN-YEAR PERIOD P. Gill
- P-384** DO IMPLANTATION AND LIVE BIRTH RATES WITH TRANSFER OF SINGLE EUPLOID BLASTOCYSTS CORRELATE TO THEIR MITOSCORE? V. Nanavaty
- P-385** NON-MEDICAL EMBRYO SEX SELECTION RESULTS IN REDUCED IMPLANTATION COMPARED TO THE TRANSFER OF THE HIGHEST MORPHOLOGICAL GRADE BLASTOCYST. A. Arnold
- P-386** DOES INDIVIDUALIZED PRE- AND POST-EMBRYO TRANSFER ACUPUNCTURE AFFECT LIVE BIRTH RATES? K. Phillippi
- P-387** A COMPREHENSIVE MODEL FOR PREDICTING THE PROBABILITY OF LIVE BIRTH PRIOR TO THE START OF PROGESTERONE DURING ARTIFICIAL FROZEN EMBRYO TRANSFER CYCLES. F. Murillo Armijo
- P-388** HOW MANY EUPLOID BLASTOCYSTS NEED TO BE TRANSFERRED IN OBESE PATIENTS TO ACHIEVE A LIVE BIRTH? AN ENDLESS PATIENT-DOCTOR NEGOTIATION STORY. L. Barbara

## POSTER PRESENTATIONS AND ABSTRACTS

**P-389** CLINICAL OUTCOME OF PERSONALIZED EMBRYO TRANSFER IN CONSIDERATION WITH EMBRYONIC DEVELOPMENTAL SPEED IN RECURRENT IMPLANTATION FAILURE PATIENTS. Y. Ohara

**P-390** THE DILEMMA FOR PATIENTS WITH A THIN ENDOMETRIAL LINING: NATURAL CYCLES OR PROGRAMMED FROZEN EMBRYO TRANSFER CYCLES? S. Wang

**P-399** IMPACT OF MATERNAL RACE AND ETHNICITY ON PREGNANCY OUTCOMES IN INFERTILE WOMEN WITH AND WITHOUT POLYCYSTIC OVARY SYNDROME (PCOS) UNDERGOING IN VITRO FERTILIZATION (IVF) IN THE UNITED STATES (US). G. J. Mora

**P-400** DAY OF SURGE HORMONAL PARAMETERS AS PREDICTORS OF OUTCOME IN NATURAL FROZEN-THAWED EMBRYO TRANSFER (FET) CYCLES – THE WINDOW OF IMPLANTATION IS WIDE. K. Koniares

### PST-18 E-POSTER ABSTRACT STATION: T18

**P-391** NOVEL TOOL FOR ENDOMETRIAL ASSESSMENT IN EMBRYO TRANSFER CYCLES: ENDOMETRIAL ELASTOGRAPHY. F. Gode

**P-392** SERUM P LEVELS MEASURED ON THE DAY OF EMBRYO TRANSFER IN FRESH IVF CYCLES WITH OWN OOCYTES ARE NOT RELATED TO PREGNANCY OUTCOME. E. Labarta

**P-393** IMPACT OF CHRONIC PROGESTERONE ELEVATION (PRE-TRIGGER) ON FROZEN EMBRYO TRANSFER OUTCOMES. A. Borazjani

**P-394** THE EMBRYO FLASH IS NOT A MEANINGFUL PREDICTOR OF EUPLOID FROZEN EMBRYO TRANSFER OUTCOMES. D. Sachdev

**P-395** LIVE BIRTH RATES AFTER EUPLOID FROZEN EMBRYO TRANSFER WITH ENDOMETRIAL THICKNESS <7mm. R. Sabbagh

**P-396** TRANSDERMAL VERSUS ORAL ESTROGEN IN ENDOMETRIAL PREPARATION FOR FROZEN THAWED EMBRYO TRANSFER CYCLES. C. E. Busso

**P-397** THE TIMING OF PROGESTERONE CORRECTED AFTER ENDOMETRIAL TRANSCRIPTOMIC ANALYSIS DOES NOT IMPROVE REPRODUCTIVE OUTCOME IN WOMEN WITH ADENOMYOSIS AND NON-RECEPTIVE ENDOMETRIUM. M. Cozzolino

**P-398** POTENTIAL INFLUENCE OF CORONAVIRUS DISEASE 2019 (COVID-19) ON THE OUTCOMES OF IN-VITRO FERTILIZATION. S. Kuzucu

### PST-19 E-POSTER ABSTRACT STATION: T19

**P-401** PREGNANCY COMPLICATIONS AND PLACENTAL HISTOLOGY IN IN-VITRO FERTILIZATION PREGNANCIES WITH INITIAL LOW SERUM B-HCG LEVELS. H. Ganer Herman

**P-402** THE EFFECT OF HIGHER ESTRADIOL LEVELS DURING STIMULATION ON PREGNANCY COMPLICATIONS AND PLACENTAL HISTOLOGY. H. Ganer Herman

**P-403** THROMBIN PRODUCTION VARIES ACROSS AN IVF CYCLE AND A SIGNIFICANT DIFFERENCE IS NOTED WITH WOMEN WHO CONCEIVE VERSUS THOSE WHO DO NOT. C. B. Nesbit

**P-404** HIGH FOLLICLE STIMULATING HORMONE (FSH) LEVEL ON THE DAY OF TRIGGER IMPACTS NEGATIVELY THE EUPLOIDY RATE OF BLASTOCYSTS. R. Del Gallego

**P-405** GONADOTROPIN BOOST ADMINISTRATION WITH OVULATORY TRIGGER IMPROVES IN VITRO FERTILIZATION CYCLE OUTCOMES IN THE SETTING OF ESTRADIOL PLATEAU. C. G. Echague

**P-406** DON'T BE TRIGGER SHY: A LOW SERUM LUTEINIZING HORMONE (LH) RESPONSE TO GONADOTROPIN-RELEASING HORMONE AGONIST (GnRH-A) HITS THE MARK IN PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A). J. Buldo-Licciardi



## POSTER PRESENTATIONS AND ABSTRACTS

**P-407** SERUM ANTI-MÜLLERIAN HORMONE TO PREDICT THE CHANCE OF LIVE BIRTH AFTER SPONTANEOUS OR ASSISTED CONCEPTION: A SYSTEMATIC REVIEW AND META-ANALYSIS. M. Grynberg

**P-408** FERTILIZATION BY INTRACYTOPLASMIC SPERM INJECTION (ICSI) IS ASSOCIATED WITH LOWER RATES OF EUPLOIDY IN NON-MALE FACTOR INFERTILITY COMPARED TO CONVENTIONAL INSEMINATION (CI). K. Patel

**P-409** EVIDENCE TO SUPPORT THE OOPLASMIC ROLE IN MODULATING MALE GENOME INTEGRITY. O. M. Kocur

**P-410** MAXIMIZING NUMBER OF OOCYTES RETRIEVED INCREASES NUMBER OF 2PNs, BLASTOCYSTS, AND CUMULATIVE LIVE BIRTH RATES, WITHOUT IMPAIRING PRIMARY TRANSFER LIVE BIRTH RATES. M. Fanton

**P-416** IN-DEPTH GLYCOSYLATION PROFILING OF R-HFSH-ALFA AND R-HFSH-DELTA IN COMPARISON WITH HUMAN PITUITARY FOLLICLE STIMULATING HORMONE (HFSH). A. Palmese

**P-417** LOOKING FOR AN OPTIMAL DURATION OF OVULATION INDUCTION BEFORE TRIGGERING TO ACHIEVE HIGHEST CUMULATIVE LIVE BIRTH RATES IN HIGH AMH PATIENTS. C. Chen

**P-418** DUAL TRIGGER IMPROVES OOCYTE YIELD AND EMBRYO QUALITY OVER HCG ONLY TRIGGER IN GnRH ANTAGONIST ICSI CYCLES. N. N. Maredia

**P-419** PREGNANCY OUTCOMES OF SINGLE PGT-A (PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY) TESTED FROZEN EMBRYO TRANSFER CYCLES IN WOMEN WITH PCOS – ANALYSIS OF 79,416 CYCLES FROM SART CORS DATABASE. S. Kuokkanen

**P-420** FACTORS INFLUENCING THE PREVALENCE OF EMBRYO PLOIDY IN IVF CYCLES. L. Barbara

### PST-20 E-POSTER ABSTRACT STATION: T20

**P-411** OOCYTE COHORT MATURITY IS POSITIVELY CORRELATED TO BLASTOCYST DEVELOPMENT AND EUPLOID RATES. I. Tur-Kaspa

**P-412** OUTCOMES OF AUTOLOGOUS SINGLE THAWED EUPLOID EMBRYO TRANSFER IN WOMEN WITH HISTORY OF A PREVIOUS CESARIAN SECTION. T. Alkon-Meadows

**P-413** LIVE BIRTH FROM NATURAL CONCEPTION FOLLOWING ASSISTED REPRODUCTIVE TECHNOLOGY: ANALYSIS OF A LARGE POPULATION RETROSPECTIVE COHORT STUDY. A. W. Alley

**P-414** HIGHER LIVE BIRTH RATES ARE ASSOCIATED WITH NORMAL BMI IN PGT-A FET CYCLES VERSUS UNDERWEIGHT, OVERWEIGHT, OR OBESE PATIENTS: A SART CORS STUDY. A. M. Peterson

**P-415** ANTI-MÜLLERIAN HORMONE (AMH) AND EMBRYO EUPLOIDY IN SUBPOPULATIONS OF WOMEN PURSUING IN VITRO FERTILIZATION (IVF) WITH PREIMPLANTATION GENETIC TESTING. P. A. Romanski

### PST-21 E-POSTER ABSTRACT STATION: T21

**P-421** SERUM ESTROGEN AND PROGESTERONE LEVELS AS PREDICTORS OF OUTCOME IN WOMEN UNDERGOING ARTIFICIALLY PREPARED FROZEN EMBRYO TRANSFER CYCLES. Y. Cakiroglu

**P-422** USE OF ASSISTED REPRODUCTIVE TECHNOLOGIES DOES NOT INCREASE RISK OF RELAPSE AMONG WOMEN WITH MULTIPLE SCLEROSIS: A MULTICENTER COHORT STUDY. J. B. Bakkensen

**P-423** VALIDATION OF SPERM CHROMATIN DISPERSION (SCD) TEST USING A MAIL-IN, AT-HOME SEMEN COLLECTION KIT. R. Abou Ghayda

**P-424** FOR INFERTILE YOUNG COUPLES WITH A VARICOCELE, MALE-FIRST EVALUATION PRODUCES COST-SAVINGS AND REDUCES TIME TO PREGNANCY: A THEORETICAL, DISCRETE-TIME MARKOV MODEL. G. Wayne



## POSTER PRESENTATIONS AND ABSTRACTS

- P-426** IS THE USE OF DONATED SPERM ADVISABLE FOR PATIENTS WITH ADVANCED PATERNAL AGE? M. Bellés
- P-427** DOES PATERNAL AGE AFFECT LIVE BIRTH RATE IN DONOR OOCYTE CYCLES? A SYSTEMATIC REVIEW AND META-ANALYSIS T. Freour
- P-428** PATERNAL AGE HAS A SIGNIFICANT EFFECT ON CUMULATIVE LIVE BIRTH RATES (CLBR) PER INSEMINATED OOCYTE, EMBRYO TRANSFER (ET) AND EMBRYO TRANSFERRED IN IVF-ICSI WITH DONATED OOCYTES. N. Garrido Puchalt
- P-429** SIGNIFICANT EFFECT OF PATERNAL AGE ON CUMULATIVE LIVE BIRTH RATES (CLBR) PER INSEMINATED OOCYTE, EMBRYO TRANSFER (ET) AND EMBRYO TRANSFERRED IN IVF-ICSI WITH AUTOLOGOUS OOCYTES. M. Gil Juliá
- P-430** GREATER CHANGES IN HEMATOCRIT PREDICT MORE FREQUENT MAJOR ADVERSE CARDIAC EVENTS IN MEN INITIATED ON TESTOSTERONE THERAPY - A LARGE CLAIMS DATABASE ANALYSIS. T. Kohn
- P-431** COMPARING PREGNANCY OUTCOMES WITH EJACULATED SPERM AND SURGICALLY RETRIEVED SPERM AMONG INDIVIDUALS WITH CRYPTOZOOSPERMIA. K. Mantravadi
- P-432** MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA AND HISTORY OF FAILED (MTESE) MICRODISSECTION TESTICULAR SPERM EXTRACTION: OUTCOMES AFTER INTRATESTICULAR INJECTION OF PLATELET RICH PLASMA (PRP). Y. Cakiroglu
- P-433** AREA DEPRIVATION INDEX (ADI) IS NOT ASSOCIATED WITH IMPAIRED SEMEN PARAMETERS IN A POPULATION-BASED COHORT. J. A. Halpern
- P-434** IMAGE BIOMARKERS FOR THE DETECTION AND MAPPING OF SPERMATOGENIC FOCI WITHIN TESTICLES BY MAGNETIC RESONANCE (MR) IMAGING, A NOVEL NON-INVASIVE TOOL FOR AZOOSPERMIC MALES. I. Hervas Herrero
- P-435** DECREASED TOTAL MOTILE SPERM COUNT IS NOT ASSOCIATED WITH INCREASED FREQUENCY OF SEGMENTAL ANEUPLOIDIES. C. M. Canon
- P-436** EXPANDING THE GENETIC ETIOLOGY OF MULTIPLE MORPHOLOGICAL ABNORMALITIES OF THE SPERM FLAGELLA: A CASE REPORT OF TWO NOVEL DNAH1 VARIANTS. E. Anderson
- P-437** ICSI OUTCOME IN PATIENTS WITH SEVERE SPERMATOGENIC FAILURE USING EJACULATE SPERMS VS TESTICULAR SPERMS. K. Khalafalla
- P-438** INCIDENCE OF Y CHROMOSOME MICRODELETIONS AND MICRODISSECTION TESTICULAR SPERM EXTRACTION (MICRO TESE) IN JAPANESE AZOOSPERMIC PATIENTS. T. Ishikawa
- P-439** CRITICAL FERTILITY ISSUES FOR MEN WITH AZOOSPERMIA FACTOR C (AZFC) MICRODELETIONS. J. A. Marinaro
- P-440** SEMEN MICROBIOME PROFILING IN MEN WITH NON-OBSTRUCTIVE AZOOSPERMIA: A NEXT-GENERATION SEQUENCING ANALYSIS. M. Suarez Arbelaez

### PST-22 E-POSTER ABSTRACT STATION: T22





Wednesday, October 26, 2022

### POSTER SESSION 3

#### PSW-01 E-POSTER ABSTRACT STATION: W1

- P-441** WHAT IS THE BEST TECHNIQUE TO RECOVER SPERMATOZOA FROM OBSTRUCTIVE AZOOSPERMIC PATIENTS? R. Fraietta
- P-442** STRENGTHENING THE NATURAL ANTI-OXIDANT LEVELS DURING SPERMATOGENESIS. R. Makloski
- P-443** PROTOCOLS DESIGNED TO IMPROVE A MAN'S OVERALL HEALTH ARE LINKED TO INCREASED CAPACITATION ABILITY: A MULTICENTRIC, PROSPECTIVE, BLINDED ANALYSIS. F. I. Sharara
- P-444** SPERM GENOMIC AND EXTRAGENOMIC CARGO IN RECURRENT MISCARRIAGE AND IMPLANTATION FAILURE. V. Dhawan
- P-445** E-CIGARETTE AEROSOL EXPOSURE DECREASES SPERM CONCENTRATION IN MICE. D. Pelzman
- P-446** THE EFFECTS OF COLLECTION LUBRICANT REVISITED: NEWER FORMULATIONS APPEAR TO HAVE LESS EFFECT ON POST-COLLECTION SEMEN QUALITY. L. L. Penrose
- P-447** DECLINE IN THE QUALITY OF SEMEN FROM SPERM DONORS ACROSS TWO DIFFERENT CLIMATES OVER THE COURSE OF A DECADE. D. Miller
- P-448** LONG-TERM EVALUATION OF SPERM PARAMETERS FOLLOWING COVID-19 mRNA VACCINATION. P. Diaz
- P-449** RACIAL DISPARITIES IN SEMEN PARAMETERS AMONG COUPLES UNDERGOING IN VITRO FERTILIZATION. T. Alkon-Meadows
- P-450** SOCIO-ECONOMIC STATUS IS ASSOCIATED WITH ASSISTED REPRODUCTIVE TECHNOLOGY (ART) UTILIZATION AND FERTILITY OUTCOMES IN A COHORT OF SUB-FERTILE MEN. J. J. Horns

#### PSW-02 E-POSTER ABSTRACT STATION: W2

- P-451** THE IMPACT OF SMOKING ON SEMINAL BIOMARKERS IN SUBFERTILE MEN. S. L. Gruhl
- P-452** LEUKOCYTOSPERMIA DOES NOT NEGATIVELY IMPACT EMBRYOLOGIC OR CLINICAL OUTCOMES IN IN-VITRO FERTILIZATION CYCLES: FINDINGS FROM 5,435 CYCLES. P. Gill
- P-454** PROTEIN TYROSINE PHOSPHORYLATION MEASUREMENT THROUGH FLOW CYTOMETRY MAY BE A POTENTIAL NOVEL BIOMARKER OF HUMAN SPERMATOZOA CAPACITATION AND FUNCTIONAL STATUS: A PILOT STUDY. A. Ortiz Vallecillo
- P-455** RAISED SPERM DNA FRAGMENTATION INDEX, IS THERE AN EFFICIENT INTERVENTION TO OPTIMIZE REPRODUCTIVE OUTCOMES? – A FOUR ARM RANDOMIZED CONTROL TRIAL K. Mantravadi
- P-456** PHOSPHATIDYL SERINE A BIOMARKER FOR FERTILIZATION COMPETENT SPERM. R. P. Smith
- P-457** OXIDATIVE STRESS IN THE NATIVE AND PROCESSED SEMEN AS PREDICTORS OF FERTILIZATION AND PREGNANCY IN THE IVF MODEL. H. Sallam
- P-458** GEOGRAPHIC VARIATION IN SEMEN PARAMETERS FROM DATA USED FOR THE WORLD HEALTH ORGANIZATION SEMEN ANALYSIS REFERENCE RANGES. I. Feferkorn
- P-459** MEN WITH LOW CAP-SCORE™ HAVE SIMILAR FERTILIZATION RATES WITH ICSI, SIMILAR EUPLOIDY RATES, AND SIMILAR FET LIVE BIRTHS COMPARED TO MEN WITH NORMAL SCORES. F. I. Sharara



## POSTER PRESENTATIONS AND ABSTRACTS

**P-460** MAY GROWTH HORMONE HAVE A ROLE IN THE TREATMENT OF SEVERE OLIGOASTHENOZOOSPERMIA? A CONTROLLED TRIAL EVALUATING THE IGF-I SERUM LEVELS. F. Scarpellini

### PSW-03 E-POSTER ABSTRACT STATION: W3

**P-461** COMPARISON OF SPERM DNA FRAGMENTATION(DFI) AMONG NON-SMOKERS, REGULAR SMOKERS, ELECTRONIC-CIGARETTE(E-CIGARETTE) SMOKERS AND REGULAR/E-CIGARETTE SMOKERS. S. Kim

**P-462** THE ASSOCIATION BETWEEN A HISTORY OF PATERNAL VAPING AND SPONTANEOUS ABORTION. M. Eisenberg

**P-463** SINGLE COMPOUND ANTIOXIDANTS ARE SIMILARLY EFFECTIVE AS MULTI-COMPOUND ANTIOXIDANTS OVER A 3-MONTH PERIOD IN MEN WITH IDIOPATHIC INFERTILITY: A SYSTEMATIC REVIEW AND META-ANALYSIS. R. Cannarella

**P-465** VARIATION IN THE SEMEN MICROBIOME OF FERTILE MEN VERSUS MEN WITH IDIOPATHIC INFERTILITY: A SINGLE-INSTITUTION COHORT STUDY. J. T. Sigalos

**P-466** DEVELOPMENT OF A NOVEL ROBUST ARTIFICIAL INTELLIGENCE DEVELOPED SPERM DNA FRAGMENTATION TEST – PRELIMINARY FINDINGS. S. Kuroda

**P-467** THE QUESTIONABLE CLINICAL UTILITY OF SPERM MORPHOLOGY: RATE OF ISOLATED TERATOSPERMIA IN A POPULATION OF FERTILE MEN. D. Miller

**P-468** DESIGN AND VALIDATION OF A 3D PRINTED VAS DEFERENS MODEL FOR MALE FERTILITY VASOVASOSTOMY TRAINING. M. Tradewell

**P-470** THE IMPACT OF VARICOCELE REPAIR ON CONVENTIONAL SEMEN PARAMETERS IN INFERTILE MEN: A META-ANALYSIS USING PRE- AND POST-OPERATIVE DATA. A. Agarwal

### PSW-04 E-POSTER ABSTRACT STATION: W4

**P-471** CONSENSUS AND DIVERSITY IN THE MANAGEMENT OF VARICOCELE FOR MALE INFERTILITY: RESULTS OF A GLOBAL PRACTICE SURVEY AND COMPARISON WITH GUIDELINES AND RECOMMENDATIONS. A. Agarwal

**P-472** A COMPARISON OF THE EFFECTS OF ANTIOXIDANT THERAPY IN INFERTILE MEN WITH VARICOCELE FOLLOWING VARICOCELE REPAIR VERSUS NO REPAIR: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. A. Agarwal

**P-473** EFFECT OF VARICOCELE REPAIR ON CONVENTIONAL SPERM PARAMETERS IN INFERTILE PATIENTS WITH CLINICAL VARICOCELE: A SYSTEMATIC REVIEW AND META-ANALYSIS. A. Agarwal

**P-475** COVID-19 IS UNLIKELY TO AFFECT MALE FERTILITY: RESULTS OF HISTOPATHOLOGIC AND RT-PCR ANALYSIS. J. M. Masterson

**P-476** EVALUATION OF ANDROGEN SATURATION IN HUMAN CORPUS CAVERNOSUM. K. Khodamoradi

**P-477** DYSREGULATION OF THE HUMAN B-DEFENSIN 128 GENE IMPACTS SPERM FUNCTION. S. Kane

**P-478** IMPACT OF COMORBIDITIES ON MALE TESTOSTERONE LEVELS WITH AGE: RESULTS FROM THE BALTIMORE LONGITUDINAL AGING STUDY. J. T. White

**P-479** HYPOGONADISM AND TESTOSTERONE THERAPY AMONG MEN WITH KLINEFELTER SYNDROME: ANALYSIS OF A GLOBAL FEDERATED RESEARCH NETWORK. J. T. White

**P-480** THE IMPACT OF PREIMPLANTATION GENETIC TESTING ON MENTAL HEALTH OF COUPLES UNDERGOING ASSISTED REPRODUCTION TREATMENT: AFFECTIVITY AS AN INDICATOR OF QUALITY OF LIFE. B. Bianco



### PSW-05 E-POSTER ABSTRACT STATION: W5

- P-481** IS TRANSABDOMINAL (TA) IMAGING AN ADEQUATE ALTERNATIVE TO TRANSVAGINAL (TV) IMAGING IN ART CYCLES? S. Finning
- P-482** PSYCHOLOGICAL DISTRESS IN WOMEN CONSIDERING OR UNDERGOING FERTILITY TREATMENTS DURING THE OMICRON SURGE OF THE COVID-19 PANDEMIC. L. A. Kass
- P-483** EMOTIONAL ASPECTS ASSESSED BY THE DASS-21 SCALE IN PREGNANT WOMEN CONCEIVED BY IN VITRO FERTILIZATION DURING THE COVID-19 PANDEMIC. C. C. Motta
- P-484** ONE EPISODE OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME (OHSS) IN AN OOCYTE DONOR INDICATES HIGH RISK FOR REOCCURRING SEVERE OHSS IN SUBSEQUENT OOCYTE DONATION CYCLES. D. M. Tober
- P-485** OBSTETRIC OUTCOMES FOLLOWING OVARIAN HYPERSTIMULATION SYNDROME IN IVF – A COMPARISON WITH UNCOMPLICATED FRESH AND FROZEN TRANSFER CYCLES. H. Ganer Herman
- P-486** HIGH ANTI-MULLERIAN HORMONE LEVEL PREDICTS OVULATION INDUCTION FAILURE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME. M. N. Wilhoite
- P-487** OUTCOMES FOLLOWING RANDOM START PLUS PROGESTIN PRIMED OVARIAN STIMULATION IN AN OOCYTE DONATION PROGRAM. J. Farfan
- P-488** THE USE OF A LEUPROLIDE ACETATE (LA) TRIGGER DURING OVARIAN STIMULATION FOR A TRANSGENDER (TG) PERSON ON LONG TERM TESTOSTERONE (T): A CASE REPORT AND LITERATURE REVIEW. A. Taggar
- P-489** A PROSPECTIVE STUDY ON THE VALUE OF MONITORING EXOGENOUS SOURCED SERUM HUMAN CHORIONIC GONADOTROPIN LEVELS DURING IVF STIMULATION: LESSONS LEARNED FROM 2,257 CYCLES. C. K. Margolis

- P-490** THE USE OF BIOSIMILAR OR ORIGINATOR FOLLITROPIN ALFA PREPARATIONS IN PROGESTIN PRIMED OVARIAN STIMULATION PROTOCOLS (PPOS) RESULT IN SIMILAR CLINICAL OUTCOMES. M. Cruz

### PSW-06 E-POSTER ABSTRACT STATION: W6

- P-491** DOES THE USE OF CLOMIPHENE CITRATE DURING GONADOTROPIN STIMULATION IMPACT ENDOMETRIAL THICKNESS AND CLINICAL PREGNANCY RATE DURING FRESH TRANSFER CYCLES? L. Ursillo
- P-492** CAN THE DUAL TRIGGER PROTOCOL IMPACT EMBRYO PLOIDIA? E. G. Lo Turco
- P-493** PROGESTERONE PRIMED OVARIAN STIMULATION PROTOCOL (PPOS) VS GNRH ANTAGONIST FOR PATIENTS OF FREEZE ALL CYCLES: A PROSPECTIVE RANDOMISED CONTROLLED TRIAL. K. D. Nayar
- P-494** WHAT EFFECTS THE NEW MARKERS OF OVARIAN STIMULATION: FOLLICULAR OUTPUT RATE (FORT), FOLLICULE -TO-OOCYTE INDEX (FOI) AND OOCYTES RETRIEVED PER FOLLICULES (OPF)? K. Boynukalin
- P-495** PREDICTORS OF LIVE BIRTH AND RECURRENT CYCLE CANCELLATION AFTER A PREVIOUS IVF CYCLE CANCELLATION: AN ANALYSIS OF 13,340 AUTOLOGOUS CYCLES REPORTED TO SART CORS. J. Kahn
- P-496** DOES LUTEAL ESTRADIOL PRIMING (E2P) IMPROVE EUPLOIDY IN PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGTA) IN VITRO FERTILIZATION (IVF) IN SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY (SART) AGES? J. Shaw
- P-497** EFFECTS OF AUTOLOGOUS PLATELET-RICH PLASMA IN WOMEN WITH POI AND POR. J. Kim



## POSTER PRESENTATIONS AND ABSTRACTS

- P-498** IMPACT OF DUAL TRIGGER WITH GONADOTROPIN RELEASING HORMONE AGONIST AND HUMAN CHORIONIC GONADOTROPIN ON IN-VITRO FERTILIZATION CYCLE OUTCOMES OF POSEIDON GROUP 3 AND 4 EXPECTED POOR RESPONDER WOMEN. F. Tulek
- P-499** BIOSIMILAR RECOMBINANT HUMAN FSH (FOLLITROPIN ALPHA) FOR CONTROLLED OVARIAN STIMULATION IN OVULATORY WOMEN UNDERGONE IVF/ICSI CYCLES? A SYSTEMATIC REVIEW AND META-ANALYSIS. M. Youssef
- P-500** THE EFFECT OF INTRA-OVARIAN INJECTION OF PLATELET RICH PLASMA ON IN VITRO FERTILIZATION OUTCOMES IN YOUNG WOMEN WITH POOR OVARIAN RESPONSE: RESULTS FROM THE PROVA (PRP FOR OVARIAN ACTIVATION) TRIAL. N. Herlihy

### PSW-07 E-POSTER ABSTRACT STATION: W7

- P-501** CHANGING STIMULATION PROTOCOL FROM A STANDARD GnRH ANTAGONIST TO CLOMIPHENE OR LETROZOLE WITH LOW DOSE GONADOTROPINS FOR SECOND STIMULATION CYCLE IN WOMEN 40 AND OLDER DOES NOT IMPROVE CYCLE OUTCOMES. N. Adjei
- P-502** ANTAGONIST VERSUS SHORT AGONIST PROTOCOL IN POSEIDON-4 CATEGORY UNDERGOING FRESH ICSI CYCLES. R. S. Hussein
- P-503** SHORT AGONIST VERSUS ANTAGONIST PROTOCOL IN THE POSEIDON 3 GROUP; DOES IT DIFFER? R. S. Hussein
- P-504** IMPACT OF ESTROGEN SUPPLEMENTATION ON INTRAUTERINE INSEMINATION PREGNANCY SUCCESS RATES. S. Jivraj
- P-505** IMMEDIATE BREAST RECONSTRUCTION AFTER MASTECTOMY FROM THE PATIENT'S POINT OF VIEW. P. Ventruba
- P-506** PATIENTS WHO CHOOSE IN PERSON VS TELEHEALTH FIRST VISIT APPOINTMENTS: DIFFERENCES IN BASELINE CHARACTERISTICS AND ENGAGEMENT IN CARE. L. M. Roberts

- P-507** INSTAGRAM CYSTERS: WHAT'S AVAILABLE ON POLYCYSTIC OVARIAN SYNDROME? J. Cruz
- P-508** IMPACT OF DECLINING FERTILITY RATES ON US STATE POLICIES. K. Bogaard
- P-509** LEGAL, ETHICAL AND REGULATORY CHALLENGES OF ASSISTED REPRODUCTIVE TECHNOLOGY IN DEVELOPING COUNTRIES – THE CASE OF GHANA. P. E. Sefogah
- P-510** THE IMPACT OF GENETIC COUNSELORS IN ASSISTED REPRODUCTION CLINICS: A SURVEY OF PRACTICE MANAGERS. J. Miller

### PSW-08 E-POSTER ABSTRACT STATION: W8

- P-511** ENDING THE ANONYMITY OF EGG DONORS IN SHARED DONATION PROGRAMS COULD REDUCE THE NUMBER OF PARTICIPANTS. E. V. Vigil
- P-512** A SURVEY OF VIRGINITY TESTING IN THE UNITED STATES. E. Sheinin
- P-513** LGBTQ+ COUPLES AND FAMILY BUILDING PRIORITIES: WOMEN PUT A LOWER PRIORITY ON THEIR GENETICS THAN MEN. L. Schuman
- P-514** THE AVAILABILITY AND TYPE OF LGBTQ+ CONTENT ON SPERM AND EGG PROVIDER WEBSITES. K. N. Le
- P-515** PATIENT'S OPINION ON THE MAINTENANCE OF THE TELEMEDICINE MODALITY IN THE POST-PANDEMIC TIME. M. Herran
- P-516** #LEARN ABOUT FERTILITY ON TIKTOK: A CROSS SECTIONAL CONTENT ANALYSIS OF FERTILITY RELATED HASHTAGS. A. Sampson
- P-517** TELEMEDICINE HAS MADE ASSISTED REPRODUCTIVE TECHNOLOGY FAR MORE CONVENIENT FOR PATIENTS, WITH HIGH PATIENT SATISFACTION AND SUCCESS RATES. K. Koniares
- P-518** SOCIAL, CLINICAL AND LABORATORY PREDICTORS OF PATIENT ENGAGEMENT IN WOMEN UNDERGOING INFERTILITY TREATMENT. L. M. Roberts



## POSTER PRESENTATIONS AND ABSTRACTS

**P-519** GONADOTROPIN UTILIZATION DATA CAN BE USED AS AN INDICATOR OF U.S. ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET DYNAMICS F. I. Sharara

**P-520** EFFECTIVENESS OF CONTINUOUS MONITORING TEMPERATURE OF EQUIPMENT IN FERTILITY LABORATORY: A TIME-SAVING QUALITY CONTROL SYSTEM. W. Wang

### PSW-09 E-POSTER ABSTRACT STATION: W9

**P-521** REMOVING ASSESSMENT POINTS FOR TIME SAVINGS IN THE EMBRYOLOGY LABORATORY. A. R. Anderson

**P-522** IMPACT OF THE USE OF RI WITNESS ELECTRONIC WITNESSING SYSTEM ON THE IVF LABORATORY STAFF AND PATIENT EXPERIENCE. C. A. Lynch

**P-523** NO DIFFERENCE IN OUTCOMES WHEN ASSISTED REPRODUCTION TECHNOLOGY (ART) PROCEDURES ARE PERFORMED ON WEEKDAYS OR WEEKENDS. A. V. Dolinko

**P-524** MORE RISK THAN REWARD: A COST ANALYSIS OF THE AMIGOS TRIAL. E. R. Cardozo

**P-525** A SMALL DIGITAL FOOTPRINT OF PSYCHOLOGICAL SERVICES IN FERTILITY CLINICS: A WEBSITE CONTENT ANALYSIS. F. Choucair

**P-526** AN ANALYSIS OF QUALITATIVE THEMES IN YELP REVIEWS OF ASSISTED REPRODUCTIVE TECHNOLOGY (ART) PRACTICES. O. Chafitz

**P-527** SARS-COV-2 VACCINATION HESITANCY IN WOMEN WHO DESIRE FUTURE FERTILITY/PREGNANCY. A. Mobaraki

**P-528** A NEW ERA: HOW SOCIAL MEDIA CONTENT SURROUNDING "ANTI MULLERIAN HORMONE" HAS CHANGED OVER TIME. J. Reich

**P-529** GLUTAMINE AND ACAÍ SUPPLEMENTATION IMPROVES OOCYTE YIELD IN AGED MICE. W. Broussard

**P-530** MURINE PREIMPLANTATION EMBRYOS IN IVF AND TIMED MATING MODELS OF AGING. L. Yang

### PSW-10 E-POSTER ABSTRACT STATION: W10

**P-531** TRANSCRIPTOMIC EVIDENCE OF AUTOPHAGY IN CYCLOPHOSPHAMIDE-INDUCED PRIMORDIAL FOLLICLE DEPLETION. X. Hao

**P-532** SENESCENCE DURING *IN VITRO* EMBRYO DEVELOPMENT IN A MURINE MODEL. E. Schenkman

**P-533** UTILIZATION OF HAPLOID ANDROGENETIC BLASTOMERES AS FUNCTIONAL REPLICATES OF THE MALE GENOME. P. Xie

**P-534** WESTERN-STYLE DIET FEEDING IN A PRIMATE MODEL OF TESTOSTERONE INDUCED POLYCYSTIC OVARIAN SYNDROME IS ASSOCIATED WITH MENSTRUAL CYCLE SPECIFIC ALTERATIONS TO THE GUT, VAGINAL, AND CERVICAL MICROBIOME. A. M. Sassin

**P-535** EVIDENCE FOR DIFFERENTIAL EFFECTS OF  $\Delta 9$ -THC ( $\Delta 9$ -TETRAHYDROCANNABINOL) ON PRE- VERSUS POST-IMPLANTATION EMBRYONIC STEM CELLS. A. A. Armstrong

**P-536** TESTOSTERONE TREATMENT NEGATIVELY IMPACTS THE REPRODUCTIVE POTENTIAL OF FIRST GENERATION FEMALE OFFSPRING CONCEIVED BY *IN VITRO* FERTILIZATION. A. R. Schwartz

**P-537** *IN VIVO* AGE-RELATED CHANGES IN THE OVARY COINCIDE WITH WIDESPREAD REPERCUSSIONS ON GENE EXPRESSION UNIQUE TO THE SPECIFIC OVARIAN CELL POPULATIONS. M. Katz-Jaffe

**P-538** THROMBOSPONDIN-1 DEPLETION SUPPRESSED FOLLICULAR GROWTH INDUCED BY STEM CELL SECRETED FACTORS-ENRICHED PLASMA ON CHEMOTHERAPY-DAMAGED MOUSE OVARIES. S. Herraiz



## POSTER PRESENTATIONS AND ABSTRACTS

**P-539** MITOCHONDRIAL FUNCTION AND OOCYTE QUALITY IMPROVED IN AN AGING MODEL BY INTRAOVARIAN ADMINISTRATION OF A COMBINATION OF STEM CELL-SECRETED- AND PLATELET-ENCLOSED GROWTH FACTORS. M. Marchante Cuevas

**P-540** CHARACTERIZATION OF THE PROTEIN CONTENT OF PLATELET RICH PLASMA (PRP) AND A COMPARATIVE ANALYSIS OF DIFFERENCES AMONG TWO STRAINS OF MICE: IMPLICATIONS FOR REGENERATIVE STUDIES. Y. Ergun

**P-548** THE IMPACT OF DEHYDROEPIANDROSTERONE SULFATE (DHEAS) ON THE TROPHOBLAST-DERIVED PRODUCTION OF STEROID HORMONE INFLUENCED METABOLITES AT THE SITE OF HUMAN IMPLANTATION. A. Taggar

**P-549** UNCOVERING THE MISSING PIECE: COMPREHENSIVE REVIEW OF THE TRANSMISSION OF MITOCHONDRIAL DNA HETEROPLASMY TO THE PREIMPLANTATION EMBRYO. A. Novoselska

**P-550** PGE2 REGULATES THE PLASMINOGEN ACTIVATOR PATHWAY IN HUMAN ENDOMETRIAL ENDOTHELIAL CELLS THROUGH PROSTAGLANDIN-E2 RECEPTORS (PTGER) 1 AND 2. M. Thomas

### PSW-11 E-POSTER ABSTRACT STATION: W11

**P-541** MITOCHONDRIAL STRESS RESPONSE GENE CLPP IS REQUIRED FOR OOCYTE FUNCTION AND FEMALE FERTILITY. Y. Ergun

**P-542** TOWARDS AN EXPLAINABLE ARTIFICIAL INTELLIGENCE TO PREDICT BLASTOCYST FORMATION POTENTIAL FROM SINGLE OOCYTE IMAGES. A. Flores Saiffe Farías

**P-543** THE REGULATORY MECHANISM OF HISTONE DEACETYLASES IN EPIGENETIC REGULATION: EMERGING PARADIGMS FROM HDAC INHIBITION STUDIES IN UTERINE LEIOMYOSARCOMA. Q. Yang

**P-544** TRANSCRIPTOMIC COMPARISON OF IN VITRO MODELS TO STUDY HUMAN PERI-IMPLANTATION STAGE PLACENTAL DEVELOPMENT. H. Ming

**P-545** VITRIFICATION WITH DIMETHYL SULFOXIDE (DMSO) CRYOPROTECTANT ALTERS GENE AND TRANSPOSABLE ELEMENT (TE) EXPRESSION IN HUMAN OOCYTES. D. L. Keefe

**P-546** ASSESSMENT OF TELOMERE PARAMETERS IN SHORT-TERM CULTURES OF GRANULOSA CELLS. L. Chico-Sordo

**P-547** THE IMPACT OF SODIUM BICARBONATE CONCENTRATION AND MEDIA pH ON MOUSE PREIMPLANTATION EMBRYO DEVELOPMENT. H. Rogers

### PSW-12 E-POSTER ABSTRACT STATION: W12

**P-551** VARIATION IN ENDOMETRIAL STROMAL STEM CELL NUMBER THROUGHOUT THE SECRETORY PHASE. D. Parvanov

**P-552** ENDOMETRIAL ADHESION G-PROTEIN COUPLED RECEPTOR EXPRESSION IS ALTERED BY OVARIAN STIMULATION. N. R. Kalakota

**P-553** STEM CELL PROPORTIONS IN ADENOMYOSIS LESIONS AND EUTOPIC FUNCTIONAL ENDOMETRIUM OF PATIENTS WITH ADENOMYOSIS. G. Stamenov

**P-554** ASSOCIATION BETWEEN STEM CELLS AND SENESCENT CELLS IN HUMAN ENDOMETRIUM. D. Parvanov

**P-555** PRELIMINARY DATA ON THE SPATIAL DISTRIBUTION OF STEM CELLS IN THE MID-LUTEAL ENDOMETRIAL STROMA OF PATIENTS WITH RECURRENT IMPLANTATION FAILURE (RIF). M. Ruseva

**P-556** ENDOMETRIAL STROMAL STEM CELLS QUANTITIES SHOW NO ASSOCIATION WITH PATIENTS' AGE. M. Ruseva



## POSTER PRESENTATIONS AND ABSTRACTS

- P-557** VAPING LIQUID EXPOSURE INDUCES METABOLIC DISRUPTION AND REDUCED DECIDUALIZATION OF HUMAN INDUCED PLURIPOTENT STEM CELL DIFFERENTIATED ENDOMETRIAL STROMAL FIBROBLASTS. M. Ho
- P-558** FUNCTIONALLY ACTIVE MICROBIOTA LANDSCAPE IN RECURRENT IMPLANTATION FAILURE. I. Pérez-Prieto
- P-559** MECHANICAL FORCES AND THEIR DIFFERENTIAL EFFECTS ON UTERINE FIBROID AND MYOMETRIAL CELLS. R. E. Warwar

- P-569** SINGLE NUCLEOTIDE POLYMORPHISMS OF FOLATE AND HOMOCYSTEINE METABOLISM AND SUCCESS OF IVF/ICSI IN EGG DONOR RECIPIENTS RECEIVING FOLIC ACID FORTIFICATION. A. Reyes Palomares
- P-570** RELATIONSHIP BETWEEN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) CONTENT AND THE SECRETION OF PRO- AND ANTI-INFLAMMATORY CYTOKINES AFTER IMMUNOMODULATION WITH HCG. D. Parvanov

### PSW-13 E-POSTER ABSTRACT STATION: W13

- P-561** INHERITANCE OF A HETEROPLASMIC mtDNA MUTATION ASSOCIATED WITH LEIGH SYNDROME. A. Koski
- P-562** MECHANICAL STIFFNESS IS A CENTRAL REGULATOR OF MULTIPLE SIGNALING PATHWAYS INVOLVED IN UTERINE FIBROID GROWTH. M. Islam
- P-563** A NOVEL SPERM MORPHOLOGICAL DEFECT. S. Gogeva
- P-565** SINGLE SPERM ATAC-SEQ REVEALS ALTERED CHROMATIN ACCESSIBILITY AT NEURODEVELOPMENTAL GENES IN ASSOCIATION WITH PATERNAL AGING. M. M. Denomme Tignanelli
- P-566** PRESENCE OF CYTOPLASMIC MICROTUBULE ORGANIZING CENTERS AND THEIR POTENTIAL ROLE IN REGULATING SPINDLE POSITIONING IN HUMAN OOCYTES. E. A. Jannaman
- P-567** IDENTIFICATION OF NOVEL OOCYTE NUCLEAR ENVELOPE STRUCTURE INVOLVING NUCLEAR ENVELOPE MEMBRANE PROTEIN 1 (Nemp1) IN HUMAN OOCYTES. E. E. Spurlin
- P-568** SUPPRESSION PATHWAY OF ANDROGEN PRODUCTION THROUGH SECRETED PROTEINS IN MSC BASED PCOS TREATMENT. H. Park

### PSW-14 E-POSTER ABSTRACT STATION: W14

- P-571** UTERINE PATHOLOGY AND THE MICROBIOME: NEXT-GENERATION SEQUENCING OF THE 16S RIBOSOMAL SUBUNIT AMONG PATIENTS WITH FIBROIDS AND ENDOMETRIAL POLYPS. J. B. Bakkensen
- P-572** PARTIAL CHROMOSOME MOSAICISM BUT NOT WHOLE CHROMOSOME MOSAICISM IS INVERSELY CORRELATED WITH COMBINED PATIENT AGE. R. Miller
- P-573** PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) FOR PATIENTS AGED  $\leq 37$  YEARS: EVIDENCE-BASED MEDICINE DOES NOT SUPPORT ITS USE. A META-ANALYSIS F. Dieamant
- P-574** TROPHOCTODERM BIOPSY AND IMPACT ON INCIDENCE OF ECTOPIC PREGNANCY. M. C. Ozcan
- P-575** RNA-SEQ ANALYSIS OF BLASTOCOEL FLUID-CONDITIONED UNCOVERS GENES INVOLVED IN CALCIUM SIGNALING AND EXTRACELLULAR MATRIX-RECEPTOR INTERACTION PATHWAYS IN EUPLOID EMBRYOS THAT SUCCESSFULLY IMPLANT. A. Conry
- P-576** CONCORDANCE OF CHROMOSOMES WITHIN RE-BIOPSY SAMPLES OF EMBRYOS FOLLOWING INITIAL CHAOTIC RESULTS. L. Rabkina



## POSTER PRESENTATIONS AND ABSTRACTS

**P-577** SPECTRUM OF EMBRYO MOSAICISM DETECTED BY PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) DETERMINES REPRODUCTIVE OUTCOME. A. G. Besser

**P-578** EFFECTS OF THE MODE OF FORMATION OF THE FIRST DIVISION PLANE TO THE MALE AND FEMALE PRONUCLEAR AXIS ON EMBRYO PLOIDY. K. Takeuchi

**P-579** ARE PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGT-A) OUTCOMES DIFFERENT IN INFERTILE (INF) AND FERTILE (FT) PATIENTS (PTS)? E. E. Auran

**P-580** COMPARISON OF REPRODUCTIVE OUTCOMES IN PATIENTS UNDERGOING PRE-IMPLANTATION GENETIC TESTING FOR ANEUPLOIDY IN ALL EMBRYOS VERSUS ONLY IN-EXCESS EMBRYOS AFTER FRESH EMBRYO TRANSFER. C. Duncan

### PSW-15 E-POSTER ABSTRACT STATION: W15

**P-581** A NOVEL APPROACH FOR RETROSPECTIVELY ESTIMATING THE EFFICIENCY OF PGT-A TESTING. J. Cho

**P-582** COMPARISON OF THE EUPLOIDY RATE AND CLINICAL PREGNANCY RATE OF PGT-A TESTED EMBRYOS BETWEEN LONG GnRH AGONIST AND GnRH ANTAGONIST PROTOCOLS: A RETROSPECTIVE STUDY. Z. Chen

**P-583** PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY (PGTA) IMPROVES ONGOING PREGNANCY RATES IN DIMINISHED OVARIAN RESERVE REGARDLESS OF AGE. A. Garneau

**P-584** THE ROLE OF PREIMPLANTATION GENETIC TESTING IN OPTIMIZING CLINICAL OUTCOMES IN INFERTILE COUPLES WITH ADVANCING MATERNAL AGE. S. Souness

**P-585** ENDOMETRIAL PREPARATION BY HORMONE REPLACEMENT AND DAY 6 BIOPSIED EUPLOID BLASTOCYST

TRANSFER (BT) INCREASES THE RISK OF MISCARRIAGE COMPARED WITH AN OVULATORY CYCLE AND DAY 5 BIOPSIED EUPLOID BT. T. Horikawa

**P-586** COMPARISON OF CLINICAL OUTCOMES IN THE SLOW-DEVELOPING BLASTOCYSTS WITH OR WITHOUT PREIMPLANTATION GENETIC TESTING-ANEUPLOIDY (PGT-A) IN THE FROZEN-THAWED CYCLE. J. Jeong

**P-587** CLINICAL AND EMBRYOLOGICAL FACTORS ASSOCIATED WITH A HIGH PROPORTION OF MOSAIC EMBRYOS: CAN WE IDENTIFY ANYONE AT RISK? C. M. Canon

**P-588** ASSESSING PATIENT COMPLIANCE WITH RECOMMENDED PRENATAL TESTING AND IDENTIFYING PREGNANCY AND NEONATAL OUTCOMES AFTER MOSAIC EMBRYO TRANSFER. S. M. Hallisey

**P-589** THE PERFORMANCE AND IMPLICATION OF TWO WHOLE GENOME AMPLIFICATION APPROACHES FOR NON-INVASIVE GENETIC TESTING. J. Yan

**P-590** IMPACT OF DISCREPANT VARIANT CLASSIFICATION ON PREIMPLANTATION GENETIC TESTING FOR MONOGENIC CONDITIONS (PGT-M). R. I. Awwad

### PSW-16 E-POSTER ABSTRACT STATION: W16

**P-591** CONFLICT RESOLUTION: DISCORDANT REPORTING OF CANCER GENE VARIANTS: VUS VS. PATHOGENIC A. Peyser

**P-592** KARYOMAPPING AS A UNIVERSAL APPROACH FOR PGT-M: OVER 14.6 THOUSAND CYCLES, 8.6 THOUSAND CASES, 4000 MUTATIONS AND 900 DISORDERS. A. Schadwell

**P-593** SHOULD MOSAIC EMBRYO TRANSFER BE CONSIDERED WHEN EUPLOID EMBRYOS ARE NOT AVAILABLE? J. Lee

**P-594** ANALYZING OUTCOMES FROM MOSAIC EMBRYO TRANSFERS IN A SINGLE ACADEMIC PRACTICE. D. Aharon



## POSTER PRESENTATIONS AND ABSTRACTS

- P-595** UTILIZING MULTI-ETHNIC DISEASE MODELING TO UNDERSTAND THE BIOLOGICAL PROCESSES OF EMBRYONIC MOSAICISM. T. Alkon-Meadows
- P-596** MOSAIC DEVELOPMENT IS MORE STRONGLY INFLUENCED BY THE FREEZE/THAW PROCESS RATHER THAN BY THE NUMBERS OF CELLS COLLECTED AND LASER IRRADIATIONS. Y. Mizobe
- P-597** PREGNANCY OUTCOMES OF EUPLOID EMBRYOS ARE COMPARABLE TO LOW-RATE MOSAIC EMBRYOS: RESULTS OF 403 EMBRYOS FROM A SINGLE ART CENTER. M. Tüfekçi
- P-598** EMBRYO QUALITY, BUT NOT THE LEVEL AND THE TYPE OF MOSAICISM IS THE MOST IMPORTANT FACTOR INFLUENCING PREGNANCY OUTCOMES OF SINGLE MOSAIC EMBRYO TRANSFERS. T. T. Nguyen Thi Nhu
- P-599** EXTENDED IN VITRO CULTURE OF HUMAN EMBRYOS DEMONSTRATES THE POOR PREDICTIVE VALUE OF DIAGNOSING CHROMOSOMAL MOSAICISM FROM A TROPHOCTODERM BIOPSY. M. Popovic
- P-600** ARE THE MORPHOKINETIC PARAMETERS OF MOSAIC EMBRYOS DIFFERENT FROM EUPLOID EMBRYOS? RESULTS OF 1167 EMBRYOS DIAGNOSED BY NEXT GENERATION SEQUENCING (NGS) FROM A SINGLE CENTER B. Yuksel
- P-604** ACCURATE DETECTION AND FREQUENCY OF ABNORMAL PLOIDY IN THE HUMAN BLASTOCYST. C. Kratka
- P-605** EVALUATION OF CELL-FREE NUCLEIC ACIDS IN BLASTOCOEL FLUID CONDITIONED MEDIA AND ITS POTENTIAL FOR NON-INVASIVE EMBRYO ASSESSMENT. J. Meyers
- P-606** SHOULD SLOW DEVELOPING BLASTOCYSTS THAT DO NOT REACH THE FULLY EXPANDED STAGE ON DAY 5 BE BIOPSIED ON DAY 6? E. Park
- P-607** CHANGES IN UTILIZATION PGT-A OVER THE LAST DECADE. S. N. Dolitsky
- P-608** GROWTH HORMONE SUPPLEMENTATION AMELIORATES BLASTOCYST EUPLOID RATES AND PREGNANCY OUTCOMES IN PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDY CYCLES. Z. Chen
- P-609** INNER CELL MASS AND TROPHOECTODERM MORPHOLOGY PATTERN IN LOW AND HIGH-LEVEL MOSAIC EMBRYOS: WHERE ARE THEY IN THE EUPLOID-ANEUPLOID LINE? A. R. Lorenzon
- P-610** SEGMENTAL ANEUPLOIDY IN PGT-A HAS THE POTENTIAL WITH EUPLOIDY IN INNER CELL MASS. E. Cheng

### PSW-18 E-POSTER ABSTRACT STATION: W18

### PSW-17 E-POSTER ABSTRACT STATION: W17

- P-601** SEGMENTAL ANEUPLOID HOTSPOTS IDENTIFIED ACROSS THE GENOME WERE HIGHLY CONCORDANT ON REANALYSIS. R. Lee
- P-602** UNBALANCED TRANSLOCATION RATES IN PREIMPLANTATION EMBRYOS FROM COUPLES WITH COMPLEX CHROMOSOMAL REARRANGEMENT. E. Yu
- P-603** IDENTIFICATION OF MATERNAL CELL CONTAMINATION IN EMBRYO CULTURE MEDIA USING PARENTAL BUCCAL SWABS AND NON-INVASIVE PGT-A. B. Nikolai
- P-611** SYSTEMATIC REVIEW OF COST EFFECTIVENESS ANALYSES OF PRE-IMPLANTATION GENETIC TESTING. A. Nadgouda
- P-612** REBIOPSY OF EMBRYOS WITH UNDETERMINED PGT-A RESULTS DOES NOT LEAD TO A HIGHER RATE OF UNDETERMINED REBIOPSY RESULTS. M. Purdy
- P-613** PREIMPLANTATION GENETIC TESTING FOR MONOGENIC CONDITIONS (PGT-M) - EXPERIENCE OVER TWELVE YEARS AT A SINGLE TESTING LABORATORY. J. Klavarian



## POSTER PRESENTATIONS AND ABSTRACTS

**P-614** DEVELOPMENT AND VALIDATION OF A PREIMPLANTATION GENOMIC TEST FOR MONOGENIC DISORDERS USING TARGETED NEXT-GENERATION SEQUENCING (PGTMXNGS). C. Weier

**P-615** LEVERAGING THE POWER OF THE TRIO IN PGT-A TO ASSESS FOR EXPECTED PARENTAL INHERITANCE IN A TROPHECTODERM BIOPSY. A. Griffith

**P-616** SINGLE-CELL MULTI-OMIC ANALYSIS REVEALS DEFECTIVE GENE EXPRESSION AND DNA METHYLATION TOGETHER WITH CELL ANEULOIDY ASSOCIATED WITH CLEAVAGE-STAGE EMBRYO ARREST. M. Meseguer

**P-617** A QUALITY IMPROVEMENT PATHWAY (QIP) FOR FERTILITY CARE (FC) IN GENERAL OBSTETRICS AND GYNECOLOGY (GYN) CLINIC AT NEW YORK CITY (NYC)'S LARGEST PUBLIC HOSPITAL. C. M. Parra

**P-618** ONLINE FINANCIAL TRANSPARENCY FOR FERTILITY CARE: A PATIENT NEEDS ASSESSMENT. B. E. Wordekemper

**P-619** RACIAL AND SOCIOECONOMIC DISPARITIES IN 2019 EMERGENCY DEPARTMENT UTILIZATION FOR FIBROIDS IN THE UNITED STATES. N. Sekula

**P-620** DISPARITIES AND BARRIERS TO ACCESS: FINDINGS FROM AN IMPLEMENTATION STUDY OF AN AI-AUGMENTED TWO-WAY CHATBOT FOR FERTILITY CARE. A. Acker

### PSW-19 E-POSTER ABSTRACT STATION: W19

**P-621** RACIAL DISPARITIES IN MATERNAL AND NEONATAL OUTCOMES IN STATES WITH AND WITHOUT IN VITRO FERTILIZATION (IVF) INSURANCE MANDATES. M. O. Solomon

**P-622** STATE-MANDATED IN VITRO FERTILIZATION (IVF) COVERAGE REDUCES ADVERSE NEONATAL OUTCOMES. P. B. Parker

**P-623** THE IMPACT OF TELEMEDICINE ON MINORITY WOMEN'S ACCESS TO GYNECOLOGIC AND FERTILITY CARE DURING THE COVID-19 PANDEMIC. N. Z. Bomani

**P-624** GEOGRAPHIC DIFFERENCES IN SELF-REPORTED SATISFACTION WITH FERTILITY CLINICS AND DOCTORS. A. Wang

**P-625** PREVALENCE AND DETECTION OF NEWLY ACQUIRED SEXUALLY TRANSMITTED INFECTIONS IN A REPRODUCTIVE MEDICINE POPULATION. E. Reznik

**P-626** WILDFIRE SMOKE EXPOSURE AND PREGNANCY LOSS. M. S. Kornfield

**P-628** THE IMPACT OF SLEEP ON IN VITRO FERTILIZATION-EMBRYO TRANSFER OUTCOMES: A PROSPECTIVE STUDY. Z. Chen

**P-629** ASSOCIATION BETWEEN BMI AND ENDOMETRIAL THICKNESS AND IVF PREGNANCY OUTCOMES WITH EUPLOID EMBRYOS. N. N. Maredia

**P-630** IS THERE A CIRCANNUAL HORMONAL SEASONALITY IN IUI CYCLES? A 14 YEAR STUDY A. Namath

### PSW-20 E-POSTER ABSTRACT STATION: W20

**P-631** ASSOCIATION OF COVID-19 VACCINATION WITH FEMALE OVARIAN RESERVE. L. Yang

**P-632** A FAILURE TO REACH DISADVANTAGED NEIGHBORHOODS: LEGISLATION IS NOT ENOUGH TO EXPAND ACCESS TO MEDICAL FERTILITY PRESERVATION. A. S. Komorowski

**P-633** SOCIOECONOMIC STATUS AND REPRODUCTIVE OUTCOMES: A POPULATION-BASED STUDY. L. Nicholls-Dempsey

**P-635** DEMOGRAPHIC DIFFERENCES IN OVULATION INDUCTION PRESCRIBING PRACTICES AMONG INFERTILE PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME. J. Applebaum





## POSTER PRESENTATIONS AND ABSTRACTS

**P-636** EXPRESSION OF RACE/ETHNICITY PATIENTS IN REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY STUDIES COMPARED WITH OTHER OBSTETRICS AND GYNECOLOGY SUBSPECIALTIES STUDIES. A. J. Roshong

**P-637** LIVE BIRTH AND NEONATAL OUTCOMES AFTER COVID-19 VACCINATION. D. Aharon

**P-638** LIFESTYLE COACHING APP MYFERTICOACH SHOWS HIGH ADHERENCE IN FERTILITY PATIENTS. J. M. Smeenk

**P-639** PHYSICAL ACTIVITY DURING FERTILITY TREATMENT IS UNRELATED TO LIVE BIRTH. L. Cooper

**P-640** BODY MASS INDEX (BMI) IS NOT ASSOCIATED WITH OVARIAN RESPONSE TO GONADOTROPIN DURING IVF/ICSI TREATMENT: AN EVALUATION OF 4499 IVF/ICSI CYCLES. C. G. Petersen

**P-647** THIRD PARTY REPRODUCTION – WHAT'S TRENDING ON INSTAGRAM. K. Wede

**P-649** CURRENT PRACTICE OF EMBRYO DONATION: DEMOGRAPHIC AND CLINICAL FINDINGS. S. M. Salari

**P-650** DIFFERENCES IN BELIEFS AND EXPERIENCES OF EMBRYO DONATION (ED) WITH OR WITHOUT USE OF DONOR GAMETES: A SURVEY STUDY. S. J. Barishansky

### PSW-22 E-POSTER ABSTRACT STATION: W22

**P-651** ON-GOING PREGNANCY RATES HIGHER WITH IN-HOUSE OOCYTE DONORS THAN COMMERCIAL OOCYTE DONORS. A. Garneau

**P-652** VITRIFIED DONOR OOCYTES ARE ASSOCIATED WITH IMPROVED PREGNANCY OUTCOMES COMPARED WITH FRESH DONOR OOCYTES IN PATIENTS UNDERGOING SINGLE FROZEN EMBRYO TRANSFER. H. N. Glatthorn

**P-653** COMPARISON OF LABORATORY OUTCOMES USING FROZEN DONOR EGGS OBTAINED FROM DIFFERENT COMMERCIAL EGG BANKS. R. Holmes

**P-654** SELECTION RATE OF OOCYTE DONORS BASED ON RACE AND ETHNICITY. L. E. Moreta

**P-655** ASSESSING THE PREVALENCE OF REPEAT SPERM DONORS. A. Brown

**P-656** IS THERE AN ASSOCIATION BETWEEN ORIGIN OF SPERM (DONOR VS. PARTNER) AND PLACENTAL PATHOLOGY FOLLOWING INTRAUTERINE INSEMINATION (IUI) TREATMENTS? P. Cherouveim

**P-657** GAMETE DONOR ANONYMITY AND THE RIGHTS OF DONOR-CONCEIVED PEOPLE: A CHANGING LEGAL LANDSCAPE IN THE UNITED STATES. A. Coughlin

### PSW-21 E-POSTER ABSTRACT STATION: W21

**P-641** FEMALE BODY MASS INDEX (BMI) INFLUENCES PREGNANCY OUTCOMES: AN EVALUATION OF 4349 IVF/ICSI CYCLES. A. Nicoletti

**P-642** THE MECHANISM OF EXCESSIVE EXTRAVILLOUS TROPHOBLAST IN RUPTURED TUBAL PREGNANCY. Q. Zhu

**P-643** SINGLE-CELL RNA ANALYSIS OF MID-SECRETORY ENDOMETRIAL IMMUNE CELL POPULATIONS IN RECURRENT PREGNANCY LOSS. A. Bui

**P-644** DUAL ROLE OF IL-22 IN ENDOMETRIUM: ENHANCED REGENERATION AND SECONDARY INFERTILITY PREVENTION. U. Ganieva

**P-646** A PILOT STUDY ON THE SPATIAL ORGANISATION OF THE ENDOMETRIAL IMMUNE POPULATIONS IN RELATION TO EMBRYO IMPLANTATION OUTCOME. R. Ganieva



## POSTER PRESENTATIONS AND ABSTRACTS

- P-658**     **MANAGEMENT OF VARIANTS OF UNCERTAIN SIGNIFICANCE IN DONORS AND DONOR-CONCEIVED INDIVIDUALS.**  
K. Lockwood
- P-659**     **EVIDENCE OF THE NEED FOR INCREASING GENETICS EDUCATION AND SUPPORT FOR GAMETE DONOR RECIPIENTS: RECOMMENDATIONS FOR REPRODUCTIVE PROVIDERS.** K. Baldwin
- P-660**     **SPERM DONOR AVAILABILITY AND SELECTION BASED ON RACE AND ETHNICITY.** L. E. Moreta



## ABSTRACT TOPIC INDEX

Access to Care	0-97, 0-208, 0-39, 0-170, 0-206, 0-102, 0-78, 0-75, 0-73, 0-54, 0-53, 0-51, 0-94, 0-77, 0-210, 0-209, P-617, P-618, P-619, P-620, P-621, P-622, P-623, P-624, P-672
Access to Care (ART Techniques)	P-107
Access to Care (Contraception/ Family Planning)	0-109, 0-113, 0-110
Access to Care (Female Infertility Diagnosis and Treatment)	0-267, 0-99, 0-101, P-205, P-206, P-207, P-208, P-209
Access to Care (Fertility Preservation)	0-212, 0-100, 0-98, P-291, P-292, P-293, P-294, P-295
Access to Care (Male Reproduction)	0-60, P-423, P-424
Access to Care (Patient Support)	0-207, 0-231, 0-230, 0-50, P-505, P-506, P-507
Access to Care (Practice Management)	0-157, 0-159, P-517, P-518, P-519
Access to Care (Third Party Reproduction)	0-144, P-647
Adenomyosis	P-261
Age as a Factor (Female Infertility Diagnosis and Treatment)	P-205, P-210
Age as a Factor (Fertility Preservation)	0-213, 0-100, P-296, P-297, P-298
Age as a Factor (Male Reproduction)	P-426, P-427, P-428, P-429, P-430
Age as a Factor (Preimplantation Genetic Testing)	0-237, 0-236, P-572
Androgen Excess	0-106, 0-103, 0-27, P-232, P-233, P-234, P-235
Animal and Experimental Studies	0-87, 0-241, 0-125, 0-186, 0-246, 0-244, 0-245, 0-242, 0-243, P-529, P-530, P-531, P-532, P-533, P-534, P-535, P-536, P-537, P-538, P-539, P-540, P-541
ART Hormone Treatment	0-7, P-108, P-109
ART Lab	P-520, P-521, P-522
ART Long-term Pregnancy Risks	0-265, 0-247, 0-187, P-353, P-354, P-355, P-356, P-666
ART Offspring	0-164, 0-247, 0-187, P-355, P-356, P-357, P-358, P-359, P-360, P-666
ART Outcomes (Practice Management)	0-159, P-517, P-523, P-524
ART Outcomes (Preimplantation Genetic Testing)	0-237, 0-236, 0-68, 0-240, 0-239, P-573, P-574, P-575, P-576, P-577, P-578, P-579, P-580, P-581, P-582, P-583, P-584, P-585, P-586
ART Procedures and Techniques	0-160, 0-158
Artificial Intelligence (ART Lab)	0-192, 0-12, 0-136, P-1, P-2, P-3, P-4, P-5, P-6, P-7, P-8, P-9, P-10, P-11, P-12, P-13, P-14, P-15, P-16, P-17, P-19, P-20
Artificial Intelligence (ART Techniques)	0-197, 0-195, 0-191, P-110, P-111, P-112
Artificial Intelligence (Pre-Clinical and Basic Research)	0-137, P-530, P-542
Azoospermia/Oligospermia	0-138, 0-217, 0-220, 0-146, P-431, P-432, P-433, P-434, P-435, P-436, P-437, P-438, P-439, P-440, P-441
Basic Reproductive Research- Other	0-189, 0-242, 0-176, 0-180, 0-179, 0-155, 0-241, 0-175, P-531, P-532, P-533, P-534, P-543, P-544, P-545, P-546
Cancer Treatment and Reproduction	0-29, 0-86, 0-30, P-291, P-292, P-293, P-299, P-300, P-301, P-302, P-303, P-304, P-305, P-306, P-307



## ABSTRACT TOPIC INDEX

Complimentary and Integrative Medicine (Male Reproduction)	P-442, P-443, P-444
Complimentary and Integrative Medicine (Patient Support)	0-233
Continuing Medical Education	P-174, P-175, P-176
Contraception	0-114, 0-113, 0-110, 0-109, P-144
Cost and Economics	P-524
Cost and Economics (Public Health and Reproduction)	0-97, P-618, P-619, P-620, P-625
Cost and insurance Coverage (Patient Support)	P-508
Cost and Insurance Coverage (Practice Management)	P-518
Cryopreservation	0-202, 0-200, 0-201, P-3, P-21, P-22, P-23, P-24, P-25, P-26, P-27, P-28, P-29, P-30, P-31, P-32, P-33, P-35
Diabetes	0-104
Donor Embryos	0-41, 0-144, 0-223, P-649, P-650
Donor Gametes-Oocytes	0-40, 0-42, 0-140, 0-144, P-651, P-652, P-653, P-654
Donor Gametes-Sperm	0-42, P-655, P-656, P-657, P-658, P-659, P-660
Early Pregnancy	P-211, P-212
Early Pregnancy - Genetic Testing	0-262, P-147, P-148, P-149, P-150
Early Pregnancy - Hormone Levels	0-259, P-147, P-151, P-152, P-153
Early Pregnancy - Other	0-259, 0-120, 0-116, 0-2, 0-260, 0-117, P-148, P-149, P-154, P-155, P-156, P-157
Early Pregnancy Loss	0-119, 0-226, 0-118, 0-260, 0-85, 0-264, 0-115, 0-259, 0-261, P-147, P-154, P-155, P-158, P-159, P-160, P-161, P-162, P-163, P-164, P-165, P-166, P-167, P-168
Embryo Biology	0-177, 0-243, 0-178, 0-176, 0-179, P-530, P-547, P-548, P-549
Embryo Biopsy	P-113, P-114, P-115, P-116, P-117, P-118, P-119
Embryo Culture	0-194, 0-201, P-28, P-29, P-36, P-37, P-38, P-39, P-40, P-41, P-42, P-43, P-44, P-46, P-47, P-48, P-49
Embryo Selection	0-190, 0-202, 0-194, 0-12, 0-192, P-3, P-4, P-5, P-6, P-7, P-8, P-9, P-10, P-11, P-12, P-13, P-14, P-30, P-31, P-39, P-40, P-50, P-51, P-52, P-53, P-54, P-55, P-56, P-57, P-58, P-59, P-60, P-61, P-62, P-63, P-64, P-65, P-66, P-67
Embryo Transfer	0-196, 0-8, P-112, P-120, P-121, P-122, P-123, P-124, P-125, P-126, P-127, P-128
Embryos	P-28, P-41, P-42, P-43, P-53, P-54, P-55, P-56, P-57, P-58, P-59, P-60, P-61, P-68, P-69, P-70, P-71, P-72, P-73, P-74, P-75, P-661
Endocrinology	0-249, 0-153, 0-52, 0-251, P-232, P-233, P-236, P-237, P-238, P-239, P-241, P-242, P-243, P-244, P-245
Endometrial Biology	0-23, 0-178, P-550, P-551, P-552, P-553, P-554, P-555, P-556, P-557
Endometriosis	0-83, 0-15, 0-18, 0-14, 0-1, 0-16, P-261, P-262, P-263, P-264, P-265, P-266, P-267, P-270, P-271, P-272, P-273, P-274, P-275



## ABSTRACT TOPIC INDEX

Endometriosis-Basic (Female Reproductive Surgery and Gynecology)	0-18, P-266, P-267
Endometriosis-Basic (Pre-Clinical and Basic Research)	0-246, 0-17, P-550
Endometrium	0-155, 0-87, P-550, P-551, P-552, P-553, P-554, P-555, P-556, P-558, P-671
Environment and Reproduction	0-205, 0-19, 0-170, 0-95, 0-73, P-626, P-628, P-629, P-630, P-631
Environment and Toxicology	0-23, 0-124, P-535, P-557
Environmental Causes and Factors (Female Infertility Diagnosis and Treatment)	0-111, P-213, P-214, P-215, P-216, P-217
Environmental Causes and Factors (Male Reproduction)	0-20, 0-22, 0-24, 0-21, P-433, P-442, P-443, P-445, P-446, P-447, P-448
Ethics	0-39
Ethics (Fertility Preservation)	0-163
Ethics (Genetics)	0-69, P-324
Ethics (Patient Support)	P-509
Ethics (Third Party Reproduction)	0-41, P-650, P-657
Family Planning	0-109, 0-114, 0-113, P-144, P-145, P-146
Fellow Education	0-173, 0-171, 0-169, P-174, P-177, P-178, P-179, P-180
Female Reproductive Hormones	0-126, 0-15
Female Reproductive Surgery	0-121, 0-80, P-277, P-278, P-279, P-281, P-282
Female Reproductive Tract	0-105
Fertility Preservation	0-167, P-206
Fertility Preservation & Embryo Disposition	0-224, 0-228
Fertility Preservation - Cancer	0-215, 0-183, 0-26, 0-98, 0-25, 0-163, 0-216, 0-86, 0-30, 0-204, P-292, P-293, P-294, P-295, P-301, P-302, P-303, P-304, P-305, P-306, P-307, P-308, P-309, P-310, P-311, P-312, P-313, P-314, P-315, P-664
Fertility Preservation - LGBTQ Reproductive Issues	0-212, 0-49, P-297, P-313
Fertility Preservation - Non-cancer	0-214, 0-168, 0-49, 0-212, 0-213, 0-98, P-294, P-298, P-303, P-304, P-313, P-314, P-315, P-317, P-318, P-319, P-320
Fertility Preservation - Planned Oocyte Cryopreservation	0-100, 0-30, 0-204, 0-213, P-298, P-305, P-306, P-319, P-320, P-321, P-322, P-323
Fertilization	P-536, P-542
Fibroid Treatment	0-123, 0-122
Fibroid Treatment- Nonsurgical	0-123, 0-122
Fibroid Treatment- Surgical	0-121, P-278, P-283, P-284
Fibroids-Basic	0-126, 0-256, P-286, P-287
Follicle Monitoring	P-107, P-129
Genetic Counseling (Genetics)	0-130, 0-128, 0-45, 0-129, 0-5, 0-44, 0-127, 0-131, 0-72, P-325, P-326, P-327, P-328, P-329, P-330, P-331, P-332, P-333, P-334, P-335, P-665
Genetic Counseling (Patient Support)	P-510
Genetic Counseling (Preimplantation Genetic Testing)	0-46, 0-238, 0-237, 0-48, P-576, P-587, P-588, P-589, P-590, P-591, P-592





## ABSTRACT TOPIC INDEX

Genetic Counseling (Third Party Reproduction)	0-140, 0-42, P-658, P-659
Genetic Screening	0-130, 0-129, 0-47, 0-128, 0-127, 0-45, 0-28, P-325, P-326, P-327, P-328, P-329, P-330, P-331, P-332, P-336, P-665
Gynecology	0-123, 0-126, 0-122, 0-1, P-261, P-267, P-270, P-271, P-272, P-287, P-288
Health Disparities	0-94, 0-78, 0-210, 0-209, 0-75, 0-205, 0-54, 0-95, 0-91, 0-53, 0-206, 0-51, 0-102, P-619, P-620, P-621, P-622, P-623, P-624, P-625, P-632, P-633, P-635, P-636, P-672
Health Disparities (ART Lab)	P-76
Health Disparities (Contraception/ Family Planning)	0-110
Health Disparities (Female Infertility Diagnosis and Treatment)	0-101, 0-267, 0-99, P-206, P-207, P-208, P-209, P-215, P-216, P-218, P-219, P-220
Health Disparities (Fertility Preservation)	0-49, 0-203, P-295, P-297, P-307
Health Disparities (Male Reproduction)	P-433, P-449, P-450, P-451
Health Disparities (Patient Support)	0-50, 0-233, 0-207
Health Disparities (Third Party Reproduction)	P-654, P-660
Health Policy and Advocacy (Patient Support)	P-508, P-509, P-511
Health Policy and Advocacy (Public Health and Reproduction)	0-97, 0-39, 0-206, 0-102, 0-94, 0-210, P-621, P-622, P-623, P-624, P-637
HPO Axis	P-246
Human Studies	0-189, 0-177, 0-176, 0-244, 0-125, 0-175, 0-243, P-552, P-559, P-561
Hysteroscopy	P-278, P-279, P-281, P-284, P-289, P-290
ICSI	P-15, P-44, P-68, P-69, P-76, P-77, P-78, P-79, P-80, P-81, P-82, P-84, P-85, P-661
Imaging (Early Pregnancy)	0-2, P-149, P-162, P-169
Imaging (Female Infertility Diagnosis and Treatment)	0-133, 0-13, P-210, P-221, P-222, P-223
Imaging (Female Reproductive Surgery and Gynecology)	0-80, 0-15
Imaging (Male Reproduction)	P-434
Implantation	0-178, 0-90, P-548, P-549, P-558, P-671
In Vitro Maturation of Oocytes	0-10, P-4, P-39, P-55, P-68, P-70, P-86, P-87, P-88, P-89
Infertility Diagnosis, Treatment & Associated Psychosocial Aspects	0-74, 0-92, P-480, P-481, P-482
Insulin Resistance	0-106, 0-103, P-234, P-247, P-248
Intrauterine Insemination (ART Techniques)	P-130
Intrauterine Insemination (Female Infertility Diagnosis and Treatment)	P-208
Intrauterine Insemination (Infertility Treatment Outcomes)	0-33, 0-79, 0-36, 0-134, P-361, P-362, P-363, P-364
IVF	0-196, P-107, P-114, P-123, P-124, P-125, P-126, P-127, P-129, P-131, P-132, P-133, P-662
IVF Outcome Predictors- Access to Care	P-358



## ABSTRACT TOPIC INDEX

IVF Outcome Predictors- Age	P-365, P-366, P-367, P-368, P-369
IVF Outcome Predictors- Artificial Intelligence	P-370, P-371, P-372, P-373
IVF Outcome Predictors- Cryopreservation	P-359, P-374, P-375, P-376
IVF Outcome Predictors- Embryo Biology	P-377, P-378, P-379
IVF Outcome Predictors- Embryo Culture	P-380, P-381, P-382
IVF Outcome Predictors- Embryo Selection	P-372, P-383, P-384, P-385, P-667
IVF Outcome Predictors- Embryo Transfer	P-359, P-360, P-384, P-386, P-387, P-388, P-389, P-390, P-391, P-392, P-393, P-394
IVF Outcome Predictors- Embryos	P-367, P-372, P-377, P-378, P-382, P-667
IVF Outcome Predictors- Endometrium	P-375, P-389, P-390, P-391, P-395, P-396, P-397
IVF Outcome Predictors- Health Disparities	0-4, P-358, P-364, P-397, P-398, P-399, P-668
IVF Outcome Predictors- Hormone Levels	0-142, P-400, P-401, P-402, P-403, P-404, P-405, P-406, P-407
IVF Outcome Predictors- ICSI	P-408
IVF Outcome Predictors- Luteal Phase Support	0-142, 0-34, P-375, P-392
IVF Outcome Predictors- Oocytes	0-141, P-367, P-377, P-398, P-409, P-410, P-411
IVF Outcome Predictors- Other (Infertility Treatment Outcomes)	0-198, 0-35, P-355, P-364, P-373, P-398, P-399, P-403, P-412, P-413, P-414
IVF Outcome Predictors- Ovarian Reserve	0-141, 0-143, P-379, P-415
IVF Outcome Predictors- Ovarian Reserve Testing	0-35, P-379, P-415
IVF Outcome Predictors- Ovarian Stimulation	0-35, 0-62, 0-4, P-368, P-393, P-404, P-405, P-410, P-411, P-416, P-417, P-418
IVF Outcome Predictors- PGT	P-369, P-376, P-378, P-382, P-384, P-385, P-404, P-406, P-408, P-411, P-415, P-418, P-419, P-420, P-667
IVF Outcome Predictors- POI	P-368
IVF Outcome Predictors- Procedures and Techniques	0-198, 0-143, P-360, P-376, P-394
IVF Outcome Predictors- Progesterone levels	0-142, P-392, P-393, P-397, P-421
IVF Outcome Predictors- Sperm	P-408
IVF Outcome Predictors- Trigger	0-32, 0-139, P-356, P-405, P-406, P-418, P-669
Laparoscopy	0-83, P-273, P-274
Legal Reproductive Issues	0-37, 0-38
Legal Reproductive Issues (Patient Support)	P-508, P-509, P-512
Legal Reproductive Issues (Third Party Reproduction)	0-41, P-657
Leiomyoma- Basic	0-124, 0-125, P-559, P-562
LGBTQ Reproductive Issues	0-54, 0-53, 0-51
LGBTQ Reproductive Issues (Female Reproductive Endocrinology)	0-52
LGBTQ Reproductive Issues (Patient Support)	0-50, P-513, P-514
LH Surge Prevention	P-132



## ABSTRACT TOPIC INDEX

Lifestyle and Reproduction	0-75, 0-73, 0-96, 0-268, 0-77, 0-76, 0-208, 0-170, 0-78, P-625, P-628, P-629, P-630, P-638, P-639
Luteal Phase Support (ART Techniques)	P-124, P-134
Luteal Phase Support (Early Pregnancy)	P-156
Male Factor ART	0-220, 0-218, 0-57, 0-22, P-428, P-429, P-435, P-436, P-437, P-444, P-446, P-450, P-452, P-454, P-455, P-456, P-457
Male Factor Infertility	0-149, 0-148, 0-221, 0-218, 0-57, 0-22, 0-55, 0-146, 0-222, 0-56, 0-20, 0-147, 0-217, O-58, P-423, P-424, P-436, P-438, P-439, P-440, P-443, P-450, P-451, P-454, P-455, P-456, P-457, P-458, P-459, P-460, P-461, P-462, P-463, P-465, P-467, P-468, P-470, P-471, P-472, P-473
Male Reproduction and Urology	0-165, 0-21, 0-56, 0-221, 0-220, 0-222, O-58, P-438, P-439, P-441, P-446, P-447, P-448, P-462, P-463, P-467, P-468, P-470, P-471
Male Reproduction and Urology - SMRU Traveling Scholars (Male Reproduction)	0-60, 0-55, 0-149, 0-148, 0-57, O-58, P-465
Male Reproduction- Basic (Male Reproduction)	0-20, 0-146, 0-181, 0-138, 0-221, 0-55, 0-222, P-423, P-444, P-451, P-454, P-467, P-475, P-476, P-477
Male Reproduction- Basic (Pre-Clinical and Basic Research)	0-137, 0-255, 0-59, P-563, P-565
Male Reproductive Endocrinology	0-145, 0-147, P-430, P-472, P-476, P-478, P-479
Male Reproductive Hormones	0-147, 0-150, 0-145, 0-181, P-430, P-476, P-478, P-479
Male Reproductive Surgery	0-219, 0-84, P-437, P-441, P-468, P-473
Medical Student Education	0-211, P-175, P-178
Menopause	0-154
Menstrual Disorders	0-166, 0-250, 0-27, P-237, P-238, P-249
Mental Health	0-115, 0-226, P-628
Mental Health (Female Infertility Diagnosis and Treatment)	P-209
Mental Health (Female Reproductive Surgery and Gynecology)	P-275
Mental Health (Male Reproduction)	0-145, 0-150
Mental Health (Patient Support)	0-230, P-507, P-512, P-513
Mental Health (Practice Management)	0-160, P-525
Mental Health (Third Party Reproduction)	0-40, P-650
Metabolic Syndrome	0-104, P-186
Minimally Invasive Surgery	0-83, 0-121, P-273, P-274, P-279, P-284
Mosaicism	0-240, 0-71, P-572, P-577, P-578, P-587, P-588, P-593, P-594, P-595, P-596, P-597, P-598, P-599, P-600
Natural Cycle/Low Stimulation IVF	P-125
Non-IVF Related Outcome Predictors	0-198, P-403, P-407, P-413, P-414, P-422
Nursing (Fertility Preservation)	0-163
Nursing (Patient Support)	P-513
Nursing (Practice Management)	0-157
Nursing (Third Party Reproduction)	0-40



## ABSTRACT TOPIC INDEX

Nutrition (Patient Support)	0-231
Nutrition (Pre-Clinical and Basic Research)	P-548
Obesity and Metabolism	0-208, 0-77, 0-270, 0-268, P-629, P-640, P-641
Office Procedures	0-157
Oocyte Biology	0-93, 0-180, P-542, P-545, P-566, P-567
Other (ART Lab)	0-10, P-32, P-46, P-56, P-78, P-87, P-88, P-90
Other (Female Reproductive Endocrinology)	0-154, 0-248, P-239, P-249, P-250, P-251, P-252
Outcomes	0-201, 0-190, 0-194, 0-9, 0-202, P-5, P-6, P-7, P-8, P-16, P-17, P-29, P-30, P-31, P-40, P-44, P-47, P-57, P-58, P-59, P-62, P-63, P-64, P-65, P-66, P-69, P-71, P-72, P-73, P-76, P-79, P-80, P-81, P-90, P-91, P-92, P-93, P-94, P-95, P-661
Ovarian Function	0-151, 0-156, 0-252, 0-152, 0-182, 0-249, 0-153, P-241, P-242, P-246, P-248, P-250
Ovarian Hyperstimulation Syndrome	P-484, P-485
Ovarian Reserve (Endocrinology)	P-187, P-188
Ovarian Reserve (Female Infertility Diagnosis and Treatment)	0-193, 0-112, 0-6, 0-88, P-212, P-217, P-224, P-225, P-227
Ovarian Reserve Testing	P-486
Ovarian Stimulation	0-135, 0-65, 0-199, 0-63, 0-61, 0-66, P-487, P-488, P-489, P-490, P-491, P-492, P-499, P-500, P-501, P-502, P-503
Ovarian Stimulation- High Responders	P-493, P-494, P-499
Ovarian Stimulation- Poor Responders	0-64, 0-188, P-486, P-495, P-496, P-497, P-498, P-500, P-501, P-502, P-503
Ovaries	0-186, P-531, P-537, P-538, P-546, P-568
Ovulation Induction	P-486, P-498, P-499, P-502, P-503, P-504
Oxidative Stress	0-180, P-532, P-539
Patient Counseling & Support	0-228, 0-74
Patient Education	0-229, 0-232, P-181, P-182, P-183
Patient Retention/Satisfaction	0-159, P-517, P-518, P-522, P-526
Pediatric and Adolescent Gynecology (Female Infertility Diagnosis and Treatment)	0-167
Pediatric and Adolescent Gynecology (Female Reproductive Endocrinology)	0-152, 0-166, 0-151, 0-156, P-250
Pediatric and Adolescent Gynecology (Female Reproductive Surgery and Gynecology)	P-275
PGT - other	0-46, 0-67, P-579, P-580, P-596, P-601, P-602, P-603, P-604, P-605
PGT-A (aneuploidy)	0-239, 0-236, 0-68, 0-240, P-572, P-576, P-577, P-578, P-579, P-580, P-581, P-582, P-583, P-584, P-585, P-586, P-588, P-589, P-597, P-598, P-599, P-600, P-603, P-604, P-605, P-606, P-607, P-608, P-609, P-610, P-611, P-612
PGT-M (monogenic)	0-235, 0-238, 0-48, P-590, P-591, P-592, P-611, P-613, P-614
Pituitary Disease	P-189, P-190



## ABSTRACT TOPIC INDEX

Polycystic Ovary Syndrome (Endocrinology)	0-104, P-186, P-190, P-191, P-192, P-193, P-194, P-195, P-196, P-197, P-198, P-201
Polycystic Ovary Syndrome (Female Reproductive Endocrinology)	0-107, 0-248, 0-251, 0-27, 0-105, 0-106, 0-103, P-232, P-233, P-234, P-235, P-243, P-244, P-253, P-255, P-257
Practice Management	0-234, P-510
Practice Management - Other	0-161, P-519, P-527
Pregnancy Loss and Termination	0-263, 0-264, 0-115, 0-2, P-150, P-154, P-157, P-163
Preimplantation Genetic Testing (ART Techniques)	P-114, P-115, P-116, P-117, P-118, P-119
Preimplantation Genetic Testing (Genetics)	0-43, 0-131, 0-185, 0-72, 0-70, 0-184, 0-69, P-324, P-328, P-329, P-330, P-331, P-333, P-334, P-335, P-337, P-338, P-339, P-340, P-341, P-342, P-343, P-345, P-346, P-347, P-348, P-349, P-350
Primary Ovarian Insufficiency (Female Reproductive Endocrinology)	0-151, 0-156, 0-152
Procedures and Techniques (ART Lab)	0-136, 0-200, P-19, P-32, P-33, P-42, P-47, P-48, P-63, P-64, P-67, P-72, P-73, P-74, P-79, P-80, P-82, P-84, P-85, P-89, P-90, P-93, P-96, P-97, P-98, P-99, P-100
Procedures and Techniques (ART Techniques)	0-11, 0-196, P-117, P-118, P-119, P-126, P-128, P-129, P-133, P-135, P-136, P-137, P-138, P-139, P-140, P-141
Procedures and Techniques (Female Infertility Diagnosis and Treatment)	0-193, 0-82, 0-81, P-215, P-223, P-227, P-228, P-229
Procedures and Techniques (Preimplantation Genetic Testing)	0-239, P-596, P-599, P-600, P-604, P-605, P-611, P-612, P-614, P-615, P-616
Professional Development	0-211, 0-3, P-176, P-179, P-180
Psychosocial Aspects of Reproduction	0-228, 0-227, 0-225, P-481, P-482, P-483
Psychosocial Issues Concerning LGBTQ+ Populations	P-481
Puberty	0-166
Public Health and Reproduction	0-108, 0-74, P-482
Recurrent Pregnancy Loss (Early Pregnancy)	0-262, 0-261, 0-264, 0-120, 0-226, P-153, P-155, P-162, P-163, P-164, P-165, P-166, P-167, P-168, P-170, P-171, P-172, P-173
Recurrent Pregnancy Loss (Preimplantation Genetic Testing)	P-586
Regenerative Medicine & Stem Cell Biology	0-245, 0-89, 0-23, 0-242, 0-87, P-533, P-535, P-538, P-539, P-553, P-554, P-555, P-556, P-557, P-568
Reproductive Anomalies	0-80, P-281, P-282
Reproductive Biology	0-258, 0-257, 0-241, 0-186, 0-175, 0-189, 0-177, 0-93, P-540, P-541, P-561, P-563
Reproductive Education - Other	0-232, 0-211, P-182, P-183, P-184
Reproductive Endocrinology	0-255, P-534, P-536, P-568
Reproductive Genetics	0-244, 0-179, 0-59, P-540, P-541, P-545, P-546, P-549, P-558, P-561, P-569
Reproductive Genetics (non-PGT)	0-129, 0-44, 0-127, 0-28, 0-72, 0-132, 0-130, 0-185, P-324, P-332, P-349, P-350, P-351, P-352, P-665





## ABSTRACT TOPIC INDEX

Reproductive Hormones	0-105, 0-251, 0-249, 0-153, 0-52, P-235, P-237, P-238, P-239, P-241, P-242, P-243, P-244, P-245, P-246, P-251, P-252, P-258, P-259, P-260
Reproductive Immunology	0-253, 0-254, P-642, P-643, P-644, P-646
Reproductive Immunology (Pre-Clinical and Basic Research)	0-255, 0-258, 0-257, P-570
Resident Education	0-169, 0-174, 0-172, P-174, P-178, P-179, P-180, P-184, P-185
Sexuality	0-233
Social Media	0-162, P-526, P-527, P-528
Sperm	0-136, P-75, P-81, P-84, P-85, P-93, P-94, P-98, P-99, P-100, P-101, P-102, P-103
Sperm Biology	0-137, 0-245, P-563, P-565
Staff Retention/Satisfaction	0-160, 0-162, P-522
Technology	0-200, P-20, P-35, P-43, P-60, P-67, P-89, P-98, P-99, P-100, P-104, P-105, P-106
Testes (Male Reproduction)	0-181, 0-138, 0-165, P-434, P-448, P-455, P-477, P-479
Testes (Pre-Clinical and Basic Research)	0-59
The Web (Education)	0-232, P-183
The Web (Patient Support)	0-231, 0-234, P-507, P-514, P-515, P-516
The Web (Practice Management)	0-162, P-525, P-526
Thin Endometrium Treatment	P-127, P-141, P-142, P-143
Third Party Screening	0-140, P-658, P-659
Thyroid Disease	P-203, P-204
Timelapse	0-12, 0-192, 0-10, 0-190, P-9, P-10, P-11, P-12, P-13, P-14, P-17, P-19, P-20, P-46, P-48, P-49, P-61, P-65, P-66, P-87, P-88, P-95
Toxicology and Reproduction	0-95, P-630, P-631
Tubal Disease	P-231
Unexplained Infertility (Female Infertility Diagnosis and Treatment)	P-216, P-663
Unexplained Infertility (Male Reproduction)	0-56, 0-148, P-440, P-456, P-457, P-465, P-477
Urology	
Uterus	0-155, 0-124, P-559, P-571, P-671
Varicocele	0-165, P-424, P-470, P-471, P-472, P-473
Weight as a Factor	0-269, 0-31, 0-266, P-186, P-201



### AUTHOR AND FAMILY DISCLOSURES INDEX: ORAL AND POSTER SESSIONS

All oral and poster presenters at the ASRM 2021 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships an immediate family member or institution disclosed.

<sup>1</sup>Company Officer    <sup>2</sup>Direct Stockholder    <sup>3</sup>Full-Time Company Employee    <sup>4</sup>Grant Recipient    <sup>5</sup>Honoraria  
<sup>6</sup>Paid Consultant    <sup>7</sup>Speaker's Bureau    <sup>8</sup>Other    <sup>a</sup>Self    <sup>b</sup>Immediate Family Member    <sup>c</sup>Institution

Abou Ghayda, R.	GiveLegacy Inc <sup>1a</sup>
Adeleye, A.	Carrot <sup>2a</sup> ; Flo Health <sup>6a</sup>
Adsit, J.	Natera, Inc. <sup>23a</sup>
Al-Hendy, A.	Abbvie <sup>6a</sup> ; Bayer <sup>6a</sup> ; Myovant <sup>6a</sup> ; Novartis <sup>6a</sup> ; OBSEVA <sup>6a</sup>
Alvero, R. J.	Hanna Life Technologies <sup>8a</sup> (Scientific Advisor); Orchid Bioscience <sup>8a</sup> (Scientific Advisor); Parity Health <sup>8a</sup> (Strategic Advisor)
Anderson, A. R.	DX Now <sup>6a</sup> ; invo bioscience <sup>6a</sup>
Anderson Bialis, D.	FertilityIQ1a
Angle, M.	DxNow <sup>6a</sup> ; HealthinCode <sup>6a</sup> ; Overture <sup>6a</sup>
Anspach Will, E.	Fertility Pharmacy of America <sup>2b</sup> ; Ovation Fertility <sup>2b</sup>
Antaki, R.	EMD Serono <sup>a</sup>
Aradhya, S.	Invitae <sup>3a</sup>
Arbo, E.	Gedeon Richter France <sup>3a</sup>
Archer, D. F.	Agile Therapeutics <sup>68a</sup> (Stock Options); bayer healthcare <sup>4a</sup> ; Dare <sup>4a</sup> ; Exeltis <sup>6a</sup> ; InnovaGyn, Inc <sup>12a</sup> ; Mithra <sup>468a</sup> (Grant Recipient); Myovant <sup>4c</sup> ; ObsEva <sup>68a</sup> (Grant); TherapeuticsMD <sup>6a</sup>
Arjona Ferreira, J.	Myovant Sciences Inc <sup>123a</sup>
As-Sanie, S.	Bayer <sup>6a</sup> ; Eximis <sup>6a</sup> ; Myovant Sciences, Inc.-Pfizer, Inc. <sup>6a</sup> ; Organon <sup>6a</sup>
Audette, C.	CooperSurgical <sup>3a</sup>
Awonuga, A. O.	AbbVie, <sup>48a</sup> (Site PI for their studies); Bayer Healthcare Pharmaceuticals Inc <sup>8a</sup> (Co-Investigator in their study); Evidera <sup>8a</sup> (Site PI for their study); ObsEva, <sup>8a</sup> (Co-Investigator in their studies); Spruce Biosciences, Inc <sup>48a</sup> (Site PI for their study)
Bahr, F.	Vitrolife <sup>3a</sup>
Baker, V. L.	American Journal of Obstetrics and Gynecology <sup>8a</sup> (Associate Editor); EMD Serono <sup>6a</sup> ; IBSA <sup>6a</sup> ; NIH <sup>48a</sup> (research support)
Bakosi, E.	Cooper Companies <sup>23a</sup>
Baldwin, M. K.	Bayer Pharmaceuticals <sup>6a</sup> ; National Hemophilia Foundation <sup>8a</sup> (Medical and Scientific Advisory Committee); Tremeau Pharmaceuticals <sup>6a</sup>
Baldwin, K.	Generate Life Sciences (CooperSurgical) <sup>3a</sup>
Barad, D. H.	Fertility Neutraceuticals <sup>8a</sup> (Patent Royalties)
Bauer, T. A.	Everly Health, Inc <sup>3a</sup>
Baum, M.	FertilAI <sup>2a</sup>
Bedient, C. E.	Fertility Docs Uncensored Podcast <sup>1a</sup>
Begon, E.	GEDEON RICHTER <sup>4a</sup>
Ben-Meir, A.	Fairtility Ltd <sup>6a</sup>
Benadiva, C. A.	Ferring Pharmaceuticals <sup>8a</sup> (Advisory Board); Merck, Inc <sup>8a</sup> (Advisory board); Natera, Inc <sup>8a</sup> (Advisory board)
Bergelson, N.	Fairtility <sup>3a</sup>
Berger, D. S.	AAB/CRB <sup>8a</sup> (Leadership roles)
Bergh, P. A.	IVIRMA <sup>12a</sup>





## ABSTRACTS AUTHORS DISCLOSURES

Bernard, V.	Besins Healthcare <sup>8a(Speaking)</sup>
Berntsen, J.	Vitrolife <sup>23a</sup>
Bishop, C. V.	21st Century Medicine <sup>4a</sup> ; Oviva <sup>6a</sup>
Blakemore, J. K.	Anya LLC <sup>8a(Womens Health Supplements, Advisory board)</sup>
Blazek, J.	CooperSurgical <sup>23a</sup>
Bopp, B.	Fertility Pharmacy of America <sup>8a(physician participant)</sup>
Borazjani, A.	COSM Medical Corp <sup>26a</sup>
Bosch, E.	Ferring <sup>6a</sup> ; Gedeon-Richter <sup>6a</sup> ; Merck <sup>6a</sup> ; Roche <sup>6a</sup>
Bove, R.	Alexion <sup>6a</sup> ; Biogen <sup>46a</sup> ; EMD Serono <sup>6a</sup> ; Novartis <sup>46a</sup> ; Roche genentech <sup>4a</sup> ; Sanofi Genzyme <sup>6a</sup> ; TG Therapeutics <sup>6a</sup>
Brannigan, R. E.	American Board of Urology <sup>8a(Examination Committee Senior Consultant)</sup> ; American Urological Association <sup>8a(AUA Update Series Editorial Committee Member)</sup>
Broekmans, F.	Ferring B.V. <sup>8a(member advisory board)</sup> ; Merck B.V. <sup>8a(member advisory board)</sup> ; Merck B.V. <sup>4a</sup> ; Merck B.V. <sup>8a(member advisory board)</sup>
Brogaard, K.	Inherent Biosciences <sup>1a</sup>
Bromer, J.	Sema4 <sup>8a(Advisory Board)</sup>
Caldwell, S.	Labcorp <sup>23a</sup>
Caldwell, M. T.	Blue Cross Blue Shield of Michigan Foundation <sup>4a</sup> ; Henry Ford Medical Group <sup>1a</sup> ; Partners in Contraceptive Choice and Knowledge <sup>6a</sup> ; Power To Decide <sup>4a</sup> ; Robert Wood Johnson Foundation <sup>4a</sup>
Callum, P.	Generate Life Sciences <sup>3a</sup> ; Tandem Genetics <sup>18a(Owner)</sup>
Cameron, E.	CooperSurgical <sup>3a</sup> ; The Cooper Companies <sup>2a</sup>
Campbell, A. J.	CARE Fertility <sup>23a</sup>
Cardona, C.	Androvia LifeSciences <sup>3a</sup>
Cardozo, E. R.	Parity Health <sup>1a</sup>
Catherino, A. B.	EMD Serono <sup>3a</sup>
Cedars, M. I.	Ferring pharmaceutical <sup>4a</sup>
Chavez-Badiola, A.	IVF 2.0 LTD <sup>128a(Founding Partner)</sup>
Chen, S. H.	Cooper Genomics <sup>57a</sup> ; EMD Serono <sup>5a</sup> ; EngagedMD <sup>6a</sup> ; FertilityAnswers <sup>2a</sup> ; Genomic Prediction <sup>8a(Medical Advisory Board)</sup>
Cheng, P.	FirmTech, Inc <sup>2a</sup>
Cho, J.	Alife Health <sup>3a</sup>
Chou, C.	Natera <sup>23a</sup>
Cinquin, A.	Fujifilm <sup>3a</sup>
Cohen, J.	Althea Science <sup>12a</sup> ; DADI <sup>2a</sup> ; IVF 2.0 <sup>12a</sup> ; KindBody <sup>2a</sup> ; TMRW <sup>2a</sup>
Collares, F.	EMD Serono Inc <sup>3a</sup>
Collins, M. G.	TMRW Life Sciences <sup>3a</sup>
Consalvo, A.	Enteris BioPharma, Inc. <sup>3a</sup>
Copperman, A. B.	Progyny <sup>18a(Medical Director)</sup> ; Sema4 <sup>18a(CMO)</sup>
Coull, B.	Johnson & Johnson <sup>2a</sup>
Coutifaris, C.	AGOS <sup>1a</sup>
Covey, J.	Kaiser Permanente Washington Health Research Institute <sup>8a(part-time employee)</sup>
D'Alton, M.	Merck for Mothers <sup>8a(Advisory Board Member)</sup>
Daggs, T.	Enteris BioPharma, Inc. <sup>3a</sup>
Dart, C.	Evoform <sup>6a</sup>
Daumeyer, N. M.	Everly Health <sup>3a</sup>



## ABSTRACTS AUTHORS DISCLOSURES

Davis, G. M.	Advocate Genetics <sup>12a</sup> ; EMPOWER DONATION LLC <sup>12a</sup>
Desai, V.	Amgen <sup>45b</sup> ; AstraZenica <sup>46b</sup> ; Bayer <sup>6b</sup> ; Boreinger-Ingelheim <sup>46b</sup> ; BristolMeyer <sup>6b</sup> ; CooperSurgical <sup>3a</sup> ; Cytokinetics <sup>46b</sup> ; Novartis <sup>45b</sup>
Di Berardino, T.	CooperSurgical <sup>3a</sup>
Diakiw, S. M.	Presagen/Life Whisperer Diagnostics <sup>23a</sup>
Diamond, M. P.	AbbVie, <sup>4a</sup> ; Advanced Reproductive Care <sup>28a(Board of Directors)</sup> ; Bayer <sup>4a</sup> ; ObsEva <sup>4a</sup> ; Seikagaku <sup>6a</sup>
Divaraniya, A.	Oova, Inc. <sup>123a</sup>
Dokras, A.	Ablacare <sup>6a</sup> ; GSK <sup>6a</sup> ; Veera Health <sup>6a</sup>
Doody, K. J.	Ferring Pharmaceutical <sup>6a</sup> ; INVO Bioscience <sup>28a(Board member)</sup> ; Organon Pharmaceutical <sup>6a</sup>
Drakeley, A. J.	IVF 2.0 <sup>12a</sup>
Dumesic, D. A.	Spruce Biosciences Inc <sup>6a</sup>
Dupree, J. M.	Blue Cross Blue Shield of Michigan <sup>4a</sup> ; Lipocine <sup>2a</sup> ; NICHD <sup>4a</sup> ; Posterity Health <sup>8a(Medical Advisory Board, with equity)</sup>
Dyr, B.	LabCorp <sup>3a</sup>
Ebner, T.	Esco <sup>5a</sup> ; Gynemed <sup>5a</sup> ; Hamilton Thorne <sup>8a(Scientific Board Member)</sup>
Eccles, J.	Genomic Prediction <sup>3a</sup>
Eckart, E.	Amgen Inc. <sup>2a</sup> ; Cassava Sciences Inc. <sup>2b</sup> ; Johnson & Johnson <sup>2a</sup> ; Johnson & Johnson <sup>2b</sup>
Eisenberg, M.	Hannah <sup>8a(Advisor)</sup> ; Ro <sup>8a(Advisor)</sup> ; Sandstone <sup>8a(Advisor)</sup>
Erllich, I.	Fairtility <sup>12a</sup>
Estes, S. J.	Abbvie <sup>68a(Research funding (Institution))</sup> ; Ferring <sup>8c(Research funding)</sup> ; Obseva <sup>8c(Research funding)</sup>
Esteves, S. C.	Medea <sup>7a</sup> ; Merck <sup>5a</sup>
Farland, L. V.	PCRS <sup>8a(Invited Speaker, Expenses paid)</sup> ; Smith and Nephew <sup>2b</sup>
Farmer, A.	Takara Bio, Inc. <sup>3a</sup>
Faulkner, N.	InVitae <sup>3a</sup>
Ferrando, C. A.	UpToDate <sup>5a</sup>
Fischer, R.	ICU Medical <sup>2a</sup> ; Johnson & Johnson <sup>2a</sup> ; Pfizer, Inc. Pharmaceuticals <sup>2a</sup>
Fjeldstad, J.	Future Fertility <sup>3a</sup>
Frakes, E. P.	AbbVie <sup>23a</sup>
Gada, R.	ReUnite Rx <sup>1a</sup>
Gamboli, R.	Lo.Li. Pharma <sup>3a</sup>
Garcia Pascual, C. M.	Igenomix <sup>3a</sup>
Garcia-Velasco, J. A.	Ferring <sup>4c</sup> ; Gedeon Richter <sup>4c</sup> ; Merck <sup>4c</sup>
Gargiulo, A. R.	Lumenis <sup>6a</sup> ; medtronic <sup>6a</sup>
Gavin, K. M.	Everly Health <sup>3a</sup>
Gilbert, M. L.	Exeltis USA, Inc <sup>3a</sup>
Ginsburg, E. S.	elsevier <sup>8a(associate editor of Fertility and Sterility)</sup> ; legal case reviewer <sup>6a</sup> ; teladoc <sup>6a</sup> ; UptoDate <sup>8a(reviewing possible malpractice cases)</sup>
Giudice, L. C.	ForEndo <sup>6a</sup> ; MERCK <sup>2a</sup> ; Myovant <sup>6a</sup> ; PFIZER <sup>2a</sup>
Gleicher, N.	Fertility Nutraceuticals <sup>2a</sup>
Goddijn, M.	Ferring, unrelated to project <sup>4a</sup> ; Guerbet, unrelated to project <sup>4a</sup> ; Merck, unrelated to project <sup>4a</sup>
Goldfarb, S.	Ms. Medicine LLC <sup>6a</sup> ; NanOlogy <sup>6a</sup> ; Paxman Cooling LTD <sup>4a</sup> ; Sprout Pharmaceuticals <sup>4a</sup>
Goodall, N.	CooperGenomics, A CooperSurgical Company <sup>3a</sup>
Goodman, L. R.	LINA Medical <sup>a</sup>
Gordon, T.	CooperGenomics <sup>23a</sup>
Gracia, C.	ABOG <sup>8a(REI Division Member)</sup>
Graham, E.	Novartis <sup>6a</sup> ; Roche <sup>6a</sup>



## ABSTRACTS AUTHORS DISCLOSURES

Griffith, A.	CooperSurgical <sup>3a</sup>
Grifo, J. A.	Inception Fertility <sup>2a</sup>
Grill, E. A.	Donor Egg Meeting <sup>567a</sup> ; FertiCalm, FertiStrong, Aliz LLC <sup>1a</sup> ; Merck <sup>7a</sup>
Groff, A.	Conception Biosciences <sup>3a</sup>
Habermann, E. B.	CDC NCIPC <sup>8a</sup> (Member, Board of Scientific Counselors)
Haddad, G.	Aspire houston fertility institute <sup>1a</sup>
Hall, J. M.	Life Whisperer Diagnostics Inc. <sup>12a</sup> ; Life Whisperer Diagnostics Pty Ltd <sup>12a</sup> ; Presagen Holdings Pty Ltd <sup>12a</sup>
Halperin, F.	Form Health <sup>23a</sup>
Handyside, A.	Vitrolife <sup>6a</sup>
Hansen, K. R.	Ablacare <sup>8a</sup> (consultant, DSMB); Ferring <sup>4a</sup> ; NICHD <sup>4a</sup>
Hanson, M.	Recurrent Pregnancy Loss Association <sup>1a</sup>
Har-Vardi, I.	Fairtility <sup>6a</sup>
Hariton, E.	ALife Health <sup>6a</sup> ; Best Shot Inc <sup>a</sup> ; Evernow <sup>6a</sup> ; Fertilidad Integral <sup>a</sup> ; Ro <sup>3b</sup> ; Ro <sup>6a</sup> ; Ro <sup>3b</sup>
Hart, R. J.	CHA-SMG <sup>26a</sup> ; Ferring pharmaceuticals <sup>4a</sup> ; Merck <sup>5a</sup>
Hawkins Bressler, L.	2 Minute Medicine <sup>1a</sup> ; Teladoc Health <sup>3b</sup>
Hayward, B.	EMD Serono, Inc. <sup>3a</sup>
Heiser, P. W.	Ferring Pharmaceuticals, Inc. <sup>3a</sup>
Heller, D. A.	Concarlo Therapeutics Inc. <sup>6a</sup> ; Goldilocks Therapeutics <sup>12a</sup> ; Lime Therapeutics <sup>12a</sup> ; Mediphage Bioceuticals Inc. <sup>6a</sup> ; Nanorobotics Inc <sup>6a</sup> ; Resident Diagnostics Inc. <sup>2a</sup>
Hennebold, J. D.	iGenomix <sup>8a</sup> (Sponsored Research Agreement); Regeneron <sup>8a</sup> (Sponsored Research Agreement)
Herati, A. S.	Dadi <sup>8a</sup> (Advisor); Lina <sup>6a</sup>
Hershlag, A.	Modern Fertility <sup>128a</sup> (Chief Medical Officer, part-time)
Hickman, C.	Fairtility <sup>12356a</sup>
Hill, M. J.	Thread Robotics <sup>a</sup>
Hilpert, J.	Bayer AG <sup>3a</sup>
Hoffman, D.	ALife <sup>28a</sup> (Consultant); US Fertility <sup>28a</sup> (Board Observer)
Homer, M. V.	U. S. Fertility <sup>2a</sup> ; USF Pharmaceutical Contracting Alliance <sup>2a</sup>
Hotaling, J.	advanced conceptions <sup>2a</sup> ; andro360 <sup>2a</sup> ; coloplast <sup>a</sup> ; FirmTech <sup>1a</sup> ; Maximus <sup>2a</sup> ; StreamDx <sup>2a</sup> ; Turtle Health <sup>6a</sup> ; UCB, Pfizer, Inc., Novartis, Abbvie, Janssen, Lilly. <sup>7b</sup>
Hourvitz, R.	FertilAI <sup>123a</sup>
Hovanes, K.	Natera <sup>23a</sup>
Howard, B.	Evoform Biosciences, Inc. <sup>3a</sup>
Howard, K. L.	Natera, Inc. <sup>23a</sup>
Howles, C. M.	AIVF <sup>6a</sup> ; Theramex UK Ltd <sup>6a</sup>
Huang, J.	PCOS Innovations LLC <sup>1a</sup>
Hullender Rubin, L. E.	Modern Fertility <sup>6a</sup> ; Rosefinch Health <sup>1a</sup>
Hunsche, E.	Myovant Sciences GmbH <sup>23a</sup>
Hurley, E. G.	Innoviva Inc <sup>2b</sup> ; Theravance Biopharma Inc <sup>2b</sup>
Isley, L.	Generate Life Sciences <sup>3a</sup>
Jackman, J. M.	Abbvie <sup>7a</sup>
Jacobs, D.	Banner Life Sciences <sup>6a</sup> ; Biogen <sup>6a</sup> ; Bristol Myers Squibb <sup>6a</sup> ; EMD Serono <sup>6a</sup> ; EMD SERONO <sup>4a</sup> ; Genentech <sup>6a</sup> ; Genentech <sup>4a</sup> ; Horizon <sup>5a</sup> ; Novartis <sup>5a</sup> ; Sanofi Genzyme <sup>5a</sup>
Jalas, C.	Juno Genetics <sup>3a</sup>
Jenkins, T. G.	Inherent Biosciences <sup>26a</sup>





## ABSTRACTS AUTHORS DISCLOSURES

Johansen, M.	Vitrolife <sup>3a</sup> ; Vitrolife <sup>2b</sup>
Johnstone, E.	American Board of Obstetrics and Gynecology <sup>8a</sup> (REI Division Member)
Jukic, A. Z.	Society for Pediatric and Perinatal Epidemiologic Research <sup>8a</sup> (executive committee member)
Kadoch, I.	Ferring <sup>45a</sup>
Kanakasabapathy, M.	XX <sup>8a</sup> (Licensed an IP)
Kang, S. M.	Quanovate Tech Inc. <sup>1a</sup>
Katz, I.	REACH <sup>3a</sup>
Kavoussi, P. K.	Acerus Pharmaceuticals <sup>7a</sup> ; Antares Pharmaceuticals <sup>7a</sup> ; Clarus Therapeutics <sup>7a</sup>
Keelan, J. A.	SpeeDx Pty Ltd <sup>8a</sup> (Patent licensed to this Company)
Kelly, L.	Ferring Pharmaceuticals <sup>3a</sup>
Kim, J.	Takara Bio USA <sup>3a</sup>
Klavanian, J.	Natera <sup>3a</sup>
Kort, J. D.	Progyny <sup>6a</sup>
Kragh, M. F.	Vitrolife <sup>34a</sup> ; Vitrolife <sup>2a</sup>
Krantz, D.	Eurofins NTD, LLC <sup>3a</sup>
Kreitzberg, D.	Everly Health <sup>3a</sup>
Krivoi, A.	Future Fertility <sup>12a</sup>
Krychman, M.	Exeltis <sup>6a</sup>
Külah, H.	Cellsway <sup>2a</sup> ; Mikro Biyosistemler <sup>8a</sup> (Board Member)
Kumar, N.	Ambit Inc <sup>6a</sup> ; Invitae Corp <sup>23a</sup> ; Oova Inc <sup>6a</sup>
Kunselman, A. R.	Merck <sup>2a</sup> ; Novavax <sup>2a</sup>
Lanes, A.	BORN Ontario <sup>6a</sup>
Languille, S.	GEDEON RICHTER <sup>8a</sup> (Agreement between Gedeon Richter France and Monitoring Force (CRO where I am an employee))
Lapczynski, M. S.	TMRW Life Sciences <sup>23a</sup>
Large, M.	CooperSurgical <sup>23a</sup>
Lassen, J. T.	Vitrolife <sup>3a</sup>
Laven, J.	Ansh Labs <sup>45a</sup> ; Ferring <sup>456a</sup> ; Titus Healthcare <sup>5a</sup>
Le, B.	Inflammatix, Inc. <sup>3a</sup>
Lee, H.	Kai Health, Inc. <sup>123a</sup>
Lee, B.	Baylor Genetics <sup>8a</sup> (Board of Directors); Biomarin <sup>6a</sup> ; Kirin Kyowa <sup>4a</sup> ; Sanofi <sup>4a</sup>
Legro, R. S.	Guerbet <sup>4a</sup> ; Insudd <sup>6a</sup> ; Novo Nordisk <sup>6a</sup>
Leondires, M. P.	Gays with Kids <sup>1a</sup> ; Nest Egg Foundation <sup>8a</sup> (Volunteer board member); Reproductive Alliance <sup>8a</sup> (Volunteer Board Member)
Lessey, B. A.	CiceroDX <sup>8a</sup> (intellectual property licensing and royalties)
Letourneau, J. M.	Alnylam Pharmaceuticals <sup>6a</sup> ; EMD Serono <sup>6a</sup>
Levy, B.	Igenomix <sup>6a</sup> ; Natera <sup>6a</sup>
Libermann, T. A.	Google Ventures <sup>8b</sup> (Part time Employee); Nimbus Therapeutics <sup>2b</sup> ; Rome Therapeutics <sup>123b</sup> ; Schroedinger <sup>2b</sup>
Lim, S.	Singapore General Hospital <sup>3a</sup>
Lin, P. C.	alto pharmacy <sup>2a</sup> ; Win Fertility <sup>8a</sup> (Medical Advisory Board)
Lispi, M.	Merck Healthcare KGaA <sup>3a</sup>
Lockwood, K.	Generate Life Sciences <sup>3a</sup>
Loewke, K. E.	Alife Health, Inc. <sup>3a</sup>
Luka, A.	Ferring Pharmaceuticals <sup>3a</sup>
Lukes, A. S.	AbbVie <sup>47a</sup> ; Astellas <sup>4c</sup> ; Bayer <sup>4c</sup> ; Ferring <sup>4c</sup> ; Forendo <sup>56a</sup> ; Gynesonics <sup>4c</sup> ; Merck <sup>4c</sup> ; Myovant <sup>456a</sup> ; ObsEva <sup>4c</sup> ; Organon <sup>c</sup> ; Sebela <sup>4c</sup>



## ABSTRACTS AUTHORS DISCLOSURES

Lundy, S.	Urology Care Foundation <sup>4a</sup> ; Wolters Kluwer <sup>6a</sup>
Luque, J.	California Cryobank/Generate Life Sciences <sup>3a</sup> ; Progenity <sup>3a</sup>
Luz, A.	FertilAI <sup>12a</sup>
Lynch, C. A.	CooperSurgical <sup>3a</sup>
Lysiak, J. J.	PS-Fertility <sup>1a</sup>
Mahony, M. C.	DxNow, Inc. <sup>6a</sup> ; EMD Serono US Medical Affairs <sup>67a</sup> ; MedTech for Solutions <sup>6a</sup> ; TMRW <sup>6a</sup>
Maisenbacher, M. K.	Natera <sup>23a</sup>
Maman, E.	FertilAI <sup>2a</sup>
Mani, K.	CooperSurgical <sup>3a</sup>
Marin, D.	Genomic Prediction <sup>3a</sup>
Martins da Silva, S.	ESHRE <sup>8a</sup> (Associate Editor)
Masterson, T. A.	endo pharmaceuticals <sup>4a</sup> ; endo pharmaceuticals <sup>6a</sup>
Mathur, V.	Equillum <sup>6a</sup> ; Escient <sup>6a</sup> ; Galderma <sup>6a</sup> ; myovant <sup>6a</sup> ; Pathyls <sup>a</sup> ; Rallybio <sup>a</sup> ; Trevi <sup>68a</sup> (DSMB); Tricida <sup>68a</sup> (stock options, patents); Unicycive <sup>a</sup> (stock options, patents)
Mayfield, B. P.	Precision Analytical <sup>3a</sup>
McClung, M. R.	Alexion <sup>7a</sup> ; Amgen <sup>567a</sup> ; Myovant <sup>6a</sup>
McCoy, R. C.	Johns Hopkins University <sup>8a</sup> (I am a co-inventor on a provisional patent application by Johns Hopkins University, where I am an employee: <a href="https://www.biorxiv.org/content/10.1101/2021.05.18.444721v1">https://www.biorxiv.org/content/10.1101/2021.05.18.444721v1</a> )
McCulloh, D. H.	Biogenetics Corporation <sup>1a</sup> ; Buffalo Infertility and IVF Associates <sup>6a</sup> ; Ferring Pharmaceuticals <sup>5a</sup> ; GranataBio <sup>68a</sup> (Member Advisory Board); NYU Langone Fertility Center <sup>3a</sup> ; ReproART: Georgian American Center for Reproductive Medicine <sup>1a</sup> ; Sperm and Embryo Bank of New York <sup>1a</sup>
McKissock, K.	CooperSurgical <sup>3a</sup>
McWilliams, K.	CooperSurgical <sup>23a</sup>
Mehta, A.	Posterity Health <sup>8a</sup> (Medical Advisory Board Member)
Meltzer, J. T.	Natera <sup>23a</sup>
Mendizabal, G.	IVF2.0 Limited <sup>6a</sup>
Mercuri, N.	Future Fertility <sup>3a</sup>
Meriano, J.	future fertility <sup>2a</sup> ; synergyne <sup>8a</sup> (consultant)
Meseguer, M.	Angelin <sup>8a</sup> (Speaker Fee); CooperSurgical <sup>18a</sup> (Speaker); Ferring <sup>8a</sup> (Speaker Fee); Merck <sup>8a</sup> (Speaker Fee); Theramex <sup>8a</sup> (Speaker fee); Vitrolife <sup>8a</sup> (speaker fee)
Meyer, E. C.	TMRW Life Sciences, Inc <sup>6a</sup>
Meyers, J.	Takara Bio USA <sup>1a</sup>
Miller, J.	CooperSurgical <sup>3a</sup>
Miller, K.	Genomic Prediction <sup>8a</sup> (Scientific Board); IFFS <sup>68a</sup> (Managing Editor, Surveillance); Igenomix <sup>8a</sup> (Scientific Board); Innovation Fertility <sup>1a</sup> ; MedTech For Solutions <sup>1a</sup>
Miller, R.	Inherent Biosciences <sup>3a</sup>
Miller, C. E.	AbbVie <sup>a</sup> ; AbbVie <sup>678a</sup> (Advisory Board Member); AbbaCare <sup>6a</sup> ; Allergen <sup>a</sup> ; Blue Seas Med Spa <sup>8a</sup> (Investor); Espiner Medical <sup>6a</sup> ; Gynesonics <sup>26a</sup> ; Halt Medical <sup>2a</sup> ; Karl Storz <sup>4a</sup> ; LiNA Medical <sup>6a</sup> ; Medtronic <sup>6a</sup> ; RF Medical USA <sup>6a</sup> ; Seikagaku Corporation <sup>6a</sup> ; Temple Therapeutics B.V. <sup>28a</sup> (Advisory Board Member)
Mills, J.	Boston Scientific <sup>4c</sup> ; Endo <sup>4c</sup>
Missmer, S. A.	Abbott <sup>a</sup> ; AbbVie <sup>a</sup> ; AbbVie <sup>4a</sup> ; Frontiers in Reproductive Health <sup>5a</sup>
Modrzejewski, K.	EMD Serono <sup>3a</sup>
Mol, B. W.	Ferring <sup>4a</sup> ; Guerbet <sup>7a</sup> ; Merck <sup>6a</sup> ; ObsEva <sup>6a</sup>
Moravek, M. B.	NUVO <sup>8b</sup> (Investor)
Morris, J. R.	Evernow <sup>6a</sup>
Morris, M. E.	Micropoint LLC <sup>6a</sup>



## ABSTRACTS AUTHORS DISCLOSURES

Mumford, S. L.	Society for Epidemiologic Research <sup>8a</sup> (Member at Large on Executive Committee)
Munne, S.	Overture Life <sup>1a</sup>
Murphy, A.	TMRW Life Sciences <sup>3a</sup>
Nahar, A.	Colorado Center for Reproductive Medicine <sup>3a</sup>
Naseri, S.	Qurasense Inc <sup>123a</sup>
Nassab, P.	Igenomix <sup>3a</sup>
Navarrete, F.	Givelegacy inc <sup>3a</sup>
Navarro Sanchez, L.	Igenomix <sup>3a</sup>
Nayot, D.	Future Fertility <sup>26a</sup>
Neal-Perry, G. S.	Astell <sup>8a</sup> (Scientific Board Member); Merck <sup>4a</sup>
Neitzel, D.	Invitae <sup>23a</sup>
Nejat, E. J.	Generation Next Fertility <sup>123a</sup>
Newman, R.	FUJIFILM Irvine Scientific <sup>13a</sup>
Newman, M.	Precision Analytical <sup>1a</sup>
Ng, J. W.	AbbVie Inc. <sup>3a</sup>
Nikolai, B.	CooperSurgical <sup>3a</sup>
Nifibhon, V.	Labcorp <sup>3a</sup>
O'Leary, K. M.	Abbvie <sup>7a</sup>
O'Neill, H. C.	Hertility Health <sup>12a</sup>
Onel, K.	Sema4 <sup>123a</sup>
Ostermeier, G. C.	Androvia LifeSciences <sup>3a</sup>
Padmanabhan, K.	Takara Bio USA <sup>3a</sup>
Pal, L.	Ferring <sup>8a</sup> (Advisory board); Flo Health <sup>6a</sup>
Paolino, N. C.	CooperSurgical <sup>a</sup>
Patrick, J. L.	Revolution Genetics <sup>1a</sup>
Patrizio, P.	FertileSafe Ltd <sup>8a</sup> (Co-founder)
Peigné, M.	Merck <sup>6a</sup>
Peng, Q.	CRaTE Fertility clinic <sup>3a</sup>
Penrose, L. L.	Reproductive Solutions <sup>26a</sup>
Penzias, A. S.	AutoIVF <sup>8a</sup> (Member - Clinical Advisory Board); Fairtility <sup>8a</sup> (Member - Scientific Advisory Board); Resolve <sup>8a</sup> (Member - Physicians Council)
Pepin, D.	Oviva Therapeutics <sup>26a</sup>
Perry, J. S.	Myovant Sciences, Inc. <sup>23a</sup>
Perugini, D.	Life Whisperer <sup>123a</sup> ; Presagen <sup>123a</sup>
Perugini, M.	Life Whisperer <sup>123a</sup> ; Presagen <sup>123a</sup>
Petersen, B. M.	CARE <sup>8a</sup> (Consultant)
Phy, J. L.	Co-founder, PCOS Innovations <sup>1a</sup>
Pisarska, M. D.	Ferring <sup>6a</sup> ; Natera <sup>5a</sup>
Poll, S.	Invitae <sup>23a</sup>
Polotsky, A. J.	PrimaTemp <sup>5a</sup>
Polpully Variam, S.	Enteris BioPharma Inc <sup>3a</sup>
Prien, S. D.	RSI Technologies Group <sup>26a</sup>
Rabkina, L.	Igenomix <sup>3a</sup> ; Medneon <sup>6a</sup>
Ramakrishnan, K.	Enteris BioPharma <sup>3a</sup>
Ramasamy, R.	Acerus Pharmaceuticals <sup>4a</sup>



## ABSTRACTS AUTHORS DISCLOSURES

Rana, B.	Genomic Prediction <sup>3a</sup>
Rasums, A.	Enteris Biopharma <sup>3a</sup>
Ratts, V.	Aesculap Implant Systems <sup>6b</sup> ; Bill and Melinda Gates Foundation <sup>4a</sup> ; Kaliber <sup>2b</sup> ; Medtronic <sup>48b</sup> (Royalties); Midwest Imaging <sup>2b</sup> ; MRI Partners of Chesterfield <sup>2b</sup> ; Nocimed <sup>2b</sup> ; Optum Fertility Solutions Expert Panel <sup>8a</sup> (Expert panel member); OuroBoros <sup>2b</sup> ; Pain and Rehabilitation Specialists, LLC <sup>2b</sup> ; Paradigm Spine <sup>2b</sup> ; St. Louis Spine and Orthopedic Surgery Center <sup>2b</sup>
Richter, K. S.	ASRM/SREI <sup>6a</sup> ; GranataBio <sup>6a</sup> ; San Diego Fertility Center <sup>a</sup> ; TMRW <sup>6a</sup>
Rimestad, J.	Vitrolife <sup>23a</sup>
Roberts, D. J.	American Registry of Pathology <sup>8a</sup> (Author); Cambridge University Press <sup>8a</sup> (Author); UpToDate <sup>8a</sup> (Author)
Rodriguez, S.	Sequence46 3a
Roudebush, W. E.	Elite Diagnostics <sup>68a</sup> (lab director consultant)
Rubin, A.	Enteris BioPharma Inc. <sup>6a</sup>
Rubio Llusa, C.	Igenomix <sup>8a</sup> (employment with Igenomix )
Rutzick, S.	Igenomix USA <sup>a</sup>
Ryan, R.	Eisai Inc <sup>3b</sup>
Sakkas, D.	ALIFE <sup>8a</sup> (Options Holder); EMD Serono <sup>7a</sup> ; Igenomix <sup>8a</sup> (Scientific Advisory Board); Legacy <sup>8a</sup> (Consultant)
Sakov, A.	Fairtility <sup>6a</sup>
Saldivar, J.	DermTech <sup>6a</sup> ; Invitae <sup>6a</sup> ; LabCorp <sup>6a</sup> ; Personalis Inc <sup>3a</sup>
Salles, A.	Intuitive Foundation <sup>6a</sup> ; Intuitive Surgical <sup>6a</sup>
Saltiel, D.	Precision Analytical <sup>6a</sup>
Sammel, M.	Astarte Medical <sup>6a</sup>
Sanchez, T. H.	Optiva Fertility, Inc. <sup>123a</sup>
Santoro, N.	Amazon (Project Ember) <sup>8a</sup> (Medical Advisory Board); Ansh Labs, Inc <sup>6a</sup> ; Astellas <sup>8a</sup> (Scientific Advisory Board); Menogenix, Inc <sup>4a</sup> ; North American Menopause Society <sup>8a</sup> (Program Committee member); Que Oncology <sup>8a</sup> (Scientific Advisory Board); Society for Reproductive Investigation <sup>8a</sup> (President)
Sasaki, K.	Abbvie <sup>7a</sup>
Sauerbrun-Cutler, M.	Allara Women's Health <sup>8a</sup> (advisory board unpaid position)
Schenkman, E.	Adonis IVF <sup>a</sup>
Schickedanz, A.	TE <sup>3b</sup>
Schlegel, P. N.	Granata Bio <sup>8a</sup> (Consultant); Posterity Health <sup>6a</sup> ; Roman Health <sup>2a</sup> ; Theralogix <sup>5a</sup>
Schon, S. B.	Fertility Forward, LLC <sup>6a</sup>
Schoolcraft, W. B.	TMRW <sup>8a</sup> (passive investment in a fund that owns stock in TMRW)
Schreiber, C. A.	Athenium Phama <sup>8a</sup> (Data Licensing Agreement); Athenium Pharma <sup>4a</sup> ; Bayer Pharma <sup>4a</sup> ; Sebela Pharma <sup>4a</sup>
Scott, R. T.	Juno Genetics <sup>8a</sup> (I own stock in a company which owns Juno genetics)
Segars, J. H.	Abbvie <sup>8a</sup> (research PI); ABOG <sup>1a</sup> ; Bayer <sup>68a</sup> (Research study PI); DOT labs <sup>8a</sup> (research PI); Ferring <sup>8a</sup> (research PI); Obseva <sup>8a</sup> (research PI); SR118a(was president, now past president for a few weeks.)
Seifer, D. B.	Rutgers Medical School/MGH <sup>8a</sup> (royalties from license with Beckman Coulter for patent of AMH determining ovarian reserve)
Seli, E.	Foundation for Embryonic Competence <sup>46a</sup>
Shafiee, H.	Firtility Inc <sup>28a</sup> (Co-founder); Verlity LLC <sup>28a</sup> (Co-founder); XX <sup>8a</sup> (IP licensing)
Shields, P.	ENTERIS BIOPHARMA <sup>1a</sup>
Simon, P.	Give Legacy Inc <sup>3a</sup>
Simon, C.	igenomix <sup>12a</sup>
Sirota, M.	Aria Pharmaceuticals <sup>2a</sup> ; Google <sup>3b</sup>
Skeet, N.	Enteris Bio Pharma <sup>3a</sup>
Sloan, J.	CooperSurgical / CooperGenomics <sup>3a</sup>



## ABSTRACTS AUTHORS DISCLOSURES

Smith, L. P.	Virginia Fertility & IVF <sup>1a</sup>
Snabes, M. C.	AbbVie <sup>23a</sup>
Snider, A.	Igenomix <sup>3a</sup>
Snyder, M.	Filtricine <sup>a</sup> ; Fodsel <sup>a</sup> ; January AI <sup>2a</sup> ; Mirvie <sup>2a</sup> ; Personalis <sup>26a</sup> ; Protosa; Qbio <sup>2a</sup> ; RTHM <sup>a</sup> ; SensOmics <sup>2a</sup>
Solignac, C.	Gedeon Richter <sup>3a</sup>
Soulban, G.	Myovant <sup>2a</sup> ; Myovant <sup>3a</sup>
Sparks, A. E.	Ferring Pharmaceuticals <sup>5a</sup>
Stachecki, J.	Innovative Cryo Enterprises II LLC <sup>1a</sup>
Su, I.	Ferring <sup>5a</sup>
Swain, J. E.	FujiFilm Irvine Scientific <sup>8a</sup> (Key Opinion Leader- lecturer)
Takacs, P.	Fempharma <sup>6a</sup>
Tal, R.	Celmatix <sup>a</sup>
Terry, J.	Society for Pediatric Pathology, Canadian Association of Pathology <sup>8a</sup> (Board member)
Thakore, S.	Swiss Precision Diagnostics <sup>6a</sup>
Thirumalaraju, P.	XX <sup>8a</sup> (IP licensee)
Thomas, M. A.	Agile <sup>4c</sup> ; Levocept <sup>4c</sup>
Timpson, A.	Hertility <sup>6a</sup>
Tipton, C. D.	MicroGenDx <sup>3a</sup>
Travis, A. J.	Androvia LifeSciences <sup>12a</sup>
Treff, N. R.	Genomic Prediction <sup>12a</sup>
Trolice, M. P.	Alto Pharmacy <sup>2a</sup> ; Cryos International <sup>6a</sup>
Tsai, S.	ME <sup>2a</sup>
Tur-Kaspa, I.	Embryonics <sup>8a</sup> (Medical Boards)
Unfer, V.	Lo.Li. Pharma <sup>1a</sup>
Vadaparampil, S. T.	BMS <sup>7b</sup> ; GSK <sup>7b</sup>
Valencia, R.	IVF 2.0 LTD <sup>3a</sup>
Vasavan, T.	Hertility Health <sup>3a</sup>
Vaughan, D. A.	Granata Bio <sup>6a</sup>
VerMilyea, M.	Alife Health <sup>2a</sup> ; Irvine Scientific <sup>5a</sup> ; Ovation Fertility <sup>1a</sup> ; Presagen <sup>2a</sup>
Visser, J. A.	Endocrine Society <sup>8a</sup> (Board member); European Society of Endocrinology <sup>8a</sup> (chair focus area)
Vrettos, J.	Enteris BioPharma, Inc <sup>3a</sup>
Wagman, R. B.	MYOVANT SCIENCES, Inc. <sup>23a</sup>
Walter, J. R.	Sibel Health <sup>2b</sup>
Walters-Sen, L.	Invitae <sup>23a</sup>
Watson, L.	FUJIFILM Irvine Scientific <sup>3a</sup>
Watts, N.	Abbvie <sup>6a</sup> ; Amgen <sup>67a</sup>
Wei, S.	Columbia University <sup>14a</sup>
Weier, C.	CooperSurgical <sup>3a</sup>
Welch, C.	Sequence46 <sup>6a</sup>
Wells, D.	Juno Genetics <sup>123a</sup>
Wemmer, N.	Natera <sup>23a</sup>
Wen, T.	Delfina, Inc. <sup>8a</sup> (Medical Advisory Board Member)
Widra, E. A.	Igenomix <sup>6a</sup> ; Resolve <sup>1a</sup>
Wilkinson, J.	Invitae <sup>23a</sup>







## ABSTRACTS AUTHORS DISCLOSURES

Will, M.	Fertility Pharmacy of America <sup>2a</sup> ; Ovation Fertility <sup>2a</sup>
Williams, D.	Haven Cryo; MRSI <sup>8a</sup> (Board Member)
Wirka, K. A.	EMD Serono, Inc. <sup>3a</sup>
Wise, L. A.	AbbVie, Inc. <sup>6a</sup>
Wittman, M. M.	FUJIFILM Irvine Scientific <sup>3a</sup>
Xanthopoulou, L.	Cooper Companies <sup>23a</sup>
Xu, Y.	AbbVie, Inc. <sup>3a</sup>
Xu, J.	Genomic Prediction, Inc. <sup>1a</sup>
Xu, H.	Takara Bio <sup>3a</sup>
Yaffe, K.	Alector <sup>8a</sup> (Board Member); Eli Lilly <sup>8a</sup> (Data and Safety Monitoring Board Member)
Yandell, M.	BackDrop Health Inc <sup>18a</sup> (CSO); Backdrop Health Inc. <sup>12a</sup>
Yang, Z.	Quanovate Tech Inc. <sup>1a</sup>
York, S. L.	Stryker <sup>6b</sup>
Young, S. L.	CiceroDX <sup>8a</sup> (patent license)
Zarytska, N.	Generate Life Sciences (CooperSurgical) <sup>3a</sup>
Zhan, Y.	Juno Genetics <sup>3a</sup>
Zhang, Y.	Cedars-Sinai <sup>3a</sup>
Zhao, L.	Takara Bio <sup>3a</sup>



### LATE-BREAKING ABSTRACTS

### AUTHOR AND FAMILY DISCLOSURES INDEX: ORAL AND POSTER SESSIONS

All oral and poster presenters at the ASRM 2021 Scientific Congress & Expo were required to complete a disclosure form. Each abstract or video author is listed below along with any relationships an immediate family member or institution disclosed.

<sup>1</sup>Company Officer    <sup>2</sup>Direct Stockholder    <sup>3</sup>Full-Time Company Employee    <sup>4</sup>Grant Recipient    <sup>5</sup>Honoraria  
<sup>6</sup>Paid Consultant    <sup>7</sup>Speaker's Bureau    <sup>8</sup>Other    <sup>a</sup>Self    <sup>b</sup>Immediate Family Member    <sup>c</sup>Institution

Brown, M. A.	Turtle Health <sup>6a</sup>
Casper, R. F.	Abbvie <sup>6a</sup> ; Circadian Light <sup>12a</sup> ; Ferring <sup>45a</sup> ; fertility <sup>2a</sup> ; Fertility Nutraceuticals <sup>6a</sup> ; Inception-Lifebank cord blood bank <sup>1a</sup> ; TRIO Fertility <sup>12a</sup>
Chen, B. A.	Medicines 360 <sup>4c</sup> ; Sebela <sup>4c</sup>
Chung, E. H.	Turtle Health <sup>8a</sup> (Clinical Trial Lead)
Conyers, J. M.	Turtle Health <sup>6</sup>
Creinin, M. D.	Estetra <sup>6a</sup> ; Evofem <sup>6a</sup> ; HRA Pharma <sup>4a</sup> ; Mayne Pharma <sup>6a</sup> ; Merck <sup>46a</sup> ; Searchlight <sup>5a</sup> ; Sebela <sup>4a</sup>
Cwiak, C.	Medicines 360 <sup>4c</sup> ; Sebela <sup>4c</sup>
Fjeldstad, J.	Future Fertility <sup>6a</sup>
Jenkins, T. G.	Inherent Biosciences <sup>26a</sup>
Johnstone, E.	American Board of Obstetrics and Gynecology <sup>8a</sup> (REI Division Member)
Jolin, J. A.	Turtle Health <sup>8a</sup> (Advisory Board Member)
Krivoi, A.	Future Fertility <sup>12a</sup>
Letourneau, J. M.	Alnylam Pharmaceuticals <sup>6a</sup> ; EMD Serono <sup>6a</sup>
Mercuri, N.	Future Fertility <sup>3a</sup>
Meriano, J.	future fertility <sup>2a</sup> ; synergyne <sup>8a</sup> (consultant)
Nayot, D.	Future Fertility <sup>26a</sup>
Olariu, A. I.	Medicines360 <sup>3a</sup>
Petishnok, L.	Turtle Health <sup>6a</sup>
Schirmer, D. A.	Turtle Health <sup>6a</sup>
Schreiber, C. A.	Athenium Pharma <sup>8a</sup> (Data Licensing Agreement); Athenium Pharma <sup>4a</sup> ; Bayer Pharma <sup>4a</sup> ; Sebela Pharma <sup>4a</sup>
Sparks, A. E.	Ferring Pharmaceuticals <sup>5a</sup>
Styer, A. K.	Turtle Health Inc <sup>6a</sup>
Turok, D. K.	Sebela Pharmaceuticals <sup>6a</sup>





*Thank You*

to Ferring Pharmaceuticals, Inc,  
Premier Sponsor  
of the 2022 President's Gala!

*Thank You*

to Organon,  
Presenting Sponsor of the  
2022 President's Gala After Party!



## Registration Opening This Fall!

# The Best of ESHRE and ASRM

Orlando, Florida  
March 2-4, 2023

The Best of ESHRE & ASRM joint conference brings together international leaders in the field of Reproductive Medicine. Along with plenary talks from experts throughout Europe and the United States, you will also experience innovative idea sharing during our “Cutting Edge” sessions, gain an understanding of the thought differences during our “Back-to-Back” sessions, while pro and con discussions will spark conversation in the “Debate” sessions.

Scan the QR code or visit [ww.asrm.org/2023BOEA](http://ww.asrm.org/2023BOEA) to view the preliminary program.

A joint meeting of the **European Society of Human Reproduction and Embryology** and the **American Society for Reproductive Medicine**





EMD  
SERONO

# 25 YEARS. 4 MILLION STORIES.<sup>1</sup>

We've come a long way since 1997. From our first to our third-generation pens, we've been committed to evolving our technology to incorporate patient and HCP feedback.

We'll continue to plant our deep roots in the community by advancing the conversation now, in the coming 25 years, and beyond.

**JOIN US AT BOOTH #641**



**Can't make it to our booth today?**

Follow up with a local EMD fertility partnership manager or scan the QR code to visit us anytime at [emdseronofertility.com](https://emdseronofertility.com).

**Reference:** 1. Chua SJ et al. *Reprod Biol Endocrinol*. 2022;19(1):15.

©2022 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada. GONAL-F and Redi-ject are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. US-RDJ-00038 08/22







# ASRM Is Paperless!

The Final Program for the ASRM 2022 Scientific Congress & Expo in Anaheim will be posted online and available for download prior to, during, and after the Scientific Congress & Expo. The downloadable online PDF program will include complete, detailed program information, including the Daily Schedule and CME/CE materials (needs assessments/descriptions, learning objectives) for all CME activities (Postgraduate courses, plenary lectures, symposia, interactive sessions).

\* \* \*

**THERE WILL NOT  
BE A PRINTED  
FINAL PROGRAM BOOK**



For your convenience, there will be free wireless mobile hotspots in the Convention Center.



At the Congress, you will receive a printed copy of:

- Pocket calendar with room numbers
- Pocket listing of oral abstracts with room numbers
- Pocket listing of poster abstracts
- Listing of exhibits

ASRM's free mobile app will list all of the activities, including oral and poster abstracts, with their room numbers for both the Postgraduate program and the Scientific Congress. The complete abstracts will be available on the:

- Mobile app
- ASRMCongress.org website

# PASSPORT GAME

PLAY ON THE CONGRESS APP!

*Must attend in-person Congress to participate.*



prizes include



- One Apple Watch
- Two Fitbits
- Three \$100 Amazon Gift Cards

*Limit one prize per person.*



# Exhibitors

- Exhibitors Booth Index 152-153
- Anaheim Convention Center Expo Floor Plan 154
- Industry Sponsored Sessions 155
- Expo Theater Schedule 156



## EXHIBITOR COMPANY LISTING

Acerus Pharmaceuticals Corporation . . . . .	300	Endometriosis Association . . . . .	1430
ACOG - FASD . . . . .	1905	EngagedMD . . . . .	904
Advocate Aurora Health . . . . .	1902	Esco Technologies Inc. . . . .	845
Aeon Biotherapeutics Corp. . . . .	401	ESHRE . . . . .	1501
AIVF . . . . .	1644	EVERSANA . . . . .	2150
Akorn Pharmaceuticals . . . . .	1102	Evofem Biosciences . . . . .	1435
Alife . . . . .	1932	ExEm Foam . . . . .	321
Allwin Medical Devices Inc. . . . .	1301	Fairfax Cryobank and Fairfax EggBank . . . . .	1741
Ally Lending . . . . .	1100	Fairhaven Health . . . . .	1300
Alto Pharmacy . . . . .	411	Fellow . . . . .	1404
America Medic & Science . . . . .	347	Femasys Inc. . . . .	1011
American Association of Bioanalysts . . . . .	1900	Ferring Pharmaceuticals Inc. . . . .	621
ARC Fertility . . . . .	1528	Ferring Pharmaceuticals Inc. . . . .	821
Artisan Medical Solutions . . . . .	500	FertilAI . . . . .	1648
Asian Egg Bank . . . . .	1945	Fertility Pharmacy of America . . . . .	400
ASRM Central . . . . .	1521	Fertility Pro . . . . .	1801
ASTEC Co. Ltd. . . . .	1641	Fertility Specialists Network . . . . .	1649
BabySentry . . . . .	1429	Fertility Storage Solutions . . . . .	1841
Basepair . . . . .	1610	Fertility Technology Resources, Inc. . . . .	504
Bastion Health . . . . .	2050	FertilityEHR . . . . .	649
Baylor University Medical Center . . . . .	1400	First Fertility . . . . .	749
BioMatrix Specialty Pharmacy . . . . .	2101	Form Health . . . . .	1904
Brown & Brown Lone Star Insurance Service Inc. . . . .	2020	Freedom Fertility Pharmacy . . . . .	941
Caerus Biotechnologies . . . . .	2002	FUJIFILM Irvine Scientific . . . . .	1421
California Cryobank . . . . .	729	Future Fertility . . . . .	1603
Canadian Fertility and Andrology Society . . . . .	2010	Galen US, Inc. . . . .	1313
Carrot Fertility . . . . .	1935	GE Healthcare . . . . .	810
Catalyst Healthcare Marketing . . . . .	920	GeneScreen Counseling, LLC. . . . .	2105
CellOxess, LLC. . . . .	1700	Genomic Prediction, Inc. . . . .	410
Cicero Diagnostics, Inc. . . . .	1103	Give Legacy, Inc. . . . .	304
CIVCO Medical Solutions . . . . .	1201	Global Premier Fertility . . . . .	1640
Cook Medical Incorporated . . . . .	549	Hamilton Thorne, Inc. . . . .	541
Cool Beans Underwear Pty Ltd. . . . .	900	IC Biomedical . . . . .	1442
CooperSurgical . . . . .	921	IFFS . . . . .	1426
Core Cryolab . . . . .	1505	Igenomix . . . . .	333
CryoFuture . . . . .	1443	Ilitia IVF Software . . . . .	313
CryoFuture . . . . .	1542	Indian Egg Donors . . . . .	711
Cryopoint . . . . .	2040	Infertility Portal, Inc. . . . .	1048
Cryoport Systems . . . . .	1213	Innovative Health Diagnostics . . . . .	1401
Cryos International - USA . . . . .	2021	Inti Labs . . . . .	1433
Cryotherm, Inc . . . . .	1304	Invitrocare, Inc. . . . .	1925
Cycle Clarity . . . . .	2001	INVO Bioscience . . . . .	1312
DeTech . . . . .	1441	IVF On Demand (IVFOD) . . . . .	1910
Digital Instruments, Inc. . . . .	1532	IVF Store   Biotech . . . . .	327
Donor Egg Bank USA . . . . .	729	IVF USA. Ltd . . . . .	1911
DotLab . . . . .	1928	IVFCloud . . . . .	1600
Doveras . . . . .	310	IVFqc . . . . .	1601
DrCatalyst . . . . .	1602	J baby . . . . .	1541
Eastern Virginia Medical School . . . . .	2013	Karl Storz Endoscopy-America . . . . .	811
eIVF . . . . .	600	Karl Storz Endoscopy-America . . . . .	811
Embryodirector.com . . . . .	1310	Kedrion Biopharma Inc. . . . .	2111
Embryotech Laboratories, Inc. . . . .	511	Kindbody . . . . .	1549
EMD Serono . . . . .	641	Kitazato Corporation . . . . .	629
Encompass Fertility . . . . .	1833	Labcorp . . . . .	801





## EXHIBITOR COMPANY LISTING

Labotect GmbH . . . . .	1101	Reproductive Possibilities LLC . . . . .	1311
LifeAire Systems LLC . . . . .	940	Reproductive Sciences Management Company	2148
LINA Medical . . . . .	501	Reproductive Solutions . . . . .	1444
Link Mobile Medical Solution, Inc. . . . .	2000	REPROLIFE/Cryotech Japan . . . . .	341
Luna Genetics . . . . .	2110	ReproSource Fertility Diagnostics . . . . .	1010
Mandell's Clinical Pharmacy . . . . .	305	ReproTech, LLC . . . . .	1929
MDR Fertility Pharmacy . . . . .	1202	Rescripted . . . . .	1448
Medical Electronic Systems, LLC . . . . .	903	Resolve: The National Infertility Association . . . . .	1513
MedTech For Solutions, Inc. . . . .	1502	Reunite RX . . . . .	1212
Medtronic . . . . .	1901	Roche Diagnostics Corporation . . . . .	2104
Mellowood Medical-Ideas . . . . .	1710	Rocket Medical PLC . . . . .	1941
Men Having Babies, Inc. . . . .	1210	SafePoint Scientific . . . . .	2112
MFB Fertility . . . . .	902	Samsung . . . . .	1604
Microgenesis Corporation . . . . .	2132	SCSA Diagnostics . . . . .	1612
Mindray North America . . . . .	1605	Seattle Sperm Bank . . . . .	1811
Minerva Surgical . . . . .	402	Sema4 . . . . .	933
Minitube USA, Inc. . . . .	1200	SensitiveMatters.net . . . . .	1004
MVE Biological Solutions . . . . .	1511	Shivani Scientific Industries (P) LTD . . . . .	311
MyEggBank/Bundl . . . . .	1749	Siemens Healthineers . . . . .	302
Myovant Sciences, Inc. . . . .	1821	SIMPLIFY Donor Egg Bank . . . . .	312
Nableivf . . . . .	1203	SMP Pharmacy Solutions . . . . .	910
Nanosonics, Inc. . . . .	2005	Society for the Study of Reproduction . . . . .	1424
Narishige International USA, Inc. . . . .	1510	Spectrum Technologies- Your Pure Sperm Source	1913
Natera, Inc. . . . .	949	Springer Nature . . . . .	1422
National Embryo Donation Center . . . . .	901	SRF Journals . . . . .	1903
NEXT Medical Products Company . . . . .	1003	Sunlight Medical Inc. . . . .	2012
NextGen Genetics . . . . .	1949	Surrogate Prime . . . . .	1540
NextGen LifeLabs . . . . .	827	Tandem Genetics . . . . .	2134
Nikon Instruments Inc. . . . .	510	The Permanente Medical Group . . . . .	301
Nodal Health . . . . .	1748	The World Egg & Sperm Bank . . . . .	1110
Northwell Health . . . . .	2100	Theralogix . . . . .	800
NxGen MDx . . . . .	1611	Thermo Fisher Scientific . . . . .	1829
OhMD . . . . .	1001	Thomas Medical (A MedGyn Company) . . . . .	705
Olympus America Inc. . . . .	1432	TMRW . . . . .	1849
Oova Inc. . . . .	2048	TOKAI HIT Co., Ltd. . . . .	405
Optum Fertility Pharmacy . . . . .	1545	Tosoh Bioscience . . . . .	505
Organon LLC . . . . .	521	Trusted Science LLC / USA Surrogacy International	1650
Ovara . . . . .	1305	United Credit . . . . .	2103
Ovation Fertility . . . . .	1841	Univfy Inc. . . . .	1921
Ovobank ID . . . . .	1500	US Fertility . . . . .	449
Pacific Coast Reproductive Society . . . . .	835	Vanguard Communications . . . . .	1410
Pacific Coast Reproductive Society . . . . .	934	Variantyx . . . . .	2011
PatientFi . . . . .	303	Veterans Health Administration . . . . .	403
PerkinElmer Inc. . . . .	701	VFP Pharmacy Group . . . . .	1111
PharmaWatch . . . . .	2044	Vial . . . . .	2102
Pinnacle Fertility . . . . .	2027	VirtaMed Inc. . . . .	1402
Posterity Health . . . . .	2004	Vitrolife, Inc. . . . .	533
Progenesis . . . . .	2041	Vitronova, LLC . . . . .	2113
Progyny . . . . .	911	Walgreens . . . . .	610
QuickSTAT Global Life Science Logistics . . . . .	2024	WINFertility . . . . .	1000
Raeyco Lab Equipment Systems Management Ltd . . . . .	322	Wuhan Huchuang Union Technology Co., Ltd. . . . .	2034
Recurrent Pregnancy Loss Association (RPLA) . . . . .	2003	XiltriX North America . . . . .	841
Rees Scientific Corp. . . . .	1002	Xytex Corporation . . . . .	1411
Reprobiogen Inc. . . . .	1446	Yikon Genomics . . . . .	1005
Reproductive Genetic Innovations . . . . .	1211	ZyMōt Fertility . . . . .	1449






# ASRM 2022 Annual Scientific Congress & Expo

Meeting Dates: October 22-26, 2022

Exhibit Dates: October 24-26, 2022

Anaheim Convention Center ~ Anaheim, CA

**Floor Plan is Subject to Change without Notice**



# **Don't Miss Our Industry-Sponsored Symposia (non-CME)**

**Monday, October 24, 2022**

**12:15 PM - 1:15 PM**

**ASRM's Corporate Member Council presents**

**Evolving With Evolving Times: A Conversation with Experts  
About Hot Topics Impacting the World of Fertility Care**

(Kim Bergman, PhD, Growing Generations; Angela K. Lawson, PhD, Northwestern University; Susan Crockin, JD, Georgetown Law Center, Crockin Law & Policy Group; Barb Collura, President/CEO, RESOLVE: The National Infertility Association)  
**(Boxed lunch provided to the first 150 attendees - first come, first served)**

**Tuesday, October 25, 2022**

**12:15 PM – 1:15 PM**

**Thermo Fisher Scientific presents**

**PGT: The Clinical Perspective**

(Catherine Welch, Founder and Managing Director of Sequence46)

**(Boxed lunch provided to the first 125 attendees - first come, first served)**

**Myovant Sciences, Inc. & Pfizer, Inc. present**

*Please see the ASRM Final (PDF) Program or the ASRM Meeting App for details on this session*

**(Boxed lunch provided: Limited, first come, first served)**

***Please refer to the ASRM Meeting App and the ASRM Final (PDF) Program for detailed information on each of these sessions and for meeting room locations.***

# ASRM 2022 Expo Theater Schedule

## Monday, October 24, 2022

**10:05 AM – 10:45 AM**

***Natural Cycle FET - is that the new program?***

*Dr. Valerie Baker, Johns Hopkins University School of Medicine,  
and Dr. Denis Vaughan, Boston IVF*

In recent years, there has been an increase in the percentage of Natural Cycle FETs being performed at US Infertility Clinics. This increase corresponds with the publication of multiple studies showing the potential obstetric and clinical benefits associated with Natural Cycle FET when compared to the current standard, Programmed FETs. During the product theater, the literature comparing these FET treatment modalities will be reviewed. We will also review outcomes from one Infertility Clinic's Natural Cycle FET data, as well as their experience with incorporating Natural Cycle FETs into their laboratory and clinical workflow.

**10:45 AM – 12:15 PM**

***ASRMed Talks: Improving the Patient Experience***

**2:50 PM – 3:20 PM**

***ASRM Top Posters Lightning Round Session***

## Tuesday, October 25, 2022

**10:05 AM – 10:45 AM**

***From Basic Research to Patient-centered Care: 115 years of Legacy in ART***

*Dr. Allison Catherino; Dr. Kaylen Silverberg; Dr. Michael Alper; Dr. Thomas D'Hooghe*

Embark on a journey in time revealing EMD Serono's legacy and the future of assisted reproduction, through scientific advances and innovative patient-centered care.

**10:45 AM – 12:15 PM**

**ASRMed Talks:**

**Third Party Reproduction**

**Disaster Preparedness**

## Wednesday, October 26, 2022

**10:45 AM – 12:15 PM**

**ASRMed Talks:**

**Surgical Options for Fertility Care**

**Mosaics**

# **Special Session: What Now? Navigating Abortion, Personhood, and IVF in a Post-Roe World**

Tuesday, October 25, 2022: 12:15 PM -1:15 PM  
ACC Ballroom CDE

**I. Glenn Cohen, JD**

Deputy Dean, Harvard Law School

**Jamila Perritt, MD, MPH**

President & CEO Physicians for Reproductive Health

**Sean Tipton, MS**

Chief Advocacy & Policy Officer, ASRM

*Moderated by*

**Marcelle Cedars, MD**

President ASRM

The overturning of the Roe vs Wade decision by the SCOTUS this year has significant potential impacts on Women's Reproductive Health thought out the United States. Join ASRM as we host a Special Session of legal, physician, and political advocates as we discuss these impacts and our potential mitigations.



FUTURE ASRM SCIENTIFIC CONGRESS & EXPO DATES



# New Orleans, Louisiana

October 14-18, 2023



# Denver, Colorado

October 19-23, 2024




# San Antonio, Texas

October 25-29, 2025



**NOW  
ONLINE!**



# Meet your professional development goals and take your career to the next level with ASRM Academy!

ASRM Academy helps reproductive health professionals grow their scientific and clinical knowledge through a diverse catalog of online modules and courses designed by experts in reproductive medicine.

- ✓ Increase your knowledge with more engaging interactive content
- ✓ Access interactive content from anywhere
- ✓ Manage courses with a user-friendly dashboard
- ✓ Download printable transcripts and certificates
- ✓ Track course progress through personal notifications
- ✓ Take full advantage of your ASRM membership through members-only pricing

**Find a  
Course**



Available at [www.asrm.org](http://www.asrm.org)



**AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE**  
1209 MONTGOMERY HIGHWAY  
BIRMINGHAM, AL 35216-2809